{"PMC7276051": [["IntroductionThe initial stages of the COVID-19 epidemic in the United States (US) were characterized by difficulties in delivering and administering diagnostic tests (1).", [["the COVID", "TEST", 34, 43], ["diagnostic tests", "TEST", 149, 165]]], ["First, the real-time quantitative PCR assay developed and distributed by the US Centers for Disease Control and Prevention (CDC) suffered from performance issues (2, 3).", [["quantitative PCR assay", "TEST", 21, 43], ["Disease Control", "TREATMENT", 92, 107]]], ["As a result, all initial and confirmatory testing needed to be carried out by the CDC, which led to reporting delays and capacity issues early in the epidemic (4, 5).", [["confirmatory testing", "TEST", 29, 49], ["capacity issues", "PROBLEM", 121, 136]]], ["Initially, tests were only administered to individuals with a history of travel to certain countries or known contact with a positive case.", [["tests", "TEST", 11, 16]]], ["By the time testing capacity increased, state and local health departments were faced with heavy demand for COVID-19 testing.", [["COVID", "TEST", 108, 113]]], ["Only individuals meeting specific criteria could receive a test, and these criteria have varied from state to state and over time (see Supporting Information (SI) Dataset).IntroductionConcurrently, mathematical modelers have been analyzing data on reported COVID-19 cases in order to develop forecasts of future incidence and evaluate the potential impact of social distancing and other control measures, often at the behest of policymakers and public health officials.", [["a test", "TEST", 57, 63], ["social distancing", "TREATMENT", 359, 376], ["other control measures", "TREATMENT", 381, 403]]], ["These models typically rely on estimates of the reproductive number of the virus.", [["the virus", "PROBLEM", 71, 80]]], ["The basic reproductive number (R0) is defined as the expected number of secondary infections produced by an infectious individual in a fully susceptible population; this can be used to derive the expected fraction of the population that will become infected in the absence of interventions and the level of control and/or immunity that is needed to eliminate the pathogen from circulation (6).", [["infections", "DISEASE", 82, 92], ["secondary infections", "PROBLEM", 72, 92], ["an infectious individual", "PROBLEM", 105, 129], ["a fully susceptible population", "PROBLEM", 133, 163], ["interventions", "TREATMENT", 276, 289], ["reproductive", "OBSERVATION_MODIFIER", 10, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["number", "OBSERVATION_MODIFIER", 62, 68], ["secondary", "OBSERVATION_MODIFIER", 72, 81], ["infections", "OBSERVATION", 82, 92], ["infectious", "OBSERVATION_MODIFIER", 108, 118], ["infected", "OBSERVATION", 249, 257]]], ["The time-varying effective reproductive number (Rt) measures the average number of secondary infections per case at each time-point in the epidemic (6), and can be used for real-time monitoring of the impact of control measures (7\u20139).", [["infections", "DISEASE", 93, 103], ["secondary infections", "PROBLEM", 83, 103], ["average", "OBSERVATION_MODIFIER", 65, 72], ["number", "OBSERVATION_MODIFIER", 73, 79], ["secondary", "OBSERVATION_MODIFIER", 83, 92], ["infections", "OBSERVATION", 93, 103]]], ["The value of R0 can be estimated from the growth rate of the number of cases early on in the epidemic and estimates of the distribution of the generation time (i.e. the time between infection events of successive cases in a transmission chain) (11), whereas instantaneous values of Rt can be estimated based on the time series of case notifications and the distribution of the generation time (7).", [["infection", "DISEASE", 182, 191], ["infection events", "PROBLEM", 182, 198]]], ["These methods have been shown to be robust to under-detection and underreporting, so long as the probability that a true case is detected and reported remains constant through time.IntroductionHere, we use simulations to explore the potential magnitude and direction of biases introduced by changes in diagnostic testing and reporting practices similar to those occurring during the early stages of the COVID-19 epidemic in the US.", [["diagnostic testing", "TEST", 302, 320], ["the COVID", "TEST", 399, 408]]], ["We examine changes in testing practices and trends of the cumulative number of tests reported to evaluate the potential that these estimates are biased.ResultsBased on our simulations (Table S1, Fig. S1), the likelihood and degree to which R0 and Rt are biased depends on the manner in which diagnostic testing practices and reporting changes over time.", [["testing practices", "TEST", 22, 39], ["tests", "TEST", 79, 84], ["our simulations", "TEST", 168, 183], ["diagnostic testing practices", "TEST", 292, 320]]], ["When the fraction of incident cases detected and reported is constant over time and testing capacity scales with the number of \u201ctrue\u201d cases, the number of confirmed positive cases provides an unbiased estimate of R0, despite possible delays in the reporting process (Fig. 1A, Fig. S2).", [["S2", "PROTEIN", 281, 283], ["testing capacity scales", "TEST", 84, 107], ["Fig", "OBSERVATION_MODIFIER", 276, 279]]], ["In this instance, the percent of individuals testing positive is expected to be stable over time.", [["individuals", "ORGANISM", 33, 44], ["the percent of individuals testing", "TEST", 18, 52], ["stable", "OBSERVATION_MODIFIER", 80, 86]]], ["Estimates of Rt are also expected to be unbiased after the first 5-6 days (approximately equal to the mean reporting delay), but lag 2-4 days behind in detecting a decrease in Rt below the threshold value of 1 (i.e. when the epidemic is receding).", [["decrease", "OBSERVATION_MODIFIER", 164, 172]]], ["If the fraction of true cases detected and reported is increasing or decreasing linearly over time, estimates of R0 based on the growth rate of confirmed cases will be over- or under-estimates, respectively, of the true R0 (Fig. 1B\u2013C).", [["R0", "TREATMENT", 113, 115], ["the growth rate", "TEST", 125, 140], ["increasing", "OBSERVATION_MODIFIER", 55, 65], ["decreasing", "OBSERVATION_MODIFIER", 69, 79], ["linearly", "OBSERVATION_MODIFIER", 80, 88]]], ["The time-varying reproductive number, Rt, will also be slightly over- or underestimated, especially early on when there is a reporting delay.", [["slightly", "OBSERVATION_MODIFIER", 55, 63]]], ["A gradual increase or decrease in the percent of individuals testing positive is a potential indicator of such bias.", [["A gradual increase", "PROBLEM", 0, 18], ["individuals testing", "TEST", 49, 68], ["such bias", "PROBLEM", 106, 115], ["gradual", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["decrease", "OBSERVATION_MODIFIER", 22, 30]]], ["However, the percent positive is also expected to decrease or increase over time if the testing capacity expands more or less quickly than the number of true cases, respectively (Fig. 1D\u2013E).", [["the testing capacity", "TEST", 84, 104], ["percent", "OBSERVATION_MODIFIER", 13, 20], ["positive", "OBSERVATION", 21, 29], ["decrease", "OBSERVATION_MODIFIER", 50, 58], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["In this instance, estimates of R0 and Rt based on the number of confirmed cases are unbiased (Fig. S2).ResultsAbrupt changes to testing criteria, affecting the fraction of true cases detected and reported, are also expected to bias estimates of R0 and lead to a large (up to two-fold) but temporary bias in estimates of Rt (Fig. 2A\u2013B).", [["S2", "PROTEIN", 99, 101], ["testing criteria", "TEST", 128, 144], ["temporary bias", "TREATMENT", 289, 303], ["large", "OBSERVATION_MODIFIER", 262, 267], ["temporary bias", "OBSERVATION", 289, 303]]], ["The potential for such bias may be indicated by a sudden change in the percent of individuals testing positive, as well as a temporary change to the slope of the log of cumulative cases.", [["such bias", "PROBLEM", 18, 27], ["a sudden change", "PROBLEM", 48, 63], ["individuals testing", "TEST", 82, 101], ["a temporary change", "TREATMENT", 123, 141]]], ["A similar change in the percent positive may also occur with an abrupt change to the testing capacity (Fig. 2C\u2013D).", [["A similar change in the percent positive", "PROBLEM", 0, 40], ["an abrupt change", "PROBLEM", 61, 77], ["the testing capacity", "TEST", 81, 101], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["change", "OBSERVATION", 10, 16], ["percent", "OBSERVATION_MODIFIER", 24, 31], ["positive", "OBSERVATION", 32, 40], ["may also occur", "UNCERTAINTY", 41, 55], ["abrupt", "OBSERVATION_MODIFIER", 64, 70], ["change", "OBSERVATION", 71, 77]]], ["The most difficult bias to detect may be due to a change in the reporting delay distribution (Fig. 2E\u2013F).", [["a change", "PROBLEM", 48, 56], ["may be due to", "UNCERTAINTY", 34, 47]]], ["In this case, the percent positive is likely to remain roughly constant through time, but estimates of R0 and Rt will be biased, especially when the reporting delay increases.ResultsWhen the bias is due to a change in the testing criteria, affecting the fraction of true cases detected and reported, fitting models to the total number of individuals tested over time can recover unbiased estimates of the reproductive numbers (Fig. S2\u2013S3).", [["S2", "PROTEIN", 432, 434], ["a change", "PROBLEM", 206, 214], ["the testing criteria", "TEST", 218, 238], ["is likely", "UNCERTAINTY", 35, 44], ["S3", "ANATOMY", 435, 437]]], ["Thus, when the percent of positive tests is changing through time and there is uncertainty over whether it is due to changes in the testing probability or the testing ratio, fitting models to both the number of positive cases and the total number of tests may provide bounds on the uncertainty in estimates of R0 and Rt. However, this approach cannot correct for bias due to changes in the reporting delay distribution.ResultsBased on the number of confirmed COVID-19 cases across the US through March 24, 2020 (before any observable impact of social distancing measures, Fig. 3), and assuming a fixed serial interval of 6.5 days, we estimate that R0 for the US is 3.45 (95% confidence interval (CI): 3.44-3.46, accounting only for uncertainty in the growth rate).", [["positive tests", "PROBLEM", 26, 40], ["the testing probability", "TEST", 128, 151], ["the testing ratio", "TEST", 155, 172], ["tests", "TEST", 250, 255], ["bias", "PROBLEM", 363, 367], ["COVID", "TEST", 459, 464], ["social distancing measures", "TREATMENT", 544, 570], ["the US", "TEST", 655, 661], ["CI", "TEST", 696, 698], ["the growth rate", "TEST", 747, 762], ["positive", "OBSERVATION", 26, 34]]], ["Estimates of R0 for all 50 states and the District of Columbia vary from 1.92 (95% CI: 1.61-2.27, South Dakota) to 5.17 (95% CI: 4.75-5.65, Missouri) (Table S2).", [["CI", "TEST", 83, 85], ["CI", "TEST", 125, 127]]], ["Estimates of R0 based on the growth rate of the number of tests performed are similar for the entire US, but are slightly larger on average for the individual states (Table S2).", [["the growth rate", "TEST", 25, 40], ["tests", "TEST", 58, 63], ["the entire US", "TEST", 90, 103], ["slightly larger", "PROBLEM", 113, 128], ["slightly", "OBSERVATION_MODIFIER", 113, 121], ["larger", "OBSERVATION_MODIFIER", 122, 128]]], ["Nationally, the percent of individuals testing positive for COVID-19 decreased from 20-25% in early March to around 15% in mid-March.", [["individuals", "ORGANISM", 27, 38], ["individuals testing", "TEST", 27, 46], ["COVID", "TEST", 60, 65]]], ["This early decline in the percent positive is likely attributable to an increase in testing capacity, rather than a decrease in the fraction of true cases detected and reported; therefore, estimates of R0 based on the number of confirmed cases should be unbiased.", [["an increase in testing capacity", "PROBLEM", 69, 100], ["likely attributable to", "UNCERTAINTY", 46, 68], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["decrease", "OBSERVATION_MODIFIER", 116, 124]]], ["However, trends in the percent of tests positive vary by state (Fig. 4).ResultsEstimates of Rt for the US and individual states were generally high (Rt>4) initially but decreased over time (Fig. S4).", [["the US", "TEST", 99, 105], ["high", "OBSERVATION_MODIFIER", 143, 147], ["decreased", "OBSERVATION_MODIFIER", 169, 178]]], ["In Washington and California, where COVID-19 cases in the US were first recognized, estimates of Rt for early March were slightly lower (Fig. 4).", [["COVID", "TEST", 36, 41], ["the US", "TEST", 54, 60], ["slightly", "OBSERVATION_MODIFIER", 121, 129], ["lower", "OBSERVATION_MODIFIER", 130, 135]]], ["Nationally, Rt had decreased to less than 2 by March 24, 2020.", [["decreased", "OBSERVATION_MODIFIER", 19, 28]]], ["As of April 5, 2020, which is the last reliable day for which we could generate estimates, Rt was less than 1 (meaning the epidemic was starting to decline) in 24 of 51 states, but was hovering around 1 in a number of states (e.g. California) (Fig. 4, Fig. S4).ResultsNationally (and in most states), the percent of individuals testing positive for COVID-19 has been gradually increasing since mid-March (Fig. 3, Fig. 4).", [["individuals testing", "TEST", 316, 335], ["COVID", "TEST", 349, 354], ["gradually", "OBSERVATION_MODIFIER", 367, 376], ["increasing", "OBSERVATION_MODIFIER", 377, 387]]], ["This could be occurring either because the fraction of individuals infected with SARS-CoV-2 detected and reported is increasing, or because states are reaching their testing capacity and individuals more likely to be infected are being prioritized for testing.", [["SARS", "DISEASE", 81, 85], ["SARS-CoV-2", "ORGANISM", 81, 91], ["SARS-CoV", "SPECIES", 81, 89], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89], ["testing", "TEST", 252, 259], ["increasing", "OBSERVATION_MODIFIER", 117, 127], ["infected", "OBSERVATION", 217, 225]]], ["If it is the former, our analysis suggests that the more recent estimates of Rt may be upwardly biased.", [["our analysis", "TEST", 21, 33]]], ["Moreover, temporary increases in Rt around mid-March in states like New York and California might be due to early restrictions to testing criteria.", [["temporary increases", "PROBLEM", 10, 29], ["testing criteria", "TEST", 130, 146], ["temporary", "OBSERVATION_MODIFIER", 10, 19], ["increases", "OBSERVATION_MODIFIER", 20, 29], ["New", "OBSERVATION_MODIFIER", 68, 71]]], ["However, abrupt decreases in the percent of tests positive were generally due to large increases in the total number of tests reported, and therefore should not reflect a bias in estimates of Rt based on the number of confirmed cases.DiscussionOver the first month and a half of the COVID-19 epidemic in the US, testing practices have varied dramatically over time and from state to state (SI Dataset) (13).", [["abrupt decreases", "PROBLEM", 9, 25], ["the percent of tests positive", "TEST", 29, 58], ["large increases", "PROBLEM", 81, 96], ["the COVID", "TEST", 279, 288], ["abrupt", "OBSERVATION_MODIFIER", 9, 15], ["decreases", "OBSERVATION_MODIFIER", 16, 25], ["large", "OBSERVATION_MODIFIER", 81, 86], ["increases", "OBSERVATION_MODIFIER", 87, 96]]], ["As of April 17, 2020, the total number of tests reported per capita has varied from 5.7 tests per 1,000 people in Virginia to 29.5 tests per 1,000 people in New York (12).", [["people", "SPECIES", 104, 110], ["people", "SPECIES", 147, 153], ["tests", "TEST", 42, 47], ["tests", "TEST", 131, 136]]], ["Due to the limited availability of tests early on, most states recommended that only those with a history of travel to affected countries or known contact with a confirmed case be tested (4, 5).", [["tests", "TEST", 35, 40]]], ["Since the disease has become more widespread throughout the US and testing capacity has increased, testing guidelines have been relaxed, but there are still considerable differences from state to state (SI Dataset).", [["the disease", "PROBLEM", 6, 17], ["the US", "TEST", 56, 62], ["testing capacity", "TEST", 67, 83], ["testing guidelines", "TEST", 99, 117], ["disease", "OBSERVATION", 10, 17], ["more", "OBSERVATION_MODIFIER", 29, 33], ["widespread", "OBSERVATION_MODIFIER", 34, 44], ["increased", "OBSERVATION_MODIFIER", 88, 97]]], ["For example, as of April 6, 2020, Washington state had no restrictions on who can be tested for COVID-19, but prioritized hospitalized individuals and essential service providers exhibiting symptoms (14).", [["COVID", "TEST", 96, 101], ["symptoms", "PROBLEM", 190, 198]]], ["As of April 15, New York still recommended restricting testing to those with a known positive contact or travel history, as well as symptomatic individuals who had tested negative for other infections (15).", [["infections", "DISEASE", 190, 200], ["individuals", "ORGANISM", 144, 155], ["other infections", "PROBLEM", 184, 200]]], ["As testing practices change over time, we have demonstrated that these changes may introduce bias into estimates of R0 and Rt, affecting inference about how much control is needed and when control measures have reduced transmission below the critical threshold necessary to sustain the epidemic.DiscussionOur estimate of the mean R0 in the US of 3.45 is reasonably consistent with published estimates.", [["the US", "TEST", 336, 342], ["reasonably consistent with", "UNCERTAINTY", 354, 380]]], ["Early analyses from China report a range for R0 of 2.24-3.58, assuming a mean serial interval of 8 days and a 2- to 8-fold increase in the reporting rate (16).", [["R0", "TEST", 45, 47], ["the reporting rate", "TEST", 135, 153], ["increase", "OBSERVATION_MODIFIER", 123, 131]]], ["However, more recent analyses estimate a median R0 of 5.7 (95% CI 3.8, 8.9) (17).", [["a median R0", "TEST", 39, 50], ["CI", "TEST", 63, 65]]], ["Analysis of data from Europe and the US present a similarly high R0, with median values ranging from 4.0 to 7.1 when assuming a serial interval of 6-9 days (18).", [["the US", "TEST", 33, 39], ["median values", "TEST", 74, 87], ["a serial interval", "TEST", 126, 143]]], ["Our estimated mean R0 is notably lower, but this was based on a similar estimated growth rate of 0.275, suggesting the difference can be attributed to different assumptions about the serial interval.", [["Our estimated mean R0", "TEST", 0, 21], ["mean R0", "OBSERVATION", 14, 21], ["lower", "OBSERVATION_MODIFIER", 33, 38]]], ["Estimates of Rt have not been widely reported for the US, but other studies have found that Rt decreased from 2-5 at the start of the epidemic to ~1 following travel restrictions in Wuhan and various European countries (19, 20), which is in line with our findings.DiscussionMonitoring the number of tests performed and the percent of tests that are positive over time can help to indicate the potential for bias in estimates of reproductive numbers.", [["the US", "TEST", 50, 56], ["other studies", "TEST", 62, 75], ["Rt", "TEST", 92, 94], ["tests", "TEST", 299, 304], ["the percent of tests", "TEST", 319, 339]]], ["In California, for example, there was a more than eight-fold increase in the number of negative tests reported on March 13, and another four-fold increase on April 4, 2020 (12).", [["-fold", "OBSERVATION_MODIFIER", 55, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["negative", "OBSERVATION", 87, 95], ["-fold", "OBSERVATION_MODIFIER", 140, 145], ["increase", "OBSERVATION_MODIFIER", 146, 154]]], ["These large increases in the number of negative tests were not accompanied by a corresponding increase in the number of confirmed cases.", [["large", "OBSERVATION_MODIFIER", 6, 11], ["increases", "OBSERVATION_MODIFIER", 12, 21], ["number", "OBSERVATION_MODIFIER", 29, 35], ["negative", "OBSERVATION", 39, 47], ["increase", "OBSERVATION_MODIFIER", 94, 102]]], ["Thus, while estimates of R0 and Rt based on the number of confirmed cases are not expected to be influenced by these abrupt changes in the number of reported tests, it becomes difficult to interpret the intervening gradual increases in the percent of tests positive.DiscussionIt is more difficult to detect whether the time between onset of infectiousness and the reporting of test results (i.e., the reporting delay) has changed over time.", [["these abrupt changes", "PROBLEM", 111, 131], ["tests positive", "PROBLEM", 251, 265], ["infectiousness", "PROBLEM", 341, 355], ["abrupt", "OBSERVATION_MODIFIER", 117, 123], ["gradual", "OBSERVATION_MODIFIER", 215, 222], ["increases", "OBSERVATION_MODIFIER", 223, 232]]], ["Our simulations suggest that such changes could bias estimates of R0 and Rt, but would not be reflected in the percent of individuals testing positive over time.", [["Our simulations", "TEST", 0, 15]]], ["Individual-level data on the date of symptom onset, date of testing, and date of reporting are needed to resolve this potential bias.", [["Individual-level data", "TEST", 0, 21], ["symptom onset", "PROBLEM", 37, 50], ["testing", "TEST", 60, 67]]], ["Estimates of Rt are also expected to lag behind true changes in the transmission rate due to reporting delays.", [["true changes", "PROBLEM", 48, 60], ["the transmission rate", "TEST", 64, 85]]], ["Now-casting approaches may be useful for resolving this by inferring the number of infections occurring on each day based on the observed cases, hospitalizations and deaths, and known reporting delays (21).DiscussionImminent decisions regarding the lifting of stay-at-home orders and loosening social distancing requirements, and when such measures may need to be reinstated, depend on having a good understanding of current levels of transmission.", [["infections", "DISEASE", 83, 93], ["deaths", "DISEASE", 166, 172], ["casting approaches", "TREATMENT", 4, 22], ["infections", "PROBLEM", 83, 93], ["infections", "OBSERVATION", 83, 93]]], ["Reliable estimates of the reproductive number are essential for quantifying the impact of control measures on transmission and making informed decisions about future interventions, e.g. (7, 19, 20, 22, 23).", [["future interventions", "TREATMENT", 159, 179]]], ["It important to carefully document and track such changes in testing and reporting practices in order to make correct inferences.Examining the impact of changes in testing using simulated data ::: MethodsWe simulated a stochastic SEIR (Susceptible-Exposed-Infected-Recovered) model to explore the potential impact of changes in testing practices on estimates of R0 and Rt. We modeled a population of 1 million individuals and initialized the epidemic with 10 infectious individuals to minimize the chances of early epidemic fadeout.", [["testing", "TEST", 61, 68], ["testing practices", "TEST", 328, 345], ["early epidemic fadeout", "PROBLEM", 509, 531]]], ["New infections were assumed to arise according to a Poisson process (approximate method); the state transitions and rates are described in Table 1, and model parameters are given in Table 2.", [["infections", "DISEASE", 4, 14], ["New infections", "PROBLEM", 0, 14], ["infections", "OBSERVATION", 4, 14]]], ["We simulated the model to day 70 using a time-step of \u0394t=0.05 days, and assumed a decrease in the transmission rate occurring on day 50, consistent with the impact of social distancing interventions.", [["social distancing interventions", "TREATMENT", 167, 198], ["decrease", "OBSERVATION_MODIFIER", 82, 90], ["consistent with", "UNCERTAINTY", 137, 152]]], ["Models were run using MATLAB v9.3 (MathWorks, Natick, MA); code is available from https://github.com/vepitzer/COVIDtestingbias.Examining the impact of changes in testing using simulated data ::: MethodsWe tracked the number of \u201ctrue cases\u201d on day d(Yd) as the number of individuals entering the infectious period each day.", [["MATLAB v", "TEST", 22, 30], ["Methods", "TREATMENT", 195, 202], ["infectious", "OBSERVATION", 295, 305]]], ["We assumed that each true case occurring on day d had a probability ptest(d) of being tested, and that for every true case that occurred on day d, there were ntest(d) individuals with similar symptoms who were tested.", [["ntest(d) individuals", "PROBLEM", 158, 178], ["similar symptoms", "PROBLEM", 184, 200]]], ["Furthermore, we assumed that testing and reporting of positive tests occurred with some delay \u03c1d(t), which followed a gamma distribution with parameters ad and bd.", [["testing", "TEST", 29, 36], ["positive tests", "PROBLEM", 54, 68]]], ["Thus, we calculated the number of individuals tested (Td) and the number of positive cases (Cd) on day d as follows:Td=\u2211i=1dntest(i)Yi\u03c1i(d\u2212i)Cd=\u2211i=1dBin(Yi,ptest(i)\u03c1i(d\u2212i))Examining the impact of changes in testing using simulated data ::: MethodsWe rounded the value of Td to the nearest integer and sampled Cd as binomial random variable.", [["Cd", "CHEMICAL", 92, 94], ["Cd", "CHEMICAL", 141, 143], ["Cd", "CHEMICAL", 309, 311], ["Cd", "CHEMICAL", 92, 94], ["Cd", "CHEMICAL", 141, 143], ["Cd", "CHEMICAL", 309, 311], ["Cd", "SIMPLE_CHEMICAL", 309, 311]]], ["We allowed for the observation of cases occurring up to day 95 (even though no new cases were modeled after day 70) to examine the impact of the reporting delay on estimates of Rt.Examining the impact of changes in testing using simulated data ::: MethodsAs our base case, we assumed that the probability of a \u201ctrue case\u201d being tested was ptest=0.1 and the number of individuals tested for each true case was ntest=0.5; we assumed a mean reporting delay between onset of infectiousness and testing results of 6.6 days (24).", [["Methods", "TREATMENT", 248, 255], ["ptest", "TEST", 339, 344], ["infectiousness", "PROBLEM", 471, 485], ["testing", "TEST", 490, 497]]], ["We then modelled scenarios in which the fraction of true cases detected and reported (as indicated by ptest) and the testing capacity (i.e. number of individuals tested for every true cases, ntest) either increased or decreased linearly between days 20 and 60 of the epidemic.", [["the testing capacity", "TEST", 113, 133], ["increased", "OBSERVATION_MODIFIER", 205, 214], ["decreased", "OBSERVATION_MODIFIER", 218, 227], ["linearly", "OBSERVATION_MODIFIER", 228, 236]]], ["To examine the impact of sudden changes to the probability of a true case being tested (e.g. associated with changes in testing criteria) and testing capacity (e.g. associated with new companies entering the market), we also explored scenarios in which ptest and ntest increased or decreased abruptly on day 40 (Table S1).", [["sudden changes", "PROBLEM", 25, 39], ["testing criteria", "TEST", 120, 136], ["testing capacity", "TEST", 142, 158]]], ["Finally, we examined the effect of a two-fold increase or decrease in the average reporting delay.Estimation of R0 from simulated data ::: MethodsWe estimated R0 from the growth rate of the epidemic, as described by Lipsitch et al (11):R0=r2f(1\u2212f)V2+rV+1,where r is the growth rate, V is the serial interval (also known at the generation interval), and f is the proportion of the serial interval spent in the latent period.", [["a two-fold increase", "PROBLEM", 35, 54], ["R0", "TEST", 236, 238], ["r2f", "TEST", 239, 242], ["rV", "TEST", 250, 252], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["decrease", "OBSERVATION_MODIFIER", 58, 66], ["rV", "ANATOMY", 250, 252], ["latent", "OBSERVATION_MODIFIER", 409, 415]]], ["The growth rate (r) was determined by fitting Poisson regression models to the cumulative number of \u201ctrue cases\u201d (Yd) and reported cases (Cd) on days d=21 to 40.", [["Cd", "CHEMICAL", 138, 140], ["Cd", "CHEMICAL", 138, 140], ["The growth rate", "TEST", 0, 15]]], ["We assumed that the serial interval is equal to the sum of the average latent period and the average infectious period (V=1/\u03bd+1/\u03b3), and that the proportion of the serial interval spent in the latent period is f=1/(V\u03bd).", [["V", "TEST", 120, 121], ["equal", "OBSERVATION_MODIFIER", 39, 44], ["average", "OBSERVATION_MODIFIER", 93, 100], ["infectious", "OBSERVATION_MODIFIER", 101, 111]]], ["We estimated 95% confidence intervals (CIs) for our estimate of R0 by incorporating uncertainty in the estimated growth rate, but did not incorporate uncertainty in f or V.Estimation of Rt from simulated data ::: MethodsWe estimated Rt using the Wallinga-Teunis method (7).", [["the estimated growth rate", "TEST", 99, 124], ["MethodsWe", "TREATMENT", 213, 222]]], ["First, the relative likelihood that case i was infected by case j is estimated based on the probability distribution of the difference in the time of symptom onset (ti\u2212tj), over the probability that case i was infected by any other case k:pij=g(ti\u2212tj)/\u2211i\u2260kg(ti\u2212tk)where g(x) is the probability distribution function for the generation interval.", [["pij=g(ti\u2212tj)/\u2211i\u2260kg(ti\u2212tk)", "TREATMENT", 239, 264]]], ["We assume all cases are equivalent in terms of infectiousness.", [["infectiousness", "PROBLEM", 47, 61]]], ["Thus, to estimate Rt based on the number of \u201ctrue\u201d cases, this can be rewritten as:pij=g(ti\u2212tj)/\u2211t=1ti\u22121g(ti\u2212t)Yt.Estimation of Rt from simulated data ::: MethodsWe do not allow for values of the generation interval less than or equal to zero; thus, we assume all cases were infected by a case that occurred on an earlier day.", [["1ti\u22121g(ti\u2212t)Yt", "CHEMICAL", 99, 113], ["pij=g(ti\u2212tj)", "TREATMENT", 83, 95], ["Methods", "TREATMENT", 155, 162]]], ["While this is not necessarily true when accounting for possible reporting delays, we make the same assumption when estimating Rt based on the number of reported cases.", [["not necessarily", "UNCERTAINTY", 14, 29]]], ["We assumed that the generation interval was gamma distributed with a mean of 6.5 days and coefficient of variation of 0.62, consistent with data from Flaxman et al (20):g(x)~Gamma(4.79,1.357)Estimation of Rt from simulated data ::: MethodsSecond, the reproductive number for case j is estimated by calculated the weighted sum of pij over all cases i:Rj=\u2211ipij.Again, assuming all cases are equally infectious, this becomes:Rj=\u2211u=t+1tmaxputYu.To estimate Rt based on the number of true cases, we set tmax=70 and estimate Rt up to day 60.", [["Rj=\u2211u=t+1tmaxputYu", "PROTEIN", 422, 440], ["Gamma", "TEST", 174, 179], ["equally infectious", "PROBLEM", 389, 407], ["tmax", "TEST", 498, 502], ["consistent with", "UNCERTAINTY", 124, 139], ["infectious", "OBSERVATION", 397, 407]]], ["We correct for right-censoring of the case data by dividing our estimates of Rt by the cumulative distribution function of the generation interval (G(x)) for tmax\u2122t:Rt=Rt/G(tmax\u2212t).To explore the potential influence of the reporting delays, we estimate Rt based on the reported positive cases for tmax=70 and tmax=95.COVID-19 testing data for the United States ::: MethodsDaily data on the reported number of positive and negative tests for COVID-19 in the US and by state were downloaded from www.covidtracking.com on April 18, 2020 (12).", [["tmax\u2122t", "TEST", 158, 164], ["Rt=Rt/G(tmax\u2212t)", "TREATMENT", 165, 180], ["tmax", "TEST", 297, 301], ["tmax", "TEST", 309, 313], ["COVID", "TEST", 317, 322], ["COVID", "TEST", 441, 446], ["right", "ANATOMY_MODIFIER", 15, 20]]], ["We analyzed the data from March 4, 2020, onward, as this is the first date that negative tests for COVID-19 were consistently reported for the entire US.COVID-19 testing data for the United States ::: MethodsTesting practices vary considerably between states, and some states changed their guidelines a few weeks into the outbreak, depending on test availability, outbreak intensity, and health systems infrastructure.", [["COVID", "TEST", 99, 104], ["the entire US", "TEST", 139, 152], ["COVID", "TEST", 153, 158], ["MethodsTesting practices", "TREATMENT", 201, 225]]], ["We extracted information on COVID-19 testing criteria from each state\u2019s website during the week of March 23 and again during the week of April 13.", [["COVID", "TEST", 28, 33]]], ["Data sources are documented in the SI Dataset.COVID-19 testing data for the United States ::: MethodsFor example, as of March 13, Louisiana recommended testing for people with fever, respiratory symptoms, and a negative influenza test, with priority given to the following categories:Hospitalized patients with a severe respiratory illness with no other known cause.Suspected outbreak of COVID-19 among associated individuals with recent onset of similar fever and lower respiratory symptoms.Recent fever and lower respiratory symptoms in a healthcare worker with direct contact to a laboratory-confirmed COVID-19 case.Suspected COVID-19 in a patient associated with a high-risk exposure setting such as a long-term care facility or a correctional facility.Suspected COVID-19 in a homeless patient.However, as of April 15, anyone with fever and respiratory symptoms was eligible to be tested, regardless of influenza status, and pharmacists were given permission to order and administer COVID-19 tests for the duration of the public health emergency.Estimation of R0 from state-level testing data ::: MethodsTo estimate R0 from data on the number of reported positive COVID-19 cases in the US and different states, we fitted Poisson regression models to the first three weeks of data (March 4 through March 24, 2020) to estimate the growth rate.", [["respiratory", "ANATOMY", 183, 194], ["respiratory", "ANATOMY", 320, 331], ["respiratory", "ANATOMY", 471, 482], ["respiratory", "ANATOMY", 515, 526], ["respiratory", "ANATOMY", 845, 856], ["fever", "DISEASE", 176, 181], ["respiratory symptoms", "DISEASE", 183, 203], ["respiratory illness", "DISEASE", 320, 339], ["COVID-19", "CHEMICAL", 388, 396], ["fever", "DISEASE", 455, 460], ["respiratory symptoms", "DISEASE", 471, 491], ["fever", "DISEASE", 499, 504], ["lower respiratory symptoms", "DISEASE", 509, 535], ["fever", "DISEASE", 835, 840], ["respiratory symptoms", "DISEASE", 845, 865], ["people", "ORGANISM", 164, 170], ["patients", "ORGANISM", 297, 305], ["patient", "ORGANISM", 643, 650], ["patient", "ORGANISM", 790, 797], ["COVID-19", "DNA", 629, 637], ["COVID-19", "DNA", 767, 775], ["people", "SPECIES", 164, 170], ["patients", "SPECIES", 297, 305], ["patient", "SPECIES", 643, 650], ["patient", "SPECIES", 790, 797], ["COVID", "TEST", 46, 51], ["testing", "TEST", 152, 159], ["fever", "PROBLEM", 176, 181], ["respiratory symptoms", "PROBLEM", 183, 203], ["a negative influenza test", "PROBLEM", 209, 234], ["a severe respiratory illness", "PROBLEM", 311, 339], ["COVID", "TEST", 388, 393], ["similar fever", "PROBLEM", 447, 460], ["lower respiratory symptoms", "PROBLEM", 465, 491], ["Recent fever", "PROBLEM", 492, 504], ["lower respiratory symptoms", "PROBLEM", 509, 535], ["fever", "PROBLEM", 835, 840], ["respiratory symptoms", "PROBLEM", 845, 865], ["influenza status", "PROBLEM", 907, 923], ["COVID", "TREATMENT", 987, 992], ["the US", "TEST", 1186, 1192], ["the growth rate", "TEST", 1329, 1344], ["severe", "OBSERVATION_MODIFIER", 313, 319], ["respiratory", "ANATOMY", 320, 331], ["illness", "OBSERVATION", 332, 339], ["no", "UNCERTAINTY", 345, 347], ["similar", "OBSERVATION_MODIFIER", 447, 454], ["fever", "OBSERVATION", 455, 460], ["lower", "ANATOMY_MODIFIER", 465, 470], ["respiratory", "ANATOMY", 471, 482], ["symptoms", "OBSERVATION", 483, 491], ["fever", "OBSERVATION", 499, 504], ["lower", "ANATOMY_MODIFIER", 509, 514], ["respiratory", "ANATOMY", 515, 526], ["symptoms", "OBSERVATION", 527, 535]]], ["We assumed that the mean serial interval was 6.5 days and that the average latent period was 4.6 days, based on (20).", [["average", "OBSERVATION_MODIFIER", 67, 74], ["latent", "OBSERVATION_MODIFIER", 75, 81]]], ["We calculated 95% CIs for the R0 estimates based on uncertainty in the estimated growth rate, but did not account for uncertainty in the serial interval or latent period.Estimation of Rt from state-level testing data ::: MethodsEstimates of the time-varying reproductive number in each state were generated using the Wallinga-Teunis method described above.", [["the R0 estimates", "TEST", 26, 42], ["the Wallinga-Teunis method", "TREATMENT", 313, 339]]], ["For later dates, we present both the uncorrected estimates and estimates corrected for right-censoring, as described above.", [["right-censoring", "TREATMENT", 87, 102], ["right", "ANATOMY_MODIFIER", 87, 92], ["censoring", "OBSERVATION", 93, 102]]]], "c87d4f4e911438b3f30bc8b68937547a2ee7110c": [["62.581Entre 1992 y 1998, publiqu\u00e9 en estas mismas p\u00e1ginas catorce art\u00edculos especiales sobre diversas cuestiones relacionadas con el lenguaje especializado de la medicina [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .", [["medicina [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]", "CHEMICAL", 162, 226], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 171, 231], ["publiqu\u00e9", "TEST", 25, 33], ["estas", "TEST", 37, 42], ["mismas", "TEST", 43, 49], ["p\u00e1ginas", "TEST", 50, 57], ["catorce", "TEST", 58, 65], ["art\u00edculos", "TEST", 66, 75], ["especiales", "TEST", 76, 86], ["diversas", "TEST", 93, 101]]], ["Los tres art\u00edculos sobre palabras de traducci\u00f3n enga\u00f1osa en el ingl\u00e9s m\u00e9dico 1,4,9 constituyeron el germen de lo que a\u00f1os despu\u00e9s ser\u00eda el Diccionario cr\u00edtico de dudas ingl\u00e9s-espa\u00f1ol de medicina 16 , donde comento m\u00e1s de 20.000 t\u00e9rminos ingleses de traducci\u00f3n dif\u00edcil, como anion gap, bypass, evidence-based medicine, managed care, natural killer cell, oxidative stress, programmed cell death, screening, stent o Western blot.", [["killer cell", "ANATOMY", 340, 351], ["cell", "ANATOMY", 382, 386], ["death", "DISEASE", 387, 392], ["natural killer cell", "CELL", 332, 351], ["cell", "CELL", 382, 386], ["Los tres art\u00edculos", "TEST", 0, 18], ["m\u00e9dico", "TEST", 70, 76], ["como anion gap", "TREATMENT", 269, 283], ["bypass", "TREATMENT", 285, 291], ["natural killer cell", "TREATMENT", 332, 351], ["oxidative stress", "PROBLEM", 353, 369], ["programmed cell death", "PROBLEM", 371, 392], ["screening", "TEST", 394, 403], ["bypass", "OBSERVATION", 285, 291], ["killer cell", "OBSERVATION", 340, 351]]], ["Neologismo ingl\u00e9s acu\u00f1ado sobre el modelo de sexism y racism para designar la discriminaci\u00f3n por motivos de edad (frecuente, por ejemplo, en algunos modelos asistenciales modernos).", [["Neologismo", "TEST", 0, 10]]], ["En espa\u00f1ol podr\u00edamos, claro, acu\u00f1ar un neologismo equivalente a partir del lat\u00edn (\u00abetatismo\u00bb) o el castellano (\u00abedadismo\u00bb), pero cualquiera de ellos, si no se define previamente, resulta mucho m\u00e1s abstruso que el ingl\u00e9s.", [["claro", "PROBLEM", 22, 27]]], ["En el caso de expresiones compuestas del tipo de sexism and ageism, ello obliga a sustituir tambi\u00e9n el primer elemento por una circunlocuci\u00f3n equivalente (p. ej., \u00abdiscriminaci\u00f3n por raz\u00f3n de sexo y edad\u00bb).62.581antisense strand (tambi\u00e9n antisense DNA, complementary strand, minus strand, noncoding strand, template strand o transcribing strand).", [["DNA", "CELLULAR_COMPONENT", 248, 251], ["62.581antisense strand", "DNA", 206, 228], ["tambi\u00e9n antisense DNA", "DNA", 230, 251], ["complementary strand", "DNA", 253, 273], ["minus strand", "DNA", 275, 287], ["noncoding strand", "DNA", 289, 305], ["template strand", "DNA", 307, 322], ["antisense strand (tambi\u00e9n antisense DNA", "TREATMENT", 212, 251]]], ["Por motivos de claridad, conviene, desde luego, unificar la nomenclatura en espa\u00f1ol y hablar siempre de \u00abhebra no codificante\u00bb (mejor que \u00abhebra antisentido\u00bb, \u00abhebra templete\u00bb, \u00abhebra minus\u00bb, etc.).", [["codificante\u00bb", "PROBLEM", 114, 126]]], ["Es preferible no hablar de \u00absentido\u00bb y \u00abantisentido\u00bb en este contexto para evitar confusiones con otros conceptos como nonsense codon o missense codon.", [["missense codon", "PROBLEM", 136, 150], ["missense codon", "OBSERVATION", 136, 150]]], ["En cuanto al sin\u00f3nimo complementary strand, tan \u00abcomplementaria\u00bb es la hebra no codificante con respecto a la hebra codificante como \u00e9sta lo es con respecto a aqu\u00e9lla; por no hablar del riesgo innegable de confusi\u00f3n con el concepto de complementary DNA o \u00abADN complementario\u00bb.", [["DNA", "CELLULAR_COMPONENT", 249, 252]]], ["La situaci\u00f3n se complica m\u00e1s a\u00fan si tenemos en cuenta que muchos cient\u00edficos llaman antisense strand precisamente a la otra hebra del ADN bicatenario, a la codificante, que para la mayor\u00eda de los cient\u00edficos es sense strand. arteriolovenular anastomosis.", [["arteriolovenular anastomosis", "TREATMENT", 225, 253], ["anastomosis", "OBSERVATION", 242, 253]]], ["En 1998, la nueva terminolog\u00eda anat\u00f3mica internacional ha dado preferencia al t\u00e9rmino anastomosis arteriolovenularis sobre el t\u00e9rmino cl\u00e1sico anastomosis arteriovenosa que hab\u00eda venido recomend\u00e1ndose hasta entonces con car\u00e1cter oficial.", [["la", "TEST", 9, 11], ["al t\u00e9rmino anastomosis", "TREATMENT", 75, 97]]], ["Este cambio obedece a un hecho incontrovertible: que esta estructura anat\u00f3mica no une una arteria y una vena, sino una arteriola y una v\u00e9nula.", [["vena", "MULTI-TISSUE_STRUCTURE", 104, 108], ["una arteria", "ANATOMY", 86, 97], ["vena", "ANATOMY", 104, 108], ["una v\u00e9nula", "OBSERVATION", 131, 141]]], ["Ahora bien, si tenemos en cuenta que la expresi\u00f3n \u00abanastomosis arteriovenosa\u00bb estaba ya consagrada por el uso y la entend\u00edan sin problemas los m\u00e9dicos de todo el mundo, cabe plantearse la necesidad y la conveniencia de cambiar la nomenclatura tradicional.", [["Ahora", "TEST", 0, 5]]], ["Habr\u00e1 que estar, en cualquier caso, muy atentos a la acogida que la comunidad m\u00e9dica mundial presta a la nueva terminolog\u00eda; a menos que sea entusi\u00e1stica y masiva (de momento, desde luego, los m\u00e9dicos apenas la han secundado), propongo seguir utilizando en espa\u00f1ol el t\u00e9rmino tradicional \u00abanastomosis arteriovenosa\u00bb. atypical pneumonia.", [["pneumonia", "DISEASE", 326, 335], ["en espa\u00f1ol el t\u00e9rmino tradicional \u00abanastomosis arteriovenosa\u00bb", "TREATMENT", 254, 315], ["atypical pneumonia", "PROBLEM", 317, 335], ["pneumonia", "OBSERVATION", 326, 335]]], ["Neumon\u00eda at\u00edpica: cualquier neumon\u00eda distinta -por sus manifestaciones cl\u00ednicas o su etiopatogenia-de la neumon\u00eda lobular cl\u00e1sica.", [["lobular cl\u00e1sica", "DISEASE", 114, 129], ["la neumon\u00eda lobular cl\u00e1sica", "PROBLEM", 102, 129], ["lobular", "OBSERVATION", 114, 121]]], ["Sin\u00f3nimo coloquial impropio de SARS (s\u00edndrome respiratorio agudo grave), que en espa\u00f1ol podemos llamar \u00abneumon\u00eda asi\u00e1tica\u00bb, \u00abneumon\u00eda at\u00edpica asi\u00e1tica\u00bb o \u00abneumon\u00eda coronav\u00edrica\u00bb, pero no \u00abneumon\u00eda at\u00edpica\u00bb a secas.62.581coxibs.", [["SARS", "DISEASE", 31, 35], ["62.581coxibs", "CHEMICAL", 214, 226], ["\u00abneumon\u00eda", "PROBLEM", 124, 133], ["\u00abneumon\u00eda", "PROBLEM", 187, 196], ["coxibs", "TREATMENT", 220, 226], ["coxibs", "OBSERVATION", 220, 226]]], ["Gracias al descubrimiento, hace poco m\u00e1s de diez a\u00f1os, de una segunda cicloxigenasa (COX), hoy sabemos que los efectos antinflamatorios de los AINE se deben a inhibici\u00f3n de la COX-2, mientras que su toxicidad digestiva se debe a inhibici\u00f3n de la COX-1.", [["COX-1", "GENE_OR_GENE_PRODUCT", 246, 251], ["la COX", "TEST", 173, 179]]], ["Ello llev\u00f3 al desarrollo de dos f\u00e1rmacos, el rofecoxib y el celecoxib, que inhib\u00edan de forma preferente la COX-2.", [["rofecoxib y el celecoxib", "CHEMICAL", 45, 69], ["celecoxib", "CHEMICAL", 60, 69], ["celecoxib", "SIMPLE_CHEMICAL", 60, 69], ["COX-2", "GENE_OR_GENE_PRODUCT", 107, 112], ["al desarrollo de dos f\u00e1rmacos", "TREATMENT", 11, 40], ["el rofecoxib y el celecoxib", "TREATMENT", 42, 69]]], ["Desde entonces, se usan mucho los t\u00e9rminos coxibs, specific COX-2 inhibitors y selective COX-2 inhibitors para referirse a este nuevo grupo farmacol\u00f3gico.", [["coxibs", "TREATMENT", 43, 49], ["specific COX", "TREATMENT", 51, 63], ["y selective COX", "TREATMENT", 77, 92]]], ["En cuanto al espa\u00f1ol, prefiero hablar de \u00abinhibidores selectivos de la COX-2\u00bb.", [["En cuanto al espa\u00f1ol", "TREATMENT", 0, 20], ["prefiero hablar", "TREATMENT", 22, 37]]], ["El problema con el t\u00e9rmino coxibs es que, antes de conocerse la existencia de la COX-2, ya se hab\u00edan comercializado otros f\u00e1rmacos que posteriormente se ha comprobado que inhiben de forma selectiva la COX-2, como el meloxicam, el etodolaco o la nimesulida.", [["meloxicam", "CHEMICAL", 216, 225], ["COX-2", "SIMPLE_CHEMICAL", 201, 206], ["El problema", "PROBLEM", 0, 11], ["con el t\u00e9rmino coxibs", "TREATMENT", 12, 33], ["la COX", "TEST", 78, 84], ["la COX", "TEST", 198, 204], ["como el meloxicam", "TREATMENT", 208, 225]]], ["Por lo tanto, y aunque qu\u00edmicamente no est\u00e9n emparentados con el rofecoxib y el celecoxib, estos f\u00e1rmacos pertenecen tambi\u00e9n al grupo farmacol\u00f3gico de los inhibidores selectivos de la COX-2.", [["rofecoxib y el celecoxib", "CHEMICAL", 65, 89], ["COX-2", "GENE_OR_GENE_PRODUCT", 184, 189], ["estos f\u00e1rmacos", "TREATMENT", 91, 105]]], ["En cuanto a specific COX-2 inhibitors, el t\u00e9rmino \u00abespec\u00edfico\u00bb se usa en farmacolog\u00eda con un sentido bien preciso, y no puede aplicarse a f\u00e1rmacos que s\u00f3lo en concentraciones terap\u00e9uticas inhiben de forma selectiva la COX-2, pero que pueden inhibir tambi\u00e9n la COX-1 en concentraciones superiores (hoy no autorizadas, pero que quiz\u00e1 lo est\u00e9n dentro de unos a\u00f1os para otras indicaciones).62.581debulking.", [["COX-2", "GENE_OR_GENE_PRODUCT", 21, 26], ["a specific COX", "TREATMENT", 10, 24], ["debulking", "TREATMENT", 392, 401], ["debulking", "OBSERVATION", 392, 401]]], ["En la actualidad, se usa sobre todo en el contexto de un c\u00e1ncer diseminado (en el que no es posible extirpar por completo el tumor), para designar toda intervenci\u00f3n en la que se extirpa la mayor cantidad posible de tejido tumoral con objeto de mejorar la respuesta posterior a la radioterapia o la quimioterapia antineopl\u00e1sicas.", [["tumor", "DISEASE", 125, 130], ["el tumor", "PROBLEM", 122, 130], ["tumor", "OBSERVATION", 125, 130], ["posterior", "ANATOMY_MODIFIER", 265, 274]]], ["En este contexto, y dado que se trata de reducir en lo posible el n\u00famero de c\u00e9lulas cancerosas, la traducci\u00f3n m\u00e1s adecuada de debulking es \u00abcirug\u00eda citorreductora\u00bb.", [["la traducci\u00f3n m\u00e1s", "TREATMENT", 96, 113]]], ["En ocasiones, debulking se utiliza como sin\u00f3nimo de downstaging (v\u00e9ase).62.581down-staging 1.", [["debulking", "TREATMENT", 14, 23]]], ["T\u00e9rmino acu\u00f1ado en ingl\u00e9s para designar la disminuci\u00f3n del grado de extensi\u00f3n anat\u00f3mica de un tumor maligno de acuerdo con el sistema TNM.", [["tumor", "DISEASE", 94, 99], ["T\u00e9rmino", "TEST", 0, 7], ["acu\u00f1ado", "TEST", 8, 15], ["tumor maligno", "PROBLEM", 94, 107], ["tumor", "OBSERVATION", 94, 99], ["sistema TNM", "OBSERVATION", 126, 137]]], ["No es una simple reducci\u00f3n del tama\u00f1o tumoral (puesto que puede tratarse de una re-misi\u00f3n del grado de afectaci\u00f3n ganglionar o grado N), ni tampoco es exactamente equivalente al concepto de \u00abremisi\u00f3n\u00bb (puesto que puede darse una remisi\u00f3n parcial del tumor sin cambios en el estadio TNM) 17 .", [["tumor", "DISEASE", 250, 255], ["ni tampoco es exactamente equivalente al concepto de \u00abremisi\u00f3n\u00bb (puesto que puede darse una remisi\u00f3n parcial del tumor sin cambios en el estadio TNM)", "SPECIES", 137, 286], ["una remisi\u00f3n parcial del tumor sin cambios en el estadio TNM)", "TREATMENT", 225, 286]]], ["Antes de utilizar el anglicismo down-staging o alg\u00fan calco confuso del tipo de \u00absubestadificaci\u00f3n\u00bb, prefiero hablar de \u00abdescenso del estadio TNM\u00bb o \u00abdescenso TNM\u00bb.", [["Antes de utilizar el anglicismo down-staging o alg\u00fan calco confuso del tipo de \u00absubestadificaci\u00f3n\u00bb, prefiero hablar de \u00abdescenso del estadio TNM\u00bb o \u00abdescenso TNM\u00bb", "SPECIES", 0, 162]]], ["En el caso concreto del carcinoma cervicouterino, los t\u00e9rminos down-staging y clinical down-staging corresponden sencillamente a la \u00abinspecci\u00f3n\u00bb (a simple vista) para el diagn\u00f3stico precoz del carcinoma cervicouterino. gamma hemolysis.", [["carcinoma cervicouterino", "DISEASE", 24, 48], ["carcinoma cervicouterino", "DISEASE", 193, 217], ["hemolysis", "DISEASE", 225, 234], ["del carcinoma", "PROBLEM", 20, 33], ["los t\u00e9rminos", "TEST", 50, 62], ["staging", "TEST", 92, 99], ["a la \u00abinspecci\u00f3n\u00bb", "PROBLEM", 127, 144], ["a simple vista) para el diagn\u00f3stico precoz del carcinoma cervicouterino", "TREATMENT", 146, 217], ["gamma hemolysis", "PROBLEM", 219, 234], ["del carcinoma", "OBSERVATION", 20, 33], ["del carcinoma", "OBSERVATION", 189, 202], ["hemolysis", "OBSERVATION", 225, 234]]], ["Algunos autores hablan de gamma hemolysis y gamma-hemolytic streptococci en referencia a este tercer grupo, lo cual es un aut\u00e9ntico sinsentido que \u00fanicamente puede confundir al lector (algo as\u00ed como si yo decidiera llamar \u00abdiab\u00e9ticos de tipo 3\u00bb a quienes no son diab\u00e9ticos).", [["hemolysis", "DISEASE", 32, 41], ["hemolysis", "TEST", 32, 41], ["gamma-hemolytic streptococci", "PROBLEM", 44, 72]]], ["Mucho m\u00e1s l\u00f3gico parece referirse a estos estreptococos como non-hemolytic streptococci (estreptococos no hemol\u00edticos).62.581gene chip (tambi\u00e9n llamado bioarray, biochip, DNA array, DNA chip, DNA microarray, gene array, gene microarray, genome array, genome chip, genome microarray o microarray a secas).", [["DNA", "CELLULAR_COMPONENT", 171, 174], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["62.581gene chip", "DNA", 119, 134], ["tambi\u00e9n llamado bioarray", "DNA", 136, 160], ["biochip, DNA array", "DNA", 162, 180], ["DNA chip", "DNA", 182, 190], ["genome array", "DNA", 237, 249], ["genome chip", "DNA", 251, 262], ["non-hemolytic streptococci", "PROBLEM", 61, 87], ["gene chip (tambi\u00e9n llamado bioarray", "TREATMENT", 125, 160], ["biochip, DNA array", "TREATMENT", 162, 180], ["DNA chip", "TREATMENT", 182, 190], ["DNA microarray", "TREATMENT", 192, 206], ["genome chip", "TREATMENT", 251, 262]]], ["La primera de estas placas, fabricada por la empresa Affymetrix, llevaba la marca comercial Gene Chip, que en ingl\u00e9s se utiliza ya mucho en contextos informales como si fuera un nombre com\u00fan (en contextos formales no es posible, pues Affymetrix proh\u00edbe a terceros el uso de su marca, protegida por la ley).", [["La primera de estas placas", "PROBLEM", 0, 26], ["fabricada", "PROBLEM", 28, 37], ["llevaba la marca", "TREATMENT", 65, 81]]], ["Partiendo del mismo principio general, la expresi\u00f3n g\u00e9nica se investiga en protein\u00f3mica mediante lo que en ingl\u00e9s llaman protein chips (o tambi\u00e9n protein microarrays o proteome microarrays), que en espa\u00f1ol propongo llamar \u00abmicromatrices prote\u00ednicas\u00bb (o, en textos de divulgaci\u00f3n, tambi\u00e9n \u00abproteinochips\u00bb o \u00abmicrochips de prote\u00ednas\u00bb). genethics.", [["llaman protein chips", "TREATMENT", 114, 134], ["tambi\u00e9n protein microarrays", "TREATMENT", 138, 165], ["proteome microarrays", "TEST", 168, 188], ["que en espa\u00f1ol propongo", "TREATMENT", 191, 214]]], ["En espa\u00f1ol, la cacofon\u00eda aliterativa \u00ab\u00e9tica gen\u00e9tica\u00bb podr\u00eda evitarse con el juego de palabras \u00abgen-\u00e9tica\u00bb (donde el gui\u00f3n servir\u00eda para impedir confusiones con la gen\u00e9tica), pero resulta m\u00e1s forzado que en ingl\u00e9s.", [["En espa\u00f1ol", "TREATMENT", 0, 10], ["la cacofon\u00eda aliterativa", "TREATMENT", 12, 36]]], ["Prefiero echar mano del prefijo \u00abgeno\u00bb, de amplio uso en medicina, para formar el neologismo \u00abgeno\u00e9tica\u00bb 18 .62.581genomic imprinting (tambi\u00e9n llamado gametic imprinting, genetic imprinting, genome imprint o parental imprinting).", [["genomic imprinting (tambi\u00e9n llamado gametic imprinting", "TREATMENT", 115, 169]]], ["Recomiendo evitar el anglicismo \u00abimprinting\u00bb, para el que se han propuesto diversas traducciones: \u00abimpresi\u00f3n\u00bb, \u00abimpronta\u00bb, \u00abestampaci\u00f3n\u00bb, \u00abmarcado\u00bb, \u00abtroquelado\u00bb y \u00abmarcaje\u00bb.", [["\u00abimpresi\u00f3n\u00bb", "TREATMENT", 98, 109], ["\u00abimpronta\u00bb", "TREATMENT", 111, 121], ["\u00abestampaci\u00f3n\u00bb", "TREATMENT", 123, 136], ["\u00abmarcado\u00bb", "TREATMENT", 138, 147], ["\u00abtroquelado\u00bb y \u00abmarcaje\u00bb", "TREATMENT", 149, 173]]], ["Ninguna de ellas resulta satisfactoria para dar nom-bre al genomic imprinting, mecanismo de regulaci\u00f3n aleloespec\u00edfica de la expresi\u00f3n g\u00e9nica por el que en algunos genes se produce un estado epigen\u00e9tico de hemicigosis funcional debido al silenciamiento de uno de los dos alelos -materno o paterno-, marcado durante la gametogenia y que no se expresa.", [["Ninguna de ellas", "TEST", 0, 16], ["bre al genomic imprinting", "PROBLEM", 52, 77], ["paterno", "TEST", 289, 296]]], ["Considero, siguiendo a Saladrigas 19,20 , que el mejor modo de traducir la doble idea de marca y silenciamiento que entra\u00f1a el vocablo ingl\u00e9s imprint es mediante un vocablo espa\u00f1ol que a\u00fana ambos conceptos: \u00absello\u00bb.", [["a Saladrigas", "TEST", 21, 33]]], ["Recomiendo, pues, traducir, genomic imprinting por \u00absellado gen\u00f3mico\u00bb.62.581HIV/AIDS.", [["HIV/AIDS", "DISEASE", 76, 84], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 76, 79]]], ["Puede usarse sin problemas, por ejemplo, para escribir \u00abcociente urea/creatinina\u00bb, pero no para \u00abVIH/sida\u00bb (\u00bfVIH partido por sida?).", [["Puede usarse sin problemas, por ejemplo, para escribir \u00abcociente urea/creatinina\u00bb, pero no para \u00abVIH/sida\u00bb", "SPECIES", 0, 106], ["para", "PROBLEM", 91, 95]]], ["El uso de la raya en la expresi\u00f3n HIV/AIDS es de lo m\u00e1s confuso para el lector, que con frecuencia se queda sin saber si hace referencia solamente a las personas infectadas por el VIH, pero sin sida; solamente a las personas infectadas por el VIH y aquejadas de sida, o a todas las personas infectadas por el VIH, con sida o sin \u00e9l.", [["AIDS", "DISEASE", 38, 42], ["frecuencia", "TEST", 88, 98]]], ["Puede ser que se refiera sencillamente al sida: Tuberculosis, malaria and HIV/AIDS are the three major causes of mortality in Africa (\u00abla tuberculosis, el paludismo y el sida son las tres causas principales de mortalidad en \u00c1frica\u00bb).O bien a las personas infectadas por el VIH: A small increase in the number of HIV/AIDS patients is to be expected(\u00abes de esperar un ligero aumento en el n\u00famero de pacientes infectados por el VIH\u00bb); porque, vamos a ver, los enfermos de sida, \u00bfno est\u00e1n tambi\u00e9n infectados por el VIH?", [["Tuberculosis, malaria", "DISEASE", 48, 69], ["HIV/AIDS", "DISEASE", 74, 82], ["tuberculosis", "DISEASE", 138, 150], ["HIV/AIDS", "DISEASE", 312, 320], ["patients", "ORGANISM", 321, 329], ["patients", "SPECIES", 321, 329], ["HIV", "SPECIES", 312, 315], ["Tuberculosis", "PROBLEM", 48, 60], ["malaria", "PROBLEM", 62, 69], ["HIV", "PROBLEM", 74, 77], ["AIDS", "PROBLEM", 78, 82], ["Africa (\u00abla tuberculosis", "PROBLEM", 126, 150], ["A small increase", "PROBLEM", 278, 294], ["HIV/AIDS", "PROBLEM", 312, 320], ["Tuberculosis", "OBSERVATION", 48, 60], ["malaria", "OBSERVATION", 62, 69], ["mortality", "OBSERVATION", 113, 122], ["small", "OBSERVATION_MODIFIER", 280, 285], ["increase", "OBSERVATION_MODIFIER", 286, 294]]], ["Si, por el motivo que sea, se quieren mencionar ambos grupos por separado, tampoco ofrece la cosa mayor dificultad: People living with HIV/AIDS puede ser \u00ablas personas infectadas por el VIH\u00bb (en sentido amplio) o \u00ablas personas infectadas por el VIH o aquejadas de sida\u00bb; cualquiera de las dos formas parece mejor y m\u00e1s clara que \u00abpersonas que viven con el VIH/sida\u00bb (\u00a1y no digamos ya \u00abgentes viviendo con HIV/AIDS\u00bb!).", [["HIV/AIDS", "DISEASE", 135, 143], ["AIDS", "DISEASE", 409, 413], ["Si", "CHEMICAL", 0, 2], ["People", "SPECIES", 116, 122], ["HIV/AIDS puede ser \u00ablas personas infectadas por el VIH\u00bb (en sentido amplio) o \u00ablas personas infectadas por el VIH o aquejadas de sida\u00bb; cualquiera de las dos formas parece mejor y m\u00e1s clara que \u00abpersonas que viven con el VIH/sida\u00bb (\u00a1y no digamos ya \u00abgentes viviendo con HIV/AIDS\u00bb!", "SPECIES", 135, 415]]], ["En estos casos, mi recomendaci\u00f3n es recurrir al gui\u00f3n y escribir en espa\u00f1ol \u00abinfecci\u00f3n por el VIH-sida\u00bb en lugar de \u00abVIH/SIDA\u00bb, del mismo modo que escribimos \u00abvaricela-z\u00f3ster\u00bb y no \u00abvaricela/z\u00f3ster\u00bb. immune globulin.", [["immune globulin", "GENE_OR_GENE_PRODUCT", 200, 215], ["immune globulin", "PROTEIN", 200, 215], ["estos casos, mi recomendaci\u00f3n es recurrir al gui\u00f3n y escribir en espa\u00f1ol \u00abinfecci\u00f3n por el VIH-sida\u00bb en lugar de \u00abVIH/SIDA\u00bb, del mismo modo que escribimos \u00abvaricela-z\u00f3ster\u00bb y no \u00abvaricela/z\u00f3ster\u00bb", "SPECIES", 3, 198], ["mi recomendaci\u00f3n", "TREATMENT", 16, 32], ["immune globulin", "TREATMENT", 200, 215]]], ["Puede tener dos significados, que conviene distinguir claramente:O bien a las personas infectadas por el VIH: A small increase in the number of HIV/AIDS patients is to be expected1.", [["HIV/AIDS", "DISEASE", 144, 152], ["HIV", "ORGANISM", 144, 147], ["patients", "ORGANISM", 153, 161], ["HIV", "SPECIES", 144, 147], ["patients", "SPECIES", 153, 161], ["HIV", "SPECIES", 144, 147], ["A small increase", "PROBLEM", 110, 126], ["HIV/AIDS", "PROBLEM", 144, 152], ["small", "OBSERVATION_MODIFIER", 112, 117], ["increase", "OBSERVATION_MODIFIER", 118, 126], ["number", "OBSERVATION_MODIFIER", 134, 140]]], ["Sin\u00f3nimo, cada vez menos frecuente en ingl\u00e9s, de immunoglobulin (inmunoglobulina).", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 49, 63], ["immunoglobulin", "PROTEIN", 49, 63], ["Sin\u00f3nimo", "TREATMENT", 0, 8], ["cada vez menos", "TREATMENT", 10, 24]]], ["Nombre oficial que recibe en la farmacopea estadounidense cualquier concentrado de inmunoglobulinas (obtenido a partir de un inmunosuero humano para su uso en terap\u00e9utica), tambi\u00e9n llamado en ingl\u00e9s immune serum globulin.", [["serum", "ORGANISM_SUBSTANCE", 206, 211], ["globulin", "ORGANISM_SUBSTANCE", 212, 220], ["tambi\u00e9n llamado", "TREATMENT", 173, 188], ["immune serum globulin", "TREATMENT", 199, 220]]], ["Obs\u00e9rvese, pues, que en el ingl\u00e9s norteamericano distinguen claramente entre immunoglobulin (inmunoglobulina) e immune globulin (concentrado de inmunoglobulinas).", [["immunoglobulin", "PROTEIN", 77, 91], ["Obs\u00e9rvese", "TEST", 0, 9], ["entre immunoglobulin", "TEST", 71, 91], ["inmunoglobulina", "TEST", 93, 108], ["e immune globulin (concentrado de inmunoglobulinas", "TREATMENT", 110, 160]]], ["En espa\u00f1ol es v\u00e1lido el uso abreviado de \u00abinmunoglobulinas\u00bb (en plural) con el sentido de \u00abconcentrado de inmunoglobuli-nas\u00bb, pero no el de \u00abinmunoglobulina\u00bb (en singular).", [["En espa\u00f1ol es v\u00e1lido el uso abreviado de \u00abinmunoglobulinas\u00bb (en plural)", "TREATMENT", 0, 71]]], ["Ej.: A total of 320 patients with idiopathic thrombopenic purpura were treated with immune globulin (\u00ab320 pacientes con p\u00farpura trombocitop\u00e9nica idiop\u00e1tica recibieron tratamiento con inmunoglobulinas, o tratamiento inmunoglobul\u00ednico\u00bb [\u00a1pero no \u00abtratamiento con inmunoglobulina\u00bb!, igual que nadie dir\u00eda \u00abtratamiento con prote\u00edna\u00bb ni \u00abtratamiento con vitamina\u00bb]). in silico.", [["idiopathic thrombopenic purpura", "DISEASE", 34, 65], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["tratamiento inmunoglobul\u00ednico\u00bb [\u00a1pero no \u00abtratamiento con inmunoglobulina\u00bb!, igual que nadie dir\u00eda \u00abtratamiento con prote\u00edna\u00bb ni \u00abtratamiento con vitamina\u00bb", "SPECIES", 203, 358], ["idiopathic thrombopenic purpura", "PROBLEM", 34, 65], ["immune globulin", "TREATMENT", 84, 99], ["pacientes con p\u00farpura trombocitop\u00e9nica idiop\u00e1tica recibieron tratamiento con inmunoglobulinas", "TREATMENT", 106, 199], ["o tratamiento inmunoglobul\u00ednico\u00bb", "TREATMENT", 201, 233], ["\u00abtratamiento con inmunoglobulina\u00bb", "TREATMENT", 244, 277], ["igual que nadie dir\u00eda \u00abtratamiento con prote\u00edna\u00bb ni \u00abtratamiento con vitamina\u00bb]", "TREATMENT", 280, 359], ["idiopathic", "OBSERVATION_MODIFIER", 34, 44], ["thrombopenic purpura", "OBSERVATION", 45, 65]]], ["Conviene no olvidar que esta expresi\u00f3n es lat\u00edn macarr\u00f3nico acu\u00f1ado en la jerga de laboratorio por cruce entre el t\u00e9rmino ingl\u00e9s silicon (silicio) y la pareja tradicional in vivo e in vitro (estas dos s\u00ed expresiones latinas correctas).", [["Conviene", "TREATMENT", 0, 8], ["entre el t\u00e9rmino ingl\u00e9s silicon (silicio)", "TREATMENT", 105, 146], ["vitro (estas dos", "TREATMENT", 184, 200]]], ["Personalmente, recomiendo su traducci\u00f3n al espa\u00f1ol por \u00abinform\u00e1tico\u00bb, otro adjetivo equivalente o una circunlocuci\u00f3n: in silico biology (bioinform\u00e1tica), in silico drug design (dise\u00f1o de f\u00e1rmacos por ordenador). kinin 1.", [["kinin 1", "GENE_OR_GENE_PRODUCT", 212, 219], ["kinin 1", "PROTEIN", 212, 219]]], ["Una vez acu\u00f1ados para \u00e9stas nombres oficiales, deben evitarse ya las antiguas designaciones, que todav\u00eda se ven con relativa frecuencia en ingl\u00e9s; p. ej., kinin-9 (bradicinina), kinin-10 (calidina).", [["kinin-9 (bradicinina", "ORGANISM", 155, 175], ["kinin-10", "ORGANISM", 178, 186], ["calidina", "ORGANISM", 188, 196], ["Una", "TEST", 0, 3], ["kinin", "TEST", 155, 160], ["kinin", "TEST", 178, 183]]], ["En ingl\u00e9s se usa en ocasiones kinin en el sentido de \u00abfitocinina\u00bb, como forma abreviada de phytokinin.", [["phytokinin", "CHEMICAL", 91, 101], ["phytokinin", "SIMPLE_CHEMICAL", 91, 101]]], ["Desaconsejo ese uso en espa\u00f1ol para evitar confusiones con las aut\u00e9nticas kinins (cininas), un grupo de hormonas locales que nada tienen que ver con las fitocininas.4.No deben confundirse los vocablos ingleses kinin (cinina) y quinine (quinina). luminescence 1.", [["quinine", "CHEMICAL", 227, 234], ["quinine", "CHEMICAL", 227, 234], ["kinin", "GENE_OR_GENE_PRODUCT", 210, 215], ["quinine", "SIMPLE_CHEMICAL", 227, 234], ["quinina", "SIMPLE_CHEMICAL", 236, 243]]], ["La emisi\u00f3n de luz sin calor no se llama en espa\u00f1ol \u00abluminescencia\u00bb, sino \u00abluminiscencia\u00bb (como derivado del lat\u00edn lumen, luminis, \u00abluz\u00bb).", [["se llama en espa\u00f1ol \u00abluminescencia\u00bb", "TREATMENT", 31, 66], ["sino \u00abluminiscencia\u00bb (como derivado del lat\u00edn lumen", "TREATMENT", 68, 119]]], ["Si en la emisi\u00f3n de luz interviene una reacci\u00f3n qu\u00edmica, hablamos entonces de \u00abquimioluminiscencia\u00bb.", [["Si", "CHEMICAL", 0, 2]]], ["Si la emisi\u00f3n de luz es consecuencia de la absorci\u00f3n previa de una radiaci\u00f3n, hablamos entonces de \u00abfotoluminiscencia\u00bb, que puede ser de dos tipos: \u00abfosforescencia\u00bb, si la fotoluminiscencia persiste alg\u00fan tiempo despu\u00e9s de cesar la radiaci\u00f3n que la provoca, y \u00abfluorescencia\u00bb, si la fotoluminiscencia se extingue al cesar la radiaci\u00f3n que la provoca.", [["si la fotoluminiscencia", "PROBLEM", 277, 300]]], ["\u00abIluminaci\u00f3n\u00bb, por \u00faltimo, es sencillamente la acci\u00f3n de un flujo luminoso sobre un objeto.", [["Iluminaci\u00f3n\u00bb", "TREATMENT", 1, 13]]], ["La confusi\u00f3n entre todos estos conceptos es tal que en dermatolog\u00eda, por ejemplo, es frecuente encontrar los t\u00e9rminos luminescence o epiluminescence para referirse a la \u00abdermatoscopia\u00bb, una t\u00e9cnica bien conocida que aprovecha un rayo de luz incidente para visualizar la superficie cut\u00e1nea, de modo que en realidad no es m\u00e1s que una microscopia por epiluminaci\u00f3n.4.naive.", [["La confusi\u00f3n", "PROBLEM", 0, 12]]], ["En los textos cient\u00edficos, se ha generalizado en ingl\u00e9s el uso de naive ya no con su sentido original de \u00abingenuo\u00bb o \u00absencillo\u00bb, sino para expresar la ausencia de exposici\u00f3n previa, como en los ejemplos que comento a continuaci\u00f3n:4.1.", [["En los textos cient\u00edficos", "TREATMENT", 0, 25], ["previa", "PROBLEM", 174, 180]]], ["La expresi\u00f3n naive patient, que se acu\u00f1\u00f3 en los estudios cl\u00ednicos sobre el sida, se usa cada vez m\u00e1s en otros contextos para hacer referencia a los pacientes sin tratamiento previo con un determinado f\u00e1rmaco.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["Ej.: Ribavirin plus interferon combination therapy is presently considered the first election treatment of interferon-naive patients with chronic hepatitis C (\u00abla biterapia con ribavirina e interfer\u00f3n est\u00e1 considerada en la actualidad como el tratamiento de elecci\u00f3n en los pacientes con hepatitis C cr\u00f3nica sin tratamiento interfer\u00f3nico previo\u00bb).", [["Ej.", "CHEMICAL", 0, 3], ["Ribavirin", "CHEMICAL", 5, 14], ["interferon", "CHEMICAL", 20, 30], ["chronic hepatitis C", "DISEASE", 138, 157], ["\u00abla biterapia con ribavirina e interfer\u00f3n est\u00e1", "CHEMICAL", 159, 205], ["hepatitis", "DISEASE", 288, 297], ["Ribavirin", "CHEMICAL", 5, 14], ["Ribavirin", "SIMPLE_CHEMICAL", 5, 14], ["patients", "ORGANISM", 124, 132], ["interferon", "PROTEIN", 20, 30], ["interferon", "PROTEIN", 107, 117], ["patients", "SPECIES", 124, 132], ["Ribavirin", "TREATMENT", 5, 14], ["interferon combination therapy", "TREATMENT", 20, 50], ["interferon", "TREATMENT", 107, 117], ["chronic hepatitis C", "PROBLEM", 138, 157], ["(\u00abla biterapia con ribavirina e", "TREATMENT", 158, 189], ["hepatitis C cr\u00f3nica sin tratamiento interfer\u00f3nico previo\u00bb", "TREATMENT", 288, 345], ["Ribavirin", "OBSERVATION", 5, 14], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["hepatitis", "OBSERVATION", 146, 155]]], ["Como ant\u00f3nimo de naive, se ve bastante en ingl\u00e9s la construcci\u00f3n treatment-experienced (generalmente aplicada al tratamiento antirretrov\u00edrico, aunque no se indique expresamente).", [["la construcci\u00f3n treatment", "TREATMENT", 49, 74], ["generalmente aplicada al tratamiento antirretrov\u00edrico", "TREATMENT", 88, 141]]], ["Ej.: Effectiveness and safety of tenofovir in treatment-experienced patients (\u00abeficacia y toxicidad del tenofovir en pacientes con tratamiento antirretrov\u00edrico previo\u00bb); heavily treatment-experienced patients (\u00abpacientes multitratados\u00bb).2.Otras expresiones m\u00e9dicas con naive son: naive animal (animal no sometido previamente a experimentaci\u00f3n) y naive CD4 cell (linfocito CD4 indiferenciado o linfocito CD4 virgen, mejor que \u00ablinfocito CD4 naive\u00bb).neglect.No deben confundirse los sustantivos ingleses negligence (negligencia) y neglect (descuido, desatenci\u00f3n, dejadez, abandono).", [["CD4 cell", "ANATOMY", 352, 360], ["tenofovir", "CHEMICAL", 33, 42], ["tenofovir", "CHEMICAL", 104, 113], ["neglect", "DISEASE", 448, 455], ["negligencia) y neglect", "DISEASE", 514, 536], ["tenofovir", "CHEMICAL", 33, 42], ["tenofovir", "SIMPLE_CHEMICAL", 33, 42], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 200, 208], ["CD4 cell", "CELL", 352, 360], ["CD4 cell", "CELL_TYPE", 352, 360], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 200, 208], ["tenofovir in treatment", "TREATMENT", 33, 55], ["patients (\u00abeficacia y toxicidad del tenofovir en pacientes con tratamiento antirretrov\u00edrico previo\u00bb", "TREATMENT", 68, 167], ["patients (\u00abpacientes multitratados\u00bb", "TREATMENT", 200, 235], ["CD4 virgen", "TREATMENT", 403, 413], ["neglect", "PROBLEM", 448, 455], ["y neglect (descuido", "PROBLEM", 527, 546], ["CD4 cell", "OBSERVATION", 352, 360]]], ["Los neur\u00f3logos denominan neglect o neglect syndrome (tambi\u00e9n llamado contralateral neglect, hemi-inattention, hemineglect, hemisensory neglect, hemispatial neglect, sensory neglect o unilateral neglect) a la ausencia de orientaci\u00f3n, atenci\u00f3n o reacci\u00f3n del paciente ante est\u00edmulos nuevos o intensos provenientes del lado contrario a la lesi\u00f3n.", [["neglect syndrome", "DISEASE", 35, 51], ["tambi\u00e9n llamado contralateral neglect", "DISEASE", 53, 90], ["hemisensory neglect", "DISEASE", 123, 142], ["hemispatial neglect", "DISEASE", 144, 163], ["sensory neglect o unilateral neglect", "DISEASE", 165, 201], ["neglect syndrome", "PROBLEM", 35, 51], ["tambi\u00e9n llamado contralateral neglect", "PROBLEM", 53, 90], ["hemi-inattention", "PROBLEM", 92, 108], ["hemineglect", "PROBLEM", 110, 121], ["hemisensory neglect", "PROBLEM", 123, 142], ["hemispatial neglect", "PROBLEM", 144, 163], ["sensory neglect", "PROBLEM", 165, 180], ["unilateral neglect", "PROBLEM", 183, 201], ["neglect syndrome", "OBSERVATION", 35, 51]]], ["\u00c9sta, casi siempre de car\u00e1cter vascular o tumoral, suele localizarse en el hemisferio derecho.", [["tumoral", "ANATOMY", 42, 49]]], ["Recomiendo evitar en espa\u00f1ol los calcos \u00abs\u00edndrome de negligencia\u00bb o \u00abs\u00edndrome de heminegligencia\u00bb, que son para nosotros confusos y pueden nombrarse de forma mucho m\u00e1s clara como \u00abs\u00edndrome de inatenci\u00f3n\u00bb o \u00abs\u00edndrome de inatenci\u00f3n unilateral\u00bb. nonsense codon (o nonsense triplet) 1.", [["nonsense triplet) 1", "GENE_OR_GENE_PRODUCT", 261, 280], ["nonsense codon", "DNA", 243, 257], ["o nonsense triplet) 1", "DNA", 259, 280], ["nonsense codon", "PROBLEM", 243, 257]]], ["Dado que el concepto de nonsense codon se utiliza en la pr\u00e1ctica como sin\u00f3nimo de terminator codon (tambi\u00e9n llamado en ingl\u00e9s termination codon o stop codon), recomiendo su traducci\u00f3n por \u00abcod\u00f3n finalizador\u00bb (aunque se ve bastante m\u00e1s en espa\u00f1ol \u00abcod\u00f3n de terminaci\u00f3n\u00bb).2.No debe confundirse el concepto de nonsense codon (cod\u00f3n finalizador) con el de missense codon (cod\u00f3n de sentido alterado), que especifica un amino\u00e1cido distinto del que especifica normalmente. nutraceuticals (tambi\u00e9n llamados foodaceuticals, pharmafood y vitafood).", [["en la pr\u00e1ctica como sin\u00f3nimo de terminator codon", "TREATMENT", 50, 98], ["tambi\u00e9n llamado en ingl\u00e9s termination codon", "TREATMENT", 100, 143], ["\u00abcod\u00f3n finalizador\u00bb", "TREATMENT", 188, 207], ["debe", "PROBLEM", 275, 279], ["nutraceuticals", "TREATMENT", 466, 480], ["tambi\u00e9n llamados foodaceuticals", "TREATMENT", 482, 513]]], ["Su adaptaci\u00f3n al espa\u00f1ol plantea dos problemas.", [["Su adaptaci\u00f3n al espa\u00f1ol plantea", "TREATMENT", 0, 32]]], ["En segundo lugar, para se\u00f1alar relaci\u00f3n con la nutrici\u00f3n, en espa\u00f1ol parece m\u00e1s l\u00f3gico recurrir a la part\u00edcula \u00abnutri-\u00bb que a la part\u00edcula \u00abnutra-\u00bb.", [["en espa\u00f1ol parece", "TREATMENT", 58, 75], ["a la part\u00edcula \u00abnutri-\u00bb", "TREATMENT", 96, 119]]], ["Adem\u00e1s, el neologismo nutraceuticals est\u00e1 utiliz\u00e1ndose en ingl\u00e9s con dos significados bien distintos: 1.", [["el neologismo nutraceuticals", "TREATMENT", 8, 36]]], ["Preparados alimenticios a los que se atribuyen virtudes profil\u00e1cticas o curativas -ya sean \u00e9stas reales o imaginadas-, pero que no necesitan demostrar su eficacia ante las autoridades sanitarias (p. ej., yogures con bacterias que revitalizan la microflora intestinal, leche enriquecida con calcio, bebidas energ\u00e9ticas para deportistas, pan enriquecido con fibra, etc.).", [["imaginadas", "TEST", 106, 116], ["necesitan demostrar su eficacia", "PROBLEM", 131, 162], ["yogures", "TEST", 204, 211], ["bacterias", "TEST", 216, 225], ["leche enriquecida", "TREATMENT", 268, 285], ["calcio", "TREATMENT", 290, 296], ["para deportistas", "TREATMENT", 318, 334], ["intestinal", "ANATOMY", 256, 266]]], ["Minerales, amino\u00e1cidos, enzimas, extractos de plantas medicinales y otras sustancias naturales usadas para preparar los alimentos del p\u00e1rrafo anterior.", [["amino\u00e1cidos", "SIMPLE_CHEMICAL", 11, 22], ["Minerales", "TREATMENT", 0, 9], ["amino\u00e1cidos", "TREATMENT", 11, 22], ["enzimas", "TREATMENT", 24, 31], ["extractos", "TREATMENT", 33, 42], ["anterior", "ANATOMY_MODIFIER", 142, 150]]], ["Sufijo neol\u00f3gico tomado de genome (\u00abgenoma\u00bb: conjunto de toda la informaci\u00f3n gen\u00e9tica de un organismo) para crear otros t\u00e9rminos afines, como proteome (\u00abproteinoma\u00bb, mejor que \u00abproteoma\u00bb: conjunto de todas las prote\u00ednas expresadas por la informaci\u00f3n contenida en el genoma), transcriptome (\u00abtranscriptoma\u00bb: conjunto de los ARNm transcritos a partir del genoma), chondriome o mitochondriome (\u00abmitocondrioma\u00bb: conjunto de las mitocondrias de una c\u00e9lula o conjunto de los determinantes hereditarios localizados en las mitocondrias), phenome (\u00abfenoma\u00bb: conjunto de las caracter\u00edsticas fenot\u00edpicas cualitativas de origen gen\u00e9tico de un organismo) e incluso envirome (\u00abambientoma\u00bb: conjunto de los factores ambientales que intervienen, junto a los factores gen\u00e9ticos del genoma, en el desarrollo de un individuo).", [["afines", "TEST", 129, 135], ["como proteome", "TEST", 137, 150], ["\u00abproteinoma\u00bb", "TEST", 152, 164]]], ["En ingl\u00e9s distinguen claramente entre este sufijo neol\u00f3gico -ome acu\u00f1ado en gen\u00e9tica y otros dos sufijos cl\u00e1sicos muy usados en el lenguaje m\u00e9dico: -oma, que significa \u00abtumor\u00bb o \u00abneoplasia\u00bb (p. ej., lipoma, carcinoma, adenoma, etc.), y -some, que significa \u00abcuerpo\u00bb (p. ej., chromosome, lysosome, liposome, etc.).", [["lipoma", "ANATOMY", 199, 205], ["carcinoma", "ANATOMY", 207, 216], ["adenoma", "ANATOMY", 218, 225], ["chromosome", "ANATOMY", 275, 285], ["lipoma", "DISEASE", 199, 205], ["carcinoma", "DISEASE", 207, 216], ["adenoma", "DISEASE", 218, 225], ["carcinoma", "CANCER", 207, 216], ["adenoma", "CANCER", 218, 225], ["chromosome", "CELLULAR_COMPONENT", 275, 285], ["lysosome", "CELLULAR_COMPONENT", 287, 295], ["En ingl\u00e9s distinguen claramente entre este sufijo neol\u00f3gico -ome acu\u00f1ado en gen\u00e9tica y otros dos sufijos cl\u00e1sicos muy usados en el lenguaje m\u00e9dico: -oma, que significa \u00abtumor\u00bb o \u00abneoplasia\u00bb (p. ej.", "SPECIES", 0, 197], ["\u00abneoplasia\u00bb", "PROBLEM", 178, 189], ["lipoma", "PROBLEM", 199, 205], ["carcinoma", "PROBLEM", 207, 216], ["adenoma", "PROBLEM", 218, 225], ["liposome", "TREATMENT", 297, 305], ["lipoma", "OBSERVATION", 199, 205], ["carcinoma", "OBSERVATION", 207, 216], ["adenoma", "OBSERVATION", 218, 225]]], ["En espa\u00f1ol el riesgo de confusi\u00f3n es mayor, pues estos tres sufijos adoptan en nuestro idioma id\u00e9ntica terminaci\u00f3n en: \u00ab-oma\u00bb. osteoporosis 1.", [["osteoporosis", "DISEASE", 127, 139], ["osteoporosis", "PROBLEM", 127, 139]]], ["\u00abOsteopenia\u00bb era el t\u00e9rmino general para cualquier trastorno de la remodelaci\u00f3n \u00f3sea caracterizado por disminuci\u00f3n de la densidad \u00f3sea.", [["Osteopenia\u00bb", "PROBLEM", 1, 12]]], ["Si la osteopenia se deb\u00eda a una deficiencia de vitamina D, se hablaba de \u00abosteomalacia\u00bb (o, en los ni\u00f1os, \u00abraquitismo\u00bb); en caso contrario, se hablaba de \u00abosteoporosis\u00bb.", [["osteopenia", "DISEASE", 6, 16], ["Si la osteopenia", "PROBLEM", 0, 16], ["a una deficiencia", "PROBLEM", 26, 43], ["osteopenia", "OBSERVATION", 6, 16]]], ["En 1994, no obstante, la terminolog\u00eda tradicional sufri\u00f3 un cambio important\u00edsimo (y poco acertado, en mi opini\u00f3n).", [["y poco acertado", "TREATMENT", 83, 98], ["en mi opini\u00f3n", "TREATMENT", 100, 113]]], ["Este grupo de estudio defini\u00f3 cuatro categor\u00edas diagn\u00f3sticas: a) normal, si el valor de densidad mineral \u00f3sea no presenta m\u00e1s de una desviaci\u00f3n t\u00edpica de diferencia con respecto al promedio de referencia; b) osteopenia (o low bone mass), si se halla entre 1 y 2,5 desviaciones t\u00edpicas por debajo del promedio de referencia; c) osteoporosis, si es 2,5 o m\u00e1s desviaciones t\u00edpicas inferior al promedio de referencia, y d) severe osteoporosis (o established osteoporosis), si es 2,5 o m\u00e1s desviaciones t\u00edpicas inferior al promedio de referencia y, adem\u00e1s, se ha producido al menos una fractura.", [["osteopenia", "DISEASE", 208, 218], ["osteoporosis", "DISEASE", 327, 339], ["osteoporosis", "DISEASE", 426, 438], ["osteoporosis", "DISEASE", 454, 466], ["bone", "TISSUE", 226, 230], ["osteopenia (o low bone mass", "PROBLEM", 208, 235], ["osteoporosis", "PROBLEM", 327, 339], ["desviaciones", "PROBLEM", 357, 369], ["severe osteoporosis", "PROBLEM", 419, 438], ["osteoporosis", "PROBLEM", 454, 466], ["osteopenia", "OBSERVATION", 208, 218], ["bone", "ANATOMY", 226, 230], ["mass", "OBSERVATION", 231, 235], ["severe", "OBSERVATION_MODIFIER", 419, 425], ["osteoporosis", "OBSERVATION", 426, 438]]], ["De acuerdo con esta clasificaci\u00f3n, la osteoporosis habr\u00eda dejado de ser una variedad de osteopenia para convertirse en un grado m\u00e1s avanzado de osteopenia.", [["osteoporosis habr\u00eda dejado", "DISEASE", 38, 64], ["osteopenia", "DISEASE", 88, 98], ["osteopenia", "DISEASE", 144, 154], ["la osteoporosis", "PROBLEM", 35, 50], ["osteopenia para", "PROBLEM", 88, 103], ["osteopenia", "PROBLEM", 144, 154], ["osteopenia", "OBSERVATION", 88, 98], ["osteopenia", "OBSERVATION", 144, 154]]], ["Y la cosa se complica m\u00e1s a\u00fan cuando los m\u00e9dicos utilizan de forma imprecisa estos y otros t\u00e9rminos afines; entre los radi\u00f3logos, por ejemplo, es frecuente usar como si fueran sin\u00f3nimos los t\u00e9rminos osteopenia (osteopenia), osteoporosis (osteoporosis), radiolucency (radiotransparencia), demineralization (desmineralizaci\u00f3n) y undermineralization (hipomineralizaci\u00f3n).", [["osteopenia", "DISEASE", 199, 209], ["osteopenia", "DISEASE", 211, 221], ["osteoporosis", "DISEASE", 224, 236], ["osteoporosis", "DISEASE", 238, 250], ["radiolucency", "DISEASE", 253, 265], ["t\u00e9rminos osteopenia (osteopenia)", "PROBLEM", 190, 222], ["osteoporosis (osteoporosis)", "PROBLEM", 224, 251], ["radiolucency (radiotransparencia)", "PROBLEM", 253, 286], ["demineralization (desmineralizaci\u00f3n) y undermineralization (hipomineralizaci\u00f3n)", "PROBLEM", 288, 367], ["osteopenia", "OBSERVATION", 199, 209], ["osteopenia", "OBSERVATION", 211, 221], ["osteoporosis", "OBSERVATION", 224, 236], ["osteoporosis", "OBSERVATION", 238, 250], ["radiolucency", "OBSERVATION", 253, 265], ["demineralization", "OBSERVATION", 288, 304]]], ["Y entre los internistas es muy frecuente utilizar de forma impropia la expresi\u00f3n bone loss (disminuci\u00f3n de la masa \u00f3sea) como si fuera sin\u00f3nima de low bone mass (osteopenia, osteoporosis).", [["bone mass", "ANATOMY", 151, 160], ["bone loss", "DISEASE", 81, 90], ["low bone mass", "DISEASE", 147, 160], ["osteopenia", "DISEASE", 162, 172], ["osteoporosis", "DISEASE", 174, 186], ["bone", "TISSUE", 81, 85], ["bone", "TISSUE", 151, 155], ["bone loss", "PROBLEM", 81, 90], ["como si fuera sin\u00f3nima de low bone mass (osteopenia", "PROBLEM", 121, 172], ["osteoporosis", "PROBLEM", 174, 186], ["bone loss", "OBSERVATION", 81, 90], ["low", "OBSERVATION_MODIFIER", 147, 150], ["bone", "ANATOMY", 151, 155], ["mass", "OBSERVATION", 156, 160], ["osteopenia", "OBSERVATION", 162, 172], ["osteoporosis", "OBSERVATION", 174, 186]]], ["Neologismo para designar el cultivo o la cr\u00eda de plantas o animales transg\u00e9nicos con fines terap\u00e9uticos.", [["Neologismo", "TEST", 0, 10]]], ["Se trata de un ingenioso juego de palabras a partir del sustantivo farm (granja, explotaci\u00f3n agr\u00edcola) y el prefijo pharm-, que expresa relaci\u00f3n con la farmacia.", [["la farmacia", "OBSERVATION", 149, 160]]], ["El traductor al espa\u00f1ol puede optar por explicar el significado o recurrir a un juego de palabras equivalente.", [["equivalente", "CHEMICAL", 98, 109]]], ["Por semejanza con \u00abpiscicultura\u00bb, \u00abviticultura\u00bb y otros tecnicismos formados en espa\u00f1ol con el sufijo \u00ab-cultura\u00bb (que indica cultivo o cr\u00eda), una buena soluci\u00f3n podr\u00eda ser acu\u00f1ar el neologismo \u00abfarmicultura\u00bb.", [["Por semejanza con \u00abpiscicultura\u00bb, \u00abviticultura\u00bb y otros tecnicismos formados en espa\u00f1ol con el sufijo \u00ab-cultura\u00bb (que indica cultivo o cr\u00eda), una buena soluci\u00f3n podr\u00eda ser acu\u00f1ar el neologismo \u00abfarmicultura\u00bb", "SPECIES", 0, 207]]], ["En cuanto a los productos farm\u00edcolas obtenidos mediante estas t\u00e9cnicas de pharming, pueden ser de dos tipos: Tenemos, en primer lugar, la obtenci\u00f3n de productos farmac\u00e9uticos de inter\u00e9s m\u00e9dico a partir de animales transg\u00e9nicos (p. ej., lactoferrina humana a partir de las vacas), que en ingl\u00e9s han llamado farmaceuticals (nuevo juego de palabras con farm), para distinguirlos de los pharmaceuticals o productos farmac\u00e9uticos tradicionales; en espa\u00f1ol podr\u00edamos traducirlo por \u00abf\u00e1rmacos grang\u00e9nicos\u00bb o \u00abf\u00e1rmacos genocultivados\u00bb.2.El segundo grupo corresponde a los productos transg\u00e9nicos destinados al consumo humano con ventajas para el productor (p. ej., ma\u00edz resistente a ciertas plagas) o el consumidor (p. ej., pl\u00e1tanos portadores de la vacuna antihepat\u00edtica B).", [["Tenemos", "TEST", 109, 116], ["que en ingl\u00e9s han llamado farmaceuticals", "TREATMENT", 280, 320], ["farmac\u00e9uticos tradicionales", "TREATMENT", 411, 438], ["en espa\u00f1ol podr\u00edamos traducirlo", "TREATMENT", 440, 471]]], ["En espa\u00f1ol, lo m\u00e1s claro ser\u00eda llamarlos \u00abalimentos transg\u00e9nicos\u00bb o \u00abalimentos genotecnol\u00f3gicos\u00bb, que es lo que son.2.plantibodies.", [["plantibodies", "PROBLEM", 118, 130]]], ["En cualquier caso, conviene explicar la primera vez que se mencione en un texto que se trata de anticuerpos humanos de origen vegetal.2.Pneumocystis.", [["Pneumocystis", "DISEASE", 136, 148], ["Pneumocystis", "PROBLEM", 136, 148]]], ["Durante decenios, se acept\u00f3 que los microbios del g\u00e9nero Pneumocystis eran protozoos.", [["Durante decenios", "TREATMENT", 0, 16], ["Pneumocystis eran protozoos", "TREATMENT", 57, 84], ["Pneumocystis eran", "OBSERVATION", 57, 74]]], ["Destacaba entre ellos la especie Pneumocystis carinii, responsable de una neumon\u00eda intersticial muy frecuente a partir de la pandemia de sida.", [["Pneumocystis carinii", "DISEASE", 33, 53], ["Destacaba", "TEST", 0, 9], ["Pneumocystis carinii", "PROBLEM", 33, 53], ["Pneumocystis carinii", "OBSERVATION", 33, 53]]], ["En 1988, no obstante, los an\u00e1lisis de ADN permitieron demostrar que son hongos y, adem\u00e1s, que existen grandes diferencias entre los hongos del g\u00e9nero Pneumocystis aislados en distintos mam\u00edferos.", [["Pneumocystis aislados", "PROBLEM", 150, 171], ["no", "UNCERTAINTY", 9, 11], ["Pneumocystis", "OBSERVATION", 150, 162]]], ["Ello oblig\u00f3 a rehacer la nomenclatura del g\u00e9nero Pneumocystis, de tal modo que en 1999 se propuso reservar el nombre Pneumocystis carinii s\u00f3lo para la especie aislada en la rata, y rebautizar a la especie aislada en el ser humano -hasta entonces llamada tambi\u00e9n Pneumocystis carinii-como Pneumocystis jiroveci, en honor al parasit\u00f3logo checo Otto Jirovec (el primero en describirlo en el ser humano) 28 .", [["Pneumocystis", "DISEASE", 49, 61], ["Pneumocystis jiroveci", "DISEASE", 288, 309], ["Pneumocystis jiroveci, en honor al parasit\u00f3logo checo Otto Jirovec (el primero en describirlo en el ser humano)", "SPECIES", 288, 399], ["Ello", "TEST", 0, 4], ["a rehacer la", "TEST", 12, 24], ["Pneumocystis", "PROBLEM", 49, 61], ["reservar", "TEST", 98, 106], ["Pneumocystis carinii", "PROBLEM", 117, 137], ["Pneumocystis", "PROBLEM", 262, 274], ["Pneumocystis jiroveci", "PROBLEM", 288, 309], ["al parasit\u00f3logo checo Otto Jirovec (el primero en describirlo en el ser humano)", "TREATMENT", 320, 399], ["Pneumocystis", "OBSERVATION", 49, 61], ["Pneumocystis carinii", "OBSERVATION", 117, 137], ["Pneumocystis jiroveci", "OBSERVATION", 288, 309]]], ["La nueva nomenclatura se adopt\u00f3 oficialmente en el 2001, con motivo de los Seminarios Internacionales sobre Protistas Oportunistas, celebrados en Cincinnati 29 .2.point-of-care (tambi\u00e9n point-of-care testing, alternate site testing, ancillary testing, bedside testing, decentralised testing, near-patient testing y patient-focused testing).", [["patient", "ORGANISM", 297, 304], ["patient", "ORGANISM", 315, 322], ["patient", "SPECIES", 297, 304], ["patient", "SPECIES", 315, 322], ["care testing", "TEST", 195, 207], ["alternate site testing", "TEST", 209, 231], ["ancillary testing", "TEST", 233, 250], ["bedside testing", "TEST", 252, 267], ["decentralised testing", "TEST", 269, 290], ["focused testing", "TEST", 323, 338]]], ["Aprovechando el doble sentido de proximidad y rapidez que tiene el adjetivo \u00abinmediato\u00bb en espa\u00f1ol, propongo traducir el concepto gen\u00e9rico de point-of-care como \u00aban\u00e1lisis de diagn\u00f3stico inmediato\u00bb o \u00abdiagn\u00f3stico anal\u00edtico inmediato\u00bb, que podemos alternar tambi\u00e9n con otra forma m\u00e1s breve e igual de gr\u00e1fica: \u00aban\u00e1lisis de cabecera\u00bb.", [["Aprovechando", "TREATMENT", 0, 12]]], ["En las acepciones m\u00e1s concretas de los t\u00e9rminos ingleses, s\u00f3lo el contexto podr\u00e1 permitirnos dar con la traducci\u00f3n m\u00e1s acertada, que puede ir desde el \u00abminilaboratorio\u00bb de los consultorios m\u00e9dicos hasta los \u00abautoan\u00e1lisis\u00bb efectuados por el propio enfermo, pasando por los \u00abminilaboratorios port\u00e1tiles\u00bb en referencia a los modernos carritos de an\u00e1lisis cl\u00ednicos utilizados en algunos hospitales, por no citar m\u00e1s que tres ejemplos.", [["ingleses", "PROBLEM", 48, 56]]], ["SARS (severe acute respiratory syndrome).", [["SARS", "DISEASE", 0, 4], ["acute respiratory syndrome", "DISEASE", 13, 39], ["SARS (severe acute respiratory syndrome", "PROBLEM", 0, 39], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["respiratory syndrome", "OBSERVATION", 19, 39]]], ["Recomiendo evitar el calco habitual \u00abs\u00edndrome respiratorio agudo severo\u00bb, que conviene sustituir por \u00abs\u00edndrome respiratorio agudo grave\u00bb (SRAG) en los textos especializados (o, tal vez, \u00abneumon\u00eda coronav\u00edrica\u00bb una vez conocido ya el virus causal), y por \u00abneumon\u00eda asi\u00e1tica\u00bb o \u00abneumon\u00eda at\u00edpica asi\u00e1tica\u00bb en los textos de divulgaci\u00f3n.2.semantide.", [["semantide", "CHEMICAL", 335, 344], ["semantide", "SIMPLE_CHEMICAL", 335, 344], ["respiratorio", "TEST", 111, 123], ["\u00abneumon\u00eda", "TEST", 186, 195], ["\u00abneumon\u00eda", "PROBLEM", 276, 285]]], ["Esta palabra inglesa plantea tres problemas principales en espa\u00f1ol:2.1.", [["palabra inglesa plantea", "SPECIES", 5, 28], ["problemas principales", "SPECIES", 34, 55], ["Esta palabra", "TEST", 0, 12]]], ["Por similitud con otros t\u00e9rminos como nuclide (n\u00faclido) y nucleotide (nucle\u00f3tido), soy partidario de adoptar en espa\u00f1ol la forma masculina \u00absem\u00e1ntido\u00bb.", [["nucleotide", "CHEMICAL", 58, 68], ["como nuclide (n\u00faclido) y nucleotide (nucle\u00f3tido)", "TREATMENT", 33, 81]]], ["Una vez acu\u00f1ado el neologismo \u00absem\u00e1ntido\u00bb, no tiene sentido traducir literalmente otras expresiones inglesas sin\u00f3nimas como semantophoretic molecule o informational macromolecule, que deben traducirse tambi\u00e9n por \u00absem\u00e1ntido\u00bb.", [["Una", "TEST", 0, 3], ["que deben traducirse tambi\u00e9n", "TREATMENT", 180, 208]]], ["Se llama \u00absem\u00e1ntido\u00bb a cualquier macromol\u00e9cula portadora de la informaci\u00f3n gen\u00e9tica desde los genes hasta las prote\u00ednas.", [["Se llama", "TEST", 0, 8]]], ["As\u00ed, el t\u00e9rmino \u00abgen\u00bb pasa ahora a ser sin\u00f3nimo de primary semantide (sem\u00e1ntido primario), e igual sucede con \u00abARN mensajero\u00bb y secondary semantide (sem\u00e1ntido secundario) o \u00abpolip\u00e9ptido\u00bb y tertiary semantide (sem\u00e1ntido terciario).2.statins.", [["primary semantide", "DISEASE", 51, 68], ["statins", "CHEMICAL", 232, 239], ["statins", "CHEMICAL", 232, 239], ["statins", "SIMPLE_CHEMICAL", 232, 239], ["As\u00ed", "TEST", 0, 3], ["sem\u00e1ntido primario)", "TREATMENT", 70, 89], ["semantide (sem\u00e1ntido secundario)", "TREATMENT", 138, 170], ["\u00abpolip\u00e9ptido\u00bb y tertiary semantide (sem\u00e1ntido terciario", "TREATMENT", 173, 228], ["statins", "TREATMENT", 232, 239]]], ["Nombre que recibe en ingl\u00e9s un moderno grupo de hipocolesterolemiantes, el de los inhibidores de la HMG-CoA-reductasa, obtenidos mediante dise\u00f1o farmacol\u00f3gico por modificaci\u00f3n de la mevastatina.", [["CoA", "ANATOMY", 104, 107]]], ["En espa\u00f1ol, no es habitual bautizar los grupos farmacol\u00f3gicos por la terminaci\u00f3n del nombre de sus integrantes.", [["no", "UNCERTAINTY", 12, 14]]], ["\u00bfLlamamos acaso \u00aboles\u00bb a los bloqueantes \u03b2, que terminan todos en \u00ab-ol\u00bb, o \u00abciclinas\u00bb a las tetraciclinas, que terminan todas en \u00ab-ciclina\u00bb?", [["a las tetraciclinas", "TREATMENT", 86, 105]]], ["En el caso que nos ocupa, el mecanismo de acci\u00f3n nos dar\u00eda un nombre excesivamente largo -\u00abhipocolesterolemiantes inhibidores de la HMG-CoA-reductasa\u00bb-, apto apenas para los textos de farmacolog\u00eda; pero el nombre de su primer representante, la mevastatina, nos permite formar un nombre mucho m\u00e1s breve y pr\u00e1ctico: \u00abmevastat\u00ednicos\u00bb.", [["largo", "TEST", 83, 88], ["CoA", "TEST", 136, 139], ["reductasa\u00bb", "TEST", 140, 150], ["CoA", "ANATOMY", 136, 139]]], ["Para poder utilizar un sufijo o una terminaci\u00f3n como nombre de grupo, es imprescindible que concurran dos circunstancias: a) que todos los f\u00e1rmacos de dicho grupo farmacol\u00f3gico incorporen esta terminaci\u00f3n, y b) que esa terminaci\u00f3n no se presente en f\u00e1rmacos de otros grupos distintos.", [["farmacol\u00f3gico incorporen esta terminaci\u00f3n", "TREATMENT", 163, 204]]], ["No hay que ser muy observador para comprobar que, en ingl\u00e9s, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pravastatin y simvastatin s\u00ed terminan en -statin; mientras que en espa\u00f1ol ni atorvastatina, ni cerivastatina, ni fluvastatina, ni lovastatina, ni mevastatina, ni pravastatina, ni sinvastatina terminan en \u00ab-estatina\u00bb.2.Adem\u00e1s, el uso de la terminaci\u00f3n statin para referirse a los derivados mevastat\u00ednicos puede llevar a graves errores.", [["atorvastatin", "CHEMICAL", 61, 73], ["cerivastatin", "CHEMICAL", 75, 87], ["fluvastatin", "CHEMICAL", 89, 100], ["lovastatin", "CHEMICAL", 102, 112], ["mevastatin", "CHEMICAL", 114, 124], ["pravastatin", "CHEMICAL", 126, 137], ["simvastatin s\u00ed terminan en -statin", "CHEMICAL", 140, 174], ["statin", "CHEMICAL", 377, 383], ["atorvastatin", "CHEMICAL", 61, 73], ["cerivastatin", "CHEMICAL", 75, 87], ["fluvastatin", "CHEMICAL", 89, 100], ["lovastatin", "CHEMICAL", 102, 112], ["pravastatin", "CHEMICAL", 126, 137], ["simvastatin", "CHEMICAL", 140, 151], ["atorvastatin", "SIMPLE_CHEMICAL", 61, 73], ["cerivastatin", "SIMPLE_CHEMICAL", 75, 87], ["fluvastatin", "SIMPLE_CHEMICAL", 89, 100], ["lovastatin", "SIMPLE_CHEMICAL", 102, 112], ["pravastatin", "SIMPLE_CHEMICAL", 126, 137], ["atorvastatin", "TREATMENT", 61, 73], ["cerivastatin", "TREATMENT", 75, 87], ["fluvastatin", "TREATMENT", 89, 100], ["lovastatin", "TREATMENT", 102, 112], ["mevastatin", "TREATMENT", 114, 124], ["pravastatin", "TREATMENT", 126, 137], ["simvastatin", "TREATMENT", 140, 151], ["statin", "TREATMENT", 168, 174], ["mientras que en espa\u00f1ol ni atorvastatina", "TREATMENT", 176, 216], ["ni cerivastatina", "TREATMENT", 218, 234], ["ni fluvastatina", "TREATMENT", 236, 251], ["ni lovastatina", "TREATMENT", 253, 267], ["ni mevastatina", "TREATMENT", 269, 283], ["ni pravastatina", "TREATMENT", 285, 300], ["ni sinvastatina terminan en \u00ab-estatina\u00bb", "TREATMENT", 302, 341], ["la terminaci\u00f3n statin para", "TREATMENT", 362, 388], ["a los derivados mevastat\u00ednicos", "TREATMENT", 399, 429], ["a graves errores", "PROBLEM", 443, 459], ["graves", "OBSERVATION", 445, 451]]], ["Muchos lectores, por ejemplo, podr\u00edan pensar que las statins engloban tambi\u00e9n a otros f\u00e1rmacos que nada tienen que ver con los hipocolesterolemiantes mevastat\u00ednicos, como es el caso de nystatin (nistatina), somatostatin (somatostatina), angiostatin (angiostatina), cystatin (cistatina) o pentostatin (pentostatina).", [["statins", "CHEMICAL", 53, 60], ["nystatin", "CHEMICAL", 185, 193], ["nistatina", "CHEMICAL", 195, 204], ["angiostatin", "CHEMICAL", 237, 248], ["angiostatina", "CHEMICAL", 250, 262], ["pentostatin", "CHEMICAL", 288, 299], ["pentostatina", "CHEMICAL", 301, 313], ["nystatin", "CHEMICAL", 185, 193], ["somatostatin", "CHEMICAL", 207, 219], ["nystatin", "SIMPLE_CHEMICAL", 185, 193], ["nistatina", "SIMPLE_CHEMICAL", 195, 204], ["somatostatin", "SIMPLE_CHEMICAL", 207, 219], ["somatostatina", "SIMPLE_CHEMICAL", 221, 234], ["angiostatin", "GENE_OR_GENE_PRODUCT", 237, 248], ["angiostatina", "SIMPLE_CHEMICAL", 250, 262], ["cystatin", "GENE_OR_GENE_PRODUCT", 265, 273], ["cistatina", "SIMPLE_CHEMICAL", 275, 284], ["pentostatin", "SIMPLE_CHEMICAL", 288, 299], ["pentostatina", "SIMPLE_CHEMICAL", 301, 313], ["statins", "TREATMENT", 53, 60], ["hipocolesterolemiantes mevastat\u00ednicos", "TREATMENT", 127, 164], ["como es el caso de nystatin (nistatina)", "TREATMENT", 166, 205], ["somatostatin (somatostatina)", "TREATMENT", 207, 235], ["angiostatin (angiostatina)", "TREATMENT", 237, 263], ["cystatin (cistatina)", "TREATMENT", 265, 285], ["pentostatin (pentostatina)", "TREATMENT", 288, 314]]], ["Si realmente consideramos \u00fatil recurrir a la terminaci\u00f3n para dar nombre a este moderno grupo de hipocolesterolemiantes, lo l\u00f3gico -de no haber mediado el ingl\u00e9s-hubiera sido escoger la terminaci\u00f3n \u00ab-vastatina\u00bb, que s\u00ed es exclusiva de ellos.", [["Si", "CHEMICAL", 0, 2]]], ["El t\u00e9rmino \u00abestatinas\u00bb, por \u00faltimo, entra\u00f1a un grave riesgo de confusi\u00f3n con las estatinas preexistentes en la nomenclatura qu\u00edmica: la que en ingl\u00e9s llaman statin (\u00abestatina\u00bb, fosfoprote\u00edna nuclear) y la que en ingl\u00e9s llaman statine (\u00abestatina\u00bb, amino\u00e1cido contenido en las posiciones 3 y 5 de la pepestatina A). stem cell 1.", [["stem cell", "ANATOMY", 314, 323], ["statin", "CHEMICAL", 157, 163], ["stem cell 1", "CELL", 314, 325], ["stem cell 1", "CELL_LINE", 314, 325], ["la que en ingl\u00e9s llaman statin", "TREATMENT", 133, 163], ["(\u00abestatina\u00bb, fosfoprote\u00edna nuclear", "TREATMENT", 164, 198], ["y la que en ingl\u00e9s llaman statine", "TREATMENT", 200, 233], ["\u00abestatina\u00bb", "TREATMENT", 235, 245], ["amino\u00e1cido contenido en las posiciones", "TREATMENT", 247, 285]]], ["As\u00ed llaman en ingl\u00e9s a cualquier c\u00e9lula inmadura capaz de reproducirse en estado indiferenciado durante un tiempo prolongado (o indefinido) y de diferenciarse para dar lugar a c\u00e9lulas especializadas 30 .", [["As\u00ed", "TEST", 0, 3]]], ["Veamos algunos de los t\u00e9rminos m\u00e1s utilizados para traducir el ingl\u00e9s stem cell: El m\u00e1s frecuente (sobre todo en los textos period\u00edsticos y de divulgaci\u00f3n) es, con mucho, \u00abc\u00e9lula madre\u00bb, admitido ya por la Real Academia Espa\u00f1ola en el 2001, pero que yo desaconsejo por dos razones: a) porque \u00abc\u00e9lula madre\u00bb puede ser, en puridad, cualquier c\u00e9lula capaz de dividirse y originar dos o m\u00e1s c\u00e9lulas hijas, y b) por el riesgo de confusi\u00f3n con lo que en ingl\u00e9s llaman mother cell, que es la c\u00e9lula original de un cultivo celular.", [["stem cell", "ANATOMY", 70, 79], ["cell", "ANATOMY", 469, 473], ["stem cell", "CELL", 70, 79], ["con lo que en ingl\u00e9s llaman mother cell", "TREATMENT", 434, 473], ["stem cell", "OBSERVATION", 70, 79]]], ["Los t\u00e9rminos \u00abc\u00e9lula germinal\u00bb, \u00abc\u00e9lula progenitora\u00bb y \u00abc\u00e9lula precursora\u00bb son informativos y aceptables (de hecho, pueden utilizarse en la pr\u00e1ctica para traducir stem cell en muchos casos), si no fuera porque muchos cient\u00edficos distinguen claramente entre el concepto de stem cell, el concepto de precursor cell (o progenitor cell) y el concepto de germ cell.", [["stem cell", "ANATOMY", 272, 281], ["precursor cell", "ANATOMY", 298, 312], ["progenitor cell", "ANATOMY", 316, 331], ["germ cell", "ANATOMY", 350, 359], ["stem cell", "CELL", 272, 281], ["el concepto de precursor cell", "CELL", 283, 312], ["o progenitor cell", "CELL", 314, 331], ["germ cell", "CELL", 350, 359], ["stem cell", "CELL_TYPE", 272, 281], ["precursor cell", "CELL_TYPE", 298, 312], ["germ cell", "CELL_TYPE", 350, 359], ["Los", "TEST", 0, 3], ["stem cell", "OBSERVATION", 272, 281], ["germ cell", "OBSERVATION", 350, 359]]], ["Los t\u00e9rminos \u00abc\u00e9lula tronco\u00bb y \u00abc\u00e9lula troncal\u00bb (este \u00faltimo admitido ya por la RAE en el 2001, pero s\u00f3lo en el sentido m\u00e1s restringido de \u00abcitoblasto histoespec\u00edfico\u00bb) son calcos directos del ingl\u00e9s y, a mi modo de ver, poco intuitivos.", [["Los t\u00e9rminos \u00abc\u00e9lula tronco\u00bb y \u00abc\u00e9lula troncal\u00bb (este \u00faltimo admitido ya por la RAE en el 2001, pero s\u00f3lo en el sentido m\u00e1s restringido de \u00abcitoblasto histoespec\u00edfico\u00bb", "SPECIES", 0, 167], ["Los", "TEST", 0, 3], ["\u00abc\u00e9lula", "TEST", 13, 20]]], ["He visto tambi\u00e9n con relativa frecuencia la expresi\u00f3n \u00abc\u00e9lula estaminal\u00bb, que considero absolutamente rechazable; no hay que olvidar que, en espa\u00f1ol, el adjetivo \u00abestaminal\u00bb existe ya en el lenguaje biol\u00f3gico para expresar relaci\u00f3n con los estambres.", [["He visto tambi\u00e9n", "TEST", 0, 16]]], ["En mi opini\u00f3n, la mejor soluci\u00f3n es acu\u00f1ar el neologismo \u00abcitoblasto\u00bb (o \u00abblastocito\u00bb), echando mano para ello de dos part\u00edculas griegas ampliamente utilizadas en el lenguaje m\u00e9dico.", [["En mi opini\u00f3n", "PROBLEM", 0, 13], ["la mejor soluci\u00f3n", "TREATMENT", 15, 32]]], ["Para los textos de divulgaci\u00f3n puede ser \u00fatil tambi\u00e9n el t\u00e9rmino \u00abc\u00e9lula primordial\u00bb, pero el tecnicismo \u00abcitoblasto\u00bb tiene la ventaja de ser m\u00e1s breve (una sola palabra) y permitir la formaci\u00f3n de derivados, como el adjetivo \u00abcitobl\u00e1stico\u00bb o los t\u00e9rminos compuestos que comento en los puntos 3 a 5.2.Las stem cells suelen clasificarse en totipotent stem cells (citoblastos totipotentes; si pueden producir un embri\u00f3n completo y, por lo tanto, un ser humano), pluripotent stem cells (citoblastos pluripotentes; si pueden producir todos los tejidos del organismo, pero no un ser humano completo) y tissue-specific stem cells (citoblastos histoespec\u00edficos; si pueden especializarse en una o varias estirpes celulares, pero no en todas).", [["stem cells", "ANATOMY", 305, 315], ["stem cells", "ANATOMY", 350, 360], ["pluripotent stem cells", "ANATOMY", 460, 482], ["stem cells", "ANATOMY", 613, 623], ["ventaja de ser m\u00e1s breve", "CHEMICAL", 127, 151], ["stem cells", "CELL", 305, 315], ["totipotent stem cells", "CELL", 339, 360], ["pluripotent stem cells", "CELL", 460, 482], ["tissue", "TISSUE", 597, 603], ["stem cells", "CELL", 613, 623], ["Las stem cells", "CELL_LINE", 301, 315], ["totipotent stem cells", "CELL_LINE", 339, 360], ["pluripotent stem cells", "CELL_TYPE", 460, 482], ["stem cells", "CELL_TYPE", 613, 623], ["citoblastos totipotentes; si pueden producir un embri\u00f3n completo y, por lo tanto, un ser humano", "SPECIES", 362, 457], ["citoblastos histoespec\u00edficos; si pueden especializarse en una o varias estirpes celulares, pero no en todas", "SPECIES", 625, 732], ["Para los textos", "TREATMENT", 0, 15], ["una sola palabra", "TREATMENT", 153, 169], ["Las stem cells", "TREATMENT", 301, 315], ["en totipotent stem cells", "TREATMENT", 336, 360], ["citoblastos totipotentes", "TREATMENT", 362, 386], ["un ser humano", "TREATMENT", 444, 457], ["pluripotent stem cells", "PROBLEM", 460, 482], ["citoblastos pluripotentes", "PROBLEM", 484, 509], ["del organismo", "PROBLEM", 548, 561], ["citoblastos histoespec\u00edficos", "PROBLEM", 625, 653], ["stem cells", "OBSERVATION", 305, 315], ["totipotent stem cells", "OBSERVATION", 339, 360], ["pluripotent stem cells", "OBSERVATION", 460, 482], ["stem cells", "OBSERVATION", 613, 623]]], ["A este \u00faltimo tipo lo llaman en ingl\u00e9s tambi\u00e9n multipotent stem-cells, pero recomiendo evitar el adjetivo \u00abmultipotente\u00bb en este sentido, pues podr\u00eda confundirse con \u00abpluripotente\u00bb (de hecho, el prefijo de origen latino \u00abmulti-\u00bb es sin\u00f3nimo absoluto del prefijo de origen griego \u00abpoli-\u00bb).", [["cells", "ANATOMY", 64, 69], ["stem-cells", "CELL", 59, 69], ["A este \u00faltimo tipo", "TREATMENT", 0, 18], ["multipotent stem", "OBSERVATION", 47, 63]]], ["Las tissue-specific stem cells o citoblastos histoespec\u00edficos reciben distintos nombres seg\u00fan el tejido en el que se localicen.", [["stem cells", "ANATOMY", 20, 30], ["stem cells", "CELL", 20, 30], ["stem cells", "CELL_TYPE", 20, 30], ["Las tissue", "TEST", 0, 10], ["specific stem cells", "TEST", 11, 30], ["citoblastos", "TEST", 33, 44], ["histoespec\u00edficos", "TEST", 45, 61], ["distintos", "TEST", 70, 79], ["stem cells", "OBSERVATION", 20, 30]]], ["En espa\u00f1ol no hay ning\u00fan problema para recurrir a los formantes griegos tradicionales para darles nombre; tendremos as\u00ed blood stem cells (hemocitoblastos), bone stem cells (osteocitoblastos), neural stem cells (neurocitoblastos) y skin stem cells (dermocitoblastos).", [["blood stem cells", "ANATOMY", 120, 136], ["bone stem cells", "ANATOMY", 156, 171], ["osteocitoblastos", "ANATOMY", 173, 189], ["neural stem cells", "ANATOMY", 192, 209], ["neurocitoblastos) y skin stem cells", "ANATOMY", 211, 246], ["dermocitoblastos", "ANATOMY", 248, 264], ["tendremos as\u00ed blood stem cells", "CELL", 106, 136], ["hemocitoblastos", "CELL", 138, 153], ["bone stem cells", "CELL", 156, 171], ["osteocitoblastos", "CELL", 173, 189], ["neural stem cells", "CELL", 192, 209], ["neurocitoblastos) y skin stem cells", "CELL", 211, 246], ["dermocitoblastos", "CELL", 248, 264], ["stem cells", "CELL_TYPE", 126, 136], ["bone stem cells", "CELL_TYPE", 156, 171], ["neural stem cells", "CELL_TYPE", 192, 209], ["skin stem cells", "CELL_TYPE", 231, 246], ["para darles", "TEST", 86, 97], ["tendremos as\u00ed blood stem cells", "PROBLEM", 106, 136], ["hemocitoblastos", "TEST", 138, 153], ["bone stem cells (osteocitoblastos)", "PROBLEM", 156, 190], ["neural stem cells (neurocitoblastos)", "PROBLEM", 192, 228], ["stem cells", "OBSERVATION", 126, 136], ["bone", "ANATOMY", 156, 160], ["stem cells", "OBSERVATION", 161, 171], ["neural", "ANATOMY", 192, 198], ["stem cells", "OBSERVATION", 199, 209], ["skin", "ANATOMY", 231, 235], ["stem cells", "OBSERVATION", 236, 246]]], ["Es frecuente en ingl\u00e9s el uso de la expresi\u00f3n stem cell en el sentido m\u00e1s restringido de embryonic stem cell (embriocitoblasto, embriocito indiferenciado).", [["embryonic stem cell", "ANATOMY", 89, 108], ["embryonic stem cell", "CELL", 89, 108], ["embryonic stem cell", "PROBLEM", 89, 108], ["stem cell", "OBSERVATION", 46, 55], ["embryonic stem cell", "OBSERVATION", 89, 108]]], ["Es asimismo muy frecuente en ingl\u00e9s el uso de la expresi\u00f3n stem cell en el sentido m\u00e1s restringido de blood stem cell (hemocitoblasto).2.theranostics.", [["blood stem cell", "ANATOMY", 102, 117], ["blood stem cell", "CELL", 102, 117], ["blood stem cell", "CELL_TYPE", 102, 117], ["stem cell", "OBSERVATION", 59, 68], ["stem cell", "OBSERVATION", 108, 117]]], ["Neologismo acu\u00f1ado en ingl\u00e9s por contracci\u00f3n de therapy y diagnostics para designar la moderna tendencia a asociar las pruebas diagn\u00f3sticas y el tratamiento farmacol\u00f3gico en una estrategia diagn\u00f3stico-terap\u00e9utica integral.", [["Neologismo acu\u00f1ado en ingl\u00e9s", "TREATMENT", 0, 28]]], ["Suponiendo que el contexto exija en espa\u00f1ol el uso de un neologismo equivalente -y no de un circunloquio del tipo de \u00abcomplementaci\u00f3n diagn\u00f3stico-terap\u00e9utica\u00bb-, yo desde luego no usar\u00eda el calco \u00abteran\u00f3stico\u00bb, por el motivo siguiente.", [["Suponiendo que el contexto exija en espa\u00f1ol el uso de un neologismo equivalente -y no de un circunloquio del tipo de \u00abcomplementaci\u00f3n diagn\u00f3stico-terap\u00e9utica\u00bb-, yo desde luego no usar\u00eda el calco \u00abteran\u00f3stico\u00bb, por el motivo siguiente", "SPECIES", 0, 233]]], ["De acuerdo con lo comentado en la entrada THERAPY del Diccionario cr\u00edtico de dudas 16 , en espa\u00f1ol se ha utilizado tradicionalmente mucho m\u00e1s \u00abtratamiento\u00bb que \u00abterapia\u00bb.", [["De acuerdo con lo comentado en la entrada THERAPY", "TREATMENT", 0, 49], ["en espa\u00f1ol se ha utilizado tradicionalmente mucho m\u00e1s \u00abtratamiento\u00bb", "TREATMENT", 88, 155]]], ["Adem\u00e1s, la relaci\u00f3n directa con therapy queda bien reflejada en ingl\u00e9s con la part\u00edcula thera-, pero no sucede igual en espa\u00f1ol con \u00abtera-\u00bb, que es el prefijo de origen griego usado de modo tradicional en medicina para expresar relaci\u00f3n con las malformaciones (p. ej., teratolog\u00eda, terat\u00f3geno, teratoma).", [["teratoma", "ANATOMY", 294, 302], ["teratoma", "DISEASE", 294, 302], ["teratoma", "CANCER", 294, 302], ["la relaci\u00f3n directa con therapy", "TREATMENT", 8, 39], ["con las malformaciones", "TREATMENT", 237, 259], ["teratoma", "PROBLEM", 294, 302], ["teratoma", "OBSERVATION", 294, 302]]], ["En ingl\u00e9s, a diferencia de lo que sucede en espa\u00f1ol, la h etimol\u00f3gica evita todo riesgo de confusi\u00f3n entre thera-(como en therapy o therapeutics) y tera-(como en teratology y teratoma).", [["teratoma", "ANATOMY", 175, 183], ["teratoma", "DISEASE", 175, 183], ["teratoma", "CANCER", 175, 183], ["a diferencia de lo que sucede en espa\u00f1ol", "TREATMENT", 11, 51], ["como en therapy o therapeutics", "TREATMENT", 114, 144], ["y tera", "TREATMENT", 146, 152]]], ["Puestos a acu\u00f1ar en espa\u00f1ol un neologismo equivalente al ingl\u00e9s theranostics, pues, me gusta mucho m\u00e1s \u00abtratan\u00f3stico\u00bb que \u00abteran\u00f3stico\u00bb.2.ubiquinone.", [["ubiquinone", "CHEMICAL", 138, 148], ["ubiquinone", "CHEMICAL", 138, 148], ["ubiquinone", "SIMPLE_CHEMICAL", 138, 148], ["ubiquinone", "TREATMENT", 138, 148]]]], "PMC7493063": [["IntroductionEmergency situations such as terrorist attacks or earthquakes occur at different scales daily around the world.", [["earthquakes", "DISEASE", 62, 73], ["IntroductionEmergency situations", "PROBLEM", 0, 32], ["terrorist attacks", "PROBLEM", 41, 58], ["earthquakes", "PROBLEM", 62, 73]]], ["They may be natural or human-caused events that occur suddenly, affect public order, and disrupt the regularity of an area\u2019s political, economic, and social life (Fogli et al. 2017; Seba et al. 2018).", [["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28]]], ["Such an emergency causes great losses and widespread impacts on society, and \u201crequires a prompt intervention by all involved stakeholders\u201d (Fogli et al. 2017; Lauras et al. 2015).", [["great losses", "PROBLEM", 25, 37], ["a prompt intervention", "TREATMENT", 87, 108], ["widespread", "OBSERVATION_MODIFIER", 42, 52], ["impacts", "OBSERVATION_MODIFIER", 53, 60]]], ["To gain public support and maintain regular social order, authorities should pay special attention to the effective management of such situations.", [["public support", "TREATMENT", 8, 22], ["such situations", "PROBLEM", 130, 145]]], ["In this study, emergency management (EM) is defined as the effective organization, direction, and management of both emergency-related humanitarian and material resources (Othman and Beydoun 2013).", [["this study", "TEST", 3, 13], ["emergency management", "TREATMENT", 15, 35]]], ["To align with such developments, scholars have swifted their attention from solving a single issue to focusing on efficient intra-organizational collaboration (Janssen et al. 2010).IntroductionLack of collaboration is the chief culprit in major failures in disaster response and takes the form of a lack of available crisis information or poorly managed information flow (Valecha 2019; Beydoun et al. 2018).", [["major", "OBSERVATION_MODIFIER", 239, 244], ["failures", "OBSERVATION", 245, 253]]], ["Information and communication technology (ICT) and information systems (ISs) are considered as crucial means to enhance the collaboration process and information flow management (Sagun et al. 2009; Ipe et al. 2010).", [["flow management", "TREATMENT", 162, 177]]], ["However, a lack of informative and appropriate data hinders further development and practical use of emergency management information systems (EMISs) (Ghosh et al. 2018; Roberts 2011).", [["emergency management", "TREATMENT", 101, 121]]], ["First, data reflecting human behaviors on a large scale are required for each phase of EM, since managing affected people is a crucial part of EM.", [["human", "ORGANISM", 23, 28], ["people", "ORGANISM", 115, 121], ["human", "SPECIES", 23, 28], ["people", "SPECIES", 115, 121], ["human", "SPECIES", 23, 28], ["human behaviors", "PROBLEM", 23, 38], ["a large scale", "TREATMENT", 42, 55]]], ["These three requirements create obstacles for the practical use of EMISs in dealing with real-world emergencies.IntroductionMany studies have regarded mobile phone data as a potential data source to fulfill these requirements, because these data reflect human behavior richly and ubiquitously.", [["human", "ORGANISM", 254, 259], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 254, 259]]], ["Globally, in 2017, mobile phones attained a registration number of 103.5 per 100 people, as reported by the International Telecommunication Union (ITU) (Sanou 2017).", [["people", "SPECIES", 81, 87]]], ["Mobile phone data such as CDRs and app data can be applied to the analysis of human mobility (Stefania et al. 2018; Duan et al. 2017; Gao et al. 2014; Lwin et al. 2018), social networks (Poblet et al. 2018; Trestian et al. 2017; Ghurye et al. 2016; Dobra et al. 2015), mobile phone usage patterns (Jia et al. 2017; Steenbruggen et al. 2016; Gundogdu et al. 2016; Gao et al. 2014), and geographic location (Lwin et al. 2018; Poblet et al. 2018; Dong et al. 2017; \u0160terk and Praprotnik 2017); these themes are discussed in additional detail in Section 3.", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["app data", "TEST", 35, 43]]], ["The results can further be developed to address various issues encountered during emergencies, such as predicting epidemic transmission (Bengtsson et al. 2015; Panigutti et al. 2017) and developing pre-warning systems (Zhang et al. 2016; Dong et al. 2017).IntroductionAlthough many efforts have been made to investigate the application of mobile phone data in EM, the knowledge and understanding in this field are still fragmented.", [["various issues", "PROBLEM", 48, 62], ["developing pre-warning systems", "PROBLEM", 187, 217], ["fragmented", "OBSERVATION", 420, 430]]], ["This study aims to propose such a framework and provide guidance for further research in this field.IntroductionThis study is related to two streams of literature reviews, which are using ICT in EM and mobile phone data analysis.", [["This study", "TEST", 0, 10], ["This study", "TEST", 112, 122], ["literature reviews", "TEST", 152, 170]]], ["On the second stream of mobile phone data analysis, Blondel et al. (2015) and Naboulsi et al. (2016) have summarized some studies on mobile data analysis, some of which can be applied in EM.", [["mobile data analysis", "TEST", 133, 153]]], ["To sum up, there is a lack of a literature review that considers both the characteristics of mobile phones and using such data for EM.IntroductionThree research objectives are undertaken to achieve the goal of synthesizing the fragmented knowledge and providing research guidance: (i) extract basic knowledge (e.g. types of mobile phone data, situations) of EM from the selected studies; (ii) break the boundaries of different disciplines and aggregate each analysis perspective; and (iii) study the identified knowledge and integrate it into a single framework that draws a comprehensive map of existing findings under this subject, and provides future implications.IntroductionTo attain these objectives, this study follows a methodology of systematic literature review (SLR) and synthesized the results of the reviewed studies into a framework, thus allowing a discussion of future implications obtained from the framework.", [["this study", "TEST", 707, 717]]], ["The next section introduces the research method applied in this systematic literature review, which is followed by an illustration of the five major themes in using mobile phone data for EM.", [["the research method", "TREATMENT", 28, 47]]], ["Finally, this paper discusses future implications and provides a conclusion.Systematic Literature ReviewBased on the systematic research methodology (Ghobadi 2015) which is considered as a means of identifying, evaluating and interpreting all available research relevant to a particular research question, or topic area, or phenomenon of interest (Budgen and Brereton 2006), this study processes three phases of work, including planning, conducting, and reporting.", [["this study", "TEST", 375, 385]]], ["The research questions and relevant studies have been identified in phase 1, and the studies we reviewed in this paper have been selected through a specific research strategy and inclusion/exclusion criteria illustrated in phase 2.", [["relevant studies", "TEST", 27, 43], ["the studies", "TEST", 81, 92]]], ["As a result, we have selected 65 papers from six document databases for this review.", [["this review", "TEST", 72, 83]]], ["The results are exhibited in Fig. 2.Emergency Situations ::: Five Themes in Using Mobile Phone Data for EMEmergencies can be divided into two categories, natural (41 papers) and man-made (16 papers).", [["EMEmergencies", "TREATMENT", 104, 117]]], ["\u2018Natural\u2019 refers to the emergencies that occurred due to processes of the earth (such as weather) that can hardly be avoided, while \u2018man-made\u2019 refers to the emergencies that occurred specifically due to human action or inaction.", [["human", "ORGANISM", 203, 208], ["man", "SPECIES", 133, 136], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208], ["inaction", "PROBLEM", 219, 227]]], ["To be more specific, this paper considers that \u2018natural\u2019 emergencies include \u2018natural disaster\u2019 (19 papers) and \u2018disease disaster\u2019 (22 papers), such as earthquakes and the Ebola virus disease, respectively.", [["earthquakes", "DISEASE", 152, 163], ["Ebola virus disease", "DISEASE", 172, 191], ["Ebola virus", "ORGANISM", 172, 183], ["Ebola virus", "SPECIES", 172, 183], ["Ebola virus", "SPECIES", 172, 183], ["the Ebola virus disease", "PROBLEM", 168, 191], ["Ebola virus", "OBSERVATION", 172, 183]]], ["Meanwhile, \u2018man-made\u2019 emergencies cover various types, among which \u2018traffic accident\u2019 (six papers), \u2018violence and terror incident\u2019 (six papers), and \u2018other\u2019 (four papers) have been regarded as three major subcategories based on the articles reviewed.", [["man", "SPECIES", 12, 15]]], ["The remaining studies (eight papers) cannot be clustered into any of the aforementioned categories or subcategories in the course of our review, as they are not clearly related to any particular type of emergency, so we have categorized them as \u2018general emergency.\u2019Emergency Situations ::: Five Themes in Using Mobile Phone Data for EMStudies paid considerably more attention to \u2018natural\u2019 emergencies compared with \u2018man-made\u2019 emergencies, and this was particularly evident in terms of disease disasters.", [["man", "SPECIES", 416, 419], ["The remaining studies", "TEST", 0, 21], ["disease disasters", "PROBLEM", 485, 502]]], ["The phenomenon may have been the result of attention drawn by the outbreak of the Ebola virus.Phases of the EM Process ::: Five Themes in Using Mobile Phone Data for EMEM generally goes through four phases, namely mitigation, preparedness, response, and recovery.", [["Ebola virus", "DISEASE", 82, 93], ["Ebola virus", "ORGANISM", 82, 93], ["Ebola virus", "SPECIES", 82, 93], ["Ebola virus", "SPECIES", 82, 93], ["the Ebola virus", "PROBLEM", 78, 93], ["Ebola virus", "OBSERVATION", 82, 93]]], ["Most of the studies investigated the response phase (39 papers).", [["the studies", "TEST", 8, 19]]], ["This phase involves activities like organizing an evacuation, mobilization, and assisting victims to manage the emergency appropriately.", [["an evacuation", "TREATMENT", 47, 60], ["mobilization", "TREATMENT", 62, 74], ["evacuation", "OBSERVATION", 50, 60]]], ["Then, 27 papers focused on the preparedness phase, and 22 papers focused on the mitigation phase.", [["the preparedness phase", "TEST", 27, 49]]], ["The mitigation phase aims to prevent a disaster or lessen its impacts by modifying the causes and vulnerabilities or distributing the losses (Oberg et al. 2011).", [["a disaster", "PROBLEM", 37, 47]]], ["This phase consists of both short-term and long-term activities that are designed for reestablishing and returning disaster areas to normal conditions.", [["normal conditions", "OBSERVATION", 133, 150]]], ["Note that the total sum according to these phases (102 papers) is greater than the number of reviewed articles (65 papers) since some studies focused on more than one phase.Types of Mobile Phone Data ::: Five Themes in Using Mobile Phone Data for EMMobile phone data consist of information collected by mobile carriers, sensors, and apps on mobile phones.", [["some studies", "TEST", 129, 141], ["greater", "OBSERVATION_MODIFIER", 66, 73]]], ["Mobile phone data collected by carriers include CDRs, SMS (short message service) information, traffic volume, etc., and data collected by phone sensors, such as GPS records, Bluetooth-sensed interaction data, etc.Types of Mobile Phone Data ::: Five Themes in Using Mobile Phone Data for EMMost of the studies applied CDRs (34 papers) for emergency analysis.", [["Bluetooth", "TEST", 175, 184], ["the studies", "TEST", 298, 309], ["emergency analysis", "TEST", 339, 357]]], ["CDRs containing both users\u2019 spatial and temporal information can support research on modeling human mobility during emergencies.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99]]], ["Moreover, information about caller and recipient IDs reveals individuals\u2019 social networks, which correlate to infectious disease dissemination (Gundogdu et al. 2016; Wesolowski et al. 2014).Types of Mobile Phone Data ::: Five Themes in Using Mobile Phone Data for EMSome studies combined CDRs with other data sources to obtain more comprehensive emergency-related information (Bharti et al. 2015; Pastor-Escuredo et al. 2014).", [["infectious disease", "DISEASE", 110, 128], ["social networks", "MULTI-TISSUE_STRUCTURE", 74, 89], ["infectious disease dissemination", "PROBLEM", 110, 142], ["EMSome studies", "TEST", 264, 278], ["infectious", "OBSERVATION_MODIFIER", 110, 120]]], ["Bharti et al. (2015) used both CDRs and nighttime lighting data from satellite imagery to analyze population sizes and human mobility (the CDRs for short-term and the satellite data for long-term assessment), which helped in making policies and understanding emergency impacts in the response phase.", [["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["nighttime lighting data", "TEST", 40, 63], ["long-term assessment", "TEST", 186, 206]]], ["Pastor-Escuredo et al. (2014) adopted both CDR and rainfall-level data in Mexico to help discover anomalous mobile phone usage patterns in seriously affected areas and assess infrastructure damage and casualty populations in time.Types of Mobile Phone Data ::: Five Themes in Using Mobile Phone Data for EMSMS (seven papers) is considered as another category of mobile phone data (separate from CDR in this study), which contains both passively collected information like communication details and actively collected information.", [["seriously affected areas", "PROBLEM", 139, 163], ["infrastructure damage", "PROBLEM", 175, 196], ["this study", "TEST", 402, 412]]], ["GPS data (11 papers) can provide the location information of individuals with higher accuracy than CDRs and can be helpful in the identification of individual locations as well as the study of human dynamics.", [["human", "ORGANISM", 193, 198], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 193, 198], ["GPS data", "TEST", 0, 8], ["the study", "TEST", 180, 189]]], ["In addition, there were some studies being developed based on app data (six papers) and others (nine papers), such as Bluetooth-sensed interaction data, mobile-phone-usage data, mobile-traffic data, etc.Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMWhen applying mobile phone data to practical problems, scholars have to gather and extract useful information from the raw mobile phone data.", [["some studies", "TEST", 24, 36], ["app data", "TEST", 62, 70]]], ["We have categorized different information processing paths from six analysis perspectives: human mobility, geographic location, social networks, mobile phone usage patterns, collected information, and information diffusion (Blondel et al. 2015).", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96]]], ["Detailed definitions for these analysis perspectives are exhibited in Table 2 (refer to Appendix 2) with specific examples.Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMAs depicted in Fig. 3, spatial-temporal information extracted from CDR and GPS data has been mostly investigated by scholars, which is reflected as human mobility (30 papers).", [["human", "ORGANISM", 342, 347], ["human", "SPECIES", 342, 347], ["human", "SPECIES", 342, 347], ["these analysis perspectives", "TEST", 25, 52], ["GPS data", "TEST", 269, 277], ["Appendix", "ANATOMY", 88, 96]]], ["Since the relationship between human movement patterns and infectious transmission routes were found (Blondel et al. 2015), the analysis of human mobility contributes to the understanding of the disease dissemination process.Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMMobile phone usage patterns perspective (10 papers) refers to various individual behavior gathered from one\u2019s mobile phone data, such as normal call volume.", [["human", "ORGANISM", 31, 36], ["human", "ORGANISM", 140, 145], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 140, 145], ["human mobility", "PROBLEM", 140, 154], ["the disease dissemination process", "PROBLEM", 191, 224], ["disease", "OBSERVATION", 195, 202]]], ["Arai et al. (2015) found clues to the whereabouts of unobserved populations by analyzing individuals\u2019 usage behaviors from CDRs, especially for the whereabouts of children, who are vulnerable to epidemics.", [["children", "ORGANISM", 163, 171], ["children", "SPECIES", 163, 171]]], ["This result contributes to tracking epidemic dissemination and the deployment of various resources.Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMSocial networks (10 papers) are constructed based on the communication information gathered from mobile phone data.", [["tracking epidemic dissemination", "PROBLEM", 27, 58]]], ["The analysis of social networks helped to reproduce disease dissemination models and predicted epidemic transmission for the preparedness phase (Y. Chen et al. 2017; Farrahi et al. 2015).Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMScholars also used spatial information extracted from mobile phone data (11 papers) at both the individual and aggregate level.", [["disease dissemination models", "PROBLEM", 52, 80]]], ["The analysis of individual geographic location benefited in tracking anomalous individual locations, and could be further applied to develop pre-warning systems, such as systems to lessen potential damage on natural gas pipelines (Dong et al. 2017).Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMThe collected information (seven papers) perspective refers to the process of gathering multiple types of information content from mobile phones, such as using a specific app to collect public opinions.", [["The analysis", "TEST", 0, 12], ["pre-warning systems", "TREATMENT", 141, 160], ["potential damage", "PROBLEM", 188, 204], ["natural gas pipelines", "TREATMENT", 208, 229]]], ["Deng et al. (2016) collected public opinions from an online opinion governance app to assist in government decision-making.Analysis Perspectives ::: Five Themes in Using Mobile Phone Data for EMIn addition, other studies focused on a more general perspective of gathering information from mobile phone data, and this kind of information was defined as information diffusion (five papers).", [["other studies", "TEST", 207, 220]]], ["Diffusion strategies of prevention knowledge could be developed to mitigate the impacts of emergencies by analyzing information diffusion networks (Lima et al. 2015).Applications ::: Five Themes in Using Mobile Phone Data for EMResearch in EM mainly focused on five kinds of problems: resource management, evacuation, pre-planning, decision-making, and education and training (Mingliang et al. 2006).", [["resource management", "TREATMENT", 285, 304], ["evacuation", "TREATMENT", 306, 316]]], ["Within these five types, various issues (such as making evacuation plans, optimizing resource allocation, predicting epidemic transmission, etc.) are defined as applications in this study.Applications ::: Five Themes in Using Mobile Phone Data for EMAlthough the selected studies developed their unique applications, this study provides a relatively broad classification, five general categories and 13 subcategories to help create a map of the existing applications.", [["this study", "TEST", 177, 187], ["this study", "TEST", 317, 327], ["the existing applications", "TREATMENT", 441, 466]]], ["This classification is exhibited in Table 3 (refer to Appendix 3) with a detailed definition and a specific example for each category.Applications ::: Five Themes in Using Mobile Phone Data for EMMost studies focused on the decision-making problem (42 papers), among which \u2018conducting public health intervention\u2019 (12 papers) and \u2018processing real-time detection\u2019 (12 papers) had been mostly developed.", [["EMMost studies", "TEST", 194, 208], ["Appendix", "ANATOMY", 54, 62]]], ["This kind of problem focuses on the appropriate allocation of both material and human resources according to the distributions of the victims and rescuers.A Framework of Using Mobile Phone Data for EMOur framework for using mobile phone data for EM is depicted in Fig. 4 and the detailed process is described in Section A.2.", [["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["human resources", "TREATMENT", 80, 95]]], ["The framework synthesizes the five aforementioned themes (i.e., emergency situations, EM phases, types of applications, analysis perspectives, and types of mobile phone data) and illustrates two logical routes with potential correspondences between each theme.", [["analysis perspectives", "TEST", 120, 141]]], ["They can make specific emergency plans involved in each phase of EM by following the steps: (i) judging what types of emergency the public are encountering; (ii) determining the phases of the emergency in different regions; (iii) figuring out general categories of applications related to the determined phase, and then referring to Table 3 and Fig. 6 (in Appendix 3) for sub-applications ought to be taken; (iv) determining procedure and activities that can be implemented in practice by considering both the characteristics of the encountered emergency and referred applications.", [["sub-applications", "TREATMENT", 372, 388], ["procedure", "TREATMENT", 425, 434]]], ["For example, during COVID-19, relevant managers can identify the situation as a disease disaster.", [["COVID", "TEST", 20, 25], ["a disease disaster", "PROBLEM", 78, 96]]], ["After referring to Table 3 and Fig. 6, they can consider implementing applications, like predicting epidemic transmission, as part of their emergency plans to protect communities and reduce loss.A Framework of Using Mobile Phone Data for EMThe second type of logical route is the problem-solving route (represented as red lines with arrows in the framework).", [["red lines", "CELL_LINE", 318, 327], ["reduce loss", "PROBLEM", 183, 194], ["logical route", "TREATMENT", 259, 272], ["red lines", "TREATMENT", 318, 327]]], ["This route assists technicians to devise solutions for emergency plans.", [["emergency plans", "TREATMENT", 55, 70]]], ["For example, to predict epidemic transmission during COVID-19 pandemic, technicians can find CDR and GPS data appropriate for gathering individuals\u2019 spatial-temporal information and analyzing human mobility.", [["human", "ORGANISM", 192, 197], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["COVID", "TEST", 53, 58], ["CDR", "TEST", 93, 96], ["GPS data", "TEST", 101, 109]]], ["Links in the framework represent existing studies in this field, thereby illuminating the established correlations between the themes and indicating potential research gaps.", [["existing studies", "TEST", 33, 49], ["research gaps", "OBSERVATION", 159, 172]]], ["For example, the studies on education and training applications mainly focus on the disease disaster and man-made disaster, while the focus on natural disasters is limited.", [["the studies", "TEST", 13, 24], ["training applications", "TREATMENT", 42, 63]]], ["Meanwhile, studies only analyze this application from four perspectives while information diffusion and geographic location are missing.", [["studies", "TEST", 11, 18]]], ["Researchers may further consider the feasibility of these two perspectives to analyze this application.EM under the COVID-19 PandemicThe outbreak of the COVID-19 pandemic in early 2020 has caused huge impacts on global political, economic, and social development (WHO 2020d; W. Chen and Bo 2020).", [["COVID-19", "ORGANISM", 153, 161], ["this application", "TREATMENT", 86, 102], ["huge", "OBSERVATION_MODIFIER", 196, 200], ["impacts", "OBSERVATION_MODIFIER", 201, 208]]], ["Both emergency-related managers and technicians can refer to the proposed framework for potential decision-making and problem-solving.EM under the COVID-19 PandemicDrawing on the decision-making route, emergency managers can determine emergency plans involved in each phase of managing the COVID-19 pandemic.", [["the COVID", "TEST", 286, 295], ["pandemic", "PROBLEM", 299, 307]]], ["Existing activities under the pandemic fit four categories of applications including predicting epidemic transmission (Jia et al. 2020; Iacus et al. 2020; Gatto et al. 2020), public health intervention (Magklaras and Nikolaia Lopez Bojorquez 2020; Ekong et al. 2020; Canada 2020), delivering emergency announcement (Barugola et al. 2020; Shi and Jiang 2020; Xinhua 2020b), and stating policy/ regulations (Speakman 2020; Hu and Zhu 2020; Canada 2020; Singapore 2020).", [["public health intervention", "TREATMENT", 175, 201], ["Magklaras and Nikolaia Lopez Bojorquez", "TREATMENT", 203, 241]]], ["In the preparedness phase, inspectors and the public have been trained and mobilized to use mobile phone security codes, which help track infection cases and contacts (AGDH 2020; Guinchard 2020; Zastrow 2020).", [["infection", "DISEASE", 138, 147]]], ["In the response phase, the World Health Organization has announced global objectives including conducting public health intervention by rapidly tracing, finding, and isolating all cases and contacts (WHO 2020b; Cozzens 2020; Magklaras and Nikolaia Lopez Bojorquez 2020).", [["Magklaras", "TREATMENT", 225, 234], ["Nikolaia Lopez Bojorquez", "TREATMENT", 239, 263], ["response phase", "OBSERVATION", 7, 21]]], ["And in the recovery phase, some governments have used mobile technology to aid business resumption with contact tracing applications (Thompson 2020a, 2020b; Sunil 2020; Devonshire-Ellis 2020; Hu and Zhu 2020).EM under the COVID-19 PandemicDrawing on the problem-solving route in our framework, relevant technicians can analyze various collected information from mobile devices to implement the aforementioned applications.", [["mobile technology", "TREATMENT", 54, 71], ["mobile devices", "TREATMENT", 362, 376]]], ["First, researchers have used CDR data (Jia et al. 2020) and mobile positioning data (Gatto et al. 2020; Iacus et al. 2020) to predict epidemic transmission by capturing and simulating population movements.", [["CDR data", "TEST", 29, 37], ["mobile positioning data", "TEST", 60, 83]]], ["They have mentioned that their prediction model can conduct risk assessments and plan limited resources allocation as well.", [["risk assessments", "TEST", 60, 76]]], ["Second, contact tracing requires various mobile tools including GPS (Cozzens 2020), Bluetooth (WHO 2020c; Xinhua 2020a), apps (Zhang et al. 2020; Singapore 2020; AGDH 2020), and SMS technology (WHO 2020c) to gather individuals\u2019 geographic and health-related information.", [["contact tracing", "TEST", 8, 23]]], ["The analysis of this information can be further applied to conduct public health intervention such as isolation strategies and travel restrictions.", [["public health intervention", "TREATMENT", 67, 93], ["isolation strategies", "TREATMENT", 102, 122], ["travel restrictions", "TREATMENT", 127, 146]]], ["Finally, as for business resumption, history trajectories and health status of individuals collected through specific mobile phone apps (Zastrow 2020), SMS (WHO 2020a; McCabe 2020) and GPS technology (Elliott 2020) helps to evaluate their infection risk, which can be used by governments to resume business and study.EM under the COVID-19 PandemicOur framework not only covers applications that have already been adopted in this EM, but also provides a reference for future EM.", [["infection", "DISEASE", 239, 248], ["their infection risk", "PROBLEM", 233, 253]]], ["For example, it is possible to consider other applications in our framework such as guiding psychology recovery in the context of COVID-19.", [["COVID", "TEST", 130, 135]]], ["The use of hedonic apps after an earthquake has been identified to reduce perceived risk effectively (Jia et al. 2017).", [["hedonic apps", "TREATMENT", 11, 23]]], ["The results shown in Section 3.1 indicate a greater emphasis on natural emergencies (41 articles reviewed in total) and less emphasis on man-made emergencies (16 articles reviewed in total).", [["greater", "OBSERVATION_MODIFIER", 44, 51]]], ["However, managing violence and terror incidents is also very vital, because these emergencies happen frequently around the world.", [["violence", "DISEASE", 18, 26]]], ["For such a crisis situation, it is challenging to gather their information due to the dark side and dynamic nature (Roberts 2011; Skillicorn 2011; Chen et al. 2011).A Focus on Man-Made Emergencies ::: Future ImplicationsIn view of these challenges, current literature has explored the suitability of using social media data (Oh et al. 2011; Cheong and Lee 2011; Prentice et al. 2011; Qin et al. 2011).", [["a crisis situation", "PROBLEM", 9, 27]]], ["Some studies have identified the feasibility of using mobile phone data in man-made emergencies, such as detecting terrorism attacks and monitoring traffic conditions (Blondel et al. 2015).", [["Some studies", "TEST", 0, 12], ["terrorism attacks", "PROBLEM", 115, 132]]], ["However, most scholars focused on the timely and effective response to emergencies, while fewer studies focused on the psychological recovery of people after emergencies.", [["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151]]], ["With the popularity and development of 4G/5G communication technology, many people use their mobile phones for obtaining emergency-related information and entertainment to ease their anxiety.", [["anxiety", "DISEASE", 183, 190], ["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["4G/5G communication technology", "TREATMENT", 39, 69], ["their anxiety", "PROBLEM", 177, 190]]], ["For example, Jia et al. (2017) discovered that the use of hedonic apps after an earthquake can help people reduce their perceived risk.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["hedonic apps", "TREATMENT", 58, 70]]], ["Therefore, there is the potential to use mobile phone data for the study of developing positive psychological structures in the recovery phase.Exploring New Applications ::: Future ImplicationsAdditional applications can be explored and expanded according to the two ways demonstrated in the framework.", [["the study", "TEST", 63, 72], ["Additional applications", "TREATMENT", 193, 216]]], ["For example, with a more comprehensive notion of human social interaction, scholars may not only investigate approaches in predicting epidemic transmission, but also apply this knowledge to develop systems in predicting crimes.", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54]]], ["As a result, additional applications can be similarly explored within and beyond the existing applications in the future.Creating Better Comprehension of the Analysis Perspective ::: Future ImplicationsFuture work should also make efforts to complement the theoretical foundation of emergency studies with theories from other fields.", [["additional applications", "TREATMENT", 13, 36], ["emergency studies", "TEST", 283, 300]]], ["Moreover, a better comprehension of the analysis perspective can be made by learning constructs about human behavior, social networks, etc. For example, scholars have found similarities between human communication and infectious disease dissemination (Blondel et al. 2015), which indicates the benefits of drawing on theories from social networks to apply to EM.", [["infectious disease", "DISEASE", 218, 236], ["human", "ORGANISM", 102, 107], ["social networks", "MULTI-TISSUE_STRUCTURE", 118, 133], ["human", "ORGANISM", 194, 199], ["social networks", "MULTI-TISSUE_STRUCTURE", 331, 346], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 194, 199], ["infectious disease dissemination", "PROBLEM", 218, 250], ["infectious", "OBSERVATION_MODIFIER", 218, 228]]], ["Meanwhile, the current understanding of human mobility is mainly based on data analysis.", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["data analysis", "TEST", 74, 87]]], ["If scholars can learn and apply aspects from relevant psychological and behavioral theories, the analysis of human mobility can be further deepened.Creating Better Comprehension of the Analysis Perspective ::: Future ImplicationsIn addition, with a better comprehension of analysis perspectives and applications, it is possible to develop new correspondences between analysis perspectives and applications.", [["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["human mobility", "TREATMENT", 109, 123]]], ["For example, human mobility can probably be analyzed in order to construct pre-warning systems.", [["human", "ORGANISM", 13, 18], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18]]], ["According to the study of daily movement patterns of individuals, a detected anomaly of movement may indicate a coming disaster, which would suggest the need to construct correlations between human mobility and pre-warning systems.", [["anomaly of movement", "DISEASE", 77, 96], ["human", "ORGANISM", 192, 197], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["the study", "TEST", 13, 22], ["a detected anomaly of movement", "PROBLEM", 66, 96]]], ["Consequently, the correspondence between analysis perspectives and applications should be considered and expanded upon in future research.Combining Other Data with Mobile Phone Data ::: Future ImplicationsAlthough mobile phone data have been successfully applied to EM, combining other micro and macro data can help the development of EM research more efficiently (Ghosh et al. 2018).", [["applications", "TREATMENT", 67, 79], ["macro data", "TEST", 296, 306]]], ["Under what circumstances it is appropriate and how to combine mobile phone data with micro (e.g., individual locations) and macro (e.g., public opinions) data from social media requires further exploration.", [["further exploration", "TEST", 186, 205]]], ["For instance, Pastor-Escuredo et al. (2014) believe there is potential in combining information from officially monitored sensors like traffic video cameras, which can provide a fine-grained validation for the existing measures.ConclusionsEmergencies have great impacts on the whole of society, affecting material facilities and social order in terms of economic losses and human casualties.", [["human", "ORGANISM", 374, 379], ["human", "SPECIES", 374, 379], ["human", "SPECIES", 374, 379]]], ["Unlike traditional management measures based on data sources with limited adaptability and low accuracy, applications for handling emergencies that utilize ubiquitous and real-time mobile phone data have greatly improved EM mechanisms and minimized their negative impacts on society.", [["traditional management measures", "TREATMENT", 7, 38], ["handling emergencies", "TREATMENT", 122, 142]]], ["This systematic literature review analyzes 65 studies concerning the use of mobile phone data for EM, and proposes a framework to synthesize the fragmented knowledge of existing studies.", [["existing studies", "TEST", 169, 185]]], ["In addition, this study discusses EM under the COVID-19 pandemic and provides a reference for future management of the pandemic.ConclusionsDespite all the contributions mentioned above, this study still possesses some inevitable limitations.", [["this study", "TEST", 13, 23], ["future management", "TREATMENT", 94, 111], ["the pandemic", "PROBLEM", 115, 127], ["this study", "TEST", 186, 196], ["pandemic", "OBSERVATION", 119, 127]]], ["First, the common limitation of literature reviews related to keywords exists in this study as well.", [["this study", "TEST", 81, 91]]], ["Making the best efforts to alleviate this drawback, this study draws on keywords about EM from previous reviews and research works in the field of EM as well as keywords about mobile phone data.", [["this drawback", "TREATMENT", 37, 50], ["this study", "TEST", 52, 62]]], ["The second limitation is that the framework develops in this study is only based on the articles reviewed, meaning that relationships not mentioned in the articles are not considered.", [["this study", "TEST", 56, 66], ["not considered", "UNCERTAINTY", 168, 182]]], ["Reviews, no matter how current, by definition focus on the past and cannot fully anticipate novel approaches or new developments.", [["no", "UNCERTAINTY", 9, 11]]], ["Finally, this study does not focus on the detailed introduction of data processing and analyzing techniques.", [["this study", "TEST", 9, 19], ["data processing", "TEST", 67, 82], ["analyzing techniques", "TEST", 87, 107]]], ["Nevertheless, we still believe this study makes a strong contribution to the field, especially toward emergency managers and scholars who are looking for direction to develop this field in the future.", [["this study", "TEST", 31, 41]]]], "PMC6159870": [["IntroductionBats (Order: Chiroptera) serve as reservoir hosts for viruses of concern for human and animal health [1,2] including SARS coronavirus, rabies virus, filoviruses, and henipaviruses [3\u20136].", [["SARS coronavirus", "DISEASE", 129, 145], ["rabies virus, filoviruses", "DISEASE", 147, 172], ["Order: Chiroptera", "ORGANISM", 18, 35], ["human", "ORGANISM", 89, 94], ["SARS coronavirus", "ORGANISM", 129, 145], ["rabies virus", "ORGANISM", 147, 159], ["filoviruses", "GENE_OR_GENE_PRODUCT", 161, 172], ["human", "SPECIES", 89, 94], ["SARS coronavirus", "SPECIES", 129, 145], ["rabies virus", "SPECIES", 147, 159], ["human", "SPECIES", 89, 94], ["SARS coronavirus", "SPECIES", 129, 145], ["rabies virus", "SPECIES", 147, 159], ["reservoir hosts", "TREATMENT", 46, 61], ["viruses", "PROBLEM", 66, 73], ["SARS coronavirus", "PROBLEM", 129, 145], ["rabies virus", "PROBLEM", 147, 159], ["filoviruses", "PROBLEM", 161, 172], ["henipaviruses", "TREATMENT", 178, 191]]], ["Bats can also harbor protozoa and bacteria of potential zoonotic relevance [7\u20139].", [["Bats", "CELL", 0, 4]]], ["Bartonella spp. are of particular interest, as these Gram-negative bacteria cause bacteremia and endocarditis in both humans and livestock [10,11] and exhibit high genetic diversity in bats across multiple continents and species [12\u201317].", [["bacteremia", "DISEASE", 82, 92], ["endocarditis", "DISEASE", 97, 109], ["Bartonella spp.", "ORGANISM", 0, 15], ["Gram", "GENE_OR_GENE_PRODUCT", 53, 57], ["humans", "ORGANISM", 118, 124], ["Bartonella spp.", "SPECIES", 0, 15], ["humans", "SPECIES", 118, 124], ["Bartonella spp.", "SPECIES", 0, 15], ["humans", "SPECIES", 118, 124], ["Bartonella spp.", "TEST", 0, 15], ["these Gram", "TEST", 47, 57], ["bacteremia", "PROBLEM", 82, 92], ["endocarditis", "PROBLEM", 97, 109], ["high genetic diversity in bats", "PROBLEM", 159, 189], ["negative bacteria", "OBSERVATION_MODIFIER", 58, 75], ["bacteremia", "OBSERVATION", 82, 92], ["endocarditis", "OBSERVATION", 97, 109], ["high", "OBSERVATION_MODIFIER", 159, 163], ["genetic diversity", "OBSERVATION", 164, 181]]], ["Moreover, phylogenetic analyses show bats are reservoirs of zoonotic Candidatus B. mayotimonensis [18\u201320], a causative agent of human endocarditis [21].IntroductionGiven the zoonotic potential of bat-associated Bartonella, understanding transmission within bats is critical for understanding how Bartonella persists in bat populations and for assessing spillover risks [22,23].", [["human endocarditis", "DISEASE", 128, 146], ["bats", "ORGANISM", 37, 41], ["B. mayotimonensis", "ORGANISM", 80, 97], ["human", "ORGANISM", 128, 133], ["bat", "ORGANISM", 196, 199], ["Bartonella", "ORGANISM", 296, 306], ["bat", "ORGANISM", 319, 322], ["Candidatus", "SPECIES", 69, 79], ["B. mayotimonensis", "SPECIES", 80, 97], ["human", "SPECIES", 128, 133], ["B. mayotimonensis", "SPECIES", 80, 97], ["human", "SPECIES", 128, 133], ["phylogenetic analyses", "TEST", 10, 31], ["human endocarditis", "PROBLEM", 128, 146], ["Bartonella", "PROBLEM", 211, 221], ["Bartonella", "PROBLEM", 296, 306], ["endocarditis", "OBSERVATION", 134, 146], ["Bartonella", "OBSERVATION", 211, 221]]], ["Ectoparasites are frequently invoked as a transmission route [12,19,24], in part because vector-borne transmission occurs in other taxa [25,26] and because Bartonella has been identified in bat flies and ticks [27\u201329].", [["Bartonella", "ORGANISM", 156, 166], ["bat flies", "ORGANISM", 190, 199], ["Ectoparasites", "PROBLEM", 0, 13], ["Bartonella", "PROBLEM", 156, 166]]], ["While some bat ticks can feed on humans [30], the high host specificity of bat flies [31,32] could limit opportunities for cross-species transmission through ectoparasites [31\u201333].", [["bat ticks", "ORGANISM", 11, 20], ["humans", "ORGANISM", 33, 39], ["bat flies", "ORGANISM", 75, 84], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39]]], ["Transmission through close contact (e.g., biting) could occur given detection of Bartonella in dog and cat saliva [34,35] as well as human infection following scratches from dogs and cats [36].", [["infection", "DISEASE", 139, 148], ["Bartonella", "ORGANISM", 81, 91], ["dog", "ORGANISM", 95, 98], ["cat", "ORGANISM", 103, 106], ["saliva", "ORGANISM_SUBSTANCE", 107, 113], ["human", "ORGANISM", 133, 138], ["dogs", "ORGANISM", 174, 178], ["dog", "SPECIES", 95, 98], ["cat", "SPECIES", 103, 106], ["human", "SPECIES", 133, 138], ["dogs", "SPECIES", 174, 178], ["cats", "SPECIES", 183, 187], ["dog", "SPECIES", 95, 98], ["human", "SPECIES", 133, 138], ["Bartonella in dog", "PROBLEM", 81, 98], ["human infection", "PROBLEM", 133, 148], ["infection", "OBSERVATION", 139, 148]]], ["Phylogenetic patterns of weak Bartonella host specificity in Neotropical bat communities could not only reflect transmission through close contacts between species in multi-species roosts, but could also stem from transmission through generalist vectors [15,24,37].", [["communities", "ANATOMY", 77, 88], ["weak Bartonella host specificity", "PROBLEM", 25, 57], ["weak", "OBSERVATION_MODIFIER", 25, 29], ["Bartonella host", "OBSERVATION", 30, 45]]], ["Bartonella might also be transmitted through exposure to feces between bats and to humans that enter roosts or to domestic animals exposed to bat feces [18,38].IntroductionIn addition to the potential risks of cross-species transmission from bats to livestock and humans, the infection dynamics of Bartonella in bats are also uncertain.", [["infection", "DISEASE", 276, 285], ["Bartonella", "ORGANISM", 0, 10], ["feces", "ORGANISM_SUBSTANCE", 57, 62], ["humans", "ORGANISM", 83, 89], ["bat feces", "ORGANISM", 142, 151], ["humans", "ORGANISM", 264, 270], ["Bartonella", "ORGANISM", 298, 308], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 264, 270], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 264, 270], ["Bartonella", "PROBLEM", 0, 10], ["cross-species transmission", "TREATMENT", 210, 236], ["the infection dynamics", "PROBLEM", 272, 294], ["Bartonella", "PROBLEM", 298, 308], ["infection", "OBSERVATION", 276, 285], ["Bartonella", "OBSERVATION", 298, 308]]], ["In rodents, Bartonella prevalence varies through time [39,40], but such patterns have not been well studied in bats [41].", [["Bartonella", "ORGANISM", 12, 22], ["Bartonella prevalence", "TEST", 12, 33]]], ["Individual heterogeneities in infection by age and sex could also inform exposure patterns.", [["infection", "DISEASE", 30, 39], ["Individual heterogeneities in infection", "PROBLEM", 0, 39], ["heterogeneities", "OBSERVATION", 11, 26], ["infection", "OBSERVATION", 30, 39]]], ["Finally, global analyses suggest geographic structure in bat Bartonella genotypes, with notable differences in genotypes from Latin American and those from Africa, Europe, and Asia [42].", [["bat Bartonella", "ORGANISM", 57, 71], ["global analyses", "TEST", 9, 24], ["geographic structure in bat Bartonella genotypes", "PROBLEM", 33, 81], ["notable differences in genotypes", "PROBLEM", 88, 120], ["geographic structure", "OBSERVATION", 33, 53], ["bat", "ANATOMY", 57, 60], ["Bartonella genotypes", "OBSERVATION", 61, 81], ["notable", "OBSERVATION_MODIFIER", 88, 95], ["differences", "OBSERVATION_MODIFIER", 96, 107]]], ["However, as such patterns appear driven by bat families restricted to different continents, analyses within narrower geographic and taxonomic ranges could inform the scale of Bartonella transmission and the role that dispersal plays in the spatial dynamics of this infection [43].IntroductionCommon vampire bats (Desmodus rotundus) have high prevalence of Bartonella throughout their large geographic range in Latin America [15,16,24,44].", [["infection", "DISEASE", 265, 274], ["vampire bats", "ORGANISM", 299, 311], ["Desmodus rotundus", "ORGANISM", 313, 330], ["Desmodus rotundus", "SPECIES", 313, 330], ["Desmodus rotundus", "SPECIES", 313, 330], ["Bartonella transmission", "PROBLEM", 175, 198], ["this infection", "PROBLEM", 260, 274], ["Bartonella", "PROBLEM", 356, 366], ["Bartonella", "OBSERVATION", 356, 366]]], ["Vampire bats are of particular concern because they subsist on blood, which could create opportunities for Bartonella transmission to humans and livestock either from bites during blood feeding or through vector sharing facilitated by close proximity [45\u201348].", [["blood", "ANATOMY", 63, 68], ["blood", "ANATOMY", 180, 185], ["Bartonella transmission to humans and livestock", "DISEASE", 107, 154], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["Bartonella", "ORGANISM", 107, 117], ["humans", "ORGANISM", 134, 140], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["humans", "SPECIES", 134, 140], ["humans", "SPECIES", 134, 140], ["Bartonella transmission", "TREATMENT", 107, 130]]], ["Here, we capitalize on a two-year, spatially replicated study of vampire bats to examine the genetic diversity and infection prevalence of Bartonella, including its geographic structure across the vampire bat range as well as individual and temporal correlates of infection status.", [["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 264, 273], ["the genetic diversity", "PROBLEM", 89, 110], ["infection prevalence of Bartonella", "PROBLEM", 115, 149], ["infection status", "PROBLEM", 264, 280], ["infection", "OBSERVATION", 115, 124], ["Bartonella", "OBSERVATION", 139, 149], ["infection", "OBSERVATION", 264, 273]]], ["To explore possible transmission routes of this bacterial pathogen, we also test for associations between bat fly infestation and Bartonella infection status, which would support vector-borne transmission, and by screening bat saliva and fecal samples for evidence of Bartonella DNA, which would support transmission through bites or grooming and environmental exposure to bacteria shed in feces, respectively.Vampire bat sampling ::: Materials and methodsSamples were collected as described in Becker et al. [49] in 2015 and 2016 across seven sites in Peru (Departments of Amazonas [AM], Cajamarca [CA], and Loreto [LR]) and two sites in Belize (Orange Walk [OW] District).", [["fecal samples", "ANATOMY", 238, 251], ["feces", "ANATOMY", 390, 395], ["Bartonella infection", "DISEASE", 130, 150], ["bat fly", "ORGANISM", 106, 113], ["bat", "ORGANISM", 223, 226], ["saliva", "ORGANISM_SUBSTANCE", 227, 233], ["fecal samples", "ORGANISM_SUBSTANCE", 238, 251], ["Bartonella", "ORGANISM", 268, 278], ["DNA", "CELLULAR_COMPONENT", 279, 282], ["feces", "ORGANISM_SUBDIVISION", 390, 395], ["bat fly", "SPECIES", 106, 113], ["this bacterial pathogen", "PROBLEM", 43, 66], ["bat fly infestation", "PROBLEM", 106, 125], ["Bartonella infection status", "PROBLEM", 130, 157], ["screening bat saliva", "TEST", 213, 233], ["fecal samples", "TEST", 238, 251], ["Bartonella DNA", "PROBLEM", 268, 282], ["transmission through bites", "PROBLEM", 304, 330], ["grooming", "PROBLEM", 334, 342], ["bacteria", "PROBLEM", 373, 381], ["methodsSamples", "TEST", 449, 463], ["Cajamarca [CA], and Loreto [LR])", "TREATMENT", 589, 621], ["Bartonella infection", "OBSERVATION", 130, 150], ["Bartonella DNA", "OBSERVATION", 268, 282]]], ["To screen for Bartonella by PCR, up to 30 \u03bcL blood was stored on Whatman FTA cards at room temperature.", [["blood", "ANATOMY", 45, 50], ["Bartonella", "ORGANISM", 14, 24], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["Bartonella", "PROBLEM", 14, 24], ["PCR", "TEST", 28, 31]]], ["To assess the presence of Bartonella in saliva and feces, we collected oral and rectal swabs from vampire bats in Peru.", [["saliva", "ANATOMY", 40, 46], ["feces", "ANATOMY", 51, 56], ["oral", "ANATOMY", 71, 75], ["rectal swabs", "ANATOMY", 80, 92], ["Bartonella", "ORGANISM", 26, 36], ["saliva", "ORGANISM_SUBSTANCE", 40, 46], ["feces", "ORGANISM_SUBSTANCE", 51, 56], ["oral", "ORGANISM_SUBDIVISION", 71, 75], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 80, 92], ["Bartonella in saliva and feces", "PROBLEM", 26, 56], ["Bartonella", "OBSERVATION", 26, 36], ["rectal", "ANATOMY", 80, 86]]], ["Swabs were preserved in 2 mL RNAlater (Invitrogen) at \u201380\u00b0C until laboratory analyses.", [["Swabs", "ANATOMY", 0, 5], ["Swabs", "TEST", 0, 5], ["laboratory analyses", "TEST", 66, 85]]], ["For Peru sites sampled in 2016, we also recorded the number of bat flies per vampire bat [32].Ethics statement ::: Materials and methodsField procedures were approved by the University of Georgia Animal Care and Use Committee (A2014 04-016-Y3-A5) and the University of Glasgow School of Medical Veterinary and Life Sciences Research Ethics Committee (Ref08a/15); all procedures were conducted in accordance with accepted guidelines for humane wildlife research as outlined by the American Society of Mammalogists [50].", [["Peru sites", "PROBLEM", 4, 14], ["all procedures", "TREATMENT", 363, 377]]], ["Bat capture, sample collection, and exportation were authorized by the Belize Forest Department under permits CD/60/3/15(21) and WL/1/1/16(17) and by the Peruvian Government under permits RD-009-2015-SERFOR-DGGSPFFS, RD-264-2015-SERFOR-DGGSPFFS, and RD-142-2015-SERFOR-DGGSPFFS.", [["sample", "ANATOMY", 13, 19], ["SERFOR-DGGSPFFS, RD-264-2015-SERFOR-DGGSPFFS, and RD-142-2015-SERFOR-DGGSPFFS", "DNA", 200, 277], ["sample collection", "TEST", 13, 30]]], ["Access to genetic resources from Peru was granted under permit RD-054-2016-SERFOR-DGGSPFFS.Sequencing and phylogenetic analysis of vampire bat Bartonella ::: Materials and methodsWe analyzed samples that were previously screened for the presence of Bartonella by Becker et al. [49] using nested PCR to amplify a region of the citrate synthase gene (gltA) [51].", [["samples", "ANATOMY", 191, 198], ["citrate", "CHEMICAL", 326, 333], ["citrate", "CHEMICAL", 326, 333], ["citrate synthase", "GENE_OR_GENE_PRODUCT", 326, 342], ["gltA", "GENE_OR_GENE_PRODUCT", 349, 353], ["SERFOR", "DNA", 75, 81], ["DGGSPFFS", "DNA", 82, 90], ["citrate synthase gene", "DNA", 326, 347], ["gltA", "DNA", 349, 353], ["Sequencing", "TEST", 91, 101], ["phylogenetic analysis", "TEST", 106, 127], ["Bartonella", "PROBLEM", 249, 259], ["nested PCR", "TREATMENT", 288, 298], ["the citrate synthase gene", "TREATMENT", 322, 347]]], ["Among the Bartonella-positive samples, we randomly selected 5\u201310 positive samples per site for Sanger sequencing (n = 51).", [["samples", "ANATOMY", 30, 37], ["samples", "ANATOMY", 74, 81], ["the Bartonella", "TEST", 6, 20], ["Sanger sequencing", "TEST", 95, 112]]], ["PCR products were purified with DNA Clean & Concentrator Kits (Zymo Research) and sequenced in both directions at the Georgia Genomics Facility.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["PCR products", "TREATMENT", 0, 12]]], ["Resulting chromatograms were checked for quality and trimmed using Geneious (Biomatters) [52].", [["Resulting chromatograms", "TEST", 0, 23]]], ["Post-trimmed forward and reverse sequences were assembled to create 348 base pair (bp) consensus sequences for each sample (n = 35; the quality of 16 chromatograms was too low).", [["sample", "ANATOMY", 116, 122], ["Post-trimmed forward and reverse sequences", "DNA", 0, 42], ["348 base pair (bp) consensus sequences", "DNA", 68, 106], ["reverse sequences", "TEST", 25, 42], ["base pair (bp) consensus sequences", "TEST", 72, 106], ["each sample", "TEST", 111, 122]]], ["Sequences were considered part of the same genotype if they had >96% identity in gltA, an established cut-off for Bartonella species identification [53].", [["gltA", "GENE_OR_GENE_PRODUCT", 81, 85], ["gltA", "DNA", 81, 85], ["gltA", "TEST", 81, 85], ["Bartonella species identification", "PROBLEM", 114, 147]]], ["Sequences with >99.7% similarity were considered the same genetic variant [54].", [["Sequences", "TEST", 0, 9]]], ["We used a Chi-squared test with the p value generated via a Monte Carlo procedure with 1000 simulations [55] to assess whether our defined Bartonella genotypes were associated with region (i.e., Belize, eastern Peruvian Amazon, western Peruvian Amazon).Sequencing and phylogenetic analysis of vampire bat Bartonella ::: Materials and methodsTwo datasets were created for phylogenetic analyses.", [["Bartonella", "ORGANISM", 139, 149], ["a Chi-squared test", "TEST", 8, 26], ["a Monte Carlo procedure", "TREATMENT", 58, 81], ["our defined Bartonella genotypes", "PROBLEM", 127, 159], ["Sequencing", "TEST", 253, 263], ["phylogenetic analysis", "TEST", 268, 289], ["phylogenetic analyses", "TEST", 371, 392], ["Bartonella", "OBSERVATION", 139, 149]]], ["Dataset 1 was designed to assess the spatial structure of vampire bat\u2013associated Bartonella across Latin America and therefore included our new sequences plus all previously reported gltA sequences from Desmodus rotundus.", [["gltA", "GENE_OR_GENE_PRODUCT", 183, 187], ["Desmodus rotundus", "ORGANISM", 203, 220], ["gltA sequences", "DNA", 183, 197], ["Desmodus rotundus", "SPECIES", 203, 220], ["Desmodus rotundus", "SPECIES", 203, 220], ["vampire bat\u2013associated Bartonella", "PROBLEM", 58, 91]]], ["Dataset 2 was designed to capture the relatedness of the new sequences to all previously described Bartonella spp. regardless of isolation source, which comprised sequences generated in this study plus sequences obtained by conducting a BLAST search of each new sequence against GenBank, selecting the top 10 hits, and removing duplicates.", [["Bartonella spp", "DISEASE", 99, 113], ["Bartonella spp", "ORGANISM", 99, 113], ["Bartonella spp", "PROBLEM", 99, 113], ["this study", "TEST", 186, 196], ["isolation", "OBSERVATION", 129, 138]]], ["For both datasets, consensus sequences were aligned using MAFFT.", [["consensus sequences", "DNA", 19, 38], ["consensus sequences", "TEST", 19, 38]]], ["Phylogenetic analyses were carried out in MrBayes using the GTR+gamma model suggested by jModeltest2 [56].", [["Phylogenetic analyses", "TEST", 0, 21], ["the GTR", "TREATMENT", 56, 63]]], ["For dataset 1 (Desmodus-associated sequences), we fit a codon partitioned substitution model by linking rates in codon positions 1 and 2 separately from codon position 3.", [["dataset 1", "DNA", 4, 13], ["Desmodus-associated sequences", "DNA", 15, 44], ["codon positions 1 and 2", "DNA", 113, 136], ["codon position 3", "DNA", 153, 169], ["a codon partitioned substitution model", "TREATMENT", 54, 92]]], ["For dataset 2, we used a simpler non-partitioned model because the more complex codon-partitioned model failed to converge.", [["a simpler non-partitioned model", "TREATMENT", 23, 54]]], ["Dataset 2 included one sequence from Brucella abortus (Genbank Locus: MIJI01000003.1) as an outgroup [13].", [["Brucella abortus", "ORGANISM", 37, 53], ["Brucella abortus", "SPECIES", 37, 53], ["Brucella abortus", "SPECIES", 37, 53]]], ["Both datasets were run for 2.5 million generations with convergence checked and burn-in periods selected by assessing posterior traces in Tracer [57].", [["burn", "PROBLEM", 80, 84]]], ["We here selected 1,000 trees from the posterior distribution of the MrBayes run and compared the country-level clustering to a null distribution from 10,000 trees with swapped tip associations [58].Statistical analyses of Bartonella infection status ::: Materials and methodsWe analyzed 193 samples from Desmodus rotundus to test whether temporal variation (season and year) and individual risk factors (e.g., age, sex) explain differences in Bartonella infection, using generalized mixed effects models (GLMMs) with binomial errors and a logit link fit with the lme4 package in R [59,60].", [["samples", "ANATOMY", 291, 298], ["Bartonella infection", "DISEASE", 222, 242], ["Bartonella infection", "DISEASE", 443, 463], ["Bartonella", "ORGANISM", 222, 232], ["Desmodus rotundus", "ORGANISM", 304, 321], ["Desmodus rotundus", "SPECIES", 304, 321], ["Desmodus rotundus", "SPECIES", 304, 321], ["Bartonella infection", "PROBLEM", 222, 242], ["Desmodus rotundus", "TEST", 304, 321], ["temporal variation", "PROBLEM", 338, 356], ["individual risk factors", "PROBLEM", 379, 402], ["Bartonella infection", "PROBLEM", 443, 463], ["generalized mixed effects models", "PROBLEM", 471, 503], ["binomial errors", "PROBLEM", 517, 532], ["posterior", "ANATOMY_MODIFIER", 38, 47], ["tip", "OBSERVATION_MODIFIER", 176, 179], ["Bartonella infection", "OBSERVATION", 222, 242], ["Bartonella infection", "OBSERVATION", 443, 463]]], ["We fit a single GLMM with an interaction between site and year to first test if prevalence varied over years across sampling locations; we excluded one site from this analysis (i.e., LR6) owing to sampling in only 2015.", [["a single GLMM", "PROBLEM", 7, 20], ["this analysis", "TEST", 162, 175]]], ["We included bat identification number (ID) as a random effect to account for multiple sampling of a small number of bats (n = 6).", [["small", "OBSERVATION_MODIFIER", 100, 105], ["number", "OBSERVATION_MODIFIER", 106, 112]]], ["To assess seasonality in infection, we fit a separate GLMM with season (spring, summer, fall) as a predictor to data from two sites in Peru (AM1 and CA1) sampled across seasons (n = 63).", [["infection", "DISEASE", 25, 34], ["seasonality in infection", "PROBLEM", 10, 34], ["infection", "OBSERVATION", 25, 34]]], ["We also fit a generalized additive model (GAM) with restricted maximum likelihood, binomial response, and a cyclic cubic regression spline for Julian date using the mgcv package [61].", [["a cyclic cubic regression spline", "TREATMENT", 106, 138], ["the mgcv package", "TREATMENT", 161, 177]]], ["We randomly selected repeatedly sampled bats, as including bat ID as a random effect here overfit the GAM.Statistical analyses of Bartonella infection status ::: Materials and methodsTo identify individual risk factors for Bartonella infection, we fit a single GLMM with bat age, forearm size, sex, and reproductive status; we also included interactions between sex and reproduction, sex and age, sex and forearm size, and reproduction and forearm size.", [["forearm", "ANATOMY", 280, 287], ["forearm", "ANATOMY", 405, 412], ["forearm", "ANATOMY", 440, 447], ["Bartonella infection", "DISEASE", 130, 150], ["Bartonella infection", "DISEASE", 223, 243], ["Bartonella", "ORGANISM", 130, 140], ["forearm", "ORGANISM_SUBDIVISION", 280, 287], ["forearm", "ORGANISM_SUBDIVISION", 405, 412], ["forearm", "ORGANISM_SUBDIVISION", 440, 447], ["GAM", "PROTEIN", 102, 105], ["Bartonella infection", "PROBLEM", 130, 150], ["individual risk factors", "PROBLEM", 195, 218], ["Bartonella infection", "PROBLEM", 223, 243], ["Bartonella infection", "OBSERVATION", 130, 150], ["forearm", "ANATOMY", 280, 287], ["size", "OBSERVATION_MODIFIER", 288, 292], ["forearm", "ANATOMY", 405, 412], ["size", "OBSERVATION_MODIFIER", 413, 417], ["forearm", "ANATOMY", 440, 447], ["size", "OBSERVATION_MODIFIER", 448, 452]]], ["We included categorical livestock biomass as a predictor in the GLMM to control for a previously observed negative association with Bartonella infection (121/173 positive bats) [49].", [["Bartonella infection", "DISEASE", 132, 152], ["categorical livestock biomass", "TREATMENT", 12, 41], ["a predictor in the GLMM", "TREATMENT", 45, 68], ["Bartonella infection", "PROBLEM", 132, 152]]], ["We fit this GLMM to a reduced dataset free of missing values (n = 189), included bat ID nested within site as a random effect, and calculated marginal R2 (R2m) to assess model fit [62].", [["this GLMM", "PROBLEM", 7, 16]]], ["Finally, for a data subset (n = 40 bats sampled in Peru in 2016), we fit two separate GLMs with bat fly intensity and presence as predictors to test whether ectoparasites explained Bartonella infection status.", [["Bartonella infection", "DISEASE", 181, 201], ["Bartonella", "ORGANISM", 181, 191], ["ectoparasites", "PROBLEM", 157, 170], ["Bartonella infection status", "PROBLEM", 181, 208]]], ["We fit a separate GLM with quasi-Poisson errors to test for sex and age differences in bat fly intensity.Assessment of Bartonella in saliva and feces ::: Materials and methodsTo examine possible transmission of Bartonella through biting, grooming, blood sharing, or fecal\u2013oral exposure, we used metagenomic data from a parallel study to screen vampire bat saliva and fecal samples for Bartonella DNA.", [["blood", "ANATOMY", 248, 253], ["fecal samples", "ANATOMY", 367, 380], ["Bartonella", "ORGANISM", 119, 129], ["saliva", "ORGANISM_SUBSTANCE", 133, 139], ["feces", "ORGANISM_SUBSTANCE", 144, 149], ["Bartonella", "ORGANISM", 211, 221], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["bat", "ORGANISM", 352, 355], ["saliva", "ORGANISM_SUBSTANCE", 356, 362], ["fecal samples", "ORGANISM_SUBSTANCE", 367, 380], ["Bartonella", "ORGANISM", 385, 395], ["DNA", "CELLULAR_COMPONENT", 396, 399], ["bat fly", "SPECIES", 87, 94], ["vampire bat", "SPECIES", 344, 355], ["Assessment of Bartonella in saliva and feces", "TEST", 105, 149], ["Bartonella", "PROBLEM", 211, 221], ["biting", "PROBLEM", 230, 236], ["grooming", "PROBLEM", 238, 246], ["blood sharing", "PROBLEM", 248, 261], ["fecal\u2013oral exposure", "PROBLEM", 266, 285], ["metagenomic data", "TEST", 295, 311], ["a parallel study", "TEST", 317, 333], ["vampire bat saliva", "TEST", 344, 362], ["fecal samples", "TEST", 367, 380], ["Bartonella DNA", "PROBLEM", 385, 399], ["Bartonella", "OBSERVATION", 119, 129], ["Bartonella", "OBSERVATION", 211, 221], ["fecal", "ANATOMY", 367, 372]]], ["Three saliva and three fecal pools were shotgun sequenced, each containing nucleic acid extractions from swabs collected from ten vampire bats from one to two colonies.", [["saliva", "ANATOMY", 6, 12], ["swabs", "ANATOMY", 105, 110], ["colonies", "ANATOMY", 159, 167], ["nucleic acid", "CHEMICAL", 75, 87], ["saliva", "ORGANISM_SUBSTANCE", 6, 12], ["Three saliva", "TREATMENT", 0, 12], ["three fecal pools", "TREATMENT", 17, 34], ["nucleic acid extractions", "TREATMENT", 75, 99], ["swabs", "TREATMENT", 105, 110]]], ["Pooled samples contained individuals from the same colonies of bats tested for Bartonella in blood through PCR, though not necessarily the same individuals.Assessment of Bartonella in saliva and feces ::: Materials and methodsAs described previously [8], total nucleic acid was extracted from swabs and pooled equally according to RNA concentration.", [["samples", "ANATOMY", 7, 14], ["colonies", "ANATOMY", 51, 59], ["blood", "ANATOMY", 93, 98], ["swabs", "ANATOMY", 293, 298], ["nucleic acid", "CHEMICAL", 261, 273], ["bats", "ORGANISM", 63, 67], ["Bartonella", "ORGANISM", 79, 89], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["Bartonella", "ORGANISM", 170, 180], ["saliva", "ORGANISM_SUBSTANCE", 184, 190], ["feces", "ORGANISM_SUBSTANCE", 195, 200], ["nucleic acid", "SIMPLE_CHEMICAL", 261, 273], ["Pooled samples", "TEST", 0, 14], ["Bartonella", "PROBLEM", 79, 89], ["blood through PCR", "TEST", 93, 110], ["Assessment of Bartonella in saliva and feces", "TEST", 156, 200], ["total nucleic acid", "TREATMENT", 255, 273], ["Bartonella", "OBSERVATION", 170, 180]]], ["Pooled samples were DNAse treated and ribosomal RNA depleted, then cDNA synthesis was performed.", [["samples", "ANATOMY", 7, 14], ["ribosomal", "ANATOMY", 38, 47], ["DNAse", "GENE_OR_GENE_PRODUCT", 20, 25], ["ribosomal", "CELLULAR_COMPONENT", 38, 47], ["DNAse", "PROTEIN", 20, 25], ["ribosomal RNA", "RNA", 38, 51], ["Pooled samples", "TEST", 0, 14], ["DNAse", "TREATMENT", 20, 25], ["ribosomal RNA depleted", "PROBLEM", 38, 60], ["cDNA synthesis", "TEST", 67, 81], ["RNA depleted", "OBSERVATION", 48, 60]]], ["Libraries were prepared using a KAPA DNA Library Preparation Kit for Illumina (KAPA Biosystems) modified for low input samples, and were individually barcoded during the PCR reamplification step [10].", [["samples", "ANATOMY", 119, 126], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["a KAPA DNA Library Preparation", "TREATMENT", 30, 60], ["Illumina (KAPA Biosystems)", "TREATMENT", 69, 95], ["low input samples", "PROBLEM", 109, 126]]], ["The libraries included in this study were combined in equimolar ratios with other metagenomic libraries for sequencing on an Illumina NextSeq500 at the University of Glasgow Centre for Virus Research.Assessment of Bartonella in saliva and feces ::: Materials and methodsReads were demultiplexed according to barcode and quality filtered using TrimGalore [63,64] with a quality threshold of 25, minimum read length of 75 bp, and clipping the first 14 bp of the read.", [["Bartonella", "ORGANISM", 214, 224], ["saliva", "ORGANISM_SUBSTANCE", 228, 234], ["feces", "ORGANISM_SUBSTANCE", 239, 244], ["Illumina NextSeq500", "DNA", 125, 144], ["this study", "TEST", 26, 36], ["equimolar ratios", "PROBLEM", 54, 70], ["other metagenomic libraries", "PROBLEM", 76, 103], ["an Illumina", "TEST", 122, 133], ["Virus Research", "TREATMENT", 185, 199], ["Assessment of Bartonella in saliva and feces", "TEST", 200, 244], ["a quality threshold", "TEST", 367, 386], ["length", "TEST", 407, 413], ["bp", "TEST", 420, 422], ["clipping", "TREATMENT", 428, 436], ["Bartonella", "OBSERVATION", 214, 224]]], ["Low complexity reads were filtered out using the DUST method and PCR duplicates removed using PRINSEQ [65].", [["DUST", "DNA", 49, 53], ["PCR duplicates", "DNA", 65, 79], ["Low complexity reads", "PROBLEM", 0, 20], ["the DUST method", "TREATMENT", 45, 60], ["PCR", "TEST", 65, 68]]], ["We screened cleaned reads for the Bartonella genotypes detected in this study using nucleotide BLAST [66] against a custom database composed of the PCR-generated Bartonella sequences from this study, retaining only the best alignment (the high-scoring segment pair with the lowest e-value) for a single query\u2013subject pair.", [["nucleotide", "CHEMICAL", 84, 94], ["nucleotide", "CHEMICAL", 84, 94], ["PCR-generated Bartonella sequences", "DNA", 148, 182], ["query\u2013subject pair", "DNA", 303, 321], ["the Bartonella genotypes", "PROBLEM", 30, 54], ["this study", "TEST", 67, 77], ["nucleotide BLAST", "TEST", 84, 100], ["a custom database", "TEST", 114, 131], ["the PCR", "TEST", 144, 151], ["Bartonella sequences", "TEST", 162, 182], ["this study", "TEST", 188, 198]]], ["To investigate the presence of Bartonella species other than genotypes detected in blood samples from vampire bats, cleaned reads were de novo assembled into contigs using the assembly only function of SPAdes [67].", [["blood samples", "ANATOMY", 83, 96], ["blood samples", "ORGANISM_SUBSTANCE", 83, 96], ["Bartonella species", "PROBLEM", 31, 49], ["genotypes", "PROBLEM", 61, 70], ["blood samples", "TEST", 83, 96], ["Bartonella", "OBSERVATION", 31, 41]]], ["Individual reads and contigs were screened for sequences matching Bartonella using protein alignment in Diamond [68], and close matches at the protein level were further characterized by nucleotide BLAST against the Genbank nt database.", [["nucleotide", "CHEMICAL", 187, 197], ["nucleotide", "CHEMICAL", 187, 197], ["Genbank nt database", "DNA", 216, 235], ["sequences matching Bartonella", "TEST", 47, 76], ["protein alignment in Diamond", "TEST", 83, 111], ["the protein level", "TEST", 139, 156], ["nucleotide BLAST", "TEST", 187, 203], ["the Genbank nt database", "TEST", 212, 235]]], ["As the gltA gene is not highly transcribed, we also tested sequences for matches to Bartonella DNA-directed RNA polymerase subunit B (rpoB).", [["gltA", "GENE_OR_GENE_PRODUCT", 7, 11], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["RNA polymerase subunit B", "GENE_OR_GENE_PRODUCT", 108, 132], ["rpoB", "GENE_OR_GENE_PRODUCT", 134, 138], ["gltA gene", "DNA", 7, 16], ["Bartonella DNA", "DNA", 84, 98], ["RNA polymerase subunit B", "PROTEIN", 108, 132], ["rpoB", "PROTEIN", 134, 138], ["Bartonella DNA", "TEST", 84, 98]]], ["We selected two rpoB sequences (Genbank accessions KY629892 and KY629911) from a study of vampire bat Bartonella [16] for which the same individuals exhibited 100% identity in the gltA gene to our blood sequences, and we used Bowtie2 to map quality filtered reads and contigs to those sequences [69].Assessment of Bartonella in saliva and feces ::: Materials and methodsLastly, because nucleic acid pools were DNase treated for metagenomic sequencing, potentially reducing detection sensitivity, we used the same nested PCR protocol as used for blood-derived DNA [51] to test for the presence of gltA in DNA from individual saliva and fecal swab samples that made up metagenomic pools (n = 58; 28 saliva and 30 feces).", [["blood", "ANATOMY", 197, 202], ["blood", "ANATOMY", 545, 550], ["saliva", "ANATOMY", 624, 630], ["fecal swab samples", "ANATOMY", 635, 653], ["saliva", "ANATOMY", 697, 703], ["feces", "ANATOMY", 711, 716], ["nucleic acid", "CHEMICAL", 386, 398], ["vampire", "ORGANISM", 90, 97], ["bat Bartonella", "ORGANISM", 98, 112], ["individuals", "ORGANISM", 137, 148], ["gltA", "GENE_OR_GENE_PRODUCT", 180, 184], ["blood", "ORGANISM_SUBSTANCE", 197, 202], ["Bartonella", "ORGANISM", 314, 324], ["saliva", "ORGANISM_SUBSTANCE", 328, 334], ["feces", "ORGANISM_SUBSTANCE", 339, 344], ["DNase", "GENE_OR_GENE_PRODUCT", 410, 415], ["blood", "ORGANISM_SUBSTANCE", 545, 550], ["DNA", "CELLULAR_COMPONENT", 559, 562], ["gltA", "GENE_OR_GENE_PRODUCT", 596, 600], ["DNA", "CELLULAR_COMPONENT", 604, 607], ["saliva", "ORGANISM_SUBSTANCE", 624, 630], ["fecal swab samples", "ORGANISM_SUBSTANCE", 635, 653], ["saliva", "ORGANISM_SUBSTANCE", 697, 703], ["feces", "ORGANISM_SUBDIVISION", 711, 716], ["rpoB sequences", "DNA", 16, 30], ["gltA gene", "DNA", 180, 189], ["blood sequences", "DNA", 197, 212], ["Bowtie2", "DNA", 226, 233], ["DNase", "PROTEIN", 410, 415], ["gltA", "DNA", 596, 600], ["vampire bat", "SPECIES", 90, 101], ["two rpoB sequences", "TEST", 12, 30], ["a study", "TEST", 79, 86], ["vampire bat Bartonella", "TEST", 90, 112], ["our blood sequences", "TEST", 193, 212], ["Assessment of Bartonella in saliva and feces", "TEST", 300, 344], ["methodsLastly", "TREATMENT", 363, 376], ["nucleic acid pools", "PROBLEM", 386, 404], ["metagenomic sequencing", "TEST", 428, 450], ["the same nested PCR protocol", "TREATMENT", 504, 532], ["gltA in DNA", "PROBLEM", 596, 607], ["individual saliva", "TEST", 613, 630], ["fecal swab samples", "TEST", 635, 653], ["metagenomic pools", "TEST", 667, 684], ["saliva", "TEST", 697, 703], ["Bartonella", "OBSERVATION", 314, 324], ["fecal", "ANATOMY", 635, 640]]], ["As with our blood samples, we randomly selected a subset of positive amplicons for Sanger sequencing.Genetic diversity of vampire bat Bartonella ::: ResultsBartonella prevalence across the 193 vampire bats included in this study was 67%.", [["blood samples", "ANATOMY", 12, 25], ["blood samples", "ORGANISM_SUBSTANCE", 12, 25], ["our blood samples", "TEST", 8, 25], ["positive amplicons", "TREATMENT", 60, 78], ["Sanger sequencing", "TEST", 83, 100], ["Bartonella prevalence", "TEST", 156, 177], ["this study", "TEST", 218, 228]]], ["Our phylogenetic analysis of 35 vampire bat Bartonella sequences showed 78.8\u2013100% pairwise identity in gltA and revealed at least 11 paraphyletic genotypes (S2 Table).", [["gltA", "CANCER", 103, 107], ["35 vampire bat Bartonella sequences", "DNA", 29, 64], ["gltA", "CELL_LINE", 103, 107], ["Our phylogenetic analysis", "TEST", 0, 25], ["vampire bat Bartonella sequences", "TEST", 32, 64], ["gltA", "TEST", 103, 107], ["paraphyletic genotypes", "OBSERVATION", 133, 155]]], ["BaTS analysis of all Desmodus-associated Bartonella showed significant phylogenetic clustering by country (association index = 3.81, parsimony score = 31.51, p<0.001), although most vampire bat Bartonella genotypes were still widely distributed (Fig 1).", [["Bartonella", "ORGANISM", 194, 204], ["BaTS analysis", "TEST", 0, 13], ["all Desmodus", "TEST", 17, 29], ["Bartonella", "PROBLEM", 41, 51], ["association index", "TEST", 107, 124], ["parsimony score", "TEST", 133, 148], ["vampire bat Bartonella genotypes", "TEST", 182, 214], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["phylogenetic clustering", "OBSERVATION", 71, 94]]], ["For the 11 genotypes delineated from our 35 sequences, we observed no association with the geographic study region (\u03c72 = 23.3, p = 0.27).", [["our 35 sequences", "TEST", 37, 53], ["the geographic study region", "TEST", 87, 114], ["p", "TEST", 127, 128]]], ["Genotypes 1 and 2 were detected across all regions, and genotypes 7\u201310 were detected within both Belize and Peru, highlighting the broad distribution of vampire bat Bartonella genotypes (Fig 2); however, genotype 3 was unique to both regions of Peru, genotypes 4\u20136 were unique to the western Peruvian Amazon, and genotype 11 was only detected in Belize.Genetic diversity of vampire bat Bartonella ::: ResultsWe also assessed the phylogenetic position of our vampire bat Bartonella sequences among known Bartonella genotypes (Fig 3, S3 Table).", [["2", "GENE_OR_GENE_PRODUCT", 16, 17], ["vampire", "ORGANISM", 153, 160], ["bat Bartonella", "ORGANISM", 161, 175], ["genotypes 7\u201310", "DNA", 56, 70], ["vampire bat", "SPECIES", 458, 469], ["Genotypes", "TEST", 0, 9], ["genotypes", "TEST", 56, 65], ["vampire bat Bartonella genotypes", "PROBLEM", 153, 185], ["genotype", "TEST", 204, 212], ["genotype", "TEST", 313, 321], ["our vampire bat Bartonella sequences", "TEST", 454, 490], ["Bartonella genotypes", "TEST", 503, 523]]], ["Half of our Peruvian and Belizian sequences (18/35) were nearly identical (>99.7% identity) to Bartonella from common vampire bats (Desmodus rotundus) from Mexico (e.g., GenBank accession numbers KY629837 and MF467803), again confirming the wide geographic distribution of these genotypes.", [["Bartonella", "ORGANISM", 95, 105], ["vampire bats", "ORGANISM", 118, 130], ["Desmodus rotundus", "ORGANISM", 132, 149], ["Peruvian and Belizian sequences", "DNA", 12, 43], ["Desmodus rotundus", "SPECIES", 132, 149], ["vampire bats", "SPECIES", 118, 130], ["Desmodus rotundus", "SPECIES", 132, 149], ["our Peruvian and Belizian sequences", "TEST", 8, 43], ["Bartonella", "PROBLEM", 95, 105], ["these genotypes", "PROBLEM", 273, 288], ["common vampire", "ANATOMY", 111, 125]]], ["Other sequences(9/35) fell within the same clade (>96% pairwise identity) as Bartonella from bat flies (Strebla diaemi) in Panama (JX416251), from Parnell's mustached bat (Pteronotus parnellii) in Mexico (e.g., KY629828), from phytophagous bats in Peru (e.g., Carollia perspicillata; JQ071384) and Guatemala (e.g., Glossophaga soricina; HM597202), or from Mexican vampire bats as noted above.", [["bat flies", "ORGANISM", 93, 102], ["Strebla diaemi", "ORGANISM", 104, 118], ["mustached bat", "ORGANISM", 157, 170], ["Pteronotus parnellii", "ORGANISM", 172, 192], ["Glossophaga soricina", "ORGANISM", 315, 335], ["Strebla diaemi", "SPECIES", 104, 118], ["Pteronotus parnellii", "SPECIES", 172, 192], ["Carollia perspicillata", "SPECIES", 260, 282], ["Glossophaga soricina", "SPECIES", 315, 335], ["bat flies", "SPECIES", 93, 102], ["Strebla diaemi", "SPECIES", 104, 118], ["mustached bat", "SPECIES", 157, 170], ["Pteronotus parnellii", "SPECIES", 172, 192], ["Carollia perspicillata", "SPECIES", 260, 282], ["Glossophaga soricina", "SPECIES", 315, 335], ["Mexican vampire bats", "SPECIES", 356, 376], ["Other sequences", "TEST", 0, 15], ["Bartonella", "TEST", 77, 87], ["Guatemala (e.g., Glossophaga soricina", "PROBLEM", 298, 335]]], ["Eight sequences were novel (<96% identity to GenBank sequences) but were most similar to Bartonella from phytophagous bats in Costa Rica (e.g., 90\u201393% to KJ816666 [Anoura geoffroyi]) and from Mexican vampire bats (e.g., 93% to MF467776).Genetic diversity of vampire bat Bartonella ::: ResultsOther novel sequences were weakly related to B. bovis from livestock in Israel and Malaysia (e.g., 89\u201390% to KJ909844 and KR733183), to B. chomelii from cattle in Spain (e.g., 89% to KM215693), to B. capreoli from elk in the United States (e.g., 89% to HM167503), and to B. schoenbuchensis from roe deer in Germany (e.g., 89% to AJ278186); indeed, posterior support for a bat\u2013ruminant clade was low (<50%; Fig 3).", [["B. bovis", "ORGANISM", 337, 345], ["B. chomelii", "ORGANISM", 428, 439], ["B. capreoli", "ORGANISM", 489, 500], ["B. schoenbuchensis", "ORGANISM", 563, 581], ["roe deer", "ORGANISM", 587, 595], ["GenBank sequences", "DNA", 45, 62], ["Anoura geoffroyi", "SPECIES", 164, 180], ["B. bovis", "SPECIES", 337, 345], ["B. chomelii", "SPECIES", 428, 439], ["cattle", "SPECIES", 445, 451], ["B. capreoli", "SPECIES", 489, 500], ["B. schoenbuchensis", "SPECIES", 563, 581], ["roe deer", "SPECIES", 587, 595], ["Anoura geoffroyi", "SPECIES", 164, 180], ["Mexican vampire bats", "SPECIES", 192, 212], ["B. bovis", "SPECIES", 337, 345], ["B. chomelii", "SPECIES", 428, 439], ["cattle", "SPECIES", 445, 451], ["B. capreoli", "SPECIES", 489, 500], ["elk", "SPECIES", 506, 509], ["B. schoenbuchensis", "SPECIES", 563, 581], ["roe deer", "SPECIES", 587, 595], ["Eight sequences", "TEST", 0, 15], ["GenBank sequences", "TEST", 45, 62], ["ResultsOther novel sequences", "TEST", 285, 313], ["posterior support", "TREATMENT", 640, 657], ["a bat\u2013ruminant clade", "TEST", 662, 682], ["bovis", "OBSERVATION", 340, 345], ["posterior", "ANATOMY_MODIFIER", 640, 649]]], ["Our BLAST procedure also identified weakly related Bartonella from rodents (e.g., 90% to Rattus norvegicus from the United States [KC763951] and 92% to Apodemus agrarius from China [KX549996]) and from carnivores (e.g., 89% to Procyon lotor from the United States [CP019786]).", [["Rattus norvegicus", "ORGANISM", 89, 106], ["Rattus norvegicus", "SPECIES", 89, 106], ["Apodemus agrarius", "SPECIES", 152, 169], ["Rattus norvegicus", "SPECIES", 89, 106], ["Apodemus agrarius", "SPECIES", 152, 169], ["Our BLAST procedure", "TREATMENT", 0, 19], ["weakly related Bartonella", "PROBLEM", 36, 61], ["Bartonella", "OBSERVATION", 51, 61]]], ["However, these livestock, rodent, and carnivore sequences formed separate phylogenetic clades from bat- and bat fly\u2013derived Bartonella sequences (Fig 3).", [["bat- and bat fly\u2013derived Bartonella sequences", "DNA", 99, 144], ["carnivore sequences", "TEST", 38, 57], ["bat", "TEST", 99, 102], ["bat fly\u2013derived Bartonella sequences", "TEST", 108, 144]]], ["Despite the geographic proximity of our field sites to Brazil, our BLAST procedure found no Bartonella seqeunces similar to those recently described in Brazilian bat or rodent species [70\u201372].", [["rodent", "SPECIES", 169, 175], ["our BLAST procedure", "TEST", 63, 82], ["Bartonella seqeunces", "PROBLEM", 92, 112]]], ["An additional phylogenetic tree that includes these recently identified Bartonella is provided in S1 Fig.Temporal patterns in infection ::: ResultsBartonella was detected by PCR in all nine sites in each year, with prevalence ranging from 30\u2013100% (Fig 4).", [["infection", "DISEASE", 126, 135], ["Bartonella", "ORGANISM", 72, 82], ["An additional phylogenetic tree", "PROBLEM", 0, 31], ["Bartonella", "PROBLEM", 72, 82], ["ResultsBartonella", "TEST", 140, 157], ["PCR", "TEST", 174, 177], ["prevalence", "TEST", 215, 225], ["phylogenetic tree", "OBSERVATION", 14, 31], ["Bartonella", "OBSERVATION", 72, 82], ["infection", "OBSERVATION", 126, 135]]], ["Prevalence did not differ by year across all sites (\u03c72 = 3.13, p = 0.54) nor within individual sites (site*year; \u03c72 = 2.82, p = 0.90).", [["p", "TEST", 124, 125]]], ["The seasonality GLMM for the western Peruvian Amazon (n = 63) showed no difference in odds of infection between spring, summer, and fall (\u03c72 = 1.99, p = 0.37; S2 Fig).", [["infection", "DISEASE", 94, 103], ["The seasonality GLMM", "PROBLEM", 0, 20], ["infection", "PROBLEM", 94, 103], ["no", "UNCERTAINTY", 69, 71], ["infection", "OBSERVATION", 94, 103]]], ["The GAM also showed no significant seasonal variation (\u03c72 = 0, p = 0.68; S2 Fig).", [["GAM", "PROTEIN", 4, 7], ["The GAM", "TEST", 0, 7], ["significant seasonal variation", "PROBLEM", 23, 53], ["p", "TEST", 63, 64], ["S2 Fig", "TEST", 73, 79], ["no", "UNCERTAINTY", 20, 22], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["seasonal variation", "OBSERVATION", 35, 53]]], ["Recaptures were rare (n = 6) but showed changes in infection from negative to positive (n = 2, 68\u2013424 days) and from positive to negative (n = 2, 15\u2013369 days; S3 Fig).Individual risk factors for infection ::: ResultsAfter controlling for site-level livestock biomass, vampire bat sex and forearm size were the strongest predictors of infection (Fig 5); no interactions were significant (all \u03c72\u22641.18, p\u22650.28) and were dropped from the final GLMM (R2m = 0.28).", [["forearm", "ANATOMY", 288, 295], ["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 195, 204], ["infection", "DISEASE", 334, 343], ["forearm", "ORGANISM_SUBDIVISION", 288, 295], ["Recaptures", "TEST", 0, 10], ["changes in infection", "PROBLEM", 40, 60], ["infection", "PROBLEM", 195, 204], ["site-level livestock biomass", "TREATMENT", 238, 266], ["vampire bat sex and forearm size", "TREATMENT", 268, 300], ["infection", "PROBLEM", 334, 343], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 195, 204], ["livestock biomass", "OBSERVATION", 249, 266], ["forearm", "ANATOMY", 288, 295], ["size", "OBSERVATION_MODIFIER", 296, 300], ["infection", "OBSERVATION", 334, 343]]], ["The odds of Bartonella infection were highest for vampire bats with larger forearms (OR = 1.2, p<0.001) and for males (OR = 5.41, p<0.01), were marginally higher for non-reproductive individuals (OR = 2.36, p = 0.10), and did not differ between subadult and adult bats (OR = 1.58, p = 0.38); our sample did not contain juveniles.", [["forearms", "ANATOMY", 75, 83], ["Bartonella infection", "DISEASE", 12, 32], ["Bartonella", "ORGANISM", 12, 22], ["forearms", "ORGANISM_SUBDIVISION", 75, 83], ["Bartonella infection", "PROBLEM", 12, 32], ["males", "TEST", 112, 117], ["non-reproductive individuals", "PROBLEM", 166, 194], ["p", "TEST", 207, 208], ["p", "TEST", 281, 282], ["our sample", "TEST", 292, 302], ["Bartonella", "OBSERVATION_MODIFIER", 12, 22], ["infection", "OBSERVATION", 23, 32], ["forearms", "ANATOMY", 75, 83]]], ["Individual bat fly intensities were highly variable (0\u201328, median = 7.5) and showed overdispersion (\u03d5 = 5.08 in an intercept-only quasi-Poisson GLM).", [["Individual bat fly intensities", "TEST", 0, 30], ["overdispersion", "TEST", 84, 98], ["an intercept", "TEST", 112, 124]]], ["The bat fly GLMs showed that neither ectoparasite intensity (OR = 0.98, p = 0.81) nor ectoparasite presence (\u03c72 = 1.13, p = 0.29) were associated with Bartonella infection status.", [["Bartonella infection", "DISEASE", 151, 171], ["bat fly", "SPECIES", 4, 11], ["The bat fly GLMs", "TEST", 0, 16], ["neither ectoparasite intensity", "PROBLEM", 29, 59], ["ectoparasite presence", "PROBLEM", 86, 107], ["Bartonella infection status", "PROBLEM", 151, 178], ["ectoparasite", "OBSERVATION_MODIFIER", 37, 49], ["Bartonella", "OBSERVATION_MODIFIER", 151, 161], ["infection", "OBSERVATION", 162, 171]]], ["We note that the majority of infected bats in this sample were infested with at least one bat fly (31/36), limiting conclusive assessment of the ectoparasite\u2013infection relationship.", [["sample", "ANATOMY", 51, 57], ["ectoparasite\u2013infection", "DISEASE", 145, 167], ["bats", "ORGANISM", 38, 42], ["infected bats", "PROBLEM", 29, 42], ["majority", "OBSERVATION_MODIFIER", 17, 25], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["bats", "OBSERVATION", 38, 42]]], ["Our multivariable quasi-Poisson GLM showed that ectoparasite load did not vary by bat sex (\u03c72 = 0.86, p = 0.35) or bat age (\u03c72 = 0.09, p = 0.77).Comparison of Bartonella detected in blood, saliva, and feces ::: ResultsThere were no matches in any of the screened saliva and fecal metagenomic pools to the Bartonella gltA sequences detected in the blood or to previously published Bartonella rpoB sequences.", [["blood", "ANATOMY", 182, 187], ["saliva", "ANATOMY", 189, 195], ["blood", "ANATOMY", 347, 352], ["Bartonella", "ORGANISM", 159, 169], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["saliva", "ORGANISM_SUBSTANCE", 189, 195], ["feces", "ORGANISM_SUBDIVISION", 201, 206], ["saliva", "ORGANISM_SUBSTANCE", 263, 269], ["fecal", "ORGANISM_SUBSTANCE", 274, 279], ["gltA", "GENE_OR_GENE_PRODUCT", 316, 320], ["blood", "ORGANISM_SUBSTANCE", 347, 352], ["Bartonella gltA sequences", "DNA", 305, 330], ["Bartonella rpoB sequences", "DNA", 380, 405], ["Bartonella gltA", "SPECIES", 305, 320], ["Our multivariable quasi-Poisson GLM", "TEST", 0, 35], ["ectoparasite load", "TEST", 48, 65], ["bat age", "TEST", 115, 122], ["Bartonella", "PROBLEM", 159, 169], ["matches", "PROBLEM", 232, 239], ["the screened saliva", "PROBLEM", 250, 269], ["fecal metagenomic pools", "PROBLEM", 274, 297], ["the Bartonella gltA sequences", "TEST", 301, 330], ["previously published Bartonella rpoB sequences", "TEST", 359, 405], ["ectoparasite load", "OBSERVATION", 48, 65], ["Bartonella", "OBSERVATION", 159, 169], ["no", "UNCERTAINTY", 229, 231], ["blood", "ANATOMY", 347, 352]]], ["The saliva pool from Amazonas had no matching Bartonella-like reads or contigs (S4 Table), while one read each from the Loreto and Cajamarca saliva pool was assigned as Bartonella by nucleotide BLAST; however, these reported species assignments should be interpreted cautiously as they are based on one read and percent identity was low.", [["nucleotide", "CHEMICAL", 183, 193], ["nucleotide", "CHEMICAL", 183, 193], ["saliva", "ORGANISM_SUBSTANCE", 4, 10], ["Bartonella-like reads", "DNA", 46, 67], ["matching Bartonella", "PROBLEM", 37, 56], ["Cajamarca saliva pool", "TREATMENT", 131, 152], ["Bartonella", "PROBLEM", 169, 179], ["nucleotide BLAST", "TEST", 183, 199]]], ["Pooled fecal samples from all departments of Peru contained Bartonella-like reads and contigs.", [["fecal samples", "ANATOMY", 7, 20], ["fecal samples", "MULTI-TISSUE_STRUCTURE", 7, 20], ["Pooled fecal samples", "TEST", 0, 20], ["Bartonella", "PROBLEM", 60, 70], ["fecal", "ANATOMY", 7, 12]]], ["Bartonella ancashensis, B. australis, and B. bacilliformis were all identified at both the read and contig level in fecal samples.", [["fecal samples", "ANATOMY", 116, 129], ["Bartonella ancashensis", "ORGANISM", 0, 22], ["B. australis", "ORGANISM", 24, 36], ["B. bacilliformis", "ORGANISM", 42, 58], ["fecal samples", "ORGANISM_SUBSTANCE", 116, 129], ["Bartonella ancashensis", "SPECIES", 0, 22], ["B. australis", "SPECIES", 24, 36], ["B. bacilliformis", "SPECIES", 42, 58], ["Bartonella ancashensis", "SPECIES", 0, 22], ["B. australis", "SPECIES", 24, 36], ["B. bacilliformis", "SPECIES", 42, 58], ["Bartonella ancashensis", "TEST", 0, 22], ["B. australis", "PROBLEM", 24, 36], ["B. bacilliformis", "PROBLEM", 42, 58], ["fecal samples", "TEST", 116, 129], ["fecal", "ANATOMY", 116, 121]]], ["Subsequent BLAST hits following the top hit also frequently (though not always) matched to Bartonella, suggesting the presence of poorly characterized Bartonella species present or that these may be matches to other bacteria.Comparison of Bartonella detected in blood, saliva, and feces ::: ResultsIn contrast, nested PCR of individual swabs detected gltA in 21.4% of saliva samples (6/28) and 30% of fecal samples (9/30).", [["blood", "ANATOMY", 262, 267], ["saliva", "ANATOMY", 269, 275], ["swabs", "ANATOMY", 336, 341], ["saliva samples", "ANATOMY", 368, 382], ["fecal samples", "ANATOMY", 401, 414], ["Bartonella species", "ORGANISM", 151, 169], ["Bartonella", "ORGANISM", 239, 249], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["saliva", "ORGANISM_SUBSTANCE", 269, 275], ["feces", "ORGANISM_SUBDIVISION", 281, 286], ["gltA", "GENE_OR_GENE_PRODUCT", 351, 355], ["saliva samples", "ORGANISM_SUBSTANCE", 368, 382], ["fecal samples", "CANCER", 401, 414], ["BLAST hits", "DNA", 11, 21], ["gltA", "SPECIES", 351, 355], ["Subsequent BLAST hits", "PROBLEM", 0, 21], ["Bartonella", "PROBLEM", 91, 101], ["poorly characterized Bartonella species", "PROBLEM", 130, 169], ["other bacteria", "PROBLEM", 210, 224], ["Bartonella", "PROBLEM", 239, 249], ["ResultsIn contrast", "TEST", 291, 309], ["nested PCR", "TEST", 311, 321], ["individual swabs", "TEST", 325, 341], ["gltA", "TEST", 351, 355], ["saliva samples", "TEST", 368, 382], ["fecal samples", "TEST", 401, 414], ["BLAST hits", "OBSERVATION", 11, 21], ["Bartonella", "OBSERVATION", 91, 101], ["poorly characterized", "OBSERVATION_MODIFIER", 130, 150], ["Bartonella species", "OBSERVATION", 151, 169], ["Bartonella", "OBSERVATION", 239, 249]]], ["For swab samples that were also assessed by PCR in blood (n = 15 for saliva, n = 28 for feces), both corresponding positive saliva samples were positive in blood; most positive fecal samples were also PCR positive in blood, although one fecal-positive sample was PCR negative in blood (S4 Fig).", [["swab samples", "ANATOMY", 4, 16], ["blood", "ANATOMY", 51, 56], ["saliva", "ANATOMY", 69, 75], ["feces", "ANATOMY", 88, 93], ["samples", "ANATOMY", 131, 138], ["blood", "ANATOMY", 156, 161], ["fecal samples", "ANATOMY", 177, 190], ["blood", "ANATOMY", 217, 222], ["sample", "ANATOMY", 252, 258], ["blood", "ANATOMY", 279, 284], ["swab samples", "ORGANISM_SUBSTANCE", 4, 16], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["saliva", "ORGANISM_SUBSTANCE", 69, 75], ["feces", "ORGANISM", 88, 93], ["saliva samples", "ORGANISM_SUBSTANCE", 124, 138], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["fecal samples", "ORGANISM_SUBSTANCE", 177, 190], ["blood", "ORGANISM_SUBSTANCE", 217, 222], ["fecal", "ORGANISM_SUBSTANCE", 237, 242], ["blood", "ORGANISM_SUBSTANCE", 279, 284], ["swab samples", "TEST", 4, 16], ["PCR", "TEST", 44, 47], ["blood", "TEST", 51, 56], ["saliva", "TEST", 69, 75], ["feces", "PROBLEM", 88, 93], ["both corresponding positive saliva samples", "PROBLEM", 96, 138], ["blood", "TEST", 156, 161], ["fecal samples", "TEST", 177, 190], ["PCR", "TEST", 201, 204], ["blood", "TEST", 217, 222], ["PCR", "TEST", 263, 266], ["fecal", "ANATOMY", 237, 242]]], ["For our random subset of sequenced positive saliva (n = 4) and fecal (n = 5) samples, phylogenetic analyses suggested that all sequences shared a minimum of 97% identity to one or more of our 35 blood-derived Bartonella sequences (S5 Table, Fig 6).", [["saliva", "ANATOMY", 44, 50], ["fecal", "ANATOMY", 63, 68], ["samples", "ANATOMY", 77, 84], ["blood", "ANATOMY", 195, 200], ["saliva", "ORGANISM_SUBSTANCE", 44, 50], ["blood", "ORGANISM_SUBSTANCE", 195, 200], ["Bartonella", "ORGANISM", 209, 219], ["Bartonella sequences", "DNA", 209, 229], ["fecal (n = 5) samples", "TEST", 63, 84], ["phylogenetic analyses", "TEST", 86, 107], ["all sequences", "TEST", 123, 136], ["Bartonella sequences", "TEST", 209, 229], ["fecal", "ANATOMY", 63, 68]]], ["In many cases, saliva and fecal sequences were the same genotype as blood sequences derived from the same geographic region (e.g., the saliva sequence from D234 shared >96% identity to the blood sequence from D98, both from AM1).", [["blood", "ANATOMY", 68, 73], ["blood", "ANATOMY", 189, 194], ["saliva", "ORGANISM_SUBSTANCE", 15, 21], ["fecal", "ORGANISM_SUBSTANCE", 26, 31], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["saliva sequence", "DNA", 135, 150], ["D234", "DNA", 156, 160], ["blood sequence", "DNA", 189, 203], ["saliva and fecal sequences", "TEST", 15, 41], ["blood sequences", "TEST", 68, 83], ["the saliva sequence", "TEST", 131, 150], ["the blood sequence", "TEST", 185, 203]]], ["For the one case in which we sequenced positive samples from the same individual bat (i.e., D203), both the blood sequence and fecal sequence shared 100% identity (S5 Table, Fig 6).", [["samples", "ANATOMY", 48, 55], ["blood", "ANATOMY", 108, 113], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["fecal", "ORGANISM_SUBSTANCE", 127, 132], ["blood sequence", "DNA", 108, 122], ["fecal sequence", "DNA", 127, 141], ["the blood sequence", "TEST", 104, 122], ["fecal sequence", "TEST", 127, 141], ["fecal", "ANATOMY", 127, 132]]], ["For the few sequences at the lower range of our similarity spectrum, BLAST still demonstrated that the closest relatives were all derived from vampire bats (i.e., 8368 from CA1 was identical to MF467797 from Mexico).DiscussionDespite an increasing focus on Bartonella genetic diversity and prevalence in bat communities, individual risk factors and transmission routes of this pathogen in bats remain largely unknown.", [["Bartonella genetic diversity", "PROBLEM", 257, 285], ["individual risk factors", "PROBLEM", 321, 344], ["this pathogen", "PROBLEM", 372, 385], ["increasing", "OBSERVATION_MODIFIER", 237, 247]]], ["For example, a survey of vampire bats within Guatemala found neither geographic, dietary, demographic, or viral coinfection correlates of Bartonella infection status [44].", [["Bartonella infection", "DISEASE", 138, 158], ["vampire bats", "PROBLEM", 25, 37], ["viral coinfection", "PROBLEM", 106, 123], ["Bartonella infection status", "PROBLEM", 138, 165]]], ["Using a larger sample across a more diverse range of study sites and timepoints, we here show that Bartonella is genetically diverse, geographically widespread and endemic within vampire bat populations, and that individual-level odds of infection are highest for large, male, and non-reproductive bats.", [["infection", "DISEASE", 238, 247], ["study sites", "TEST", 53, 64], ["Bartonella", "PROBLEM", 99, 109], ["infection", "PROBLEM", 238, 247], ["Bartonella", "OBSERVATION", 99, 109], ["diverse", "OBSERVATION_MODIFIER", 125, 132], ["geographically", "OBSERVATION_MODIFIER", 134, 148], ["widespread", "OBSERVATION_MODIFIER", 149, 159], ["endemic", "OBSERVATION_MODIFIER", 164, 171], ["infection", "OBSERVATION", 238, 247], ["highest", "OBSERVATION_MODIFIER", 252, 259], ["large", "OBSERVATION_MODIFIER", 264, 269], ["non-reproductive bats", "OBSERVATION", 281, 302]]], ["Furthermore, we use several approaches to suggest vector-borne transmission to be likely in addition to possible direct contact and environmental sources of Bartonella exposure in bats.DiscussionThe Bartonella genotypes we identified were paraphyletic and closely related to those from other vampire bat populations, other Neotropical bat species, or bat flies.", [["Bartonella", "ORGANISM", 157, 167], ["Bartonella", "ORGANISM", 199, 209], ["several approaches", "TREATMENT", 20, 38], ["vector-borne transmission", "TREATMENT", 50, 75], ["direct contact", "PROBLEM", 113, 127], ["Bartonella exposure", "PROBLEM", 157, 176], ["The Bartonella genotypes", "PROBLEM", 195, 219], ["paraphyletic", "PROBLEM", 239, 251]]], ["Although BLAST also identified Bartonella spp. sequenced from rodents, carnivores, and livestock within our hit selection criteria, these consistently formed separate phylogenetic clades that did not contain bat- or bat fly\u2013derived Bartonella (Fig 3).", [["Bartonella spp", "DISEASE", 31, 45], ["Bartonella spp", "ORGANISM", 31, 45], ["BLAST", "PROBLEM", 9, 14], ["Bartonella spp", "PROBLEM", 31, 45], ["bat", "TEST", 208, 211], ["Bartonella spp", "OBSERVATION", 31, 45], ["carnivores", "OBSERVATION_MODIFIER", 71, 81]]], ["These phylogenetic patterns indicate that Bartonella has commonly shifted between bat host species in the Americas but do not support frequent transmission between bats and other host groups.", [["Bartonella", "PROBLEM", 42, 52], ["Bartonella", "OBSERVATION", 42, 52], ["host species", "OBSERVATION", 86, 98]]], ["Our BaTS analysis also showed that vampire bat Bartonella sequences clustered by country more than expected by chance.", [["BaTS", "DNA", 4, 8], ["Our BaTS analysis", "TEST", 0, 17], ["vampire bat Bartonella sequences", "TEST", 35, 67]]], ["However, given that several Bartonella genotypes were present in vampire bats from both Central and South America, we suspect this clustering mostly resulted from variation in locally abundant genotypes rather than true barriers to the spread of Bartonella.", [["Bartonella", "ORGANISM", 28, 38], ["several Bartonella genotypes", "PROBLEM", 20, 48], ["locally abundant genotypes", "PROBLEM", 176, 202], ["Bartonella", "PROBLEM", 246, 256], ["several", "OBSERVATION_MODIFIER", 20, 27], ["Bartonella", "OBSERVATION", 28, 38], ["Central", "ANATOMY_MODIFIER", 88, 95], ["Bartonella", "OBSERVATION", 246, 256]]], ["Because vampire bats are largely sedentary and non-migratory [45], dispersal of these Bartonella genotypes across large distances is unlikely to be attributable to bat movement alone.", [["vampire bats", "ORGANISM", 8, 20], ["Bartonella", "ORGANISM", 86, 96], ["these Bartonella genotypes", "PROBLEM", 80, 106], ["Bartonella", "OBSERVATION", 86, 96], ["unlikely to be", "UNCERTAINTY", 133, 147]]], ["Bartonella genotypes may also have infected vampire bats over long evolutionary timescales, and thus the biogeography of the pathogen may have followed that of its host.", [["Bartonella genotypes", "PROBLEM", 0, 20], ["infected vampire bats", "PROBLEM", 35, 56], ["the pathogen", "PROBLEM", 121, 133], ["infected", "OBSERVATION_MODIFIER", 35, 43]]], ["Alternatively, Bartonella dispersal by other arthropod vectors (e.g., ticks) or other bat species that share Bartonella genotypes with vampire bats may be conceivable and could be resolved by further field surveys combined with population genetic analyses of alternative bat host species, arthropod vector species, and Bartonella genotypes.DiscussionFew studies have examined temporal patterns of bat Bartonella, emphasizing the general need for more longitudinal studies to understand how pathogens persist in bat populations [1,6].", [["bat species", "ORGANISM", 86, 97], ["Bartonella", "ORGANISM", 109, 119], ["vampire bats", "ORGANISM", 135, 147], ["bat Bartonella", "ORGANISM", 397, 411], ["Bartonella dispersal", "PROBLEM", 15, 35], ["other bat species", "PROBLEM", 80, 97], ["Bartonella genotypes", "PROBLEM", 109, 129], ["vampire bats", "PROBLEM", 135, 147], ["further field surveys", "TEST", 192, 213], ["population genetic analyses", "PROBLEM", 228, 255], ["alternative bat host species", "PROBLEM", 259, 287], ["arthropod vector species", "PROBLEM", 289, 313], ["Bartonella genotypes", "PROBLEM", 319, 339], ["Few studies", "TEST", 350, 361], ["bat Bartonella", "PROBLEM", 397, 411], ["longitudinal studies", "TEST", 451, 471]]], ["Here, Bartonella was detected at relatively high prevalence across both study years within each sampling site, and neither year nor its interaction with site were predictive within our analyses.", [["Bartonella", "ORGANISM", 6, 16], ["Bartonella", "PROBLEM", 6, 16], ["Bartonella", "OBSERVATION", 6, 16]]], ["Similarly, no temporal patterns in Bartonella were observed for a limited sample of Myotis mystacinus, Pipistrellus spp., Myotis daubentonii, and Nyctalus noctula in the United Kingdom [41].", [["Bartonella", "ORGANISM", 35, 45], ["Myotis mystacinus", "ORGANISM", 84, 101], ["Pipistrellus spp.", "ORGANISM", 103, 120], ["Myotis daubentonii", "ORGANISM", 122, 140], ["Nyctalus noctula", "ORGANISM", 146, 162], ["Myotis mystacinus", "SPECIES", 84, 101], ["Pipistrellus spp.", "SPECIES", 103, 120], ["Myotis daubentonii", "SPECIES", 122, 140], ["Nyctalus noctula", "SPECIES", 146, 162], ["Myotis mystacinus", "SPECIES", 84, 101], ["Pipistrellus spp.", "SPECIES", 103, 120], ["Myotis daubentonii", "SPECIES", 122, 140], ["Nyctalus noctula", "SPECIES", 146, 162], ["temporal patterns in Bartonella", "PROBLEM", 14, 45], ["Myotis mystacinus", "TEST", 84, 101], ["no", "UNCERTAINTY", 11, 13], ["temporal", "OBSERVATION_MODIFIER", 14, 22], ["Bartonella", "OBSERVATION", 35, 45], ["Myotis daubentonii", "OBSERVATION", 122, 140]]], ["Such findings contrast with highly seasonal Bartonella infections in rodents, which show high prevalence in summer and fall due to seasonality in birth and ectoparasite intensity [39,40].", [["Bartonella infections", "DISEASE", 44, 65], ["highly seasonal Bartonella infections", "PROBLEM", 28, 65], ["seasonality in birth and ectoparasite intensity", "PROBLEM", 131, 178], ["Bartonella", "OBSERVATION_MODIFIER", 44, 54], ["infections", "OBSERVATION", 55, 65], ["high prevalence", "OBSERVATION_MODIFIER", 89, 104]]], ["The lack of seasonality in our western Peruvian Amazon sample in particular could simply be due to low statistical power; alternatively, no seasonality in infection could also be explained by the non-seasonal or less-pronounced birth pulses observed for vampire bats (but see [73]).", [["infection", "DISEASE", 155, 164], ["low statistical power", "PROBLEM", 99, 120], ["seasonality in infection", "PROBLEM", 140, 164], ["pronounced birth pulses", "PROBLEM", 217, 240], ["vampire bats", "PROBLEM", 254, 266], ["seasonality", "OBSERVATION_MODIFIER", 12, 23], ["infection", "OBSERVATION", 155, 164]]], ["While high Bartonella prevalence in bats has been proposed to stem from persistent infection [15], this seems unlikely, as we observed possible clearance of infection in some recaptured bats.", [["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 157, 166], ["persistent infection", "PROBLEM", 72, 92], ["infection", "PROBLEM", 157, 166], ["persistent", "OBSERVATION_MODIFIER", 72, 82], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 157, 166]]], ["While this could also reflect bacteria DNA loads too low to be detected by PCR, infection risk did not increase with age, as would also be expected if bats could not clear infection [74].", [["infection", "DISEASE", 80, 89], ["infection", "DISEASE", 172, 181], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["bacteria DNA loads", "PROBLEM", 30, 48], ["PCR", "TEST", 75, 78], ["infection risk", "PROBLEM", 80, 94], ["clear infection", "PROBLEM", 166, 181], ["bacteria", "OBSERVATION", 30, 38]]], ["However, we do note that our sample only contained adult (n = 162) and subadult (n = 28) bats, limiting more robust tests of age-dependent infection.", [["infection", "DISEASE", 139, 148], ["bats", "ORGANISM", 89, 93], ["our sample", "TEST", 25, 35], ["subadult (n = 28) bats", "PROBLEM", 71, 93], ["dependent infection", "PROBLEM", 129, 148], ["dependent", "OBSERVATION_MODIFIER", 129, 138], ["infection", "OBSERVATION", 139, 148]]], ["Alternatively, Bartonella infections could be chronic and vary in infection intensity over time or could become latent (i.e., be undetectable in erythrocytes but persist in endothelial cells), particularly as infection does not appear to confer long-term immunity [36].", [["erythrocytes", "ANATOMY", 145, 157], ["endothelial cells", "ANATOMY", 173, 190], ["Bartonella infections", "DISEASE", 15, 36], ["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 209, 218], ["Bartonella", "ORGANISM", 15, 25], ["erythrocytes", "CELL", 145, 157], ["endothelial cells", "CELL", 173, 190], ["erythrocytes", "CELL_TYPE", 145, 157], ["endothelial cells", "CELL_TYPE", 173, 190], ["Bartonella infections", "PROBLEM", 15, 36], ["chronic", "PROBLEM", 46, 53], ["infection intensity", "PROBLEM", 66, 85], ["erythrocytes", "PROBLEM", 145, 157], ["endothelial cells", "PROBLEM", 173, 190], ["infection", "PROBLEM", 209, 218], ["Bartonella infections", "OBSERVATION", 15, 36], ["could be", "UNCERTAINTY", 37, 45], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["infection", "OBSERVATION", 66, 75], ["latent", "OBSERVATION", 112, 118], ["endothelial cells", "OBSERVATION", 173, 190]]], ["Such explanations could be confronted in future work with larger sample sizes of recaptured bats, multiple assessments of infection status over time, and quantitative PCR.DiscussionBat forearm size, sex, and reproductive status were important predictors of Bartonella infection status, with odds of infection being higher in larger, male, and non-reproductive bats.", [["forearm", "ANATOMY", 185, 192], ["infection", "DISEASE", 122, 131], ["Bartonella infection", "DISEASE", 257, 277], ["infection", "DISEASE", 299, 308], ["forearm", "MULTI-TISSUE_STRUCTURE", 185, 192], ["Bartonella", "ORGANISM", 257, 267], ["infection status", "PROBLEM", 122, 138], ["quantitative PCR", "TEST", 154, 170], ["Bartonella infection status", "PROBLEM", 257, 284], ["infection", "PROBLEM", 299, 308], ["infection", "OBSERVATION", 122, 131], ["forearm", "ANATOMY", 185, 192], ["size", "OBSERVATION_MODIFIER", 193, 197], ["infection", "OBSERVATION", 299, 308], ["larger", "OBSERVATION_MODIFIER", 325, 331], ["non-reproductive bats", "OBSERVATION", 343, 364]]], ["While subadult status itself was not an important predictor of Bartonella infection, these findings could suggest higher risk in young male bats that are relatively large for their age.", [["Bartonella infection", "DISEASE", 63, 83], ["Bartonella", "ORGANISM", 63, 73], ["bats", "ORGANISM", 140, 144], ["Bartonella infection", "PROBLEM", 63, 83], ["Bartonella", "OBSERVATION_MODIFIER", 63, 73], ["infection", "OBSERVATION", 74, 83], ["higher", "OBSERVATION_MODIFIER", 114, 120], ["young", "OBSERVATION_MODIFIER", 129, 134], ["male bats", "OBSERVATION", 135, 144], ["large", "OBSERVATION_MODIFIER", 165, 170]]], ["Our previous work has shown stronger innate immune defense (i.e., bacterial killing ability) in reproductive (mostly male) vampire bats, also suggesting greater susceptibility of non-reproductive hosts [49].", [["bats", "ORGANISM", 131, 135], ["bacterial killing ability", "PROBLEM", 66, 91], ["greater susceptibility", "OBSERVATION_MODIFIER", 153, 175]]], ["Similarly, subadults across a Mexican bat community also had higher odds of Bartonella infection [16], and young male vampire bats play key roles in the long-distance dispersal of rabies virus [43] and display higher rates of rabies exposure, possibly owing to more direct contacts during the first year of life [75].", [["Bartonella infection", "DISEASE", 76, 96], ["rabies", "DISEASE", 180, 186], ["rabies", "DISEASE", 226, 232], ["bat", "ORGANISM", 38, 41], ["vampire bats", "ORGANISM", 118, 130], ["rabies virus", "ORGANISM", 180, 192], ["rabies", "ORGANISM", 226, 232], ["rabies virus", "SPECIES", 180, 192], ["rabies virus", "SPECIES", 180, 192], ["rabies", "SPECIES", 226, 232], ["Bartonella infection", "PROBLEM", 76, 96], ["rabies virus", "PROBLEM", 180, 192], ["Bartonella infection", "OBSERVATION", 76, 96]]], ["Larger forearm size could also relate to direct contact if larger bats are more dominant and aggressive, as found in other phyllostomid bat species [76].DiscussionAlthough vector-borne transmission is generally assumed for Bartonella in other hosts [12,19,25,77], including some Neotropical bats [16,78], infection status in vampire bats was not associated with bat fly intensity.", [["forearm", "ANATOMY", 7, 14], ["infection", "DISEASE", 305, 314], ["forearm", "ORGANISM_SUBDIVISION", 7, 14], ["vampire", "ORGANISM", 325, 332], ["bat fly", "SPECIES", 362, 369], ["Larger forearm size", "PROBLEM", 0, 19], ["larger bats", "PROBLEM", 59, 70], ["Bartonella", "PROBLEM", 223, 233], ["infection status in vampire bats", "PROBLEM", 305, 337], ["forearm", "ANATOMY", 7, 14], ["size", "OBSERVATION_MODIFIER", 15, 19], ["more dominant", "OBSERVATION_MODIFIER", 75, 88], ["infection", "OBSERVATION", 305, 314]]], ["Further supporting this observation, male bats had higher odds of Bartonella infection but did not differ in their bat fly intensities compared to females.", [["Bartonella infection", "DISEASE", 66, 86], ["bats", "ORGANISM", 42, 46], ["Bartonella", "ORGANISM", 66, 76], ["Bartonella infection", "PROBLEM", 66, 86], ["Bartonella", "OBSERVATION_MODIFIER", 66, 76], ["infection", "OBSERVATION", 77, 86]]], ["Weak correspondence between bat fly intensity at the time of sampling and Bartonella infection thus may cast doubt on bat flies as a primary transmission route.", [["Bartonella infection", "DISEASE", 74, 94], ["Weak correspondence between bat fly intensity", "PROBLEM", 0, 45], ["sampling", "TEST", 61, 69], ["Bartonella infection", "PROBLEM", 74, 94], ["intensity", "OBSERVATION_MODIFIER", 36, 45], ["Bartonella", "OBSERVATION_MODIFIER", 74, 84], ["infection", "OBSERVATION", 85, 94]]], ["Time lags could provide one reason for this discrepancy, given that new Bartonella infections may take days or weeks to develop and become detectable and over which time ectoparasite load may have changed due to the mobile nature of bat flies [26,36,79].", [["Bartonella infections", "DISEASE", 72, 93], ["Bartonella", "ORGANISM", 72, 82], ["bat flies", "ORGANISM", 233, 242], ["this discrepancy", "PROBLEM", 39, 55], ["new Bartonella infections", "PROBLEM", 68, 93], ["infections", "OBSERVATION", 83, 93]]], ["Unfortunately, nearly all bats in this study had ectoparasites, so comparisons of Bartonella presence in bats with and without bat flies had little statistical power (31/36 Bartonella-positive bats were infested with at least one bat fly).", [["Bartonella", "ORGANISM", 82, 92], ["bats", "ORGANISM", 105, 109], ["this study", "TEST", 34, 44], ["ectoparasites", "PROBLEM", 49, 62], ["Bartonella", "PROBLEM", 82, 92], ["Bartonella", "TEST", 173, 183]]], ["Given that ectoparasitism predicted Bartonella infection more generally across a Mexian bat community [16], larger sample sizes with greater variation in bat fly intensity could provide better inference.", [["sample", "ANATOMY", 115, 121], ["Bartonella infection", "DISEASE", 36, 56], ["Mexian bat", "SPECIES", 81, 91], ["ectoparasitism", "PROBLEM", 11, 25], ["Bartonella infection", "PROBLEM", 36, 56], ["larger sample sizes", "PROBLEM", 108, 127], ["greater variation in bat fly intensity", "PROBLEM", 133, 171], ["infection", "OBSERVATION", 47, 56], ["larger", "OBSERVATION_MODIFIER", 108, 114], ["sizes", "OBSERVATION_MODIFIER", 122, 127], ["greater", "OBSERVATION_MODIFIER", 133, 140], ["variation", "OBSERVATION_MODIFIER", 141, 150]]], ["However, our phylogenetic analysis does provide a tentative line of evidence supporting vector-borne transmission, as several of Bartonella genotypes fell within the same clade as Bartonella from streblid bat flies [29].", [["Bartonella", "ORGANISM", 129, 139], ["streblid bat flies", "ORGANISM", 196, 214], ["streblid bat flies", "SPECIES", 196, 214], ["our phylogenetic analysis", "TEST", 9, 34], ["Bartonella genotypes", "PROBLEM", 129, 149], ["Bartonella", "TEST", 180, 190]]], ["A recent survey of Mexican bats and their sympatric bat flies suggested that corresponding hosts and their bat flies had varied Bartonella genotypes, although one vampire bat did show complete sequence homology with the Bartonella from its paired bat flies [37].", [["bat", "ORGANISM", 52, 55], ["bat flies", "ORGANISM", 107, 116], ["Mexican bats", "SPECIES", 19, 31], ["varied Bartonella genotypes", "PROBLEM", 121, 148], ["the Bartonella", "PROBLEM", 216, 230]]], ["As genetic similarity between Bartonella in bat flies and hosts has been interpreted as evidence of vector-borne transmission in other bat species [29,54], further assessments of Bartonella genotypes between vampire bats and their various ectoparasites (bat flies but also ticks) would shed additional light on possible routes of vector-borne transmission.DiscussionLastly, we analyzed bat saliva and feces using metagenomics and PCR to explore alternative transmission routes, namely through close contact and fecal exposure.", [["feces", "ANATOMY", 401, 406], ["Bartonella", "ORGANISM", 30, 40], ["bat flies", "ORGANISM", 44, 53], ["Bartonella", "ORGANISM", 179, 189], ["bat flies", "ORGANISM", 254, 263], ["bat", "ORGANISM", 386, 389], ["saliva", "ORGANISM_SUBSTANCE", 390, 396], ["feces", "ORGANISM_SUBSTANCE", 401, 406], ["fecal", "ORGANISM_SUBSTANCE", 511, 516], ["vector-borne transmission in other bat species", "PROBLEM", 100, 146], ["further assessments", "TEST", 156, 175], ["Bartonella genotypes", "PROBLEM", 179, 199], ["metagenomics", "TREATMENT", 413, 425], ["PCR", "TREATMENT", 430, 433], ["fecal exposure", "OBSERVATION", 511, 525]]], ["Metagenomics detected no Bartonella DNA matching to gltA or rpoB in either saliva or fecal pools.", [["saliva", "ANATOMY", 75, 81], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["gltA", "GENE_OR_GENE_PRODUCT", 52, 56], ["rpoB", "GENE_OR_GENE_PRODUCT", 60, 64], ["saliva", "ORGANISM_SUBSTANCE", 75, 81], ["fecal", "ORGANISM_SUBSTANCE", 85, 90], ["Bartonella DNA", "DNA", 25, 39], ["gltA", "DNA", 52, 56], ["rpoB", "DNA", 60, 64], ["Metagenomics", "TEST", 0, 12], ["Bartonella DNA", "PROBLEM", 25, 39], ["rpoB", "PROBLEM", 60, 64], ["no", "UNCERTAINTY", 22, 24]]], ["This absence could be explained in that the short sequences (345\u2013425 bp) used as targets, and the large size of bacterial genomes together make the likelihood of detecting a specific gene low.", [["short sequences", "DNA", 44, 59], ["bacterial genomes", "DNA", 112, 129], ["the short sequences", "TEST", 40, 59], ["bp", "TEST", 69, 71], ["bacterial genomes", "PROBLEM", 112, 129], ["could be explained", "UNCERTAINTY", 13, 31], ["large", "OBSERVATION_MODIFIER", 98, 103], ["size", "OBSERVATION_MODIFIER", 104, 108], ["bacterial genomes", "OBSERVATION", 112, 129], ["low", "OBSERVATION_MODIFIER", 188, 191]]], ["However, the Bartonella-like reads and contigs recovered from saliva and feces were short fragments (51\u2013258 bp) and showed low homology to known Bartonella from GenBank (S4 Table).", [["saliva", "ORGANISM_SUBSTANCE", 62, 68], ["feces", "ORGANISM_SUBSTANCE", 73, 78], ["Bartonella-like reads", "DNA", 13, 34], ["the Bartonella", "TEST", 9, 23], ["contigs", "TEST", 39, 46], ["saliva and feces", "TEST", 62, 78], ["short fragments", "PROBLEM", 84, 99], ["bp", "TEST", 108, 110], ["low homology to known Bartonella", "PROBLEM", 123, 155], ["Bartonella", "OBSERVATION", 13, 23], ["Bartonella", "OBSERVATION", 145, 155]]], ["Notably, we used a similar approach to search for other bacteria (i.e., hemoplasmas) and found clear evidence of their presence [8].", [["a similar approach", "TREATMENT", 17, 35], ["other bacteria", "PROBLEM", 50, 64]]], ["While this could suggest true absence of Bartonella from bat saliva and feces, our PCR found Bartonella in a subset of individual saliva and fecal samples.", [["feces", "ANATOMY", 72, 77], ["saliva", "ANATOMY", 130, 136], ["fecal samples", "ANATOMY", 141, 154], ["bat", "ORGANISM", 57, 60], ["saliva", "ORGANISM_SUBSTANCE", 61, 67], ["feces", "ORGANISM_SUBSTANCE", 72, 77], ["saliva", "ORGANISM_SUBSTANCE", 130, 136], ["fecal samples", "ORGANISM_SUBSTANCE", 141, 154], ["Bartonella from bat saliva and feces", "PROBLEM", 41, 77], ["our PCR", "TEST", 79, 86], ["Bartonella", "PROBLEM", 93, 103], ["fecal samples", "TEST", 141, 154], ["Bartonella", "OBSERVATION", 41, 51]]], ["This discrepancy between methods could stem from treating saliva and fecal pools with DNase before metagenomic sequencing.", [["saliva", "ORGANISM_SUBSTANCE", 58, 64], ["fecal", "ORGANISM_SUBSTANCE", 69, 74], ["DNase", "GENE_OR_GENE_PRODUCT", 86, 91], ["DNase", "PROTEIN", 86, 91], ["This discrepancy between methods", "PROBLEM", 0, 32], ["treating saliva", "PROBLEM", 49, 64], ["fecal pools", "PROBLEM", 69, 80], ["DNase", "TREATMENT", 86, 91], ["metagenomic sequencing", "TEST", 99, 121]]], ["Furthermore, phylogenetic analyses confirmed that these sequences were closely related to those identified in blood, which argues against these PCR positives only representing bacteria derived from environmental contamination or from feeding on prey.", [["blood", "ANATOMY", 110, 115], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["phylogenetic analyses", "TEST", 13, 34], ["these sequences", "TEST", 50, 65], ["these PCR positives", "TEST", 138, 157], ["bacteria", "PROBLEM", 176, 184], ["environmental contamination", "PROBLEM", 198, 225]]], ["PCR results further showed strong correspondence between blood and saliva, suggesting that Bartonella infection may be systemic in vampire bats.", [["blood", "ANATOMY", 57, 62], ["saliva", "ANATOMY", 67, 73], ["Bartonella infection", "DISEASE", 91, 111], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["saliva", "ORGANISM_SUBSTANCE", 67, 73], ["Bartonella", "ORGANISM", 91, 101], ["PCR", "TEST", 0, 3], ["strong correspondence between blood and saliva", "PROBLEM", 27, 73], ["Bartonella infection", "PROBLEM", 91, 111], ["Bartonella", "OBSERVATION_MODIFIER", 91, 101], ["infection", "OBSERVATION", 102, 111], ["may be", "UNCERTAINTY", 112, 118], ["systemic", "OBSERVATION_MODIFIER", 119, 127], ["vampire bats", "OBSERVATION", 131, 143]]], ["While fecal and blood PCR results also mostly matched, we found one case where a bat was negative in blood but positive in feces.", [["fecal", "ANATOMY", 6, 11], ["blood", "ANATOMY", 16, 21], ["blood", "ANATOMY", 101, 106], ["feces", "ANATOMY", 123, 128], ["fecal", "ORGANISM_SUBSTANCE", 6, 11], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["bat", "ORGANISM", 81, 84], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["feces", "ORGANISM_SUBSTANCE", 123, 128], ["fecal and blood PCR", "TEST", 6, 25], ["a bat", "TEST", 79, 84], ["positive in feces", "PROBLEM", 111, 128], ["fecal", "ANATOMY", 6, 11], ["feces", "OBSERVATION", 123, 128]]], ["As consumption of ectoparasites during grooming has been observed in other bat families (e.g., Pteropodidae [80]), this discrepancy could suggest the incidental ingestion of ectoparasites during grooming and that this does not lead to systemic infection more generally indicated by the concordance between blood, saliva, and fecal positives and their close genetic similarity.DiscussionSimilar prevalence of Bartonella in saliva and feces suggests that direct contact and environmental exposure could serve as complemenry transmission routes to arthropod vectors.", [["blood", "ANATOMY", 306, 311], ["saliva", "ANATOMY", 313, 319], ["saliva", "ANATOMY", 422, 428], ["feces", "ANATOMY", 433, 438], ["infection", "DISEASE", 244, 253], ["blood", "ORGANISM_SUBSTANCE", 306, 311], ["saliva", "ORGANISM_SUBSTANCE", 313, 319], ["fecal", "ORGANISM_SUBSTANCE", 325, 330], ["Bartonella", "ORGANISM", 408, 418], ["saliva", "ORGANISM_SUBSTANCE", 422, 428], ["feces", "ORGANISM_SUBSTANCE", 433, 438], ["ectoparasites", "PROBLEM", 18, 31], ["ectoparasites", "PROBLEM", 174, 187], ["systemic infection", "PROBLEM", 235, 253], ["the concordance between blood, saliva, and fecal positives", "PROBLEM", 282, 340], ["Bartonella in saliva and feces", "PROBLEM", 408, 438], ["ectoparasites", "OBSERVATION", 18, 31], ["infection", "OBSERVATION", 244, 253], ["fecal", "ANATOMY", 325, 330], ["Bartonella", "OBSERVATION", 408, 418]]], ["The presence of Bartonella in saliva samples contrasts with previous work showing an absence of Bartonella in vampire bat saliva [44,81], providing evidence for possible direct transmission.", [["saliva samples", "ANATOMY", 30, 44], ["Bartonella", "ORGANISM", 16, 26], ["saliva samples", "ORGANISM_SUBSTANCE", 30, 44], ["Bartonella", "ORGANISM", 96, 106], ["bat", "ORGANISM", 118, 121], ["saliva", "ORGANISM_SUBSTANCE", 122, 128], ["Bartonella in saliva samples contrasts", "PROBLEM", 16, 54], ["previous work", "TEST", 60, 73], ["Bartonella", "PROBLEM", 96, 106], ["direct transmission", "PROBLEM", 170, 189], ["Bartonella", "OBSERVATION", 16, 26], ["Bartonella", "OBSERVATION", 96, 106], ["evidence for possible", "UNCERTAINTY", 148, 169]]], ["Bartonella in fecal samples could also suggest environmental transmission between bats [18].", [["fecal samples", "ANATOMY", 14, 27], ["Bartonella", "ORGANISM", 0, 10], ["fecal samples", "ORGANISM_SUBSTANCE", 14, 27], ["Bartonella in fecal samples", "TEST", 0, 27], ["fecal", "ANATOMY", 14, 19]]], ["Both saliva-borne and fecal\u2013oral transmission of vampire bat Bartonella could further pose potential risks to humans or livestock, either through bites during feeding or by environmental exposure of humans that enter roosts or to domestic animals exposed to bat feces [18,38,48,82].", [["saliva", "ORGANISM_SUBSTANCE", 5, 11], ["vampire", "ORGANISM", 49, 56], ["bat Bartonella", "ORGANISM", 57, 71], ["humans", "ORGANISM", 110, 116], ["humans", "ORGANISM", 199, 205], ["bat feces", "ORGANISM", 258, 267], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 199, 205], ["vampire bat", "SPECIES", 49, 60], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 199, 205], ["fecal\u2013oral transmission", "TREATMENT", 22, 45], ["vampire bat Bartonella", "TREATMENT", 49, 71]]], ["For the former pathway, however, a recent survey of Bartonella in Mexican ruminants did not identify being bitten by vampire bats as a risk factor for infection [81], and our phylogenetic results provide relatively more support for the possibility of vector-borne transmission.", [["infection", "DISEASE", 151, 160], ["Bartonella", "ORGANISM", 52, 62], ["Bartonella", "PROBLEM", 52, 62], ["infection", "PROBLEM", 151, 160]]], ["Vector-borne transmission of vampire bat Bartonella might reduce their potential to infect humans or livestock, given the high host specificity of most bat flies [31,32].", [["vampire", "ORGANISM", 29, 36], ["bat Bartonella", "ORGANISM", 37, 51], ["humans", "ORGANISM", 91, 97], ["bat flies", "ORGANISM", 152, 161], ["humans", "SPECIES", 91, 97], ["vampire bat", "SPECIES", 29, 40], ["humans", "SPECIES", 91, 97], ["Vector", "TREATMENT", 0, 6], ["vampire bat Bartonella", "PROBLEM", 29, 51]]], ["However, ectoparasite transfer between individuals could still occur during pupal deposition and close contact [83], facilitating Bartonella transmission within vampire bat colonies and to other bat species.", [["pupal", "ANATOMY", 76, 81], ["colonies", "ANATOMY", 173, 181], ["pupal", "DEVELOPING_ANATOMICAL_STRUCTURE", 76, 81], ["facilitating Bartonella transmission within vampire bat colonies", "PROBLEM", 117, 181]]], ["While our analyses of ectoparasitism only considered bat flies, we have observed heavy tick burdens of vampire bats in other field sites (e.g., Belize).", [["ectoparasitism", "PROBLEM", 22, 36], ["heavy", "OBSERVATION_MODIFIER", 81, 86], ["tick", "OBSERVATION_MODIFIER", 87, 91], ["vampire bats", "OBSERVATION", 103, 115]]], ["Bartonella has been detected in ticks infesting other bats [28], and these ectoparasites could also be more likely to facilitate cross-species transmission [30].", [["Bartonella", "ORGANISM", 0, 10], ["Bartonella", "PROBLEM", 0, 10], ["these ectoparasites", "PROBLEM", 69, 88], ["could also be more likely", "UNCERTAINTY", 89, 114]]], ["Metagenomics also potentially identified Bartonella ancashensis and B. bacilliformis in vampire bat fecal samples, and these species cause notable infectious disease in humans likely through phlebotomine sand flies in Andean regions of Peru [84,85].", [["fecal samples", "ANATOMY", 100, 113], ["infectious disease", "DISEASE", 147, 165], ["Bartonella ancashensis", "ORGANISM", 41, 63], ["B. bacilliformis", "ORGANISM", 68, 84], ["bat", "ORGANISM", 96, 99], ["fecal samples", "ORGANISM_SUBSTANCE", 100, 113], ["humans", "ORGANISM", 169, 175], ["Bartonella ancashensis", "SPECIES", 41, 63], ["B. bacilliformis", "SPECIES", 68, 84], ["humans", "SPECIES", 169, 175], ["Bartonella ancashensis", "SPECIES", 41, 63], ["B. bacilliformis", "SPECIES", 68, 84], ["humans", "SPECIES", 169, 175], ["Bartonella ancashensis", "TEST", 41, 63], ["B. bacilliformis", "PROBLEM", 68, 84], ["vampire bat fecal samples", "TEST", 88, 113], ["notable infectious disease in humans", "PROBLEM", 139, 175], ["notable", "OBSERVATION_MODIFIER", 139, 146], ["infectious", "OBSERVATION", 147, 157]]], ["Controlled infection trials and more extensive phylogenetic analyses of Bartonella in vampire bats, their various ectoparasites, and sympatric prey are therefore needed to examine the contributions of different transmission routes for bacterial spread within vampire bats and to recipient prey and to confirm whether saliva and feces represent viable transmission routes.", [["feces", "ANATOMY", 328, 333], ["infection", "DISEASE", 11, 20], ["Bartonella", "ORGANISM", 72, 82], ["vampire bats", "ORGANISM", 86, 98], ["saliva", "ORGANISM_SUBSTANCE", 317, 323], ["feces", "ORGANISM_SUBSTANCE", 328, 333], ["Controlled infection trials", "PROBLEM", 0, 27], ["Bartonella", "PROBLEM", 72, 82], ["their various ectoparasites", "PROBLEM", 100, 127], ["bacterial spread", "PROBLEM", 235, 251], ["saliva and feces", "PROBLEM", 317, 333], ["infection", "OBSERVATION", 11, 20], ["Bartonella", "OBSERVATION", 72, 82]]], ["Given the high rates of bat bites and proximity to wildlife, humans, and domestic animals that define vampire bat ecology, such efforts to verify the possibility and frequency of oral and environmental exposures would elucidate Bartonella transmission dynamics in this common host species and the risks of cross-species transmission.", [["oral", "ANATOMY", 179, 183], ["humans", "ORGANISM", 61, 67], ["oral", "ORGANISM_SUBDIVISION", 179, 183], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67], ["oral and environmental exposures", "TREATMENT", 179, 211], ["Bartonella transmission dynamics", "PROBLEM", 228, 260]]]], "PMC7383177": [["Background ::: IntroductionThe novel coronavirus (COVID-19) pandemic has strained the healthcare system beyond its usual capacity to accommodate such a large influx of seriously ill patients.1,2 This has created the need to bring palliative care medicine practices to the frontline across specialties.6 Many clinicians who have not been specially trained in palliative care do not feel adequately prepared to facilitate difficult conversations with patients or their family members about goals of care.7 Providing these clinicians with convenient access to focused education, clinical reference materials, and specialist palliative care support may improve end of life care for patients.1", [["1,2", "CHEMICAL", 191, 194], ["coronavirus", "ORGANISM", 37, 48], ["COVID-19", "ORGANISM", 50, 58], ["patients", "ORGANISM", 182, 190], ["patients", "ORGANISM", 449, 457], ["patients", "ORGANISM", 678, 686], ["patients", "SPECIES", 182, 190], ["patients", "SPECIES", 449, 457], ["patients", "SPECIES", 678, 686], ["COVID", "TEST", 50, 55], ["pandemic", "PROBLEM", 60, 68], ["palliative care medicine", "TREATMENT", 230, 254], ["palliative care", "TREATMENT", 358, 373], ["palliative care support", "TREATMENT", 621, 644], ["large", "OBSERVATION_MODIFIER", 152, 157], ["influx", "OBSERVATION_MODIFIER", 158, 164]]]], "72bba75363aed2f0b02b8c02893d42622658baa3": [["As of April 15, 2020, the number of confirmed COVID-19 cases in New York City (NYC) was >110,000, making it the global epicenter of the pandemic.", [["COVID", "DISEASE", 46, 51], ["pandemic", "OBSERVATION", 136, 144]]], ["(1) This rapid surge in the number of cases imposed a major burden on all hospitals in NYC, as well as a significant stress in Emergency Departments (ED).", [["major", "OBSERVATION_MODIFIER", 54, 59], ["burden", "OBSERVATION_MODIFIER", 60, 66]]], ["In addition, public health messages promoting social distancing and news reports focused on the death toll associated with COVID-19 have created a sense of generalized anxiety in society.", [["death", "DISEASE", 96, 101], ["anxiety", "DISEASE", 168, 175], ["generalized anxiety in society", "PROBLEM", 156, 186], ["generalized", "OBSERVATION_MODIFIER", 156, 167], ["anxiety", "OBSERVATION", 168, 175]]], ["Changes in the observed incidence of acute cardiovascular conditions have been anecdotally reported, including the occurrence of STelevation myocardial infarctions 2 .", [["cardiovascular", "ANATOMY", 43, 57], ["myocardial", "ANATOMY", 141, 151], ["STelevation myocardial infarctions", "DISEASE", 129, 163], ["myocardial", "MULTI-TISSUE_STRUCTURE", 141, 151], ["acute cardiovascular conditions", "PROBLEM", 37, 68], ["STelevation myocardial infarctions", "PROBLEM", 129, 163], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["cardiovascular conditions", "OBSERVATION", 43, 68], ["myocardial", "ANATOMY", 141, 151], ["infarctions", "OBSERVATION", 152, 163]]], ["Incidentally, the number of at-home deaths in NYC have reached an 8-to 10-fold increase compared to the same time period in 2019, raising concerns about the impact of the pandemic on non-COVID related health conditions.", [["deaths", "DISEASE", 36, 42]]], ["Acute type A aortic dissection is a life-threatening condition for which the only effective treatment requires a surgical intervention and the portal to initial diagnosis is invariably the ED.", [["aortic", "ANATOMY", 13, 19], ["type A aortic dissection", "DISEASE", 6, 30], ["aortic", "ORGAN", 13, 19], ["portal", "MULTI-TISSUE_STRUCTURE", 143, 149], ["Acute type A aortic dissection", "PROBLEM", 0, 30], ["effective treatment", "TREATMENT", 82, 101], ["a surgical intervention", "TREATMENT", 111, 134], ["aortic", "ANATOMY", 13, 19], ["dissection", "OBSERVATION", 20, 30], ["portal", "ANATOMY", 143, 149]]]], "9d5f75e025f6ba577403aab0eba629ac9433c3a4": [["INTRODUCTIONsles associated with a progressive and fatal human disease, subacute sclerosing panen-There is abundant evidence implicating cephalitis (SSPE) (Horta- Barbosa et al., viruses in the etiology of neurological diseases in both animals and man.", [["neurological", "ANATOMY", 206, 218], ["cephalitis", "DISEASE", 137, 147], ["SSPE", "DISEASE", 149, 153], ["neurological diseases", "DISEASE", 206, 227], ["human", "ORGANISM", 57, 62], ["man", "ORGANISM", 248, 251], ["human", "SPECIES", 57, 62], ["man", "SPECIES", 248, 251], ["human", "SPECIES", 57, 62], ["a progressive and fatal human disease", "PROBLEM", 33, 70], ["subacute sclerosing panen", "PROBLEM", 72, 97], ["cephalitis (SSPE)", "PROBLEM", 137, 154], ["viruses", "PROBLEM", 179, 186], ["neurological diseases", "PROBLEM", 206, 227], ["progressive", "OBSERVATION_MODIFIER", 35, 46], ["fatal human disease", "OBSERVATION", 51, 70], ["subacute", "OBSERVATION_MODIFIER", 72, 80], ["sclerosing panen", "OBSERVATION", 81, 97], ["abundant evidence implicating", "UNCERTAINTY", 107, 136], ["cephalitis", "OBSERVATION", 137, 147], ["neurological diseases", "OBSERVATION", 206, 227]]], ["Studies in 1971) , and the JHM strain of murine hepvitro and in vivo using spontaneous and atitis virus pathogenic for rodents Bailey et al., 1949; Weiner, selected virus mutants have shown that 1973).", [["murine", "ORGANISM", 41, 47], ["atitis virus", "ORGANISM", 91, 103], ["murine", "SPECIES", 41, 47], ["Studies", "TEST", 0, 7], ["murine hepvitro", "TREATMENT", 41, 56], ["spontaneous and atitis virus pathogenic", "PROBLEM", 75, 114]]], ["The SSPE agent known to prevail when the infection becomes defective, persistent, or latent, the agent sometimes persistently in the brain of afflicted individspreads along neuronal tracts, causes exten-uals has been evoked by growing brain explants in continuity with permissive cells sive cytopathology including demyelina- (Horta-Barbosa et al., 1969; Burnstein et tion, or may establish slow and chronic al., 1974) .", [["brain", "ANATOMY", 133, 138], ["neuronal tracts", "ANATOMY", 173, 188], ["brain explants", "ANATOMY", 235, 249], ["cells", "ANATOMY", 280, 285], ["SSPE", "DISEASE", 4, 8], ["infection", "DISEASE", 41, 50], ["individspreads", "DISEASE", 152, 166], ["brain", "ORGAN", 133, 138], ["neuronal tracts", "TISSUE", 173, 188], ["brain explants", "TISSUE", 235, 249], ["cells", "CELL", 280, 285], ["The SSPE agent", "TREATMENT", 0, 14], ["the infection", "PROBLEM", 37, 50], ["defective", "PROBLEM", 59, 68], ["growing brain explants", "PROBLEM", 227, 249], ["demyelina", "PROBLEM", 315, 324], ["infection", "OBSERVATION", 41, 50], ["persistent", "OBSERVATION_MODIFIER", 70, 80], ["brain", "ANATOMY", 133, 138], ["neuronal tracts", "ANATOMY", 173, 188], ["permissive cells", "OBSERVATION", 269, 285]]], ["The emergent virus has close infections.INTRODUCTIONThe mechanisms underlying serological identity with measles virus such virus-cell interactions in the nervous system have been elucidated in part for the (Baublis and Payne, 1963) (Herndon et al., 1975) , suggesting this as a useful model for certain human demyelinating diseases.", [["cell", "ANATOMY", 129, 133], ["nervous system", "ANATOMY", 154, 168], ["infections", "DISEASE", 29, 39], ["demyelinating diseases", "DISEASE", 309, 331], ["measles virus", "ORGANISM", 104, 117], ["cell", "CELL", 129, 133], ["nervous system", "ANATOMICAL_SYSTEM", 154, 168], ["human", "ORGANISM", 303, 308], ["measles virus", "SPECIES", 104, 117], ["human", "SPECIES", 303, 308], ["measles virus", "SPECIES", 104, 117], ["human", "SPECIES", 303, 308], ["The emergent virus", "PROBLEM", 0, 18], ["close infections", "PROBLEM", 23, 39], ["The mechanisms underlying serological identity", "PROBLEM", 52, 98], ["measles virus such virus", "PROBLEM", 104, 128], ["certain human demyelinating diseases", "PROBLEM", 295, 331], ["virus", "OBSERVATION", 13, 18], ["infections", "OBSERVATION", 29, 39], ["nervous", "ANATOMY", 154, 161], ["demyelinating", "OBSERVATION", 309, 322]]], ["In a recent publication we described an in vitro correlate to this in uiuo model (Lucas et al., 1977) , involving a rat Schwannoma RN2-2 cell line, which functions as a discriminating host for the JHM virus.", [["Schwannoma RN2-2 cell line", "ANATOMY", 120, 146], ["rat", "ORGANISM", 116, 119], ["Schwannoma RN2-2 cell line", "CELL", 120, 146], ["JHM virus", "ORGANISM", 197, 206], ["rat Schwannoma RN2-2 cell line", "CELL_LINE", 116, 146], ["rat", "SPECIES", 116, 119], ["JHM virus", "SPECIES", 197, 206], ["a rat Schwannoma", "PROBLEM", 114, 130], ["the JHM virus", "PROBLEM", 193, 206], ["Schwannoma", "OBSERVATION", 120, 130], ["cell line", "OBSERVATION", 137, 146]]], ["JHM readily established a persistent infection in RN2-2 cells during which there occurred cyclical variations in the titer of virus released into the medium and selflimiting syncytiogenesis.", [["RN2-2 cells", "ANATOMY", 50, 61], ["JHM", "CHEMICAL", 0, 3], ["infection", "DISEASE", 37, 46], ["RN2-2 cells", "CELL", 50, 61], ["RN2-2 cells", "CELL_LINE", 50, 61], ["JHM", "PROBLEM", 0, 3], ["a persistent infection in RN2-2 cells", "PROBLEM", 24, 61], ["cyclical variations in the titer of virus", "PROBLEM", 90, 131], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["infection", "OBSERVATION", 37, 46], ["2 cells", "ANATOMY_MODIFIER", 54, 61], ["cyclical", "OBSERVATION_MODIFIER", 90, 98], ["variations", "OBSERVATION_MODIFIER", 99, 109], ["medium", "OBSERVATION_MODIFIER", 150, 156]]], ["In contrast, infection of the RN2-2 cells with a prototype murine hepatitis virus, MHVR, was aborted immediately.INTRODUCTIONIn this report we describe further experiments on the two virus models in which we have compared replication of JHM versus MHV3 and the Halle versus Edmonston strains of measles virus in continuous cell lines of neural and other origin.MATERIALS AND METHODSCells and cell culture.", [["RN2-2 cells", "ANATOMY", 30, 41], ["cell lines", "ANATOMY", 323, 333], ["neural", "ANATOMY", 337, 343], ["cell", "ANATOMY", 392, 396], ["infection", "DISEASE", 13, 22], ["murine hepatitis virus", "DISEASE", 59, 81], ["measles virus", "DISEASE", 295, 308], ["RN2-2 cells", "CELL", 30, 41], ["murine hepatitis virus", "ORGANISM", 59, 81], ["MHVR", "CANCER", 83, 87], ["JHM", "GENE_OR_GENE_PRODUCT", 237, 240], ["MHV3", "CELL", 248, 252], ["Edmonston strains", "ORGANISM", 274, 291], ["measles virus", "ORGANISM", 295, 308], ["cell lines", "CELL", 323, 333], ["neural", "CELL", 337, 343], ["cell culture", "CELL", 392, 404], ["RN2-2 cells", "CELL_LINE", 30, 41], ["continuous cell lines", "CELL_LINE", 312, 333], ["murine", "SPECIES", 59, 65], ["hepatitis virus", "SPECIES", 66, 81], ["measles virus", "SPECIES", 295, 308], ["murine hepatitis virus", "SPECIES", 59, 81], ["measles virus", "SPECIES", 295, 308], ["infection of the RN2-2 cells", "PROBLEM", 13, 41], ["a prototype murine hepatitis virus", "PROBLEM", 47, 81], ["MHVR", "TREATMENT", 83, 87], ["the two virus models", "TREATMENT", 175, 195], ["JHM", "PROBLEM", 237, 240], ["MHV3", "TREATMENT", 248, 252], ["measles virus", "PROBLEM", 295, 308], ["continuous cell lines", "TREATMENT", 312, 333], ["METHODSCells", "TEST", 375, 387], ["cell culture", "TEST", 392, 404], ["infection", "OBSERVATION", 13, 22], ["measles virus", "OBSERVATION", 295, 308], ["continuous cell lines", "OBSERVATION", 312, 333], ["neural", "ANATOMY_MODIFIER", 337, 343], ["origin", "ANATOMY_MODIFIER", 354, 360]]], ["The rat astrocytoma C6 cells were obtained from Dr. A. Marks (Banting and Best Institute, Toronto), the rat hepatoma HTC cells from Dr. K. Yamamoto (University of California, San Francisco), and the rat myoblast L6 cell line from Dr. D. B. Sanwal (University of Western Ontario, London).", [["astrocytoma C6 cells", "ANATOMY", 8, 28], ["hepatoma HTC cells", "ANATOMY", 108, 126], ["myoblast L6 cell line", "ANATOMY", 203, 224], ["astrocytoma", "DISEASE", 8, 19], ["rat", "ORGANISM", 4, 7], ["astrocytoma C6 cells", "CELL", 8, 28], ["rat", "ORGANISM", 104, 107], ["hepatoma HTC cells", "CELL", 108, 126], ["rat", "ORGANISM", 199, 202], ["myoblast L6 cell line", "CELL", 203, 224], ["rat astrocytoma C6 cells", "CELL_LINE", 4, 28], ["rat hepatoma HTC cells", "CELL_LINE", 104, 126], ["rat myoblast L6 cell line", "CELL_LINE", 199, 224], ["rat", "SPECIES", 4, 7], ["rat", "SPECIES", 104, 107], ["rat", "SPECIES", 199, 202], ["rat", "SPECIES", 199, 202], ["The rat astrocytoma C6 cells", "PROBLEM", 0, 28], ["the rat hepatoma HTC cells", "PROBLEM", 100, 126], ["astrocytoma", "OBSERVATION_MODIFIER", 8, 19], ["C6 cells", "OBSERVATION", 20, 28], ["hepatoma", "ANATOMY", 108, 116], ["L6", "ANATOMY", 212, 214], ["cell line", "OBSERVATION", 215, 224]]], ["Dr. S. E. Pfeiffer (University of Connecticut, Farmington) kindly supplied the murine glioblastoma cell lines, G26-20 and G26-24.", [["glioblastoma cell lines", "ANATOMY", 86, 109], ["G26-20", "ANATOMY", 111, 117], ["glioblastoma", "DISEASE", 86, 98], ["murine", "ORGANISM", 79, 85], ["glioblastoma cell lines", "CELL", 86, 109], ["G26-20", "CELL", 111, 117], ["G26-24", "CELL", 122, 128], ["murine glioblastoma cell lines", "CELL_LINE", 79, 109], ["G26-20", "CELL_LINE", 111, 117], ["G26-24", "CELL_LINE", 122, 128], ["murine", "SPECIES", 79, 85], ["the murine glioblastoma cell lines", "TEST", 75, 109], ["G26", "TEST", 111, 114], ["G26", "TEST", 122, 125], ["glioblastoma cell lines", "OBSERVATION", 86, 109]]], ["The murine neuroblastoma Cl300 cells were obtained in 1971 from Dr. J. P. Broome (New York University Medical School) and the African green monkey kidney Vero cells from Dr. L. Hatch (St. Joseph's Hospital, London).", [["neuroblastoma Cl300 cells", "ANATOMY", 11, 36], ["kidney Vero cells", "ANATOMY", 147, 164], ["murine", "ORGANISM", 4, 10], ["neuroblastoma Cl300 cells", "CELL", 11, 36], ["monkey", "ORGANISM", 140, 146], ["kidney Vero cells", "CELL", 147, 164], ["murine neuroblastoma Cl300 cells", "CELL_LINE", 4, 36], ["African green monkey kidney Vero cells", "CELL_LINE", 126, 164], ["murine", "SPECIES", 4, 10], ["monkey", "SPECIES", 140, 146], ["African green monkey", "SPECIES", 126, 146], ["The murine neuroblastoma Cl300 cells", "TEST", 0, 36], ["neuroblastoma Cl300 cells", "OBSERVATION", 11, 36], ["kidney", "ANATOMY", 147, 153], ["Vero cells", "OBSERVATION", 154, 164]]], ["The sources of the rat Schwannoma RN2-2 cell line and the murine fibroblast L-2 line were previously described (Lucas et al., 1977) .MATERIALS AND METHODSPrior to use, the cells were cloned by limit dilution in 96-well Microtest II trays (Falcon Plastics), and a representative clone of each cell line was used in this particular study.MATERIALS AND METHODSThe cells were routinely propagated as monolayers in Eagle's minimal essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Microbiological Associates), sodium bicarbonate (2 g/liter), penicillin (100 U/ml), and streptomycin (100 mg/ml) at 37\" in a humidified atmosphere containing 5% COz.MATERIALS AND METHODSViruses.", [["Schwannoma RN2-2 cell line", "ANATOMY", 23, 49], ["fibroblast L-2 line", "ANATOMY", 65, 84], ["cells", "ANATOMY", 172, 177], ["clone", "ANATOMY", 278, 283], ["cell line", "ANATOMY", 292, 301], ["cells", "ANATOMY", 361, 366], ["monolayers", "ANATOMY", 396, 406], ["fetal bovine serum", "ANATOMY", 488, 506], ["FBS", "ANATOMY", 508, 511], ["sodium bicarbonate", "CHEMICAL", 543, 561], ["penicillin", "CHEMICAL", 575, 585], ["streptomycin", "CHEMICAL", 602, 614], ["COz", "CHEMICAL", 675, 678], ["sodium bicarbonate", "CHEMICAL", 543, 561], ["penicillin", "CHEMICAL", 575, 585], ["streptomycin", "CHEMICAL", 602, 614], ["rat", "ORGANISM", 19, 22], ["Schwannoma RN2-2 cell line", "CELL", 23, 49], ["murine", "ORGANISM", 58, 64], ["fibroblast L-2 line", "CELL", 65, 84], ["cells", "CELL", 172, 177], ["clone", "CELL", 278, 283], ["cell line", "CELL", 292, 301], ["cells", "CELL", 361, 366], ["monolayers", "CELL", 396, 406], ["bovine", "ORGANISM", 494, 500], ["serum", "ORGANISM_SUBSTANCE", 501, 506], ["FBS", "ORGANISM_SUBSTANCE", 508, 511], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 543, 561], ["penicillin", "SIMPLE_CHEMICAL", 575, 585], ["streptomycin", "SIMPLE_CHEMICAL", 602, 614], ["rat Schwannoma RN2-2 cell line", "CELL_LINE", 19, 49], ["murine fibroblast L-2 line", "CELL_LINE", 58, 84], ["cell line", "CELL_LINE", 292, 301], ["rat", "SPECIES", 19, 22], ["murine", "SPECIES", 58, 64], ["bovine", "SPECIES", 494, 500], ["bovine", "SPECIES", 494, 500], ["the rat Schwannoma RN2", "TEST", 15, 37], ["2 cell line", "TREATMENT", 38, 49], ["the murine fibroblast L-2 line", "TREATMENT", 54, 84], ["the cells", "TREATMENT", 168, 177], ["a representative clone of each cell line", "TREATMENT", 261, 301], ["this particular study", "TEST", 314, 335], ["METHODSThe cells", "TREATMENT", 350, 366], ["essential medium (MEM)", "TREATMENT", 426, 448], ["sodium bicarbonate", "TREATMENT", 543, 561], ["penicillin", "TREATMENT", 575, 585], ["streptomycin", "TREATMENT", 602, 614], ["a humidified atmosphere", "TREATMENT", 637, 660], ["rat", "OBSERVATION_MODIFIER", 19, 22], ["Schwannoma", "OBSERVATION", 23, 33], ["cell line", "OBSERVATION", 40, 49], ["murine", "OBSERVATION_MODIFIER", 58, 64], ["fibroblast", "OBSERVATION_MODIFIER", 65, 75], ["cell line", "OBSERVATION", 292, 301]]], ["The source and routine propagation of the MHVs and JHM strains of mouse hepatitis virus have been previously described (Lucas et al., 1977) .MATERIALS AND METHODSThe Hall4 strain of SSPE and the Edmonston strain of measles virus were obtained from the American Type Culture Collection at passage levels of HeLa/2-Vera/S and HK/24-HAM 141, respectively.", [["HeLa", "ANATOMY", 306, 310], ["hepatitis virus", "DISEASE", 72, 87], ["SSPE", "DISEASE", 182, 186], ["measles virus", "DISEASE", 215, 228], ["MHVs", "GENE_OR_GENE_PRODUCT", 42, 46], ["JHM strains", "ORGANISM", 51, 62], ["mouse hepatitis virus", "ORGANISM", 66, 87], ["SSPE", "CANCER", 182, 186], ["Edmonston strain", "ORGANISM", 195, 211], ["measles virus", "ORGANISM", 215, 228], ["HeLa", "CELL", 306, 310], ["mouse", "SPECIES", 66, 71], ["hepatitis virus", "SPECIES", 72, 87], ["measles virus", "SPECIES", 215, 228], ["mouse hepatitis virus", "SPECIES", 66, 87], ["measles virus", "SPECIES", 215, 228], ["the MHVs", "TREATMENT", 38, 46], ["JHM strains", "PROBLEM", 51, 62], ["mouse hepatitis virus", "PROBLEM", 66, 87], ["SSPE", "PROBLEM", 182, 186], ["measles virus", "PROBLEM", 215, 228], ["HeLa", "TEST", 306, 310], ["Vera/S", "TEST", 313, 319], ["HK", "TEST", 324, 326], ["hepatitis virus", "OBSERVATION", 72, 87]]], ["Both viruses were routinely maintained by passage on Vero cell monolayers.", [["Vero cell monolayers", "ANATOMY", 53, 73], ["Vero cell monolayers", "CELL", 53, 73], ["Vero cell monolayers", "CELL_LINE", 53, 73], ["Both viruses", "PROBLEM", 0, 12], ["Vero cell monolayers", "TREATMENT", 53, 73], ["viruses", "OBSERVATION", 5, 12], ["Vero cell monolayers", "OBSERVATION", 53, 73]]], ["Diluted virus was allowed to adsorb at a multiplicity of infection (m.0.i.) of 0.01 at 32.5 or 37\" for 1 hr before medium was added.MATERIALS AND METHODSPlaque assay.", [["infection", "DISEASE", 57, 66], ["Diluted virus", "TREATMENT", 0, 13], ["infection", "PROBLEM", 57, 66], ["METHODSPlaque assay", "TEST", 146, 165], ["virus", "OBSERVATION", 8, 13], ["infection", "OBSERVATION", 57, 66]]], ["MHVa and JHM virus production was determined by a plaque assay on L-2 cell monolayers as previously described (Lucas et al., 1977) .", [["plaque", "ANATOMY", 50, 56], ["L-2 cell monolayers", "ANATOMY", 66, 85], ["MHVa", "GENE_OR_GENE_PRODUCT", 0, 4], ["JHM virus", "ORGANISM", 9, 18], ["L-2 cell monolayers", "CELL", 66, 85], ["L-2 cell monolayers", "CELL_LINE", 66, 85], ["MHVa", "SPECIES", 0, 4], ["JHM virus", "SPECIES", 9, 18], ["MHVa", "TREATMENT", 0, 4], ["JHM virus production", "PROBLEM", 9, 29], ["a plaque assay", "TEST", 48, 62], ["plaque", "OBSERVATION", 50, 56], ["cell monolayers", "OBSERVATION", 70, 85]]], ["Measles virus production was ascertained using a similar plaque assay on Vero cell monolayers.", [["plaque", "ANATOMY", 57, 63], ["Vero cell monolayers", "ANATOMY", 73, 93], ["Measles virus", "ORGANISM", 0, 13], ["Vero cell monolayers", "CELL", 73, 93], ["Vero cell monolayers", "CELL_LINE", 73, 93], ["Measles virus", "SPECIES", 0, 13], ["Measles virus production", "PROBLEM", 0, 24], ["a similar plaque assay", "PROBLEM", 47, 69], ["Vero cell monolayers", "TREATMENT", 73, 93], ["plaque", "OBSERVATION", 57, 63], ["Vero cell monolayers", "OBSERVATION", 73, 93]]], ["For plaque assays after overlaying with MEM containing 5% FBS and 0.5% methyl cellulose, 4000 cps, the infected monolayers were incubated at 32.5\" for 4 days in the case of Halle virus and 5 days when assaying the Edmonston strain, then were fixed and stained.", [["plaque", "ANATOMY", 4, 10], ["FBS", "ANATOMY", 58, 61], ["monolayers", "ANATOMY", 112, 122], ["MEM", "CHEMICAL", 40, 43], ["methyl cellulose", "CHEMICAL", 71, 87], ["methyl", "CHEMICAL", 71, 77], ["FBS", "ORGANISM_SUBSTANCE", 58, 61], ["methyl cellulose", "SIMPLE_CHEMICAL", 71, 87], ["monolayers", "CELL", 112, 122], ["Halle virus", "ORGANISM", 173, 184], ["Halle virus", "SPECIES", 173, 184], ["plaque assays", "PROBLEM", 4, 17], ["MEM", "TREATMENT", 40, 43], ["5% FBS", "TREATMENT", 55, 61], ["0.5% methyl cellulose", "TREATMENT", 66, 87], ["the infected monolayers", "PROBLEM", 99, 122], ["Halle virus", "PROBLEM", 173, 184], ["the Edmonston strain", "PROBLEM", 210, 230]]], ["To determine the fraction of cells able to release PFU during the state of persistence, the monolayers were washed, and the cells were released from them by trypsinization and then plated at serial dilutions on either L-2 monolayers in the case of JHM and MHVs infections or on Vero monolayers when Hall& and Edmonston infections were involved.", [["cells", "ANATOMY", 29, 34], ["monolayers", "ANATOMY", 92, 102], ["cells", "ANATOMY", 124, 129], ["L-2 monolayers", "ANATOMY", 218, 232], ["monolayers", "ANATOMY", 283, 293], ["JHM", "CHEMICAL", 248, 251], ["MHVs", "CHEMICAL", 256, 260], ["infections", "DISEASE", 261, 271], ["Hall&", "CHEMICAL", 299, 304], ["infections", "DISEASE", 319, 329], ["cells", "CELL", 29, 34], ["monolayers", "CELL", 92, 102], ["cells", "CELL", 124, 129], ["L-2 monolayers", "CELL", 218, 232], ["JHM", "SIMPLE_CHEMICAL", 248, 251], ["MHVs", "SIMPLE_CHEMICAL", 256, 260], ["Vero monolayers", "CELL", 278, 293], ["L-2 monolayers", "CELL_LINE", 218, 232], ["Vero monolayers", "CELL_LINE", 278, 293], ["serial dilutions", "TEST", 191, 207], ["JHM", "PROBLEM", 248, 251], ["MHVs infections", "PROBLEM", 256, 271], ["Vero monolayers", "TREATMENT", 278, 293], ["Edmonston infections", "PROBLEM", 309, 329], ["infections", "OBSERVATION", 261, 271]]], ["After 3 to 5 hr attachment period at 32.5\", the plates were overlaid with the methyl cellulose-MEM mixture and incubated until plaques developed as above.MATERIALS AND METHODSInfection of cell lines.", [["plaques", "ANATOMY", 127, 134], ["cell lines", "ANATOMY", 188, 198], ["methyl cellulose", "CHEMICAL", 78, 94], ["MEM", "CHEMICAL", 95, 98], ["methyl", "CHEMICAL", 78, 84], ["methyl cellulose", "SIMPLE_CHEMICAL", 78, 94], ["cell lines", "CELL", 188, 198], ["cell lines", "CELL_LINE", 188, 198], ["the methyl cellulose-MEM mixture", "TREATMENT", 74, 106], ["plaques", "PROBLEM", 127, 134], ["cell lines", "TREATMENT", 188, 198], ["plaques", "OBSERVATION", 127, 134], ["cell lines", "OBSERVATION", 188, 198]]], ["Various cell lines grown into monolayers were inoculated at a m.o.i. of 0.01 at 32.5 or 39.5' with one of MHV3, JHM, Hall& or Edmonston viruses.", [["cell lines", "ANATOMY", 8, 18], ["monolayers", "ANATOMY", 30, 40], ["cell lines", "CELL", 8, 18], ["monolayers", "CELL", 30, 40], ["Edmonston viruses", "ORGANISM", 126, 143], ["cell lines", "CELL_LINE", 8, 18], ["Various cell lines", "TREATMENT", 0, 18], ["MHV3", "PROBLEM", 106, 110], ["JHM", "PROBLEM", 112, 115], ["Edmonston viruses", "PROBLEM", 126, 143], ["cell lines", "OBSERVATION", 8, 18], ["grown", "OBSERVATION_MODIFIER", 19, 24], ["monolayers", "OBSERVATION_MODIFIER", 30, 40], ["Edmonston viruses", "OBSERVATION", 126, 143]]], ["Following adsorption for 1 hr, unadsorbed virus was removed, and the cultures were overlaid with nutrient medium.", [["unadsorbed virus", "PROBLEM", 31, 47], ["the cultures", "TEST", 65, 77], ["nutrient medium", "TREATMENT", 97, 112], ["virus", "OBSERVATION", 42, 47]]], ["The infected monolayers were examined for development of virus-induced cytopathology and monitored daily for production of free plaque-forming units per milliliter necessitating the complete replacement of the medium each day.MATERIALS AND METHODSDetermination of cerebroside sulfate.", [["monolayers", "ANATOMY", 13, 23], ["plaque", "ANATOMY", 128, 134], ["cerebroside sulfate", "CHEMICAL", 264, 283], ["cerebroside sulfate", "CHEMICAL", 264, 283], ["monolayers", "CELL", 13, 23], ["cerebroside sulfate", "SIMPLE_CHEMICAL", 264, 283], ["The infected monolayers", "PROBLEM", 0, 23], ["virus", "PROBLEM", 57, 62], ["free plaque", "PROBLEM", 123, 134], ["the complete replacement of the medium each day", "TREATMENT", 178, 225], ["cerebroside sulfate", "TREATMENT", 264, 283], ["infected monolayers", "OBSERVATION", 4, 23], ["virus", "OBSERVATION", 57, 62], ["replacement", "OBSERVATION", 191, 202], ["cerebroside sulfate", "OBSERVATION", 264, 283]]], ["Confluent monolayers of the various cell lines were incubated for 48 hr at 37\" in MEM supplemented with 2.5% FBS and containing 40 pCi/ml of [35S]sulfate (43 Ci/mg; New England Nuclear).", [["Confluent monolayers", "ANATOMY", 0, 20], ["cell lines", "ANATOMY", 36, 46], ["FBS", "ANATOMY", 109, 112], ["[35S]sulfate", "CHEMICAL", 141, 153], ["[35S]sulfate", "CHEMICAL", 141, 153], ["Confluent monolayers", "CELL", 0, 20], ["cell lines", "CELL", 36, 46], ["FBS", "ORGANISM_SUBSTANCE", 109, 112], ["[35S]sulfate", "SIMPLE_CHEMICAL", 141, 153], ["various cell lines", "CELL_LINE", 28, 46], ["Confluent monolayers of the various cell lines", "PROBLEM", 0, 46], ["2.5% FBS", "TREATMENT", 104, 112], ["35S]sulfate", "TREATMENT", 142, 153], ["monolayers", "OBSERVATION_MODIFIER", 10, 20], ["cell lines", "OBSERVATION", 36, 46]]], ["Cells were harvested by scraping and washed three times with phosphate-buffered saline.", [["Cells", "ANATOMY", 0, 5], ["phosphate", "CHEMICAL", 61, 70], ["phosphate", "CHEMICAL", 61, 70], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 61, 86], ["phosphate-buffered saline", "TREATMENT", 61, 86]]], ["Aliquots were kept for protein determination by the method of Lowry et al. (1951) using bovine serum albumin as standard, but the bulk of material was extracted with chloroformmethanol according to the method of Bligh and Dyer (1959) .", [["Aliquots", "ANATOMY", 0, 8], ["serum", "ANATOMY", 95, 100], ["chloroformmethanol", "CHEMICAL", 166, 184], ["chloroformmethanol", "CHEMICAL", 166, 184], ["Aliquots", "ORGANISM_SUBSTANCE", 0, 8], ["bovine", "ORGANISM", 88, 94], ["serum", "ORGANISM_SUBSTANCE", 95, 100], ["albumin", "GENE_OR_GENE_PRODUCT", 101, 108], ["chloroformmethanol", "SIMPLE_CHEMICAL", 166, 184], ["bovine", "SPECIES", 88, 94], ["bovine", "SPECIES", 88, 94], ["Aliquots", "TREATMENT", 0, 8], ["protein determination", "TEST", 23, 44], ["bovine serum albumin", "TEST", 88, 108], ["chloroformmethanol", "TREATMENT", 166, 184]]], ["The lower phase lipids were subjected to mild alkaline hydrolysis (Kates, 1972) and chromatographed in chloroform:methanol:water (65:25:4, v/v/v), on silica gel H thin-layer plates using cerebroside sulfate as a standard.", [["silica gel H", "CHEMICAL", 150, 162], ["cerebroside sulfate", "CHEMICAL", 187, 206], ["chloroform", "CHEMICAL", 103, 113], ["methanol", "CHEMICAL", 114, 122], ["silica", "CHEMICAL", 150, 156], ["H", "CHEMICAL", 161, 162], ["cerebroside sulfate", "CHEMICAL", 187, 206], ["chloroform", "SIMPLE_CHEMICAL", 103, 113], ["methanol", "SIMPLE_CHEMICAL", 114, 122], ["water", "SIMPLE_CHEMICAL", 123, 128], ["silica", "SIMPLE_CHEMICAL", 150, 156], ["cerebroside sulfate", "SIMPLE_CHEMICAL", 187, 206], ["The lower phase lipids", "TEST", 0, 22], ["mild alkaline hydrolysis", "PROBLEM", 41, 65], ["silica gel H thin-layer plates", "TREATMENT", 150, 180], ["cerebroside sulfate", "TREATMENT", 187, 206], ["lower phase", "OBSERVATION_MODIFIER", 4, 15], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["alkaline hydrolysis", "OBSERVATION", 46, 65]]], ["After preparative isolation of the cerebroside sulfate band and elution with chloroform:methanol:water (95:95:10, v/v/v), the counts per minute of [35S]sulfate incorporated were determined by liquid scintillation counting in a Beckman LS-350 instrument.Properties of Cell LinesThe origin and nature of continuous cell lines used in the present study are shown in Table 1 .", [["Cell", "ANATOMY", 267, 271], ["cell lines", "ANATOMY", 313, 323], ["cerebroside sulfate", "CHEMICAL", 35, 54], ["chloroform:methanol", "CHEMICAL", 77, 96], ["[35S]sulfate", "CHEMICAL", 147, 159], ["cerebroside sulfate", "CHEMICAL", 35, 54], ["chloroform", "CHEMICAL", 77, 87], ["methanol", "CHEMICAL", 88, 96], ["[35S]sulfate", "CHEMICAL", 147, 159], ["cerebroside sulfate", "SIMPLE_CHEMICAL", 35, 54], ["chloroform", "SIMPLE_CHEMICAL", 77, 87], ["methanol", "SIMPLE_CHEMICAL", 88, 96], ["water", "SIMPLE_CHEMICAL", 97, 102], ["[35S]sulfate", "SIMPLE_CHEMICAL", 147, 159], ["Cell Lines", "CELL", 267, 277], ["cell lines", "CELL", 313, 323], ["continuous cell lines", "CELL_LINE", 302, 323], ["the cerebroside sulfate band", "TREATMENT", 31, 59], ["35S]sulfate", "TREATMENT", 148, 159], ["a Beckman LS", "TEST", 225, 237], ["Cell Lines", "TREATMENT", 267, 277], ["continuous cell lines", "TREATMENT", 302, 323], ["the present study", "TEST", 332, 349], ["Cell Lines", "OBSERVATION", 267, 277], ["origin", "OBSERVATION_MODIFIER", 281, 287], ["continuous cell lines", "OBSERVATION", 302, 323]]], ["L-2 cells were found to be satisfactory as a fully permissive host in which MHVS and JHM can be grown to high titer and assayed.", [["L-2 cells", "ANATOMY", 0, 9], ["L-2 cells", "CELL", 0, 9], ["MHVS", "CELL", 76, 80], ["JHM", "CANCER", 85, 88], ["L-2 cells", "CELL_LINE", 0, 9], ["JHM", "PROBLEM", 85, 88], ["satisfactory", "OBSERVATION", 27, 39]]], ["In the case of measles, Vero cells originating from monkey kidney served as the host for virus production and quantification.Properties of Cell LinesCells of neural origin are identified according to the type of tumor from which they originated and by salient biochemical properties which they have retained.", [["Vero cells", "ANATOMY", 24, 34], ["kidney", "ANATOMY", 59, 65], ["Cell", "ANATOMY", 139, 143], ["neural", "ANATOMY", 158, 164], ["tumor", "ANATOMY", 212, 217], ["measles", "DISEASE", 15, 22], ["tumor", "DISEASE", 212, 217], ["measles", "ORGANISM", 15, 22], ["Vero cells", "CELL", 24, 34], ["monkey", "ORGANISM", 52, 58], ["kidney", "ORGAN", 59, 65], ["Cell", "CELL", 139, 143], ["tumor", "CANCER", 212, 217], ["Vero cells", "CELL_LINE", 24, 34], ["monkey", "SPECIES", 52, 58], ["measles", "SPECIES", 15, 22], ["Vero", "SPECIES", 24, 28], ["monkey", "SPECIES", 52, 58], ["measles", "PROBLEM", 15, 22], ["Vero cells", "PROBLEM", 24, 34], ["virus production", "PROBLEM", 89, 105], ["tumor", "PROBLEM", 212, 217], ["Vero cells", "OBSERVATION", 24, 34], ["kidney", "ANATOMY", 59, 65], ["Cell LinesCells", "OBSERVATION", 139, 154], ["neural origin", "ANATOMY", 158, 171], ["tumor", "OBSERVATION", 212, 217]]], ["Thus, lines C6 (Benda et al, 1968) , RN2-2 (Pfeiffer and Wechsler, 1972; Lucas et al., 1977) , G26-20, and G26-24 (Sundarraj et al., 1975) continue to synthesize in vitro the nervous- specific SlOO protein and contain high concentrations of the 2':3'-cyclic nucleotide 3'phosphohydrolase.", [["nervous", "ANATOMY", 175, 182], ["nucleotide", "CHEMICAL", 258, 268], ["2':3'-cyclic nucleotide", "CHEMICAL", 245, 268], ["lines C6", "CELL", 6, 14], ["G26-20", "CELL", 95, 101], ["G26-24", "CELL", 107, 113], ["nervous", "ANATOMICAL_SYSTEM", 175, 182], ["SlOO", "GENE_OR_GENE_PRODUCT", 193, 197], ["cyclic nucleotide 3'phosphohydrolase", "GENE_OR_GENE_PRODUCT", 251, 287], ["SlOO protein", "PROTEIN", 193, 205], ["cyclic nucleotide 3'phosphohydrolase", "PROTEIN", 251, 287], ["lines C6", "TEST", 6, 14], ["RN2", "TEST", 37, 40], ["Lucas et al.", "TEST", 73, 85], ["G26", "TEST", 95, 98], ["G26", "TEST", 107, 110], ["cyclic nucleotide 3'phosphohydrolase", "TREATMENT", 251, 287]]], ["Furthermore, G26-20, G26-24 (Dawson et al., 1977) , and RN2-2 cells (Lucas et al., 1977) contain cerebroside sulfate, a lipid characteristically present in myelin.", [["RN2-2 cells", "ANATOMY", 56, 67], ["myelin", "ANATOMY", 156, 162], ["cerebroside sulfate", "CHEMICAL", 97, 116], ["G26-20", "CHEMICAL", 13, 19], ["cerebroside sulfate", "CHEMICAL", 97, 116], ["G26-24", "CELL", 21, 27], ["RN2-2 cells", "CELL", 56, 67], ["cerebroside sulfate", "SIMPLE_CHEMICAL", 97, 116], ["myelin", "CELLULAR_COMPONENT", 156, 162], ["Furthermore", "TEST", 0, 11], ["G26", "TEST", 13, 16], ["G26", "TEST", 21, 24], ["Dawson et al.", "TEST", 29, 42], ["RN2", "TEST", 56, 59], ["cerebroside sulfate", "TREATMENT", 97, 116], ["cerebroside sulfate", "OBSERVATION", 97, 116], ["myelin", "ANATOMY", 156, 162]]], ["Absence of this sulfated glycolipid from C6 astrocytoma and mouse neuroblastoma Cl300 cells is not surprising since neither originated from myelin-producing cells; however, the presence of detectable levels of this sulfolipid in Vero cells from monkey kidney and the HTC line of rat hepatoma shows that occurrence of cerebroside sulfate is not per se an adequate diagnostic marker for cells of glial origin.Persistence of MHV, and JHM in NeuralCell LinesPersistence of MHV, and JHM in NeuralThe previously established tropism of the JHM agent for RN2-2 cells (Lucas et al., 1977) led us to investigate in detail whether a similar interaction occurs with other neural lines.", [["C6 astrocytoma", "ANATOMY", 41, 55], ["neuroblastoma Cl300 cells", "ANATOMY", 66, 91], ["myelin", "ANATOMY", 140, 146], ["cells", "ANATOMY", 157, 162], ["Vero cells", "ANATOMY", 229, 239], ["kidney", "ANATOMY", 252, 258], ["HTC line", "ANATOMY", 267, 275], ["hepatoma", "ANATOMY", 283, 291], ["cells", "ANATOMY", 385, 390], ["glial", "ANATOMY", 394, 399], ["Neural", "ANATOMY", 485, 491], ["RN2-2 cells", "ANATOMY", 547, 558], ["neural lines", "ANATOMY", 660, 672], ["astrocytoma", "DISEASE", 44, 55], ["neuroblastoma", "DISEASE", 66, 79], ["hepatoma", "DISEASE", 283, 291], ["cerebroside sulfate", "CHEMICAL", 317, 336], ["sulfolipid", "CHEMICAL", 215, 225], ["cerebroside sulfate", "CHEMICAL", 317, 336], ["C6 astrocytoma", "CANCER", 41, 55], ["mouse", "ORGANISM", 60, 65], ["neuroblastoma Cl300 cells", "CELL", 66, 91], ["myelin", "GENE_OR_GENE_PRODUCT", 140, 146], ["cells", "CELL", 157, 162], ["sulfolipid", "GENE_OR_GENE_PRODUCT", 215, 225], ["Vero cells", "CELL", 229, 239], ["monkey", "ORGANISM", 245, 251], ["kidney", "ORGAN", 252, 258], ["HTC line", "CELL", 267, 275], ["rat", "ORGANISM", 279, 282], ["hepatoma", "CANCER", 283, 291], ["cerebroside sulfate", "SIMPLE_CHEMICAL", 317, 336], ["cells", "CELL", 385, 390], ["glial", "CELL", 394, 399], ["MHV", "ORGANISM", 422, 425], ["MHV", "ORGANISM", 469, 472], ["JHM", "SIMPLE_CHEMICAL", 533, 536], ["RN2-2 cells", "CELL", 547, 558], ["neural lines", "CELL", 660, 672], ["C6 astrocytoma", "CELL_LINE", 41, 55], ["mouse neuroblastoma Cl300 cells", "CELL_LINE", 60, 91], ["myelin-producing cells", "CELL_TYPE", 140, 162], ["sulfolipid", "PROTEIN", 215, 225], ["Vero cells", "CELL_LINE", 229, 239], ["HTC line", "CELL_LINE", 267, 275], ["RN2-2 cells", "CELL_LINE", 547, 558], ["neural lines", "CELL_LINE", 660, 672], ["mouse", "SPECIES", 60, 65], ["rat", "SPECIES", 279, 282], ["mouse", "SPECIES", 60, 65], ["rat", "SPECIES", 279, 282], ["MHV", "SPECIES", 422, 425], ["MHV", "SPECIES", 469, 472], ["this sulfated glycolipid", "TEST", 11, 35], ["C6 astrocytoma", "PROBLEM", 41, 55], ["mouse neuroblastoma Cl300 cells", "PROBLEM", 60, 91], ["myelin-producing cells", "PROBLEM", 140, 162], ["detectable levels", "PROBLEM", 189, 206], ["this sulfolipid in Vero cells", "PROBLEM", 210, 239], ["the HTC line", "TEST", 263, 275], ["rat hepatoma", "PROBLEM", 279, 291], ["cerebroside sulfate", "TREATMENT", 317, 336], ["MHV", "PROBLEM", 422, 425], ["JHM", "PROBLEM", 431, 434], ["MHV", "PROBLEM", 469, 472], ["JHM", "PROBLEM", 478, 481], ["the JHM agent", "TREATMENT", 529, 542], ["RN2", "TEST", 547, 550], ["C6", "ANATOMY", 41, 43], ["astrocytoma", "OBSERVATION", 44, 55], ["neuroblastoma Cl300 cells", "OBSERVATION", 66, 91], ["Vero cells", "OBSERVATION", 229, 239], ["kidney", "ANATOMY", 252, 258], ["cerebroside sulfate", "OBSERVATION", 317, 336], ["glial origin", "OBSERVATION", 394, 406], ["MHV", "OBSERVATION", 422, 425], ["JHM", "OBSERVATION_MODIFIER", 431, 434], ["MHV", "OBSERVATION", 469, 472], ["Neural", "ANATOMY", 485, 491], ["neural lines", "OBSERVATION", 660, 672]]], ["Following inoculation of monolayers with either JHM or MHV3 viruses, persistent infections could be readily established.", [["monolayers", "ANATOMY", 25, 35], ["infections", "DISEASE", 80, 90], ["monolayers", "CELL", 25, 35], ["JHM", "GENE_OR_GENE_PRODUCT", 48, 51], ["MHV3 viruses", "ORGANISM", 55, 67], ["JHM", "PROBLEM", 48, 51], ["MHV3 viruses", "PROBLEM", 55, 67], ["persistent infections", "PROBLEM", 69, 90], ["persistent", "OBSERVATION_MODIFIER", 69, 79], ["infections", "OBSERVATION", 80, 90]]], ["In the case of the mouse hepatitis viruses, infection in RN2-2 cells was rapidly aborted with MHVZ but became cyclical in the case of JHM, as shown in Fig. 1A and previously described (Lucas et al., 1977) .", [["RN2-2 cells", "ANATOMY", 57, 68], ["hepatitis viruses", "DISEASE", 25, 42], ["infection", "DISEASE", 44, 53], ["MHVZ", "CHEMICAL", 94, 98], ["MHVZ", "CHEMICAL", 94, 98], ["mouse", "ORGANISM", 19, 24], ["hepatitis viruses", "ORGANISM", 25, 42], ["RN2-2 cells", "CELL", 57, 68], ["MHVZ", "SIMPLE_CHEMICAL", 94, 98], ["JHM", "CANCER", 134, 137], ["RN2-2 cells", "CELL_LINE", 57, 68], ["mouse", "SPECIES", 19, 24], ["mouse hepatitis viruses", "SPECIES", 19, 42], ["the mouse hepatitis viruses", "PROBLEM", 15, 42], ["infection in RN2-2 cells", "PROBLEM", 44, 68], ["MHVZ", "TREATMENT", 94, 98], ["JHM", "PROBLEM", 134, 137], ["hepatitis viruses", "OBSERVATION", 25, 42], ["infection", "OBSERVATION", 44, 53]]], ["Thus the RN2-2 cell line is able to discriminate between the two coronaviruses.", [["RN2-2 cell line", "ANATOMY", 9, 24], ["RN2-2 cell line", "CELL", 9, 24], ["coronaviruses", "ORGANISM", 65, 78], ["RN2-2 cell line", "CELL_LINE", 9, 24], ["the RN2", "TEST", 5, 12], ["cell line", "OBSERVATION", 15, 24], ["two", "OBSERVATION_MODIFIER", 61, 64], ["coronaviruses", "OBSERVATION", 65, 78]]], ["Associated with the JHM virus release, one could observe development of syncytia which were self-limiting in area, disappearing and reappearing continually, without ever completely destroying the monolayer.", [["syncytia", "ANATOMY", 72, 80], ["monolayer", "ANATOMY", 196, 205], ["syncytia", "DISEASE", 72, 80], ["JHM virus", "ORGANISM", 20, 29], ["syncytia", "CELL", 72, 80], ["monolayer", "CELL", 196, 205], ["JHM virus", "SPECIES", 20, 29], ["the JHM virus release", "PROBLEM", 16, 37], ["syncytia", "PROBLEM", 72, 80], ["syncytia", "OBSERVATION", 72, 80]]], ["Infectious center assays demonstrated that during persistence there was also a cyclical increase in the fraction of virus-producing cells, ranging between 0.01 and 1%.Inoculationof the C6 rat astrocytoma failed to elicit any evidence for virus-induced cytopathology (CPE) or virus replication.", [["cells", "ANATOMY", 132, 137], ["C6 rat astrocytoma", "ANATOMY", 185, 203], ["astrocytoma", "DISEASE", 192, 203], ["cells", "CELL", 132, 137], ["rat", "ORGANISM", 188, 191], ["astrocytoma", "CANCER", 192, 203], ["virus-producing cells", "CELL_TYPE", 116, 137], ["rat", "SPECIES", 188, 191], ["Infectious center assays", "TEST", 0, 24], ["a cyclical increase", "PROBLEM", 77, 96], ["virus", "PROBLEM", 116, 121], ["the C6 rat astrocytoma", "PROBLEM", 181, 203], ["virus", "PROBLEM", 238, 243], ["induced cytopathology", "PROBLEM", 244, 265], ["CPE", "PROBLEM", 267, 270], ["virus replication", "PROBLEM", 275, 292], ["cyclical", "OBSERVATION_MODIFIER", 79, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["C6 rat", "ANATOMY", 185, 191], ["astrocytoma", "OBSERVATION", 192, 203]]], ["Within 1 day after inoculation, the titer commenced to decline and become nil within 3 to 5 days.", [["inoculation", "TREATMENT", 19, 30]]], ["By contrast, infection of murine oligodendroglioma lines, G26-20 and G26-24, and neuroblastoma Cl300 cell lines with MHV3 and JHM readily initiated persistent infections, characterized also in each case by a cyclical rise and fall in titer (Figs. lB, C, and D).", [["oligodendroglioma lines", "ANATOMY", 33, 56], ["G26-20", "ANATOMY", 58, 64], ["G26-24", "ANATOMY", 69, 75], ["neuroblastoma Cl300 cell lines", "ANATOMY", 81, 111], ["infection", "DISEASE", 13, 22], ["oligodendroglioma", "DISEASE", 33, 50], ["neuroblastoma", "DISEASE", 81, 94], ["infections", "DISEASE", 159, 169], ["murine", "ORGANISM", 26, 32], ["oligodendroglioma lines", "CELL", 33, 56], ["G26-20", "CELL", 58, 64], ["G26-24", "CELL", 69, 75], ["neuroblastoma Cl300 cell lines", "CELL", 81, 111], ["MHV3", "CELL", 117, 121], ["JHM", "CELL", 126, 129], ["murine oligodendroglioma lines", "CELL_LINE", 26, 56], ["G26-20", "CELL_LINE", 58, 64], ["G26-24", "CELL_LINE", 69, 75], ["neuroblastoma Cl300 cell lines", "CELL_LINE", 81, 111], ["lB", "PROTEIN", 247, 249], ["murine", "SPECIES", 26, 32], ["MHV3", "SPECIES", 117, 121], ["infection of murine oligodendroglioma lines", "PROBLEM", 13, 56], ["G26", "TEST", 58, 61], ["G26", "TEST", 69, 72], ["neuroblastoma", "PROBLEM", 81, 94], ["MHV3", "PROBLEM", 117, 121], ["JHM", "PROBLEM", 126, 129], ["persistent infections", "PROBLEM", 148, 169], ["a cyclical rise", "PROBLEM", 206, 221], ["fall in titer", "PROBLEM", 226, 239], ["infection", "OBSERVATION", 13, 22], ["murine oligodendroglioma lines", "OBSERVATION", 26, 56], ["neuroblastoma", "ANATOMY", 81, 94], ["Cl300 cell lines", "OBSERVATION", 95, 111], ["persistent", "OBSERVATION_MODIFIER", 148, 158], ["infections", "OBSERVATION", 159, 169]]], ["Unlike the CPE present with JHM in RN2-2 cells, the infection of G26-20 or G26-24 cells did not elicit any syncytiogenesis, despite the fact that high titers comparable to those found in lytic infections of L-2 cells were recorded.", [["RN2-2 cells", "ANATOMY", 35, 46], ["G26-20", "ANATOMY", 65, 71], ["G26-24 cells", "ANATOMY", 75, 87], ["L-2 cells", "ANATOMY", 207, 216], ["infection", "DISEASE", 52, 61], ["infections", "DISEASE", 193, 203], ["RN2-2 cells", "CELL", 35, 46], ["G26-20", "CELL", 65, 71], ["G26-24 cells", "CELL", 75, 87], ["L-2 cells", "CELL", 207, 216], ["JHM", "PROTEIN", 28, 31], ["RN2-2 cells", "CELL_LINE", 35, 46], ["G26-24 cells", "CELL_LINE", 75, 87], ["L-2 cells", "CELL_LINE", 207, 216], ["G26-20", "SPECIES", 65, 71], ["the CPE", "TEST", 7, 14], ["JHM in RN2", "TEST", 28, 38], ["the infection", "TEST", 48, 61], ["G26", "TEST", 65, 68], ["G26", "TEST", 75, 78], ["any syncytiogenesis", "PROBLEM", 103, 122], ["high titers", "PROBLEM", 146, 157], ["lytic infections of L-2 cells", "PROBLEM", 187, 216], ["infection", "OBSERVATION", 52, 61], ["lytic", "OBSERVATION_MODIFIER", 187, 192], ["infections", "OBSERVATION", 193, 203]]], ["Throughout the 50-day duration of the experiments, the fraction of cells scored as infectious centers also fluctuated between 0.1 and 100% in the case of JHM and between 0.06 and 100% for MHVS infecting either G26-20 or G26-24 cells.InoculationInoculation of the Cl300 neuroblastoma with either coronavirus produced a more extensive and destructive CPE than observed when JHM infects RN2-2 cells.", [["cells", "ANATOMY", 67, 72], ["G26-20", "ANATOMY", 210, 216], ["G26-24 cells", "ANATOMY", 220, 232], ["Cl300 neuroblastoma", "ANATOMY", 263, 282], ["RN2-2 cells", "ANATOMY", 384, 395], ["JHM", "CHEMICAL", 154, 157], ["neuroblastoma", "DISEASE", 269, 282], ["cells", "CELL", 67, 72], ["G26-20", "CELL", 210, 216], ["G26-24 cells", "CELL", 220, 232], ["Cl300 neuroblastoma", "CANCER", 263, 282], ["coronavirus", "ORGANISM", 295, 306], ["RN2-2 cells", "CELL", 384, 395], ["G26-24 cells", "CELL_LINE", 220, 232], ["Cl300 neuroblastoma", "CELL_LINE", 263, 282], ["RN2-2 cells", "CELL_LINE", 384, 395], ["MHVS", "SPECIES", 188, 192], ["JHM", "TEST", 154, 157], ["MHVS", "TEST", 188, 192], ["the Cl300 neuroblastoma", "PROBLEM", 259, 282], ["coronavirus", "PROBLEM", 295, 306], ["a more extensive and destructive CPE", "PROBLEM", 316, 352], ["JHM infects RN2", "TEST", 372, 387], ["Cl300", "ANATOMY", 263, 268], ["neuroblastoma", "OBSERVATION", 269, 282], ["coronavirus", "OBSERVATION", 295, 306], ["more", "OBSERVATION_MODIFIER", 318, 322], ["extensive", "OBSERVATION_MODIFIER", 323, 332], ["destructive", "OBSERVATION_MODIFIER", 337, 348]]], ["Most of the cells in Cl300 monolayers were eventually involved.", [["cells", "ANATOMY", 12, 17], ["Cl300 monolayers", "ANATOMY", 21, 37], ["Cl300", "CHEMICAL", 21, 26], ["cells", "CELL", 12, 17], ["Cl300 monolayers", "CELL", 21, 37], ["Cl300 monolayers", "CELL_LINE", 21, 37]]], ["The remaining cells not recruited into the massive syncytia could repopulate the cultures but thereafter the CPE was again manifested.", [["cells", "ANATOMY", 14, 19], ["syncytia", "ANATOMY", 51, 59], ["cells", "CELL", 14, 19], ["syncytia", "CELL", 51, 59], ["the massive syncytia", "PROBLEM", 39, 59], ["the cultures", "TEST", 77, 89], ["the CPE", "TEST", 105, 112], ["massive", "OBSERVATION_MODIFIER", 43, 50], ["syncytia", "OBSERVATION", 51, 59]]], ["Over long term, cultures of Cl300 continue to generate PFU for 3 or more months indicating that the infection is continually held in balance between a lytic and persistent state.", [["Cl300", "CHEMICAL", 28, 33], ["infection", "DISEASE", 100, 109], ["Cl300", "GENE_OR_GENE_PRODUCT", 28, 33], ["cultures", "TEST", 16, 24], ["Cl300", "TEST", 28, 33], ["the infection", "PROBLEM", 96, 109], ["a lytic and persistent state", "PROBLEM", 149, 177], ["infection", "OBSERVATION", 100, 109], ["lytic", "OBSERVATION_MODIFIER", 151, 156], ["persistent", "OBSERVATION_MODIFIER", 161, 171]]], ["Duration of infection could also be prolonged deliberately by reseeding almost completely destroyed cultures with uninfected Cl300 cells.", [["cultures", "ANATOMY", 100, 108], ["Cl300 cells", "ANATOMY", 125, 136], ["infection", "DISEASE", 12, 21], ["Cl300 cells", "CELL", 125, 136], ["Cl300 cells", "CELL_LINE", 125, 136], ["infection", "PROBLEM", 12, 21], ["uninfected Cl300 cells", "PROBLEM", 114, 136], ["infection", "OBSERVATION", 12, 21], ["could also be", "UNCERTAINTY", 22, 35], ["Cl300 cells", "OBSERVATION", 125, 136]]], ["The number of infectious centers could not be determined because the cells released by trypsinization that remained as intact units and could be plated on indicator L-2 monolayers were not virus producers.", [["cells", "ANATOMY", 69, 74], ["cells", "CELL", 69, 74], ["L-2 monolayers", "CELL", 165, 179], ["L-2 monolayers", "CELL_LINE", 165, 179], ["the cells", "PROBLEM", 65, 74], ["infectious", "OBSERVATION", 14, 24]]], ["Perhaps use of trypsin in this case eliminated all C1300-infected cells.Persistence of MHVY and JHM in CellLines not Originating in the Nervous SystemPersistence of MHVY and JHM in CellIt is, apparent that both the JHM and MHV, strains readily establish persistent infections in several neural cell lines, al-though the ability to discriminate in favor of JHM, with complete suppression of MHV3, was an unique property of the RN2-2 rat Schwannoma..", [["cells", "ANATOMY", 66, 71], ["neural cell lines", "ANATOMY", 287, 304], ["JHM", "ANATOMY", 356, 359], ["JHM", "DISEASE", 96, 99], ["infections", "DISEASE", 265, 275], ["JHM", "DISEASE", 356, 359], ["Schwannoma", "DISEASE", 436, 446], ["trypsin", "GENE_OR_GENE_PRODUCT", 15, 22], ["C1300", "SIMPLE_CHEMICAL", 51, 56], ["cells", "CELL", 66, 71], ["JHM", "GENE_OR_GENE_PRODUCT", 215, 218], ["MHV", "ORGANISM", 223, 226], ["neural cell lines", "CELL", 287, 304], ["JHM", "CANCER", 356, 359], ["MHV3", "GENE_OR_GENE_PRODUCT", 390, 394], ["rat", "ORGANISM", 432, 435], ["trypsin", "PROTEIN", 15, 22], ["C1300-infected cells", "CELL_LINE", 51, 71], ["neural cell lines", "CELL_LINE", 287, 304], ["JHM", "PROTEIN", 356, 359], ["MHV3", "DNA", 390, 394], ["rat", "SPECIES", 432, 435], ["MHV", "SPECIES", 223, 226], ["trypsin", "TREATMENT", 15, 22], ["infected cells", "PROBLEM", 57, 71], ["MHVY", "PROBLEM", 87, 91], ["JHM in CellLines", "PROBLEM", 96, 112], ["JHM", "PROBLEM", 174, 177], ["the JHM and MHV", "PROBLEM", 211, 226], ["strains", "PROBLEM", 228, 235], ["persistent infections in several neural cell lines", "PROBLEM", 254, 304], ["JHM", "PROBLEM", 356, 359], ["complete suppression of MHV3", "PROBLEM", 366, 394], ["Schwannoma", "PROBLEM", 436, 446], ["infected cells", "OBSERVATION", 57, 71], ["JHM", "OBSERVATION_MODIFIER", 96, 99], ["JHM", "OBSERVATION", 215, 218], ["MHV", "ANATOMY", 223, 226], ["persistent", "OBSERVATION_MODIFIER", 254, 264], ["infections", "OBSERVATION", 265, 275], ["several", "OBSERVATION_MODIFIER", 279, 286], ["neural cell lines", "OBSERVATION", 287, 304], ["JHM", "OBSERVATION", 356, 359], ["Schwannoma", "OBSERVATION", 436, 446]]], ["It remained possible that this type of host regulation might be a species-related characteristic, although this seemed unlikely in view of the inability of either virus to replicate in the C6 rat astrocytoma.", [["C6 rat astrocytoma", "ANATOMY", 189, 207], ["astrocytoma", "DISEASE", 196, 207], ["rat", "ORGANISM", 192, 195], ["astrocytoma", "CANCER", 196, 207], ["rat", "SPECIES", 192, 195], ["a species", "PROBLEM", 64, 73], ["the inability of either virus", "PROBLEM", 139, 168], ["the C6 rat astrocytoma", "PROBLEM", 185, 207], ["C6 rat", "ANATOMY", 189, 195], ["astrocytoma", "OBSERVATION", 196, 207]]], ["To further investigate species-related control of infectiousness, monolayers of rat HTC hepatoma and L6 myoblast cells were inoculated with JHM and MHVa.", [["monolayers", "ANATOMY", 66, 76], ["HTC hepatoma", "ANATOMY", 84, 96], ["L6 myoblast cells", "ANATOMY", 101, 118], ["monolayers", "CELL", 66, 76], ["rat", "ORGANISM", 80, 83], ["HTC hepatoma", "CELL", 84, 96], ["L6 myoblast cells", "CELL", 101, 118], ["rat HTC hepatoma", "CELL_LINE", 80, 96], ["L6 myoblast cells", "CELL_LINE", 101, 118], ["rat", "SPECIES", 80, 83], ["rat", "SPECIES", 80, 83], ["species", "PROBLEM", 23, 30], ["infectiousness", "PROBLEM", 50, 64], ["rat HTC hepatoma", "PROBLEM", 80, 96], ["L6 myoblast cells", "PROBLEM", 101, 118], ["JHM", "PROBLEM", 140, 143], ["MHVa", "TREATMENT", 148, 152], ["L6", "ANATOMY", 101, 103], ["myoblast cells", "OBSERVATION", 104, 118]]], ["Both corona agents elicited the characteristic CPE within 2 days postinfection.", [["the characteristic CPE", "PROBLEM", 28, 50], ["corona", "OBSERVATION_MODIFIER", 5, 11], ["characteristic", "OBSERVATION_MODIFIER", 32, 46], ["CPE", "OBSERVATION", 47, 50]]], ["The syncytiogenesis was limited, never resulting in the complete destruction of the monolayers, despite the continuous elaboration of PFU in cyclical waves (Figs.", [["monolayers", "ANATOMY", 84, 94], ["syncytiogenesis", "DISEASE", 4, 19], ["monolayers", "CELL", 84, 94], ["the complete destruction of the monolayers", "PROBLEM", 52, 94], ["complete", "OBSERVATION_MODIFIER", 56, 64], ["destruction", "OBSERVATION", 65, 76], ["monolayers", "OBSERVATION_MODIFIER", 84, 94]]], ["Throughout the period of the experiments, the fraction of cells scored as infectious centers fluctuated between 0.7 and 22.4% in the case of HTC infected with JHM, and between 3 and 45% for the MHVz infection.", [["cells", "ANATOMY", 58, 63], ["HTC infected", "DISEASE", 141, 153], ["JHM", "DISEASE", 159, 162], ["MHVz", "CHEMICAL", 194, 198], ["infection", "DISEASE", 199, 208], ["cells", "CELL", 58, 63], ["JHM", "CANCER", 159, 162], ["MHVz", "SPECIES", 194, 198], ["infectious centers", "TEST", 74, 92], ["HTC infected with JHM", "PROBLEM", 141, 162], ["the MHVz infection", "PROBLEM", 190, 208], ["infectious", "OBSERVATION_MODIFIER", 74, 84], ["infected", "OBSERVATION", 145, 153], ["MHVz", "ANATOMY", 194, 198], ["infection", "OBSERVATION", 199, 208]]], ["The infectious centers with L6 cells remained relatively constant between 6.3 and 11.5% when JHM was the infecting agent and between 14 and 30% if inoculated with MHV3.", [["L6 cells", "ANATOMY", 28, 36], ["JHM", "CHEMICAL", 93, 96], ["L6 cells", "CELL", 28, 36], ["L6 cells", "CELL_LINE", 28, 36], ["MHV3", "SPECIES", 163, 167], ["L6 cells", "PROBLEM", 28, 36], ["JHM", "PROBLEM", 93, 96], ["infectious", "OBSERVATION", 4, 14], ["L6 cells", "ANATOMY", 28, 36], ["constant", "OBSERVATION_MODIFIER", 57, 65]]], ["From this it becomes apparent that the capacity for discriminating between JHM and MHV3 is an unique property of RN2-2 Schwannoma cells and is not species-related.", [["RN2-2 Schwannoma cells", "ANATOMY", 113, 135], ["Schwannoma", "DISEASE", 119, 129], ["JHM", "GENE_OR_GENE_PRODUCT", 75, 78], ["MHV3", "GENE_OR_GENE_PRODUCT", 83, 87], ["RN2-2 Schwannoma cells", "CELL", 113, 135], ["JHM", "PROTEIN", 75, 78], ["MHV3", "DNA", 83, 87], ["RN2-2 Schwannoma cells", "CELL_LINE", 113, 135], ["the capacity", "PROBLEM", 35, 47], ["JHM", "PROBLEM", 75, 78], ["Schwannoma cells", "PROBLEM", 119, 135], ["Schwannoma cells", "OBSERVATION", 119, 135]]], ["These data also show that establishment of persistence by JHM and MHVS is not exclusive to neural cells but may also occur readily in cells originating from a hepatoma and in myoblasts.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesThe relative ease in establishing persistence with the coronaviruses led us to investigate in the same cell lines comparable associations with measles virus.", [["neural cells", "ANATOMY", 91, 103], ["cells", "ANATOMY", 134, 139], ["hepatoma", "ANATOMY", 159, 167], ["myoblasts", "ANATOMY", 175, 184], ["Neural", "ANATOMY", 239, 245], ["Cell", "ANATOMY", 260, 264], ["cell lines", "ANATOMY", 373, 383], ["hepatoma", "DISEASE", 159, 167], ["measles virus", "DISEASE", 413, 426], ["JHM", "CANCER", 58, 61], ["neural cells", "CELL", 91, 103], ["cells", "CELL", 134, 139], ["hepatoma", "CANCER", 159, 167], ["myoblasts", "CELL", 175, 184], ["Hall6", "GENE_OR_GENE_PRODUCT", 200, 205], ["Edmonston Measles Viruses", "ORGANISM", 210, 235], ["Neural", "CELL", 239, 245], ["Nonneural Cell Lines", "CELL", 250, 270], ["coronaviruses", "ORGANISM", 325, 338], ["cell lines", "CELL", 373, 383], ["measles virus", "ORGANISM", 413, 426], ["JHM", "PROTEIN", 58, 61], ["MHVS", "PROTEIN", 66, 70], ["neural cells", "CELL_TYPE", 91, 103], ["myoblasts", "CELL_TYPE", 175, 184], ["Neural and Nonneural Cell Lines", "CELL_LINE", 239, 270], ["cell lines", "CELL_LINE", 373, 383], ["measles virus", "SPECIES", 413, 426], ["JHM", "PROBLEM", 58, 61], ["MHVS", "PROBLEM", 66, 70], ["a hepatoma", "PROBLEM", 157, 167], ["Hall6", "TREATMENT", 200, 205], ["Edmonston", "TREATMENT", 210, 219], ["Measles Viruses", "PROBLEM", 220, 235], ["Neural and Nonneural Cell Lines", "TREATMENT", 239, 270], ["the coronaviruses", "PROBLEM", 321, 338], ["measles virus", "PROBLEM", 413, 426], ["not exclusive", "UNCERTAINTY", 74, 87], ["neural cells", "OBSERVATION", 91, 103], ["hepatoma", "OBSERVATION", 159, 167], ["myoblasts", "ANATOMY", 175, 184], ["Nonneural Cell Lines", "OBSERVATION", 250, 270], ["cell lines", "OBSERVATION", 373, 383]]], ["For this purpose, the Hall6 and Edmonston strains were used.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesWhen fully permissive, Vero cell monolayers were inoculated with either strain at 32.5; at an m.o.i. of 0.01, large polykaryocytes first became apparent within 24 hr using the Hall6 virus and within 36 hr with the Edmonston virus.", [["Neural", "ANATOMY", 114, 120], ["Cell", "ANATOMY", 135, 139], ["Vero cell monolayers", "ANATOMY", 168, 188], ["polykaryocytes", "ANATOMY", 261, 275], ["Hall6", "GENE_OR_GENE_PRODUCT", 22, 27], ["Hall6", "GENE_OR_GENE_PRODUCT", 75, 80], ["Edmonston Measles Viruses", "ORGANISM", 85, 110], ["Neural", "CELL", 114, 120], ["Nonneural Cell LinesWhen", "CELL", 125, 149], ["Vero cell monolayers", "CELL", 168, 188], ["polykaryocytes", "CANCER", 261, 275], ["Edmonston virus", "ORGANISM", 359, 374], ["Neural and Nonneural Cell LinesWhen", "CELL_LINE", 114, 149], ["Vero cell monolayers", "CELL_LINE", 168, 188], ["Hall6 virus", "SPECIES", 321, 332], ["Edmonston virus", "SPECIES", 359, 374], ["the Hall6 and Edmonston strains", "TREATMENT", 18, 49], ["Hall6", "TREATMENT", 75, 80], ["Edmonston", "TREATMENT", 85, 94], ["Measles Viruses", "PROBLEM", 95, 110], ["Vero cell monolayers", "TEST", 168, 188], ["large polykaryocytes", "PROBLEM", 255, 275], ["the Hall6 virus", "TREATMENT", 317, 332], ["the Edmonston virus", "PROBLEM", 355, 374], ["Nonneural Cell", "ANATOMY", 125, 139], ["Vero cell monolayers", "OBSERVATION", 168, 188], ["large", "OBSERVATION_MODIFIER", 255, 260], ["polykaryocytes", "OBSERVATION", 261, 275]]], ["Titers as high as lo8 PFU/ml were determined on cell-free me-dium removed 4 days postinfection with the Ha116 strain.", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["Titers", "TEST", 0, 6], ["the Ha116 strain", "PROBLEM", 100, 116]]], ["At this time the entire monolayers had become virtually one continuous syncytium.", [["monolayers", "ANATOMY", 24, 34], ["syncytium", "ANATOMY", 71, 80], ["monolayers", "CELL", 24, 34], ["syncytium", "CELL", 71, 80]]], ["Infection with the Edmonston strain produced lower titers, only lo7 PFU/ml, of cell-free virus and at a slower rate since the peak was not reached until 6 to 7 days postinfection.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesTo investigate the replication of measles in the other non-neural and neural continuous cell lines, monolayer cultures were inoculated at 32.5\" and examined for cytopathology, virus production, and development of infectious centers.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesInfection of G26-20 and G26-24 cells proved to be aborted since there was no CPE or infectious virus formation.", [["cell", "ANATOMY", 79, 83], ["Neural", "ANATOMY", 233, 239], ["Cell", "ANATOMY", 254, 258], ["non-neural", "ANATOMY", 319, 329], ["neural continuous cell lines", "ANATOMY", 334, 362], ["monolayer cultures", "ANATOMY", 364, 382], ["Neural", "ANATOMY", 550, 556], ["Cell", "ANATOMY", 571, 575], ["G26-20", "ANATOMY", 594, 600], ["G26-24 cells", "ANATOMY", 605, 617], ["measles", "DISEASE", 298, 305], ["Edmonston strain", "ORGANISM", 19, 35], ["cell", "CELL", 79, 83], ["-free virus", "ORGANISM", 83, 94], ["Hall6", "GENE_OR_GENE_PRODUCT", 194, 199], ["Edmonston Measles Viruses", "ORGANISM", 204, 229], ["Neural", "CELL", 233, 239], ["Nonneural Cell LinesTo", "CELL", 244, 266], ["measles", "ORGANISM", 298, 305], ["non-neural", "CELL", 319, 329], ["neural continuous cell lines", "CELL", 334, 362], ["monolayer cultures", "CELL", 364, 382], ["Hall6", "GENE_OR_GENE_PRODUCT", 511, 516], ["Edmonston Measles Viruses", "ORGANISM", 521, 546], ["Neural", "CELL", 550, 556], ["Nonneural Cell", "CELL", 561, 575], ["G26-20", "CELL", 594, 600], ["G26-24 cells", "CELL", 605, 617], ["non-neural and neural continuous cell lines", "CELL_LINE", 319, 362], ["monolayer cultures", "CELL_LINE", 364, 382], ["G26-20", "CELL_LINE", 594, 600], ["G26-24 cells", "CELL_LINE", 605, 617], ["Infection", "PROBLEM", 0, 9], ["the Edmonston strain", "TEST", 15, 35], ["lower titers", "PROBLEM", 45, 57], ["cell-free virus", "PROBLEM", 79, 94], ["Hall6", "TREATMENT", 194, 199], ["Edmonston Measles Viruses", "TREATMENT", 204, 229], ["Neural and Nonneural Cell LinesTo", "TREATMENT", 233, 266], ["measles", "PROBLEM", 298, 305], ["monolayer cultures", "TEST", 364, 382], ["cytopathology", "TEST", 425, 438], ["virus production", "PROBLEM", 440, 456], ["Hall6", "TREATMENT", 511, 516], ["Edmonston", "TREATMENT", 521, 530], ["Measles Viruses", "PROBLEM", 531, 546], ["Neural and Nonneural Cell LinesInfection", "TEST", 550, 590], ["G26", "TEST", 594, 597], ["G26", "TEST", 605, 608], ["CPE", "PROBLEM", 658, 661], ["infectious virus formation", "PROBLEM", 665, 691], ["free virus", "OBSERVATION", 84, 94], ["Nonneural Cell", "OBSERVATION", 244, 258], ["cell lines", "OBSERVATION", 352, 362], ["infectious", "OBSERVATION", 477, 487], ["Nonneural Cell", "ANATOMY", 561, 575], ["no", "UNCERTAINTY", 655, 657], ["infectious", "OBSERVATION_MODIFIER", 665, 675], ["virus", "OBSERVATION", 676, 681]]], ["Instead, commencing 1 day after infection, there was a progressive eclipse of the inoculum to zero titer within 5 days.", [["infection", "DISEASE", 32, 41], ["infection", "PROBLEM", 32, 41], ["a progressive eclipse of the inoculum", "PROBLEM", 53, 90], ["infection", "OBSERVATION", 32, 41], ["progressive", "OBSERVATION_MODIFIER", 55, 66], ["eclipse", "OBSERVATION_MODIFIER", 67, 74]]], ["Restriction on virus production was maintained for longer than several weeks.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesBy comparison, inoculation of RN2-2, C6, HTC, and L6 rat cell lines with either Ha& or Edmonston virus readily established persistent infections.", [["Neural", "ANATOMY", 131, 137], ["Cell", "ANATOMY", 152, 156], ["RN2-2", "ANATOMY", 192, 197], ["C6", "ANATOMY", 199, 201], ["HTC", "ANATOMY", 203, 206], ["L6 rat cell lines", "ANATOMY", 212, 229], ["infections", "DISEASE", 296, 306], ["Hall6", "GENE_OR_GENE_PRODUCT", 92, 97], ["Edmonston Measles Viruses", "ORGANISM", 102, 127], ["Neural", "CELL", 131, 137], ["Nonneural Cell", "CELL", 142, 156], ["RN2-2", "CELL", 192, 197], ["C6, HTC", "CELL", 199, 206], ["L6 rat cell lines", "CELL", 212, 229], ["Ha&", "GENE_OR_GENE_PRODUCT", 242, 245], ["Edmonston virus", "ORGANISM", 249, 264], ["RN2-2, C6, HTC, and L6 rat cell lines", "CELL_LINE", 192, 229], ["rat", "SPECIES", 215, 218], ["Edmonston virus", "SPECIES", 249, 264], ["virus production", "TREATMENT", 15, 31], ["Hall6", "TREATMENT", 92, 97], ["Edmonston Measles Viruses", "PROBLEM", 102, 127], ["inoculation of RN2", "TEST", 177, 195], ["HTC", "TEST", 203, 206], ["Edmonston virus", "PROBLEM", 249, 264], ["persistent infections", "PROBLEM", 285, 306], ["virus", "OBSERVATION", 15, 20], ["Nonneural Cell", "OBSERVATION", 142, 156], ["C6", "ANATOMY", 199, 201], ["L6", "ANATOMY", 212, 214], ["cell lines", "OBSERVATION", 219, 229], ["persistent", "OBSERVATION_MODIFIER", 285, 295], ["infections", "OBSERVATION", 296, 306]]], ["2A-D, in all cases tested infectious particles were produced and released into the medium in a cyclical manner over a period of 1 to 2 months.", [["2A-D", "CHEMICAL", 0, 4], ["2A-D", "SIMPLE_CHEMICAL", 0, 4], ["infectious", "OBSERVATION", 26, 36]]], ["Initially, the titers were relatively low, but with time higher virus yields were recorded.", [["the titers", "TEST", 11, 21], ["time higher virus yields", "PROBLEM", 52, 76]]], ["In none of the above associations was there any evidence of CPE, despite the fact that in some instances virtually all cells became infectious centers.", [["cells", "ANATOMY", 119, 124], ["CPE", "DISEASE", 60, 63], ["cells", "CELL", 119, 124], ["CPE", "PROBLEM", 60, 63], ["CPE", "OBSERVATION", 60, 63], ["infectious", "OBSERVATION", 132, 142]]], ["Usually the fraction of cells shown to be infectious centers fluctuated between 5 and 80% with C6 cells, 0.05 and 60% with RN2-2 cells, 0.1 and 0.5% in the case of HTC cells and 1 and 10% with the L6 cells as the host for either virus.", [["cells", "ANATOMY", 24, 29], ["C6 cells", "ANATOMY", 95, 103], ["RN2-2 cells", "ANATOMY", 123, 134], ["HTC cells", "ANATOMY", 164, 173], ["L6 cells", "ANATOMY", 197, 205], ["cells", "CELL", 24, 29], ["C6 cells", "CELL", 95, 103], ["RN2-2 cells", "CELL", 123, 134], ["HTC cells", "CELL", 164, 173], ["L6 cells", "CELL", 197, 205], ["C6 cells", "CELL_LINE", 95, 103], ["HTC cells", "CELL_LINE", 164, 173], ["L6 cells", "CELL_LINE", 197, 205], ["infectious centers", "PROBLEM", 42, 60], ["C6 cells", "TEST", 95, 103], ["RN2", "TEST", 123, 126], ["HTC cells", "TEST", 164, 173], ["virus", "PROBLEM", 229, 234], ["infectious", "OBSERVATION", 42, 52], ["C6 cells", "ANATOMY", 95, 103], ["L6", "ANATOMY", 197, 199]]], ["From the foregoing it is evident that inoculation of these particular rat cell lines at low m.o.i. with Hal16 or Edmonston measles viruses leads directly to the establishment of persistent but inapparent infections. outgrowth of or selection for a variant progeny virus that is temperature-sensitive for growth (Haspel et al., 1973; Preble and Youngner, 1973; Shenk et al., 1974; Gould and Linton, 1975; Kimura et cd., 1975; Youngner and Quagliana, 1975; Youngner et al., 1976; Armen et al., 1977; Truant and Hallum, 1977) .", [["cell lines", "ANATOMY", 74, 84], ["Hal16", "CHEMICAL", 104, 109], ["infections", "DISEASE", 204, 214], ["rat", "ORGANISM", 70, 73], ["cell lines", "CELL", 74, 84], ["Hal16", "GENE_OR_GENE_PRODUCT", 104, 109], ["Edmonston measles viruses", "ORGANISM", 113, 138], ["rat cell lines", "CELL_LINE", 70, 84], ["rat", "SPECIES", 70, 73], ["rat", "SPECIES", 70, 73], ["Edmonston measles viruses", "SPECIES", 113, 138], ["Hal16", "TREATMENT", 104, 109], ["Edmonston measles viruses", "TREATMENT", 113, 138], ["inapparent infections", "PROBLEM", 193, 214], ["a variant progeny virus", "PROBLEM", 246, 269], ["temperature", "TEST", 278, 289], ["cell lines", "OBSERVATION", 74, 84], ["persistent", "OBSERVATION_MODIFIER", 178, 188], ["inapparent", "OBSERVATION_MODIFIER", 193, 203], ["infections", "OBSERVATION", 204, 214]]], ["To determine whether a similar appearance of thermolabile progeny occurred in the cell-virus systems being examined here, temperature-shift experiments were conducted after initiating persistent infections.", [["cell", "ANATOMY", 82, 86], ["infections", "DISEASE", 195, 205], ["cell", "CELL", 82, 86], ["thermolabile progeny", "CELL_LINE", 45, 65], ["thermolabile progeny", "PROBLEM", 45, 65], ["persistent infections", "PROBLEM", 184, 205], ["thermolabile progeny", "OBSERVATION", 45, 65], ["persistent", "OBSERVATION_MODIFIER", 184, 194], ["infections", "OBSERVATION", 195, 205]]], ["In some instances, cultures actively producing virus at 32.5\" were moved to incubators set at 39.5\", then the medium was changed daily and assayed at 32.5' for PFU per milliliter.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesWith the Halle and Edmonston persistent infections of RN2-2 cells, the elevated temperature caused an abrupt cessation of virus release.", [["Neural", "ANATOMY", 233, 239], ["Cell", "ANATOMY", 254, 258], ["RN2-2 cells", "ANATOMY", 318, 329], ["infections", "DISEASE", 304, 314], ["Hall6", "GENE_OR_GENE_PRODUCT", 194, 199], ["Edmonston Measles Viruses", "ORGANISM", 204, 229], ["Neural", "CELL", 233, 239], ["Nonneural Cell", "CELL", 244, 258], ["RN2-2 cells", "CELL", 318, 329], ["RN2-2 cells", "CELL_LINE", 318, 329], ["cultures", "TEST", 19, 27], ["virus", "PROBLEM", 47, 52], ["Hall6", "TREATMENT", 194, 199], ["Edmonston", "TREATMENT", 204, 213], ["Measles Viruses", "PROBLEM", 214, 229], ["persistent infections of RN2-2 cells", "PROBLEM", 293, 329], ["the elevated temperature", "PROBLEM", 331, 355], ["virus release", "TREATMENT", 386, 399], ["Nonneural Cell", "OBSERVATION", 244, 258], ["persistent", "OBSERVATION_MODIFIER", 293, 303], ["infections", "OBSERVATION", 304, 314], ["abrupt", "OBSERVATION_MODIFIER", 366, 372]]], ["3A and B, the titer declined within 1 day, and no virus at all was present within 2 or 3 days following shift-up of the temperature, while yield PFU in the characterisic cycling fashion.", [["B", "GENE_OR_GENE_PRODUCT", 7, 8], ["B", "PROTEIN", 7, 8], ["virus", "PROBLEM", 50, 55], ["the temperature", "TEST", 116, 131], ["no", "UNCERTAINTY", 47, 49], ["virus", "OBSERVATION", 50, 55]]], ["Overall, very similar effects were observed with other persistently infected cell lines.", [["cell lines", "ANATOMY", 77, 87], ["cell lines", "CELL", 77, 87], ["persistently infected cell lines", "CELL_LINE", 55, 87], ["other persistently infected cell lines", "PROBLEM", 49, 87], ["infected cell lines", "OBSERVATION", 68, 87]]], ["One exception was L6 myoblasts carrying the Edmonston measles virus which continued to elaborate PFU at 39.5\", although the yield of virus was 1 log lower than at 32.5\".Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesThe production of PFU from the majority of the coronavirus persistent infections was inhibited or profoundly reduced at the elevated temperature.", [["L6 myoblasts", "ANATOMY", 18, 30], ["Neural", "ANATOMY", 223, 229], ["Cell", "ANATOMY", 244, 248], ["measles", "DISEASE", 54, 61], ["coronavirus", "DISEASE", 301, 312], ["infections", "DISEASE", 324, 334], ["L6 myoblasts", "CELL", 18, 30], ["Edmonston measles virus", "ORGANISM", 44, 67], ["Hall6", "GENE_OR_GENE_PRODUCT", 184, 189], ["Edmonston Measles Viruses", "ORGANISM", 194, 219], ["Neural", "CELL", 223, 229], ["Nonneural Cell Lines", "CELL", 234, 254], ["PFU", "ORGANISM", 272, 275], ["coronavirus", "ORGANISM", 301, 312], ["L6 myoblasts", "CELL_LINE", 18, 30], ["Neural and Nonneural Cell Lines", "CELL_LINE", 223, 254], ["coronavirus", "SPECIES", 301, 312], ["Edmonston measles virus", "SPECIES", 44, 67], ["L6 myoblasts", "PROBLEM", 18, 30], ["the Edmonston measles virus", "PROBLEM", 40, 67], ["virus", "PROBLEM", 133, 138], ["Hall6", "TREATMENT", 184, 189], ["Edmonston Measles Viruses", "TREATMENT", 194, 219], ["Neural and Nonneural Cell Lines", "TREATMENT", 223, 254], ["PFU", "PROBLEM", 272, 275], ["the coronavirus persistent infections", "PROBLEM", 297, 334], ["the elevated temperature", "PROBLEM", 374, 398], ["L6 myoblasts", "ANATOMY", 18, 30], ["Nonneural Cell Lines", "OBSERVATION", 234, 254], ["coronavirus", "OBSERVATION_MODIFIER", 301, 312], ["persistent", "OBSERVATION_MODIFIER", 313, 323], ["infections", "OBSERVATION", 324, 334], ["reduced", "OBSERVATION_MODIFIER", 363, 370], ["elevated", "OBSERVATION_MODIFIER", 378, 386], ["temperature", "OBSERVATION_MODIFIER", 387, 398]]], ["Coincidentally the cytopathology evident with several of the infections at 32.5\" was absent at 39.5\".", [["infections", "DISEASE", 61, 71], ["the cytopathology", "TEST", 15, 32], ["the infections", "PROBLEM", 57, 71], ["several", "OBSERVATION_MODIFIER", 46, 53], ["infections", "OBSERVATION", 61, 71]]], ["Only partial reduction of replication of JHM in HTC, L6, and G26-24 cells was demonstrated at 39.5\", whereby the titer was 2 log units lower than at 32.5\".", [["JHM", "ANATOMY", 41, 44], ["HTC", "ANATOMY", 48, 51], ["L6", "ANATOMY", 53, 55], ["G26-24 cells", "ANATOMY", 61, 73], ["JHM", "CELL", 41, 44], ["HTC", "CELL", 48, 51], ["L6", "CELL", 53, 55], ["G26-24 cells", "CELL", 61, 73], ["JHM", "CELL_LINE", 41, 44], ["HTC", "CELL_LINE", 48, 51], ["L6", "CELL_LINE", 53, 55], ["G26-24 cells", "CELL_LINE", 61, 73], ["JHM", "PROBLEM", 41, 44], ["HTC", "TEST", 48, 51], ["partial", "OBSERVATION_MODIFIER", 5, 12], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["replication", "OBSERVATION_MODIFIER", 26, 37], ["JHM", "OBSERVATION_MODIFIER", 41, 44], ["L6", "ANATOMY", 53, 55]]], ["With neuroblastoma Cl300 there was no appreciable difference in JHM titer at the two temperatures.", [["neuroblastoma", "ANATOMY", 5, 18], ["neuroblastoma", "DISEASE", 5, 18], ["neuroblastoma Cl300", "CANCER", 5, 24], ["JHM", "CANCER", 64, 67], ["neuroblastoma Cl300", "CELL_LINE", 5, 24], ["JHM", "PROTEIN", 64, 67], ["neuroblastoma", "PROBLEM", 5, 18], ["appreciable difference in JHM titer", "PROBLEM", 38, 73], ["neuroblastoma", "OBSERVATION", 5, 18], ["no", "UNCERTAINTY", 35, 37], ["appreciable", "OBSERVATION_MODIFIER", 38, 49], ["difference", "OBSERVATION_MODIFIER", 50, 60]]], ["It should be remembered that coronavirus infection of Cl300 cells borders between the persistent and lytic type.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesRestriction of virus replication at 39.5' could also be instituted from the time of inoculation if infection was also made at 39.5' as shown in Figs murine hepatitis viruses.", [["Cl300 cells", "ANATOMY", 54, 65], ["Neural", "ANATOMY", 166, 172], ["Cell", "ANATOMY", 187, 191], ["coronavirus infection", "DISEASE", 29, 50], ["Measles Viruses", "DISEASE", 147, 162], ["infection", "DISEASE", 296, 305], ["hepatitis viruses", "DISEASE", 353, 370], ["coronavirus", "ORGANISM", 29, 40], ["Cl300 cells", "CELL", 54, 65], ["Hall6", "GENE_OR_GENE_PRODUCT", 127, 132], ["Edmonston Measles Viruses", "ORGANISM", 137, 162], ["Neural", "CELL", 166, 172], ["Nonneural Cell", "CELL", 177, 191], ["murine hepatitis viruses", "ORGANISM", 346, 370], ["Cl300 cells", "CELL_LINE", 54, 65], ["murine", "SPECIES", 346, 352], ["coronavirus infection of Cl300 cells", "PROBLEM", 29, 65], ["the persistent and lytic type", "PROBLEM", 82, 111], ["Hall6", "TREATMENT", 127, 132], ["Edmonston", "TREATMENT", 137, 146], ["Measles Viruses", "PROBLEM", 147, 162], ["Neural and Nonneural Cell LinesRestriction", "TREATMENT", 166, 208], ["virus replication", "TREATMENT", 212, 229], ["infection", "PROBLEM", 296, 305], ["Figs murine hepatitis viruses", "PROBLEM", 341, 370], ["coronavirus", "OBSERVATION_MODIFIER", 29, 40], ["infection", "OBSERVATION", 41, 50], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["lytic", "OBSERVATION_MODIFIER", 101, 106], ["Nonneural Cell", "OBSERVATION", 177, 191], ["hepatitis viruses", "OBSERVATION", 353, 370]]], ["In most cases, for some of which the data are not shown, the results were like those with JHM infection of RN2-2 cells at 39.5\" in which CPE was absent and virus production declined sharply until none was being made within 4 to 5 days.", [["RN2-2 cells", "ANATOMY", 107, 118], ["infection", "DISEASE", 94, 103], ["RN2-2 cells", "CELL", 107, 118], ["JHM infection", "PROBLEM", 90, 103], ["CPE", "TEST", 137, 140], ["virus production", "PROBLEM", 156, 172]]], ["As in the exceptions described above for shift-up experiments, JHM infection of the G26-24, HTC, and L6 cells which commenced at 39.5' was incompletely suppressed and that of Cl300 cells not at all inhibited.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesParallel infections commenced and maintained at 39.5\" with the Hall6 or Edmonston measles viruses in RN2-2, C6, HTC, and L6 cells gave results identical to those obtained after shift of carrier cultures from 32.5 to 39.5\".", [["G26-24", "ANATOMY", 84, 90], ["HTC", "ANATOMY", 92, 95], ["L6 cells", "ANATOMY", 101, 109], ["Cl300 cells", "ANATOMY", 175, 186], ["Neural", "ANATOMY", 262, 268], ["Cell", "ANATOMY", 283, 287], ["RN2-2", "ANATOMY", 394, 399], ["C6", "ANATOMY", 401, 403], ["HTC", "ANATOMY", 405, 408], ["L6 cells", "ANATOMY", 414, 422], ["infection", "DISEASE", 67, 76], ["Measles Viruses", "DISEASE", 243, 258], ["infections", "DISEASE", 302, 312], ["G26-24", "CELL", 84, 90], ["HTC", "CELL", 92, 95], ["L6 cells", "CELL", 101, 109], ["Cl300 cells", "CELL", 175, 186], ["Hall6", "GENE_OR_GENE_PRODUCT", 223, 228], ["Edmonston Measles Viruses", "ORGANISM", 233, 258], ["Neural", "CELL", 262, 268], ["Nonneural Cell", "CELL", 273, 287], ["RN2-2", "CELL", 394, 399], ["C6", "CELL", 401, 403], ["HTC", "CELL", 405, 408], ["L6 cells", "CELL", 414, 422], ["G26-24", "CELL_LINE", 84, 90], ["HTC", "CELL_LINE", 92, 95], ["L6 cells", "CELL_LINE", 101, 109], ["Cl300 cells", "CELL_LINE", 175, 186], ["RN2-2, C6, HTC, and L6 cells", "CELL_LINE", 394, 422], ["JHM infection", "PROBLEM", 63, 76], ["the G26", "TEST", 80, 87], ["HTC, and L6 cells", "PROBLEM", 92, 109], ["Cl300 cells", "PROBLEM", 175, 186], ["Hall6", "TREATMENT", 223, 228], ["Edmonston", "TREATMENT", 233, 242], ["Measles Viruses", "PROBLEM", 243, 258], ["Neural and Nonneural Cell LinesParallel infections", "TREATMENT", 262, 312], ["the Hall6", "TREATMENT", 352, 361], ["Edmonston measles viruses", "PROBLEM", 365, 390], ["HTC", "TEST", 405, 408], ["carrier cultures", "TEST", 479, 495], ["infection", "OBSERVATION", 67, 76], ["L6 cells", "ANATOMY", 101, 109], ["Neural", "ANATOMY", 262, 268], ["Nonneural Cell", "ANATOMY", 273, 287], ["L6", "ANATOMY", 414, 416]]], ["In all cases except that of the Edmonston virus infection of L6 cells, no PFU were formed.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesIt was possible that thermosensitivity of the replication process described above was due to the selection for and appearance of thermolabile variants of the measles and coronaviruses employed.", [["L6 cells", "ANATOMY", 61, 69], ["Neural", "ANATOMY", 144, 150], ["Cell", "ANATOMY", 165, 169], ["infection", "DISEASE", 48, 57], ["Measles Viruses", "DISEASE", 125, 140], ["measles", "DISEASE", 333, 340], ["Edmonston virus", "ORGANISM", 32, 47], ["L6 cells", "CELL", 61, 69], ["Hall6", "GENE_OR_GENE_PRODUCT", 105, 110], ["Edmonston Measles Viruses", "ORGANISM", 115, 140], ["Neural", "CELL", 144, 150], ["Nonneural Cell Lines", "CELL", 155, 175], ["measles", "ORGANISM", 333, 340], ["L6 cells", "CELL_LINE", 61, 69], ["Edmonston virus", "SPECIES", 32, 47], ["the Edmonston virus infection of L6 cells", "PROBLEM", 28, 69], ["PFU", "PROBLEM", 74, 77], ["Hall6", "TREATMENT", 105, 110], ["Edmonston", "TREATMENT", 115, 124], ["Measles Viruses", "PROBLEM", 125, 140], ["Neural and Nonneural Cell Lines", "TREATMENT", 144, 175], ["the replication process", "PROBLEM", 217, 240], ["thermolabile variants", "PROBLEM", 304, 325], ["the measles", "PROBLEM", 329, 340], ["coronaviruses", "PROBLEM", 345, 358], ["L6 cells", "ANATOMY", 61, 69], ["no", "UNCERTAINTY", 71, 73], ["Nonneural Cell Lines", "OBSERVATION", 155, 175]]], ["This idea seemed unlikely, however, because thermosensitivity of infections carried out at 39.5\" was immediate.", [["infections", "DISEASE", 65, 75], ["infections", "PROBLEM", 65, 75], ["seemed unlikely", "UNCERTAINTY", 10, 25]]], ["Otherwise all four agents used must themselves have been thermolabile.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesAn answer to these alternatives was sought by plaque assays of progeny derived from lytic or persistent infections.", [["Neural", "ANATOMY", 124, 130], ["Cell", "ANATOMY", 145, 149], ["plaque", "ANATOMY", 201, 207], ["infections", "DISEASE", 259, 269], ["Hall6", "GENE_OR_GENE_PRODUCT", 85, 90], ["Edmonston Measles Viruses", "ORGANISM", 95, 120], ["Neural", "CELL", 124, 130], ["Nonneural Cell", "CELL", 135, 149], ["Hall6", "TREATMENT", 85, 90], ["Edmonston", "TREATMENT", 95, 104], ["Measles Viruses", "PROBLEM", 105, 120], ["Neural and Nonneural Cell LinesAn", "TREATMENT", 124, 157], ["these alternatives", "TREATMENT", 168, 186], ["persistent infections", "PROBLEM", 248, 269], ["Nonneural Cell", "OBSERVATION", 135, 149], ["lytic", "OBSERVATION_MODIFIER", 239, 244], ["persistent", "OBSERVATION_MODIFIER", 248, 258], ["infections", "OBSERVATION", 259, 269]]], ["Titers were compared on indicator cultures incubated at 32.5 or 39.5\".", [["indicator cultures", "TEST", 24, 42]]], ["A summary of the data shown in Table 2 revealed that, with two partial exceptions, none of the progeny was thermolabile, whether originating from long-term or newly established cultures, nor was there any evident alteration in the plaque morphology which might have implied a change of the virus during passage in carrier cells.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesOne exception concerned the Hall& virus which was minimally temperature-sensitive whether it originated from permissive or partially restrictive host cells.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesFollowing long-term MHV, infection of Cl300 cells, it appears that there may have been some selection for somewhat temperature-sensitive progeny viruses as indicated by reduction of 1 log in titer at 39.5 versus 32.5'.Replication of Hall6 and Edmonston Measles Viruses in Neural and Nonneural Cell LinesIt thus appears that in the majority of the carrier cultures, the host was conferring thermosensitivity upon the replication process without altering the genotype of the progeny.", [["cultures", "ANATOMY", 177, 185], ["plaque", "ANATOMY", 231, 237], ["cells", "ANATOMY", 322, 327], ["Neural", "ANATOMY", 382, 388], ["Cell", "ANATOMY", 403, 407], ["cells", "ANATOMY", 563, 568], ["Neural", "ANATOMY", 623, 629], ["Cell", "ANATOMY", 644, 648], ["Cl300 cells", "ANATOMY", 692, 703], ["Neural", "ANATOMY", 926, 932], ["Cell", "ANATOMY", 947, 951], ["plaque", "DISEASE", 231, 237], ["Measles Viruses", "DISEASE", 363, 378], ["infection", "DISEASE", 679, 688], ["plaque", "PATHOLOGICAL_FORMATION", 231, 237], ["cells", "CELL", 322, 327], ["Hall6", "GENE_OR_GENE_PRODUCT", 343, 348], ["Edmonston Measles Viruses", "ORGANISM", 353, 378], ["Neural", "CELL", 382, 388], ["Nonneural Cell Lines", "CELL", 393, 413], ["Hall& virus", "ORGANISM", 441, 452], ["host cells", "CELL", 558, 568], ["Hall6", "GENE_OR_GENE_PRODUCT", 584, 589], ["Edmonston Measles Viruses", "ORGANISM", 594, 619], ["Neural", "CELL", 623, 629], ["Nonneural Cell", "CELL", 634, 648], ["MHV", "ORGANISM", 674, 677], ["Cl300 cells", "CELL", 692, 703], ["Hall6", "GENE_OR_GENE_PRODUCT", 887, 892], ["Edmonston Measles Viruses", "ORGANISM", 897, 922], ["Neural", "CELL", 926, 932], ["Nonneural Cell Lines", "CELL", 937, 957], ["long-term or newly established cultures", "CELL_LINE", 146, 185], ["carrier cells", "CELL_TYPE", 314, 327], ["permissive or partially restrictive host cells", "CELL_TYPE", 522, 568], ["Cl300 cells", "CELL_LINE", 692, 703], ["Neural and Nonneural Cell Lines", "CELL_LINE", 926, 957], ["carrier cultures", "CELL_LINE", 1001, 1017], ["Hall& virus", "SPECIES", 441, 452], ["MHV", "SPECIES", 674, 677], ["the data", "TEST", 13, 21], ["newly established cultures", "TEST", 159, 185], ["the plaque morphology", "PROBLEM", 227, 248], ["the virus", "PROBLEM", 286, 295], ["passage in carrier cells", "TREATMENT", 303, 327], ["Hall6", "TREATMENT", 343, 348], ["Edmonston", "TREATMENT", 353, 362], ["Measles Viruses", "PROBLEM", 363, 378], ["Neural and Nonneural Cell Lines", "TREATMENT", 382, 413], ["the Hall& virus", "PROBLEM", 437, 452], ["minimally temperature", "PROBLEM", 463, 484], ["partially restrictive host cells", "PROBLEM", 536, 568], ["Hall6", "TREATMENT", 584, 589], ["Edmonston", "TREATMENT", 594, 603], ["Measles Viruses", "PROBLEM", 604, 619], ["long-term MHV", "TREATMENT", 664, 677], ["infection of Cl300 cells", "PROBLEM", 679, 703], ["somewhat temperature-sensitive progeny viruses", "PROBLEM", 760, 806], ["Hall6", "TREATMENT", 887, 892], ["Edmonston", "TREATMENT", 897, 906], ["Measles Viruses", "PROBLEM", 907, 922], ["Neural and Nonneural Cell Lines", "TREATMENT", 926, 957], ["the carrier cultures", "TEST", 997, 1017], ["plaque", "OBSERVATION", 231, 237], ["virus", "OBSERVATION", 290, 295], ["Nonneural Cell Lines", "OBSERVATION", 393, 413], ["restrictive", "OBSERVATION_MODIFIER", 546, 557], ["host cells", "OBSERVATION", 558, 568], ["Nonneural Cell", "OBSERVATION", 634, 648], ["long-term MHV", "OBSERVATION_MODIFIER", 664, 677], ["infection", "OBSERVATION", 679, 688], ["Nonneural Cell Lines", "OBSERVATION", 937, 957]]], ["Furthermore, as summarized in Table 3 , there was an almost absolute ' The virus being produced by cultures at 32.5\" was assayed for temperature sensitivity.", [["The virus", "PROBLEM", 71, 80], ["cultures", "TEST", 99, 107], ["temperature sensitivity", "PROBLEM", 133, 156], ["virus", "OBSERVATION", 75, 80]]], ["Aliquots of the medium were removed and assayed for the ability to form plaques on monolayers of either L cells (for JHM and MHV,,) or Vero cells (for Ha116 and Edmonston) at both 32.5 and 39.5' as described in Materials and Methods.", [["Aliquots", "ANATOMY", 0, 8], ["plaques", "ANATOMY", 72, 79], ["monolayers", "ANATOMY", 83, 93], ["L cells", "ANATOMY", 104, 111], ["JHM", "ANATOMY", 117, 120], ["Vero cells", "ANATOMY", 135, 145], ["monolayers", "CELL", 83, 93], ["L cells", "CELL", 104, 111], ["MHV", "ORGANISM", 125, 128], ["Vero cells", "CELL", 135, 145], ["Ha116", "CELL", 151, 156], ["L cells", "CELL_TYPE", 104, 111], ["Vero cells", "CELL_LINE", 135, 145], ["MHV", "SPECIES", 125, 128], ["plaques", "PROBLEM", 72, 79], ["JHM", "PROBLEM", 117, 120], ["MHV", "PROBLEM", 125, 128], ["Vero cells", "PROBLEM", 135, 145], ["plaques", "OBSERVATION", 72, 79]]], ["R(-) indicates replication negative. correlation between the ability of specific cell types to undergo chronic infection and thermosensitivity of the replication process.Reversibility of Temperature Restriction on Virus ReplicationThe host-regulated temperature sensitivity observed in cells persistently infected with the hepatitis and measles viruses raised questions concerning the reversibility of the thermosensitive restriction.", [["cell", "ANATOMY", 81, 85], ["cells", "ANATOMY", 286, 291], ["infection", "DISEASE", 111, 120], ["hepatitis", "DISEASE", 323, 332], ["R", "GENE_OR_GENE_PRODUCT", 0, 1], ["cell", "CELL", 81, 85], ["cells", "CELL", 286, 291], ["measles viruses", "ORGANISM", 337, 352], ["replication", "PROBLEM", 15, 26], ["chronic infection", "PROBLEM", 103, 120], ["the replication process", "PROBLEM", 146, 169], ["Temperature Restriction", "PROBLEM", 187, 210], ["Virus Replication", "TREATMENT", 214, 231], ["temperature sensitivity", "TEST", 250, 273], ["the hepatitis", "PROBLEM", 319, 332], ["measles viruses", "PROBLEM", 337, 352], ["the thermosensitive restriction", "TREATMENT", 402, 433], ["replication", "OBSERVATION_MODIFIER", 15, 26], ["negative", "OBSERVATION", 27, 35], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["infection", "OBSERVATION", 111, 120], ["Temperature Restriction", "OBSERVATION", 187, 210], ["infected", "OBSERVATION_MODIFIER", 305, 313], ["hepatitis", "OBSERVATION", 323, 332]]], ["To study this, we utilized persistent infections of RN2-2 cells by the JHM or the Ha116 viruses.", [["RN2-2 cells", "ANATOMY", 52, 63], ["infections", "DISEASE", 38, 48], ["RN2-2 cells", "CELL", 52, 63], ["JHM", "GENE_OR_GENE_PRODUCT", 71, 74], ["Ha116 viruses", "ORGANISM", 82, 95], ["RN2-2 cells", "CELL_LINE", 52, 63], ["persistent infections of RN2-2 cells", "PROBLEM", 27, 63], ["the JHM", "PROBLEM", 67, 74], ["the Ha116 viruses", "PROBLEM", 78, 95], ["persistent", "OBSERVATION_MODIFIER", 27, 37], ["infections", "OBSERVATION", 38, 48]]], ["Long-term cultures actively producing virus at 32.5\" were shifted to 39.5\" and incubated until no PFU were being formed, usually 3 to 5 days.", [["Long-term cultures", "TEST", 0, 18], ["virus", "PROBLEM", 38, 43], ["PFU", "PROBLEM", 98, 101]]], ["Then such cultures were returned to 32.5\", and the medium was changed and assayed daily for PFU per milliliter.", [["such cultures", "TEST", 5, 18]]], ["With the JHM infection, if cultures were kept at 39.5' for up to 6 days, virus production recovered in most cases in 2 to 3 days following shift-down to 32.5\".", [["infection", "DISEASE", 13, 22], ["the JHM infection", "PROBLEM", 5, 22], ["cultures", "TEST", 27, 35], ["virus production", "PROBLEM", 73, 89], ["JHM", "OBSERVATION_MODIFIER", 9, 12], ["infection", "OBSERVATION", 13, 22]]], ["In some instances when cultures were kept at 39.5' for 10 days, production of PFU resumed after shift-down.", [["cultures", "TEST", 23, 31]]], ["This recovery, however, required a longer duration at 32.5\" before progeny reappeared.Reversibility of Temperature Restriction on Virus ReplicationAnalogous data were derived from the measles infection.", [["measles infection", "DISEASE", 184, 201], ["Temperature Restriction", "PROBLEM", 103, 126], ["Virus Replication", "TREATMENT", 130, 147], ["Analogous data", "PROBLEM", 147, 161], ["the measles infection", "PROBLEM", 180, 201], ["Temperature Restriction", "OBSERVATION", 103, 126], ["measles", "OBSERVATION_MODIFIER", 184, 191], ["infection", "OBSERVATION", 192, 201]]], ["In most instances, virus production was resumed several days after shift-down of cultures that had been kept for as long as 10 days at the elevated temperature.Reversibility of Temperature Restriction on Virus ReplicationTo discount the possibility that resumption of virus replication after temperature reversal from 39.5 to 32.5\" was due to uneclipsed virus adsorbed at the cell surface, cultures were inoculated with JHM or Hall6 viruses at 32.5 or 39.5\".", [["cell surface", "ANATOMY", 376, 388], ["Virus", "ORGANISM", 204, 209], ["cell surface", "CELLULAR_COMPONENT", 376, 388], ["virus production", "PROBLEM", 19, 35], ["cultures", "TEST", 81, 89], ["the elevated temperature", "PROBLEM", 135, 159], ["Temperature Restriction", "PROBLEM", 177, 200], ["Virus", "TREATMENT", 204, 209], ["virus replication", "TREATMENT", 268, 285], ["temperature reversal", "TEST", 292, 312], ["uneclipsed virus", "PROBLEM", 343, 359], ["cultures", "TEST", 390, 398], ["JHM", "PROBLEM", 420, 423], ["Hall6 viruses", "PROBLEM", 427, 440], ["most instances", "OBSERVATION_MODIFIER", 3, 17], ["virus production", "OBSERVATION", 19, 35]]], ["After 1 hr to allow for adsorption, extracellular virus remaining was neutralized by adding specific antisera to cultures maintained at their respective temperatures.", [["extracellular", "ANATOMY", 36, 49], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 49], ["extracellular virus", "PROBLEM", 36, 55], ["cultures", "TEST", 113, 121]]], ["Some cultures were kept at 39.5\" for several days with daily changes of medium, then were moved to an incubator set at 32.5\".", [["Some cultures", "TEST", 0, 13]]], ["Treatment with antiserum did not alter the recovery following shift-down indicating that intracellular genome expression must have been involved in resumption of virus production.", [["intracellular", "ANATOMY", 89, 102], ["antiserum", "ORGANISM_SUBSTANCE", 15, 24], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["intracellular genome expression", "PROBLEM", 89, 120], ["virus production", "PROBLEM", 162, 178], ["virus", "OBSERVATION", 162, 167]]], ["These results further imply that both the JHM and Ha116 viruses were maintained in a latent form at the restrictive temperature.Replication of Vaccinia and Vesicular Stomatitis VirusesThe relative ease with which persistent infections with the coronaviruses and measles strains were established and the associated thermosensitivity of the replication suggested that infections with many virus lowing 1 hr of adsorption, unadsorbed virus types may indiscriminately become persist-was washed away, and cultures were covent.", [["Vesicular Stomatitis", "DISEASE", 156, 176], ["infections", "DISEASE", 224, 234], ["infections", "DISEASE", 366, 376], ["JHM", "GENE_OR_GENE_PRODUCT", 42, 45], ["Ha116 viruses", "ORGANISM", 50, 63], ["Vaccinia", "ORGANISM", 143, 151], ["Vesicular Stomatitis Viruses", "ORGANISM", 156, 184], ["coronaviruses", "ORGANISM", 244, 257], ["measles strains", "ORGANISM", 262, 277], ["the JHM and Ha116 viruses", "PROBLEM", 38, 63], ["Vaccinia", "TREATMENT", 143, 151], ["Vesicular Stomatitis Viruses", "PROBLEM", 156, 184], ["persistent infections", "PROBLEM", 213, 234], ["the coronaviruses", "PROBLEM", 240, 257], ["measles strains", "PROBLEM", 262, 277], ["infections", "PROBLEM", 366, 376], ["many virus", "PROBLEM", 382, 392], ["unadsorbed virus types", "PROBLEM", 420, 442], ["cultures", "TEST", 500, 508], ["restrictive temperature", "OBSERVATION", 104, 127], ["Vaccinia", "OBSERVATION", 143, 151], ["Vesicular Stomatitis Viruses", "OBSERVATION", 156, 184], ["persistent", "OBSERVATION_MODIFIER", 213, 223], ["infections", "OBSERVATION", 224, 234]]], ["To investigate this possibility mono-ered with nutrient medium.", [["nutrient medium", "TREATMENT", 47, 62]]], ["After 24 hr of layers of the various cell types were infected incubation at 32.5 or 39.5\", the concentraat 32.5 and 39.5\" with IHD-W vaccinia virus tion of VSV in the medium was determined at an m.o.i. of 5 PFU or vesicular stomatitis by plaque titration on L-2 cell monolayers. virus (VSV) at an m.o.i. of 0.01 PFU.", [["cell", "ANATOMY", 37, 41], ["vesicular", "ANATOMY", 214, 223], ["plaque", "ANATOMY", 238, 244], ["L-2 cell monolayers", "ANATOMY", 258, 277], ["vesicular stomatitis", "DISEASE", 214, 234], ["cell", "CELL", 37, 41], ["IHD-W vaccinia virus", "ORGANISM", 127, 147], ["VSV", "ORGANISM", 156, 159], ["vesicular stomatitis", "ORGANISM", 214, 234], ["L-2 cell monolayers", "CELL", 258, 277], ["virus", "ORGANISM", 279, 284], ["VSV", "ORGANISM", 286, 289], ["L-2 cell monolayers", "CELL_LINE", 258, 277], ["VSV", "SPECIES", 156, 159], ["virus", "SPECIES", 279, 284], ["VSV", "SPECIES", 286, 289], ["IHD", "PROBLEM", 127, 130], ["W vaccinia virus", "TREATMENT", 131, 147], ["VSV", "TREATMENT", 156, 159], ["vesicular stomatitis", "PROBLEM", 214, 234], ["plaque titration", "TREATMENT", 238, 254], ["L-2 cell monolayers", "TREATMENT", 258, 277], ["virus", "PROBLEM", 279, 284], ["vesicular stomatitis", "OBSERVATION", 214, 234], ["plaque", "OBSERVATION", 238, 244], ["cell monolayers", "OBSERVATION", 262, 277]]], ["Fol-With vaccinia virus, combined cell-associ-DISCUSSIONResults from these studies focus attention on three salient findings: (1) The strains of measles and mouse hepatitis viruses used can readily become established in a persistent form of infection in cell lines of neural and non-neural origin; (2) almost invariably when the infection is of the persistent type, virus replication becomes thermosensitive due to unknown factors under host control; the virus progeny from persistent infections are themselves not thermolabile; and (3) among the many cell types tested a rat RN2-2 Schwannoma has the unique ability to discriminate between the prototype MHV, and the neurotropic variant, JHM, supporting the persistence of only the latter.DISCUSSIONThe usual outcome of infecting a spectrum of cells originating from neural and non-neural tissue with any one among JHM, MHV3, Hall& or Edmonston viruses is the development of persistence as documented in Table 3 .", [["cell", "ANATOMY", 34, 38], ["cell lines", "ANATOMY", 254, 264], ["neural", "ANATOMY", 268, 274], ["non-neural", "ANATOMY", 279, 289], ["cell", "ANATOMY", 552, 556], ["RN2-2 Schwannoma", "ANATOMY", 576, 592], ["cells", "ANATOMY", 794, 799], ["neural", "ANATOMY", 817, 823], ["non-neural tissue", "ANATOMY", 828, 845], ["measles", "DISEASE", 145, 152], ["hepatitis viruses", "DISEASE", 163, 180], ["infection", "DISEASE", 241, 250], ["infection", "DISEASE", 329, 338], ["infections", "DISEASE", 485, 495], ["Schwannoma", "DISEASE", 582, 592], ["Edmonston viruses", "DISEASE", 885, 902], ["vaccinia virus", "ORGANISM", 9, 23], ["cell", "CELL", 34, 38], ["measles", "ORGANISM", 145, 152], ["mouse hepatitis viruses", "ORGANISM", 157, 180], ["cell lines", "CELL", 254, 264], ["neural", "CELL", 268, 274], ["non-neural", "TISSUE", 279, 289], ["cell", "CELL", 552, 556], ["rat", "ORGANISM", 572, 575], ["RN2-2 Schwannoma", "CANCER", 576, 592], ["MHV", "ORGANISM", 654, 657], ["JHM", "CANCER", 688, 691], ["cells", "CELL", 794, 799], ["neural", "TISSUE", 817, 823], ["non-neural tissue", "TISSUE", 828, 845], ["MHV3", "GENE_OR_GENE_PRODUCT", 870, 874], ["Edmonston viruses", "ORGANISM", 885, 902], ["cell lines", "CELL_LINE", 254, 264], ["mouse", "SPECIES", 157, 162], ["rat", "SPECIES", 572, 575], ["vaccinia virus", "SPECIES", 9, 23], ["mouse", "SPECIES", 157, 162], ["MHV", "SPECIES", 654, 657], ["vaccinia virus", "PROBLEM", 9, 23], ["these studies", "TEST", 69, 82], ["measles", "PROBLEM", 145, 152], ["mouse hepatitis viruses", "PROBLEM", 157, 180], ["infection in cell lines", "PROBLEM", 241, 264], ["the infection", "PROBLEM", 325, 338], ["the persistent type, virus replication", "PROBLEM", 345, 383], ["host control", "TREATMENT", 437, 449], ["the virus progeny", "PROBLEM", 451, 468], ["persistent infections", "PROBLEM", 474, 495], ["a rat RN2", "TEST", 570, 579], ["Schwannoma", "PROBLEM", 582, 592], ["JHM", "PROBLEM", 688, 691], ["infecting a spectrum of cells", "PROBLEM", 770, 799], ["neural and non-neural tissue", "PROBLEM", 817, 845], ["Edmonston viruses", "PROBLEM", 885, 902], ["persistent", "OBSERVATION_MODIFIER", 222, 232], ["infection", "OBSERVATION", 241, 250], ["cell lines", "OBSERVATION", 254, 264], ["neural", "ANATOMY_MODIFIER", 268, 274], ["non-neural origin", "ANATOMY", 279, 296], ["infection", "OBSERVATION", 329, 338], ["persistent", "OBSERVATION_MODIFIER", 349, 359], ["persistent", "OBSERVATION_MODIFIER", 474, 484], ["infections", "OBSERVATION", 485, 495], ["cell types", "OBSERVATION", 552, 562], ["Schwannoma", "OBSERVATION", 582, 592], ["neurotropic variant", "OBSERVATION", 667, 686], ["neural", "ANATOMY_MODIFIER", 817, 823], ["non-neural tissue", "ANATOMY", 828, 845], ["viruses", "OBSERVATION", 895, 902], ["persistence", "OBSERVATION_MODIFIER", 925, 936]]], ["The systems under investigation here differ from some of those examined previously by others in the directness, speed, simplicity, and reproducibility in establishment of chronic infections after inoculation at low m.o.i.", [["infections", "DISEASE", 179, 189], ["chronic infections", "PROBLEM", 171, 189], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["infections", "OBSERVATION", 179, 189]]], ["The latent period may be less than 1 day in duration, and no additional manipulation is required, such as repeated virus passage at high titer or the addition of neutralizing antibody.", [["neutralizing antibody", "PROTEIN", 162, 183], ["repeated virus passage", "PROBLEM", 106, 128], ["high titer", "PROBLEM", 132, 142], ["neutralizing antibody", "PROBLEM", 162, 183], ["latent", "OBSERVATION_MODIFIER", 4, 10], ["period", "OBSERVATION_MODIFIER", 11, 17], ["may be", "UNCERTAINTY", 18, 24], ["less", "OBSERVATION_MODIFIER", 25, 29], ["neutralizing antibody", "OBSERVATION", 162, 183]]], ["Although each type of cell-virus association examined here exhibits some individual peculiarity, one feature characteristic of all is the cyclical rise and fall of low virus titers extending over a period of at least several weeks and perhaps continuing indefinitely.", [["cell", "ANATOMY", 22, 26], ["cell", "CELL", 22, 26], ["some individual peculiarity", "PROBLEM", 68, 95], ["the cyclical rise", "PROBLEM", 134, 151], ["low virus titers", "PROBLEM", 164, 180], ["cell", "OBSERVATION", 22, 26], ["low virus", "OBSERVATION_MODIFIER", 164, 173]]], ["The murine hepatitis viruses can infect chronically both murine and rat cell lines, but a small fraction of the cells in culture become infectious centers.", [["cell lines", "ANATOMY", 72, 82], ["cells", "ANATOMY", 112, 117], ["hepatitis viruses", "DISEASE", 11, 28], ["murine hepatitis viruses", "ORGANISM", 4, 28], ["murine", "ORGANISM", 57, 63], ["rat", "ORGANISM", 68, 71], ["cell lines", "CELL", 72, 82], ["cells", "CELL", 112, 117], ["murine and rat cell lines", "CELL_LINE", 57, 82], ["murine", "SPECIES", 4, 10], ["murine", "SPECIES", 57, 63], ["rat", "SPECIES", 68, 71], ["murine hepatitis viruses", "SPECIES", 4, 28], ["rat", "SPECIES", 68, 71], ["The murine hepatitis viruses", "PROBLEM", 0, 28], ["rat cell lines", "TREATMENT", 68, 82], ["a small fraction of the cells", "PROBLEM", 88, 117], ["hepatitis viruses", "OBSERVATION", 11, 28], ["rat cell lines", "OBSERVATION", 68, 82], ["small", "OBSERVATION_MODIFIER", 90, 95], ["fraction", "OBSERVATION_MODIFIER", 96, 104], ["infectious", "OBSERVATION", 136, 146]]], ["The cytopathology produced may be self-limiting as in the case of rat cells RN2-2, HTC, and L6, or verge on the lytic when Cl300 neuroblastoma is the host, or exhibit no evident CPE as with murine oligodendroglioma lines G26-20 and G26-24.DISCUSSIONThe Ha116 and Edmonston strains are incapable of infecting the murine cells tested indicating that in this case there may exist a species-related restriction.", [["cells", "ANATOMY", 70, 75], ["HTC", "ANATOMY", 83, 86], ["L6", "ANATOMY", 92, 94], ["Cl300 neuroblastoma", "ANATOMY", 123, 142], ["oligodendroglioma lines", "ANATOMY", 197, 220], ["cells", "ANATOMY", 319, 324], ["neuroblastoma", "DISEASE", 129, 142], ["oligodendroglioma", "DISEASE", 197, 214], ["rat", "ORGANISM", 66, 69], ["cells", "CELL", 70, 75], ["RN2-2", "CELL", 76, 81], ["HTC", "CELL", 83, 86], ["L6", "CELL", 92, 94], ["Cl300 neuroblastoma", "CANCER", 123, 142], ["murine", "ORGANISM", 190, 196], ["oligodendroglioma lines G26-20", "CELL", 197, 227], ["G26-24", "CELL", 232, 238], ["Ha116", "GENE_OR_GENE_PRODUCT", 253, 258], ["Edmonston strains", "ORGANISM", 263, 280], ["murine", "ORGANISM", 312, 318], ["cells", "CELL", 319, 324], ["rat cells", "CELL_TYPE", 66, 75], ["HTC", "CELL_LINE", 83, 86], ["L6", "CELL_LINE", 92, 94], ["Cl300 neuroblastoma", "CELL_LINE", 123, 142], ["murine oligodendroglioma lines", "CELL_LINE", 190, 220], ["G26-24", "CELL_LINE", 232, 238], ["murine cells", "CELL_TYPE", 312, 324], ["rat", "SPECIES", 66, 69], ["murine", "SPECIES", 190, 196], ["murine", "SPECIES", 312, 318], ["rat", "SPECIES", 66, 69], ["The cytopathology", "TEST", 0, 17], ["rat cells RN2", "TEST", 66, 79], ["HTC", "TEST", 83, 86], ["Cl300 neuroblastoma", "PROBLEM", 123, 142], ["evident CPE", "PROBLEM", 170, 181], ["murine oligodendroglioma lines G26", "TEST", 190, 224], ["G26", "TEST", 232, 235], ["Edmonston strains", "PROBLEM", 263, 280], ["infecting the murine cells", "PROBLEM", 298, 324], ["a species", "PROBLEM", 377, 386], ["may be", "UNCERTAINTY", 27, 33], ["self-limiting", "OBSERVATION_MODIFIER", 34, 47], ["L6", "ANATOMY", 92, 94], ["lytic", "OBSERVATION_MODIFIER", 112, 117], ["no evident", "UNCERTAINTY", 167, 177], ["CPE", "OBSERVATION", 178, 181], ["oligodendroglioma", "OBSERVATION", 197, 214]]], ["A large fraction of measles-infected cells in a culture can become infectious centers without any apparent relationship to the extent of CPE, if any, associated with the infectious process.DISCUSSIONAlthough the molecular events underlying the maintenance of persistence in the systems under study here remain to be elucidated, in other virus carrier states chronic infections have been explained by effects involving the formation of and competition from defective interfering (DI) particles for host synthetic machinery (Holland et al., 1976; Kawai and Matsumoto, 1977) , or by inhibition of virus production due to interferon, sometimes in a cyclical fashion (Wiktor and Clark, 1972) , or due to selection of genotypically changed variants of the virus (Thacore and Youngner, 1969; Kawai et al., 1975; Youngner et al., 1976; Truant and Hallum, 1977) .DISCUSSIONInvolvement of DI particles in the present studies seems to be unlikely because the inoculation was made at low m.o.i. and medium was changed daily which should have minimized the production or accumulation of DI particles, unless such particles can somehow be maintained in a cellassociated state.", [["cells", "ANATOMY", 37, 42], ["measles-infected", "DISEASE", 20, 36], ["chronic infections", "DISEASE", 358, 376], ["measles", "ORGANISM", 20, 27], ["cells", "CELL", 37, 42], ["interferon", "GENE_OR_GENE_PRODUCT", 618, 628], ["measles-infected cells", "CELL_TYPE", 20, 42], ["interferon", "PROTEIN", 618, 628], ["A large fraction of measles", "PROBLEM", 0, 27], ["infected cells", "PROBLEM", 28, 42], ["a culture", "TEST", 46, 55], ["CPE", "PROBLEM", 137, 140], ["the infectious process.DISCUSSIONAlthough", "PROBLEM", 166, 207], ["the systems under study", "TEST", 274, 297], ["chronic infections", "PROBLEM", 358, 376], ["defective interfering (DI) particles", "PROBLEM", 456, 492], ["virus production", "PROBLEM", 594, 610], ["interferon", "TREATMENT", 618, 628], ["DI particles", "PROBLEM", 879, 891], ["the inoculation", "PROBLEM", 944, 959], ["accumulation of DI particles", "PROBLEM", 1058, 1086], ["large", "OBSERVATION_MODIFIER", 2, 7], ["fraction", "OBSERVATION_MODIFIER", 8, 16], ["measles", "OBSERVATION", 20, 27], ["infected cells", "OBSERVATION", 28, 42], ["CPE", "OBSERVATION", 137, 140], ["infectious", "OBSERVATION", 170, 180], ["chronic", "OBSERVATION_MODIFIER", 358, 365], ["infections", "OBSERVATION", 366, 376], ["DI particles", "OBSERVATION", 879, 891], ["seems to be unlikely", "UNCERTAINTY", 915, 935], ["DI particles", "OBSERVATION", 1074, 1086]]], ["Nevertheless, some direct proof for discounting any role for DI particles has not been provided.DISCUSSIONEvidence with the JHM persistent infec-tion of RN2-2 cells for the involvement of during suppression remain unknown.", [["RN2-2 cells", "ANATOMY", 153, 164], ["RN2-2 cells", "CELL", 153, 164], ["RN2-2 cells", "CELL_LINE", 153, 164], ["DI particles", "PROBLEM", 61, 73], ["the JHM persistent infec-tion of RN2-2 cells", "PROBLEM", 120, 164]]], ["The an interferon-like mechanism comes from data already in hand strongly indicate that the partial resistance to superinfection with at elevated temperatures both the corona VSV (Lucas et al., 1977) .", [["superinfection", "DISEASE", 114, 128], ["VSV", "ORGANISM", 175, 178], ["interferon", "PROTEIN", 7, 17], ["The an interferon", "TREATMENT", 0, 17], ["the partial resistance to superinfection", "PROBLEM", 88, 128], ["elevated temperatures", "PROBLEM", 137, 158], ["interferon", "OBSERVATION", 7, 17], ["superinfection", "OBSERVATION", 114, 128], ["corona VSV", "ANATOMY", 168, 178]]], ["It was not possi-and measles agents can be maintained in ble, however, to transfer interference some latent form; however, preliminary reagainst VSV to uninfected RN2-2 cells by sults based on infectious center assays with material in medium taken from persistently the measles-infected cells suggest that un-JHM-infected RN2-2 cultures.", [["RN2-2 cells", "ANATOMY", 163, 174], ["cells", "ANATOMY", 287, 292], ["RN2-2 cultures", "ANATOMY", 322, 336], ["measles-infected", "DISEASE", 270, 286], ["VSV", "ORGANISM", 145, 148], ["RN2-2 cells", "CELL", 163, 174], ["measles", "ORGANISM", 270, 277], ["cells", "CELL", 287, 292], ["RN2-2 cultures", "CELL", 322, 336], ["uninfected RN2-2 cells", "CELL_LINE", 152, 174], ["measles-infected cells", "CELL_TYPE", 270, 292], ["JHM-infected RN2-2 cultures", "CELL_LINE", 309, 336], ["VSV", "SPECIES", 145, 148], ["measles agents", "TREATMENT", 21, 35], ["infectious center assays", "TEST", 193, 217], ["infected cells", "PROBLEM", 278, 292], ["JHM", "PROBLEM", 309, 312], ["2 cultures", "TEST", 326, 336]]], ["Clearly ad-der the nonpermissive conditions, the virus ditional work is required to ascertain information is segregated unequally among whether interferon or some other factors all the daughter cells. function in the chronic infectious processDISCUSSIONThe ability to distinguish specifically beunder study by us.DISCUSSIONtween the JHM and MHV, viruses de-As indicated earlier, a common feature of scribed previously (Lucas et al., 1977) andDISCUSSIONother virus-carrier systems is the outgrowth in this report appears to be an unique propof or selection for a variant progeny virus erty of the rat RN2-2 cell line.", [["daughter cells", "ANATOMY", 185, 199], ["RN2-2 cell line", "ANATOMY", 600, 615], ["interferon", "GENE_OR_GENE_PRODUCT", 144, 154], ["daughter cells", "CELL", 185, 199], ["MHV", "ORGANISM", 341, 344], ["andDISCUSSIONother virus", "ORGANISM", 439, 463], ["rat", "ORGANISM", 596, 599], ["RN2-2 cell line", "CELL", 600, 615], ["interferon", "PROTEIN", 144, 154], ["daughter cells", "CELL_TYPE", 185, 199], ["rat RN2-2 cell line", "CELL_LINE", 596, 615], ["rat", "SPECIES", 596, 599], ["MHV", "SPECIES", 341, 344], ["rat", "SPECIES", 596, 599], ["interferon", "TREATMENT", 144, 154], ["chronic", "OBSERVATION_MODIFIER", 217, 224], ["infectious", "OBSERVATION", 225, 235], ["cell line", "OBSERVATION", 606, 615]]], ["The capathat is temperature-sensitive for growth. bility for discrimination between the pro-But, for a majority of chronic infections totype and neurotropic variant is not spewith mouse hepatitis and measles viruses cies-related because neither virus can repexamined currently, the situation is quite licate in the rat C6 astrocytomas, yet both different.", [["C6 astrocytomas", "ANATOMY", 319, 334], ["infections", "DISEASE", 123, 133], ["hepatitis", "DISEASE", 186, 195], ["astrocytomas", "DISEASE", 322, 334], ["capathat", "SIMPLE_CHEMICAL", 4, 12], ["mouse", "ORGANISM", 180, 185], ["measles viruses", "ORGANISM", 200, 215], ["rat", "ORGANISM", 315, 318], ["C6 astrocytomas", "CANCER", 319, 334], ["mouse", "SPECIES", 180, 185], ["rat", "SPECIES", 315, 318], ["mouse", "SPECIES", 180, 185], ["rat", "SPECIES", 315, 318], ["chronic infections totype", "PROBLEM", 115, 140], ["mouse hepatitis", "PROBLEM", 180, 195], ["measles viruses cies", "PROBLEM", 200, 220], ["neither virus", "PROBLEM", 237, 250], ["the rat C6 astrocytomas", "PROBLEM", 311, 334], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["infections", "OBSERVATION", 123, 133], ["hepatitis", "OBSERVATION", 186, 195], ["C6", "ANATOMY", 319, 321], ["astrocytomas", "OBSERVATION", 322, 334]]], ["Despite a drastic suppression of agents readily establish persistence in the virus production at the elevated tempera-rat L6 myoblasts and HTC hepatoma cell ture, the progeny with one exception, are lines.", [["L6 myoblasts", "ANATOMY", 122, 134], ["HTC hepatoma cell", "ANATOMY", 139, 156], ["rat", "ORGANISM", 118, 121], ["L6 myoblasts", "CELL", 122, 134], ["HTC hepatoma cell", "CELL", 139, 156], ["tempera-rat L6 myoblasts", "CELL_LINE", 110, 134], ["HTC hepatoma cell ture", "CELL_LINE", 139, 161], ["rat", "SPECIES", 118, 121], ["a drastic suppression of agents", "TREATMENT", 8, 39], ["the virus production", "PROBLEM", 73, 93], ["the elevated tempera-rat L6 myoblasts", "PROBLEM", 97, 134], ["HTC hepatoma cell ture", "PROBLEM", 139, 161], ["virus", "OBSERVATION", 77, 82], ["L6 myoblasts", "ANATOMY", 122, 134], ["hepatoma cell ture", "OBSERVATION", 143, 161], ["lines", "OBSERVATION", 199, 204]]], ["Some preliminary experiments indinot thermolabile when tested in permissive cate, however, that the restriction on MHV3 cells.", [["MHV3 cells", "ANATOMY", 115, 125], ["MHV3 cells", "CELL", 115, 125], ["MHV3 cells", "CELL_LINE", 115, 125], ["Some preliminary experiments indinot thermolabile", "PROBLEM", 0, 49], ["the restriction on MHV3 cells", "PROBLEM", 96, 125]]], ["The thermal restriction instead ap-multiplication can be circumvented if RN2pears to be host-controlled.DISCUSSIONIn fact, there is 2 cells are inoculated at an m.o.i. of 10 or a close correlation between the capability greater.", [["cells", "ANATOMY", 134, 139], ["cells", "CELL", 134, 139], ["The thermal restriction", "TREATMENT", 0, 23], ["ap-multiplication", "TREATMENT", 32, 49]]], ["Under such circumstances, the for establishment of persistence and ther-CPE becomes extensive and rapid, resulting mosensitivity of the virus replication proc-in a total destruction of the monolayer culess (Table 3 ).", [["monolayer culess", "ANATOMY", 189, 205], ["CPE", "PROBLEM", 72, 75], ["the virus replication proc", "TREATMENT", 132, 158], ["a total destruction of the monolayer culess", "TREATMENT", 162, 205], ["total", "OBSERVATION_MODIFIER", 164, 169], ["destruction", "OBSERVATION", 170, 181]]], ["The basis for temperature ture.", [["temperature ture", "TEST", 14, 30]]], ["Progeny from this infection when inrestriction at 39.5\" remains unknown.", [["infection", "DISEASE", 18, 27], ["this infection", "PROBLEM", 13, 27], ["infection", "OBSERVATION", 18, 27]]], ["It jected into mice cause necrotizing meninshould not be forgotten that control leading gitis essentially identical to that characterto persistence and thermosensitivity of the izing infection with MHV3 propagated in replication process with other agents can the permissive L cells (Lucas et al., 1977) .DISCUSSIONbe virus-as well as host-specified as indi-Thus, the restriction on MHVj appears to cated in the case of VW which has a full involve some quantitative equilibrium conproductive cycle at 32.5 and 39.5' in the trolled by both the virus and its host.", [["L cells", "ANATOMY", 274, 281], ["infection", "DISEASE", 183, 192], ["MHV3", "CHEMICAL", 198, 202], ["mice", "ORGANISM", 15, 19], ["MHV3", "GENE_OR_GENE_PRODUCT", 198, 202], ["L cells", "CELL", 274, 281], ["Nbe virus", "ORGANISM", 313, 322], ["MHV3", "PROTEIN", 198, 202], ["L cells", "CELL_TYPE", 274, 281], ["MHVj", "DNA", 382, 386], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["necrotizing meninshould", "PROBLEM", 26, 49], ["the izing infection", "PROBLEM", 173, 192], ["MHV3", "TREATMENT", 198, 202], ["other agents", "TREATMENT", 242, 254], ["necrotizing", "OBSERVATION", 26, 37], ["virus", "OBSERVATION", 542, 547]]], ["RN2-2, C6, C1300, or HTC cells, but is Taken together, the results described in restricted to a chronic infection in G26-20 this report suggest that the host cell has a or G26-24 cells.", [["RN2-2", "ANATOMY", 0, 5], ["C6", "ANATOMY", 7, 9], ["C1300", "ANATOMY", 11, 16], ["HTC cells", "ANATOMY", 21, 30], ["cell", "ANATOMY", 158, 162], ["G26-24 cells", "ANATOMY", 172, 184], ["infection", "DISEASE", 104, 113], ["RN2-2", "CELL", 0, 5], ["C6, C1300", "CELL", 7, 16], ["HTC cells", "CELL", 21, 30], ["host cell", "CELL", 153, 162], ["G26-24 cells", "CELL", 172, 184], ["RN2-2, C6, C1300, or HTC cells", "CELL_LINE", 0, 30], ["G26-24 cells", "CELL_LINE", 172, 184], ["RN2", "TEST", 0, 3], ["a chronic infection", "PROBLEM", 94, 113], ["C6", "ANATOMY", 7, 9], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["infection", "OBSERVATION", 104, 113], ["host cell", "OBSERVATION", 153, 162]]], ["Similarly, replication of profound influence in regulating the replivaccinia is fully productive at 39.5\" in the cation process of agents with neurotropic RN2-2 and HTC cells and is only partially potential.", [["RN2-2", "ANATOMY", 155, 160], ["HTC cells", "ANATOMY", 165, 174], ["cation", "SIMPLE_CHEMICAL", 113, 119], ["RN2-2", "CELL", 155, 160], ["HTC cells", "CELL", 165, 174], ["neurotropic RN2-2", "CELL_LINE", 143, 160], ["HTC cells", "CELL_LINE", 165, 174], ["profound influence", "PROBLEM", 26, 44], ["fully productive", "PROBLEM", 80, 96], ["neurotropic RN2", "TEST", 143, 158], ["profound", "OBSERVATION_MODIFIER", 26, 34]]], ["The relative ease with which perdepressed in C6 and Cl300 cells.", [["C6", "ANATOMY", 45, 47], ["Cl300 cells", "ANATOMY", 52, 63], ["C6", "CELL", 45, 47], ["Cl300 cells", "CELL", 52, 63], ["C6", "CELL_LINE", 45, 47], ["Cl300 cells", "CELL_LINE", 52, 63], ["C6", "ANATOMY", 45, 47]]], ["The host sistence and thermosensitivity develop in function(s) controlling the temperature re-the cell lines examined provides new sysstriction of virus production do not appear tems for inquiries into the molecular events to be involved in the growth and viability and mechanisms by means of which certain of host cells as shown by growth rates or viruses operate as slowly acting pathogens plating efficiencies which are similar at 32.5 in the nervous system. and 39.5\" for several of the lines tested (unpublished observations).ACKNOWLEDGMENTSThe present experimental data indicate that thermosensitivity is a reversible proc-", [["cell lines", "ANATOMY", 98, 108], ["cells", "ANATOMY", 315, 320], ["nervous system", "ANATOMY", 446, 460], ["thermosensitivity", "DISEASE", 590, 607], ["cell lines", "CELL", 98, 108], ["host cells", "CELL", 310, 320], ["nervous system", "ANATOMICAL_SYSTEM", 446, 460], ["cell lines", "CELL_LINE", 98, 108], ["host cells", "CELL_TYPE", 310, 320], ["the temperature", "TEST", 75, 90], ["the cell lines", "TREATMENT", 94, 108], ["new sysstriction of virus production", "PROBLEM", 127, 163], ["host cells", "PROBLEM", 310, 320], ["viruses", "PROBLEM", 349, 356], ["slowly acting pathogens plating efficiencies", "PROBLEM", 368, 412], ["the lines", "TREATMENT", 487, 496], ["a reversible proc-", "PROBLEM", 611, 629], ["cell lines", "OBSERVATION", 98, 108], ["nervous system", "ANATOMY", 446, 460]]]], "5bcfc90e5a920b30815fab2910be058fa8a3c3dd": [["It feels like the world has been frozen under the SARS-CoV-2 threat, we have all felt its disruptive impact on the delivery of cancer services.", [["cancer", "ANATOMY", 127, 133], ["SARS", "DISEASE", 50, 54], ["cancer", "DISEASE", 127, 133], ["cancer", "CANCER", 127, 133], ["cancer services", "TREATMENT", 127, 142]]], ["Oncology health care professionals across the globe have shown their commitment to patients by adapting to our new reality.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["globe", "ANATOMY", 46, 51]]], ["Under duress they have maintained cancer services in their communities and worked to provide patients with optimal treatments and outcomes.", [["cancer", "ANATOMY", 34, 40], ["cancer", "DISEASE", 34, 40], ["cancer", "CANCER", 34, 40], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["optimal treatments", "TREATMENT", 107, 125], ["cancer", "OBSERVATION", 34, 40]]]], "932853ef64d77a7a2b32147aefe22e0bea3538b5": [["Proposed imaging guidelines for pregnant women suspected of having COVID-19In view of the indispensable role of imaging studies and CT scans in the diagnosis and follow up of COVID-19 patients, there are reports that CT has a higher sensitivity than PCR in detecting COVID-19 (1).", [["women", "ORGANISM", 41, 46], ["patients", "ORGANISM", 184, 192], ["women", "SPECIES", 41, 46], ["patients", "SPECIES", 184, 192], ["imaging studies", "TEST", 112, 127], ["CT scans", "TEST", 132, 140], ["COVID", "TEST", 175, 180], ["CT", "TEST", 217, 219], ["PCR", "TEST", 250, 253], ["COVID", "TEST", 267, 272]]], ["Also, CT scan has been considered as a necessary part of the evaluation in most suspected subjects (2) or in patients with respiratory complications in order to rule out a wide spectrum of diseases in the differential diagnosis.", [["respiratory", "ANATOMY", 123, 134], ["respiratory complications", "DISEASE", 123, 148], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["CT scan", "TEST", 6, 13], ["the evaluation", "TEST", 57, 71], ["respiratory complications", "PROBLEM", 123, 148], ["a wide spectrum of diseases", "PROBLEM", 170, 197], ["respiratory", "ANATOMY", 123, 134], ["complications", "OBSERVATION", 135, 148], ["diseases", "OBSERVATION", 189, 197]]], ["Given the importance of a closer review of the imaging studies, we decided to evaluate chest CT scans through telemedicine and counseling groups by expert radiologists in our country (3, 4) .Proposed imaging guidelines for pregnant women suspected of having COVID-19One of the important patient groups in this pandemic is pregnant women.", [["COVID-19One", "CHEMICAL", 258, 269], ["women", "ORGANISM", 232, 237], ["patient", "ORGANISM", 287, 294], ["women", "ORGANISM", 331, 336], ["women", "SPECIES", 232, 237], ["patient", "SPECIES", 287, 294], ["women", "SPECIES", 331, 336], ["the imaging studies", "TEST", 43, 62], ["chest CT scans", "TEST", 87, 101], ["chest", "ANATOMY", 87, 92]]], ["Because of the associated higher risk of COVID-19 in pregnancy (5) and the defined constraints for use of ionizing radiation in pregnant women (6) , the Iranian Society of Radiology devised the following guidelines to gain the maximum benefit from imaging techniques along with optimal protection and safety for pregnant women.", [["women", "ORGANISM", 137, 142], ["women", "ORGANISM", 321, 326], ["women", "SPECIES", 137, 142], ["women", "SPECIES", 321, 326], ["COVID", "TEST", 41, 46], ["ionizing radiation", "TREATMENT", 106, 124], ["imaging techniques", "TEST", 248, 266], ["optimal protection", "TREATMENT", 278, 296]]], ["In general, ionizing radiation must be avoided in pregnant women as much as possible.", [["women", "ORGANISM", 59, 64], ["women", "SPECIES", 59, 64], ["ionizing radiation", "TREATMENT", 12, 30]]], ["Its utilization must be narrowed to limited indications with a high level of protection.", [["a high level of protection", "TREATMENT", 61, 87]]], ["The maximum permitted dose of radiation exposure is below 50 mGy in pregnant women.", [["women", "ORGANISM", 77, 82], ["women", "SPECIES", 77, 82], ["radiation exposure", "TREATMENT", 30, 48], ["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["The absorbed dose of radiation for a fetus whose mother undergoes chest x-ray and chest CT scan are 0.002 mGy and 0.2 mGy respectively, which are not associated with known adverse effects on fetal health and thus are safe (3).Proposed imaging guidelines for pregnant women suspected of having COVID-191-It is prudent to avoid radiation imaging modalities such as chest x-ray or CT scans in pregnant women suspected of having COVID-19, as much as possible.Proposed imaging guidelines for pregnant women suspected of having COVID-192-Chest x-ray or CT scan requests must be based on thorough examination, in case of investigating differential diagnoses of respiratory problems during the COVID-19 pandemic, along with other conditions like pulmonary edema etc. or appraisement of COVID-19 pulmonary infection in case of clinical indications.Proposed imaging guidelines for pregnant women suspected of having COVID-193-The patient must be well informed of the necessity, benefits and possible risks of the imaging procedures (chest radiography or CT scan), by the attending physician.", [["fetus", "ANATOMY", 37, 42], ["chest", "ANATOMY", 66, 71], ["fetal", "ANATOMY", 191, 196], ["respiratory", "ANATOMY", 654, 665], ["pulmonary", "ANATOMY", 738, 747], ["pulmonary", "ANATOMY", 787, 796], ["COVID-191", "CHEMICAL", 293, 302], ["respiratory problems", "DISEASE", 654, 674], ["pulmonary edema", "DISEASE", 738, 753], ["pulmonary infection", "DISEASE", 787, 806], ["COVID-193", "CHEMICAL", 906, 915], ["fetus", "ORGANISM", 37, 42], ["chest", "ORGAN", 66, 71], ["fetal", "ANATOMICAL_SYSTEM", 191, 196], ["women", "ORGANISM", 267, 272], ["women", "ORGANISM", 399, 404], ["women", "ORGANISM", 496, 501], ["pulmonary", "ORGAN", 738, 747], ["pulmonary", "ORGAN", 787, 796], ["women", "ORGANISM", 880, 885], ["patient", "ORGANISM", 920, 927], ["women", "SPECIES", 267, 272], ["women", "SPECIES", 399, 404], ["women", "SPECIES", 496, 501], ["women", "SPECIES", 880, 885], ["patient", "SPECIES", 920, 927], ["radiation", "TREATMENT", 21, 30], ["chest x-ray", "TEST", 66, 77], ["chest CT scan", "TEST", 82, 95], ["known adverse effects on fetal health", "PROBLEM", 166, 203], ["COVID", "TEST", 293, 298], ["radiation imaging modalities", "TEST", 326, 354], ["chest x-ray", "TEST", 363, 374], ["CT scans", "TEST", 378, 386], ["COVID", "TEST", 425, 430], ["COVID", "TEST", 522, 527], ["Chest x-ray", "TEST", 532, 543], ["CT scan", "TEST", 547, 554], ["thorough examination", "TEST", 581, 601], ["respiratory problems", "PROBLEM", 654, 674], ["the COVID", "TEST", 682, 691], ["pandemic", "PROBLEM", 695, 703], ["pulmonary edema", "PROBLEM", 738, 753], ["COVID-19 pulmonary infection", "PROBLEM", 778, 806], ["COVID", "TEST", 906, 911], ["the imaging procedures", "TEST", 999, 1021], ["chest radiography", "TEST", 1023, 1040], ["CT scan", "TEST", 1044, 1051], ["chest", "ANATOMY", 66, 71], ["chest", "ANATOMY", 82, 87], ["not associated with", "UNCERTAINTY", 146, 165], ["chest", "ANATOMY", 363, 368], ["Chest", "ANATOMY", 532, 537], ["respiratory problems", "OBSERVATION", 654, 674], ["pulmonary", "ANATOMY", 738, 747], ["edema", "OBSERVATION", 748, 753], ["pulmonary", "ANATOMY", 787, 796], ["infection", "OBSERVATION", 797, 806], ["chest", "ANATOMY", 1023, 1028]]], ["4-If requested by the physician, the imaging procedure (chest X-ray or CT scan) maybe done if the following conditions apply from the admitted ward to the imaging department: The CT scan request in the hospital information system is marked in red, and in coordination with the radiology department admission, the pregnant patient is transferred to the ward when no other patient is there and the ward is disinfected.", [["patient", "ORGANISM", 322, 329], ["patient", "ORGANISM", 371, 378], ["patient", "SPECIES", 322, 329], ["patient", "SPECIES", 371, 378], ["the imaging procedure", "TEST", 33, 54], ["chest X-ray", "TEST", 56, 67], ["CT scan)", "TEST", 71, 79], ["The CT scan", "TEST", 175, 186], ["chest", "ANATOMY", 56, 61], ["marked", "OBSERVATION_MODIFIER", 233, 239]]], ["Also, the patients' files should be placed in the red cover and the patient's clothing should be marked with a sign related to high-risk patients, so that maximum protection measures can be implemented as soon as they enter the imaging section and eliminate any possible errors.", [["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 68, 75], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 68, 75], ["patients", "SPECIES", 137, 145], ["the red cover", "TREATMENT", 46, 59], ["the patient's clothing", "TREATMENT", 64, 86], ["maximum protection measures", "TREATMENT", 155, 182], ["the imaging section", "TEST", 224, 243]]], ["5-To minimize the dose of exposure, the minimum possible dose for radiography must be utilized and CT scans must be carried out in accordance with the low dose CT protocol.Proposed imaging guidelines for pregnant women suspected of having COVID-196-When Chest CTs and Chest X rays are indicated, local protection for the fetus (abdominal lead shields) must be utilized.", [["fetus", "ANATOMY", 321, 326], ["abdominal", "ANATOMY", 328, 337], ["COVID-196", "CHEMICAL", 239, 248], ["women", "ORGANISM", 213, 218], ["fetus", "ORGANISM_SUBDIVISION", 321, 326], ["abdominal", "ORGANISM_SUBDIVISION", 328, 337], ["women", "SPECIES", 213, 218], ["radiography", "TEST", 66, 77], ["CT scans", "TEST", 99, 107], ["the low dose CT protocol", "TEST", 147, 171], ["COVID", "TEST", 239, 244], ["Chest CTs", "TEST", 254, 263], ["Chest X rays", "TEST", 268, 280], ["local protection", "TREATMENT", 296, 312], ["the fetus (abdominal lead shields", "TREATMENT", 317, 350], ["Chest", "ANATOMY", 254, 259], ["Chest", "ANATOMY", 268, 273], ["abdominal", "ANATOMY", 328, 337]]], ["7-Standard personal protection equipment for the Corona virus like masks, gloves, gowns, goggles, and disinfectants must be available for the patients, the accompanying people and all other personnel who are involved in the procedure , in accordance with the relevant protection protocols.Proposed imaging guidelines for pregnant women suspected of having COVID-198-During the first trimester of pregnancy, the decision to proceed with Chest X-ray or CT scan must be made with meticulous consideration of the risks involved.", [["COVID-198", "CHEMICAL", 356, 365], ["patients", "ORGANISM", 142, 150], ["people", "ORGANISM", 169, 175], ["women", "ORGANISM", 330, 335], ["patients", "SPECIES", 142, 150], ["people", "SPECIES", 169, 175], ["women", "SPECIES", 330, 335], ["Standard personal protection equipment", "TREATMENT", 2, 40], ["the Corona virus like masks", "TREATMENT", 45, 72], ["disinfectants", "TREATMENT", 102, 115], ["the procedure", "TREATMENT", 220, 233], ["COVID", "TEST", 356, 361], ["Chest X-ray", "TEST", 436, 447], ["CT scan", "TEST", 451, 458], ["Chest", "ANATOMY", 436, 441]]], ["It is advisable to initially perform Chest X ray with abdominal shield and then proceed to CT only if the Chest X ray turns out to be inconclusive.", [["abdominal", "ANATOMY", 54, 63], ["abdominal", "ORGANISM_SUBDIVISION", 54, 63], ["Chest X ray", "TEST", 37, 48], ["abdominal shield", "TREATMENT", 54, 70], ["CT", "TEST", 91, 93], ["the Chest X ray", "TEST", 102, 117], ["Chest", "ANATOMY", 37, 42], ["abdominal", "ANATOMY", 54, 63], ["Chest", "ANATOMY", 106, 111]]], ["During the 2nd and 3rd trimesters, low dose CT may be requested in the first stage.", [["the 2nd and 3rd trimesters", "TREATMENT", 7, 33], ["low dose CT", "TREATMENT", 35, 46]]], ["9-The attending physician is responsible for making decisions on requesting or repeating imaging procedures and continuation or termination of pregnancy.", [["repeating imaging procedures", "TEST", 79, 107], ["pregnancy", "PROBLEM", 143, 152]]], ["10-It is compulsory to use lead abdominal shields especially in the 1st trimester, even if it hampers visualization of the sub-diaphragmatic areas in the imaging field.", [["abdominal", "ANATOMY", 32, 41], ["abdominal", "ORGANISM_SUBDIVISION", 32, 41], ["diaphragmatic", "ORGAN", 127, 140], ["lead abdominal shields", "TREATMENT", 27, 49], ["abdominal", "ANATOMY", 32, 41], ["sub", "OBSERVATION_MODIFIER", 123, 126], ["diaphragmatic", "ANATOMY", 127, 140], ["areas", "ANATOMY_MODIFIER", 141, 146]]]], "PMC6751661": [["BackgroundIn recent years, reports about human cases of infected emerging avian influenza virus has become more and more common [1\u20134].", [["avian influenza virus", "DISEASE", 74, 95], ["human", "ORGANISM", 41, 46], ["avian influenza virus", "ORGANISM", 74, 95], ["human", "SPECIES", 41, 46], ["avian influenza virus", "SPECIES", 74, 95], ["human", "SPECIES", 41, 46], ["avian influenza virus", "SPECIES", 74, 95], ["infected emerging avian influenza virus", "PROBLEM", 56, 95]]], ["Human infected H5N1 virus was first reported in 1997 in Hong Kong, China, and then was spread widely in mainland China [5] as well as many other countries in Southeast Asia [6, 7], West Asia [8, 9], and Africa [10].", [["Human infected H5N1 virus", "DISEASE", 0, 25], ["Human", "ORGANISM", 0, 5], ["H5N1 virus", "ORGANISM", 15, 25], ["Human", "SPECIES", 0, 5], ["H5N1 virus", "SPECIES", 15, 25], ["Human infected H5N1 virus", "SPECIES", 0, 25], ["Human infected H5N1 virus", "PROBLEM", 0, 25], ["infected", "OBSERVATION_MODIFIER", 6, 14], ["H5N1", "OBSERVATION", 15, 19]]], ["Thereafter, human cases infected with emerging influenza viruses were reported in the subsequent years, especially in China.", [["influenza viruses", "DISEASE", 47, 64], ["human", "ORGANISM", 12, 17], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["human cases", "TREATMENT", 12, 23], ["emerging influenza viruses", "PROBLEM", 38, 64]]], ["For example, H7N9 was reported in 2013 [11], H5N6 in 2014 [2, 12\u201315], H10N8 in 2013 [1], and H9N2 in 2013 in Hunan province, China [16].", [["H9N2", "DISEASE", 93, 97], ["H7N9", "SPECIES", 13, 17], ["H7N9", "PROBLEM", 13, 17], ["H5N6", "TEST", 45, 49], ["H9N2", "PROBLEM", 93, 97]]], ["It is important to detect these emerging viruses in and out of China.BackgroundThere are currently two main surveillance systems focused on detecting / monitoring the virus in China.", [["viruses", "OBSERVATION", 41, 48], ["virus", "OBSERVATION", 167, 172]]], ["One is China\u2019s national sentinel surveillance system for influenza-like illness (ILI) in sentinel hospitals across 31 provinces in mainland China.", [["influenza-like illness", "DISEASE", 57, 79], ["ILI", "DISEASE", 81, 84], ["influenza", "PROBLEM", 57, 66]]], ["The other one is the national pneumonia surveillance system, which was built by the Chinese Center for Disease Control and Prevention (CDC) in 2004.", [["pneumonia", "DISEASE", 30, 39], ["the national pneumonia surveillance system", "PROBLEM", 17, 59], ["Disease Control", "TREATMENT", 103, 118], ["pneumonia", "OBSERVATION", 30, 39]]], ["The system is mainly to monitor pneumonia of unknown etiology (PUE) to facilitate timely detection of novel respiratory pathogens, such as severe acute respiratory syndrome (SARS) and avian influenza [18].", [["respiratory", "ANATOMY", 108, 119], ["pneumonia", "DISEASE", 32, 41], ["PUE", "DISEASE", 63, 66], ["respiratory pathogens", "DISEASE", 108, 129], ["acute respiratory syndrome", "DISEASE", 146, 172], ["SARS", "DISEASE", 174, 178], ["avian influenza", "DISEASE", 184, 199], ["avian influenza", "SPECIES", 184, 199], ["pneumonia", "PROBLEM", 32, 41], ["novel respiratory pathogens", "PROBLEM", 102, 129], ["severe acute respiratory syndrome", "PROBLEM", 139, 172], ["SARS", "PROBLEM", 174, 178], ["avian influenza", "PROBLEM", 184, 199], ["pneumonia", "OBSERVATION", 32, 41], ["respiratory pathogens", "OBSERVATION", 108, 129], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["respiratory syndrome", "OBSERVATION", 152, 172]]], ["The two systems have played significant roles in monitoring the activity of influenza, controlling and preventing emerging avian influenza [17\u201319].BackgroundTraditionally, the number of ILI cases was counted manually by influenza surveillance staff.", [["influenza", "DISEASE", 76, 85], ["influenza", "DISEASE", 129, 138], ["ILI", "DISEASE", 186, 189], ["avian influenza", "ORGANISM", 123, 138], ["avian influenza", "SPECIES", 123, 138], ["influenza", "PROBLEM", 76, 85], ["emerging avian influenza", "PROBLEM", 114, 138], ["significant", "OBSERVATION_MODIFIER", 28, 39]]], ["The PUE surveillance system was not (and is still not) used consistently because most cases on community-acquired pneumonia met the PUE criteria, but were not reported to the PUE system [18].", [["pneumonia", "DISEASE", 114, 123], ["acquired pneumonia", "PROBLEM", 105, 123], ["pneumonia", "OBSERVATION", 114, 123]]], ["The PUE surveillance system was not sensitive enough to detect the emerging avian influenza virus.BackgroundTo explore a new way to monitor influenza virus by using HIS and improve the sensitivity of detecting emerging avian influenza virus, we modified the influenza surveillance system (ISS) and built a pneumonia surveillance system (PSS) in Changsha City, China.", [["avian influenza virus", "DISEASE", 76, 97], ["influenza", "DISEASE", 140, 149], ["avian influenza virus", "DISEASE", 219, 240], ["pneumonia", "DISEASE", 306, 315], ["avian", "ORGANISM", 76, 81], ["influenza virus", "ORGANISM", 82, 97], ["influenza virus", "ORGANISM", 140, 155], ["avian influenza virus", "ORGANISM", 219, 240], ["avian influenza virus", "SPECIES", 76, 97], ["avian influenza virus", "SPECIES", 219, 240], ["influenza virus", "SPECIES", 140, 155], ["avian influenza virus", "SPECIES", 219, 240], ["The PUE surveillance system", "TEST", 0, 27], ["the emerging avian influenza virus", "PROBLEM", 63, 97], ["influenza virus", "PROBLEM", 140, 155], ["emerging avian influenza virus", "PROBLEM", 210, 240], ["a pneumonia surveillance system", "PROBLEM", 304, 335], ["pneumonia", "OBSERVATION", 306, 315]]], ["In this study, we separately reported the roles of the ISS and the PSS systems in detecting influenza and emerging avian influenza virus.Study area ::: MethodsChangsha (27\u00b051\u2032~ 28\u00b041\u2032 N, 111\u00b053\u2032~ 114\u00b015\u2032 E), a large city with 7.04 million people in central south China, is the capital of Hunan Province.", [["influenza", "DISEASE", 92, 101], ["avian influenza virus", "DISEASE", 115, 136], ["avian influenza virus", "ORGANISM", 115, 136], ["avian influenza virus", "SPECIES", 115, 136], ["people", "SPECIES", 239, 245], ["this study", "TEST", 3, 13], ["the ISS", "TEST", 51, 58], ["the PSS systems", "TEST", 63, 78], ["influenza", "PROBLEM", 92, 101], ["emerging avian influenza virus", "PROBLEM", 106, 136], ["influenza", "OBSERVATION", 92, 101], ["large", "OBSERVATION_MODIFIER", 210, 215]]], ["In this study, there were 49 secondary and tertiary hospitals included into the PSS system and 2 tertiary hospitals into the ISS system, respectively.", [["this study", "TEST", 3, 13]]], ["The two hospitals in ISS system were also included in the PSS.", [["PSS", "DISEASE", 58, 61], ["ISS system", "TREATMENT", 21, 31]]]]}